**History and Physical Examination**

**Identifying Data:** Patient's name; age, race, sex. List the patient's significant medical problems. Name of informant (patient, relative).

**Chief Complaint:** Reason given by patient for seeking medical care and the duration of the symptom. List all of the patient's medical problems.

**History of Present Illness (HPI):** Describe the course of the patient's illness, including when it began, character of the symptoms, location where the symptoms began; aggravating or alleviating factors; pertinent positives and negatives. Describe past illnesses or surgeries, and past diagnostic testing.

**Past Medical History (PMH):** Past diseases, surgeries, hospitalizations; medical problems; history of diabetes, hypertension, peptic ulcer disease, asthma, myocardial infarction, cancer. In children include birth history, prenatal history, immunizations, and type of feedings.

**Medications:**

**Allergies:** Penicillin, codeine?

**Family History:** Medical problems in family, including the patient's disorder. Asthma, coronary artery disease, heart failure, cancer, tuberculosis.

**Social History:** Alcohol, smoking, drug usage. Marital status, employment situation. Level of education.

**Review of Systems (ROS):**

- **General:** Weight gain or loss, loss of appetite, fever, chills, fatigue, night sweats.
- **Skin:** Rashes, skin discolorations.
- **Head:** Headaches, dizziness, masses, seizures.
- **Eyes:** Visual changes, eye pain.
- **Ears:** Tinnitus, vertigo, hearing loss.
- **Nose:** Nose bleeds, discharge, sinus diseases.
- **Mouth and Throat:** Dental disease, hoarseness, throat pain.
- **Respiratory:** Cough, shortness of breath, sputum (color).
- **Cardiovascular:** Chest pain, orthopnea, paroxysmal nocturnal dyspnea; dyspnea on exertion, claudication, edema, valvular disease.
- **Gastrointestinal:** Dysphagia, abdominal pain, nausea, vomiting, hematemesis, diarrhea, constipation, melena (black tarry stools), hematochezia (bright red blood per rectum).
- **Genitourinary:** Polyuria, polydipsia, skin or hair changes, heat intolerance.
- **Musculoskeletal:** Joint pain or swelling, arthritis, myalgias.
- **Skin and Lymphatics:** Easy bruising, lymphadenopathy.
- **Neuropsychiatric:** Weakness, seizures, memory changes, depression.

**Physical Examination**

**General appearance:** Note whether the patient appears ill, well, or malnourished.

**Vital Signs:** Temperature, heart rate, respirations, blood pressure.

**Skin:** Rashes, scars, moles, capillary refill (in seconds).

**Lymph Nodes:** Cervical, supraclavicular, axillary, inguinal nodes; size, tenderness.

**Head:** Bruising, masses. Check fontanels in pediatric patients.

**Eyes:** Pupils equal round and react to light and accommodation (PERRLA); extra ocular movements intact (EOMI), and visual fields. Funduscopy (papilledema, arteriovenous nicking, hemorrhages, exudates); scleral icterus, ptosis.

**Ears:** Acuity, tympanic membranes (dull, shiny, intact, injected, bulging).

**Mouth and Throat:** Mucus membrane color and moisture; oral lesions, dentition, pharynx, tonsils.

**Neck:** Jugular venous distention (JVD) at a 45 degree incline, thyromegaly, lymphadenopathy, masses, bruits, abdominom jugular reflux.

**Chest:** Equal expansion, tactile fremitus, percussion, auscultation, rhonchi, crackles, rubs, breath sounds, egophony, whispered pectoriloquy.

**Heart:** Point of maximal impulse (PMI), thrills (palpable turbulence); regular rate and rhythm (RRR), first and second heart sounds (S1, S2), gallop (S3, S4), murmurs (grade 1-6), pulses (graded 0-2+).

**Breast:** Dimpling, tenderness, masses, nipple discharge; axillary masses.

**Abdomen:** Contour (flat, scaphoid, obese, distended); scars, bowel sounds, bruits, tenderness, masses, liver span by percussion; hepatomegaly, splenomegaly; guarding, rebound, percussion note (tonypalic), costovertebral angle tenderness (CVAT), suprapubic tenderness.

**Genitourinary:** Inguinal masses, hernias, scrotum, testicles, varicoceles.

**Pelvic Examination:** Vaginal mucosa, cervical discharge, uterine size, masses, adnexal masses, ovaries.
Extremities: Joint swelling, range of motion, edema (grade 1-4+); cyanosis, clubbing, edema (CCE); pulses (radial, ulnar, femoral, popliteal, posterior tibial, dorsalis pedis; simultaneous palpation of radial and femoral pulses).

Rectal Examination: Sphincter tone, masses, fissures; test for occult blood, prostate (nodules, tenderness, size).

Neurological: Mental status and affect; gait, strength (graded 0-5); touch sensation, pressure, pain, position and vibration; deep tendon reflexes (biceps, triceps, patellar, ankle; graded 0-4+); Romberg test (ability to stand erect with arms outstretched and eyes closed).

Cranial Nerve Examination:
I: Smell
II: Vision and visual fields
III, IV, VI: Pupil responses to light, extraocular eye movements, ptosis
V: Facial sensation, ability to open jaw against resistance, corneal reflex.
VII: Close eyes tightly, smile, show teeth
VIII: Hears watch tic; Weber test (lateralization of sound when tuning fork is placed on top of head); Rinne test (air conduction last longer than bone conduction when tuning fork is placed on mastoid process)
IX, X: Palate moves in midline when patient says "ah," speech
XI: Shoulder shrug and turns head against resistance
XII: Stick out tongue in midline

Labs: Electrolytes (sodium, potassium, bicarbonate, chloride, BUN, creatinine), CBC (hemoglobin, hematocrit, WBC count, platelets, differential); X-rays, ECG, urine analysis (UA), liver function tests (LFTs).

Assessment (Impression): Assign a number to each problem and discuss separately. Discuss differential diagnosis and give reasons that support the working diagnosis; give reasons for excluding other diagnoses.

Plan: Describe therapeutic plan for each numbered problem, including testing, laboratory studies, medications, and antibiotics.

Admission Check List
1. Call and request old chart, ECG, and X-rays.
3. Labs: Toxicology screens and drug levels.
4. Cultures: Blood culture x 2, urine and sputum culture (before initiating antibiotics), sputum Gram stain, urinalysis.
5. CXR, ECG, diagnostic studies.
6. Discuss case with resident, attending, and family.

Progress Notes
Daily progress notes should summarize developments in a patient's hospital course, problems that remain active, plans to treat those problems, and arrangements for discharge. Progress notes should address every element of the problem list.

<table>
<thead>
<tr>
<th>Progress Note</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date/time:</strong></td>
</tr>
<tr>
<td><strong>Subjective:</strong> Any problems and symptoms of the patient should be charted. Appetite, pain, headaches or insomnia may be included.</td>
</tr>
<tr>
<td><strong>Objective:</strong> General appearance. Vitals, including highest temperature over past 24 hours. Fluid I/O (inputs and outputs), including oral, parenteral, urine, and stool volumes. Physical exam, including chest and abdomen, with particular attention to active problems. Emphasize changes from previous physical exams.</td>
</tr>
<tr>
<td><strong>Labs:</strong> Include new test results and circle abnormal values.</td>
</tr>
<tr>
<td><strong>Current medications:</strong> List all medications and dosages.</td>
</tr>
<tr>
<td><strong>Assessment and Plan:</strong> This section should be organized by problem. A separate assessment and plan should be written for each problem.</td>
</tr>
</tbody>
</table>
Procedure Note

A procedure note should be written in the chart when a procedure is performed. Procedure notes are brief operative notes.

**Procedure Note**

<table>
<thead>
<tr>
<th>Date and time:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure:</td>
</tr>
<tr>
<td>Indications:</td>
</tr>
<tr>
<td>Patient Consent: Document that the indications and risks were explained to the patient and that the patient consented: “The patient understands the risks of the procedure and consents in writing.”</td>
</tr>
<tr>
<td>Lab tests: Relevant labs, such as the INR and CBC</td>
</tr>
<tr>
<td>Anesthesia: Local with 2% lidocaine</td>
</tr>
<tr>
<td>Description of Procedure: Briefly describe the procedure, including sterile prep, anesthesia method, patient position, devices used, anatomic location of procedure, and outcome.</td>
</tr>
<tr>
<td>Complications and Estimated Blood Loss (EBL):</td>
</tr>
<tr>
<td>Disposition: Describe how the patient tolerated the procedure.</td>
</tr>
<tr>
<td>Specimens: Describe any specimens obtained and labs tests which were ordered.</td>
</tr>
</tbody>
</table>

Discharge Note

The discharge note should be written in the patient’s chart prior to discharge.

**Discharge Note**

<table>
<thead>
<tr>
<th>Date/time:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnoses:</td>
</tr>
<tr>
<td>Treatment: Briefly describe treatment provided during hospitalization, including surgical procedures and antibiotic therapy.</td>
</tr>
<tr>
<td>Studies Performed: Electrocardiograms, CT scans.</td>
</tr>
<tr>
<td>Discharge Medications:</td>
</tr>
<tr>
<td>Follow-up Arrangements:</td>
</tr>
</tbody>
</table>

Discharge Summary

**Patient’s Name and Medical Record Number:**

**Date of Admission:**

**Date of Discharge:**

**Admitting Diagnosis:**

**Discharge Diagnosis:**

**Attending or Ward Team Responsible for Patient:**

**Surgical Procedures, Diagnostic Tests, Invasive Procedures:**

**Brief History, Pertinent Physical Examination, and Laboratory Data:** Describe the course of the patient’s disease up until the time that the patient came to the hospital, including physical exam and laboratory data.

**Hospital Course:** Describe the course of the patient’s illness while in the hospital, including evaluation, treatment, medications, and outcome of treatment.

**Discharged Condition:** Describe improvement or deterioration in the patient’s condition, and describe present status of the patient.

**Disposition:** Describe the situation to which the patient will be discharged (home, nursing home), and indicate who will take care of patient.

**Discharged Medications:** List medications and instructions for patient on taking the medications.

**Discharged Instructions and Follow-up Care:** Date of return for follow-up care at clinic; diet, exercise.

**Problem List:** List all active and past problems.

**Copies:** Send copies to attending, clinic, consultants.

Prescription Writing

- Patient’s name:
- Date:
- Drug name, dosage form, dose, route, frequency (include concentration for oral liquids or mg strength for oral solids): Amoxicillin 125mg/5mL 5 mL PO tid
- Quantity to dispense: mL for oral liquids, # of oral solids
- Refills: If appropriate
- Signature
ST-Segment Elevation Myocardial Infarction

1. Admit to: Coronary care unit
2. Diagnosis: Rule out myocardial infarction
3. Condition:
4. Vital Signs: q1h. Call physician if pulse >90, <60; BP >150/90, <90/60; R>25, <12; T >38.5°C.
5. Activity: Bed rest with bedside commode.
6. Nursing: Guaiac stools. If patient has chest pain, obtain 12-lead ECG and call physician.
7. Diet: Cardiac diet, 1-2 gm sodium, low fat, low cholesterol diet. No caffeine or temperature extremes.
8. IV Fluids: D5W at TKO

10. Special Medications:
   - Oxygen 2-4 L/min by NC.
   - Aspirin 325 mg PO, chew and swallow, then aspirin EC 162 mg PO qd OR Clopidogrel (Plavix) 75 mg PO qd (if allergic to aspirin).
   - Nitroglycerine 10 mcg/min infusion (50 mcg in 250-500 mL D5W, 100-200 mcg/mL). Titrate to control symptoms in 5-10 mcg/min steps, up to 200-300 mcg/min; maintain systolic BP >90 OR
   - Nitroglycerine SL, 0.4 mg (0.15-0.6 mg) SL q5min until pain free (up to 3 tabs) OR
   - Nitroglycerin spray (0.4 mg/aerosol spray)1-2 sprays under the tongue q 5min; may repeat x 2.
   - Heparin 60 U/kg IV push, then 12 U/kg/hr by continuous IV infusion for 48 hours to maintain aPTT of 50-70 seconds. Check aPTT q6h x 4, then qd. Repeat aPTT 6 hours after each heparin dosage change.

Thrombolytic Therapy

Absolute Contraindications to Thrombolitics: Active internal bleeding, suspected aortic dissection, known intracranial neoplasm, previous intracranial hemorrhagic stroke at any time, other strokes or cerebrovascular events within 1 year, head trauma, pregnancy, recent non-compressible vascular puncture, uncontrolled hypertension (>180/110 mmHg).

Relative Contraindications to Thrombolitics: Absence of ST-segment elevation, severe hypertension, cerebrovascular disease, recent surgery (within 2 weeks), cardiopulmonary resuscitation.

A. Alteplase (tPA, tissue plasminogen activator, Actilysse):
   1. 15 mg IV push over 2 min, followed by 0.75 mg/kg (max 50 mg) IV infusion over 30 min, followed by 0.5 mg/kg (max 35 mg) IV infusion over 60 min (max total dose 100 mg).
   2. Labs: INR/PTT, CBC, fibrinogen.

B. Reteplase (Retavase):
   1. 10 U IV push over 2 min; repeat second 10 U IV push after 30 min.
   2. Labs: INR, aPTT, CBC, fibrinogen.

C. Tenecteplase (TNKase):
   - <60 kg 30 mg IVP
   - 60-69 kg 35 mg IVP
   - 70-79 kg 40 mg IVP
   - 80-89 kg 45 mg IVP
   - 90 kg 50 mg IVP

D. Streptokinase (Streptase):
   1. 1.5 million IU in 100 mL NS IV over 60 min. Pretreat with diphenhydramine (Benadryl) 50 mg IV push AND Metyldrenodiolone (Soln-Medrol) 250 mg IV push.
   2. Check fibrinogen level now and q6h for 24h until level >100 mg/dL.
   3. No IM or arterial punctures, watch IV for bleeding.

Angiotensin Converting Enzyme Inhibitor:
   - Lisinopril (Zestril, Prinivil) 2.5-5 mg PO qd; titrate to 10-20 mg qd.

Long-acting Nitrates:
   - Nitroglycerin patch 0.2 mg/hr qd. Allow for nitrate-free period to prevent tachyphylaxis.
   - Isosorbide dinitrate (Isordil) 10-60 mg PO tid [5,10,20, 30,40 mg] OR
   - Isosorbide mononitrate (Imdur) 30-60 mg PO qd.

Beta-Blockers:
   - Metoprolol (Lopressor) 5 mg IV q2-5min x 3 doses; then 25 mg PO q6h for 48h, then 100 mg PO q12h; hold if heart rate <60/min or systolic BP <100 mmHg OR
   - Atenolol (Tenorman), 5 mg IV, repeated in 5 minutes, followed by 50-100 mg PO qd OR
   - Esmolol hydrochloride (Brevibloc) 500 mcg/kg IV over 1 min, then 50 mcg/kg/min IV infusion, titrated to heart rate <60 bpm (max 300 mcg/kg/min).

Statins:
   - Atorvastatin (Lipitor) 10 mg PO qhs OR
   - Pravastatin (Pravachol) 40 mg PO qhs OR
   - Simvastatin (Zocor) 20 mg PO qhs OR
   - Lovastatin (Mevacor) 20 mg PO qhs OR
   - Fluvastatin (Lescol) 10-20 mg PO qhs.

11. Symptomatic Medications:
   - Morphine sulfate 2-4 mg IV push pm chest pain.
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h pm headache.
   - Lorazepam (Ativan) 1-2 mg PO tid-qid pm anxiety
   - Zolpidem (Ambien) 5-10 mg qhs pm insomnia.
   - Docusate (Colace) 100 mg PO bid.
   - Dimenhydrinate (Dramamine) 25-50 mg IV over 2-5 min q4-6h or 50 mg PO q4-6h pm nausea.
   - Famotidine (Pepcid) 20 mg PO bid.

12. Extras: ECG stat and in 12h and in AM, portable
Non-ST Segment Elevation Myocardial Infarction (NSTEMI)

1. Admit to: Coronary care unit
2. Diagnosis: Unstable Angina
3. Condition:
4. Vital Signs: q1h. Call physician if pulse >90, <60; BP >150/90, <90/60; R >25, <12; T >38.5°C.
5. Activity: Bed rest with bedside commode.
6. Nursing: Guaiac stools. If patient has chest pain, obtain 12-lead ECG and call physician.
7. Diet: Cardiac diet, 1-2 gm sodium, low fat, low cholesterol diet. No caffeine or temperature extremes.
8. IV Fluids: D5W at TKO

10. Special Medications:
- Oxygen 2-4 L/min by NC.
- Aspirin 325 mg PO, chew and swallow, then aspirin EC 162 mg PO qd OR
- Clopidogrel (Plavix) 75 mg PO qd (if allergic to aspirin).
- Nitroglycerine infusion 10 mcg/min infusion (50 mg in 250-500 mL D5W, 100-200 mcg/mL). Titrate to control symptoms in 5-10 mcg/min steps, up to 200-300 mcg/min: maintain systolic BP >90 OR
- Nitroglycerine SL 0.4 mg (0.15-0.6 mg) SL q5min until pain free (up to 3 tabs) OR
- Nitroglycerin spray (0.4 mg/aerosol spray) 1-2 sprays under the tongue q5min; MR x2.
- Heparin 60 U/kg IV push, then 12 U/kg/hr by continuous IV infusion for 48 hours to maintain aPTT of 50-70 seconds. Check aPTT q6h x 4, then qd. Repeat aPTT 6 hours after each heparin dosage change.

Glycoprotein IIb/IIIa Blockers:
- Eptifibatide (Integrilin) 180 mcg/kg IVP, then 2 mcg/kg/min for 72 hours OR
- Tirofiban (Aggrastat) 0.4 mcg/kg/min for 30 min, then 0.1 mcg/kg/min for 48-72 hours.

Glycoprotein IIb/IIIa blockers for Use With Angioplasty:
- Abciximab (ReoPro) 0.25 mg/kg IVP, then 0.125 mcg/kg/min IV infusion for 12 hours OR
- Eptifibatide (Integrilin) 180 mcg/kg IVP, then 2 mcg/kg/min for 20-24 hours.

Angiotensin Converting Enzyme Inhibitor:
- Lisinopril (Zestril, Prinivil) 2.5-5 mg PO qd; titrate to 10-20 mg qd.

Long-acting Nitrates:
- Nitroglycerin patch 0.2 mg/hr qd. Allow for nitrate-free period to prevent tachyphylaxis.
- Isosorbide dinitrate (Isordil) 10-60 mg PO bd [5, 10, 20, 30, 40 mg] OR
- Isosorbide mononitrate (Imdur) 30-60 mg PO qd.

Beta-Blockers: Contraindicated in cardiogenic shock.
- Metoprolol (Lopressor) 5 mg IV q2-q5min x 3 doses; then 25 mg PO q6h for 48h, then 100 mg PO q12h; keep HR <60/min, hold if systolic BP <100 mmHg OR
- Atenolol (Tenormin) 5 mg IV, repeated in 5 minutes, followed by 50-100 mg PO qd OR
- Esmolol (Brevibloc) 500 mcg/kg IV over 1 min, then 50 mcg/kg/min IV infusion, titrated to heart rate >60 bpm (max 300 mcg/kg/min).

Statins:
- Atorvastatin (Lipitor) 10 mg PO qhs OR
- Pravastatin (Pravachol) 40 mg PO qhs OR
- Simvastatin (Zocor) 20 mg PO qhs OR
- Lovastatin (Mevacor) 20 mg PO qhs OR
- Fluvastatin (Lescol) 10-20 mg PO qhs.

11. Symptomatic Medications:
- Morphine sulfate 2-4 mg IV push prn chest pain.
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.
- Lorazepam (Ativan) 1-2 mg PO tid-qid prn anxiety.
- Zolpidem (Ambien) 5-10 mg qhs prn insomnia.
- Docusate (Colace) 100 mg PO bid.
- Dimenhydrinate (Dramamine) 25-50 mg IV over 2-5 min q4-8h or 50 mg PO q4-6h prn nausea.
- Famotidine (Pepcid) 20 mg IVq12h.

12. Extras: ECG stat and in 12h and in AM, portable CXR, impedance cardiography, echocardiogram. Cardiology consult.

13. Labs: SMA7 and 12, magnesium. Cardiac enzymes: CPK-MB, troponin T, myoglobin STAT and q6h for 24h. CBC, INR/PTT, UA.
Congestive Heart Failure

1. Admit to: 
2. Diagnosis: Congestive Heart Failure
3. Condition: 
4. Vital Signs: q1h. Call physician if P >120; BP >150/-100 <80/60; T >38.5°C; R >25, <10.
5. Activity: Bed rest with bedside commode.
8. IV Fluids: Heparin lock with flush q shift.
9. Special Medications: 
   - Oxygen 2-4 L/min by NC.
   - Furosemide (Lasix) 10-160 mg IV qd-bid or 20-80 mg PO qAM-bid [20,40,60 mg] or 10-40 mg/hr IV infusion OR
   - Torsemide (Demadex) 10-40 mg IV or PO qd; max 200 mg/day [5, 10, 20, 100 mg] OR
   - Bumetanide (Bumex) 0.5-1 mg IV q2-3h until response; then 0.5-1.0 mg IV q8-24h (max 10 mg/d); or 0.5-2.0 mg PO qAM
   - Metolazone (Zaroxolyn) 2.5-10 mg PO qd, max 20 mg/d; 30 min before loop diuretic [2.5,5,10 mg].

ACE Inhibitors: 
- Quinapril (Accupril) 5-10 mg PO qd x 1 dose, then 20-80 mg PO qd in 1 to 2 divided doses [5,10,20,40 mg] OR
- Lisinopril (Zestril, Prinivil) 5-40 mg PO qd [5,10,20,40 mg] OR
- Benazepril (Lotensin) 10-20 mg PO qd-bid, max 80 mg/d [5,10,20,40 mg] OR
- Foapril (Monopril) 40-100 mg PO qd, max 80 mg/d [10,20 mg] OR
- Ramipril (Altace) 2.5-10 mg PO qd, max 20 mg/d [1,2.5,5,10 mg].
- Captopril (Capoten) 6.25-50 mg PO qd [12.5, 25,50,100 mg] OR
- Enalapril (Vasotec) 12.5-5 mg slow IV push q6h or 2.5-20 mg PO bid [5,10,20 mg] OR
- Moexipril (Univasc) 7.5 mg PO qd x 1 dose, then 7.5-15 mg PO qbid [7.5, 15 mg tabs] OR
- Trandolapril (Mavik) 1 mg qd x 1 dose, then 2-4 mg qd [1, 2, 4 mg tabs].

Angiotensin-II Receptor Blockers: 
- Irbesartan (Avapro) 150 mg qd, max 300 mg qd [75, 150, 300 mg].
- Losartan (Cozaar) 25-50 mg bid [25, 50 mg].
- Valsartan (Diovan) 80 mg qd; max 320 mg qd [80, 160 mg].
- Candesartan (Atacand) 8-16 mg qd-bid [4, 8, 16, 32 mg].

Beta-blockers: 
- Carvedilol (Coreg) 1.625-3.125 mg PO bid, then slowly increase the dose every 2 weeks to target dose of 25-50 mg bid [1.25, 2.5, 5, 10, 15, 20 mg] OR
- Metoprolol (Lopressor) start at 12.5 mg bid, then slowly increase to target dose of 100 mg bid [50, 100 mg].
- Bisoprolol (Zebeta) start at 1.25 mg qd, then slowly increase to target of 10 mg qd [5, 10 mg].

Digoxin: (Lanoxin) 0.125-0.5 mg PO or IV qd [0.125,0.25, 0.5 mg].

Inotropic Agents: 
- Dobutamine (Dobutrex) 2.5-10 mcg/kg/min IV, max of 14 mcg/kg/min (500 mg in 250 mL D5W, 2 mcg/mL) OR
- Dopamine (Intropin) 3-15 mcg/kg/min IV (400 mg in 250 cc D5W, 1600 mcg/mL), titrate to CO >4, CI >2; systolic >90 OR
- Milrinone (Primacor) 0.375 mcg/kg/min IV infusion (40 mg in 200 mL NS, 0.2 mg/mL); titrate to 0.75 mcg/kg/min; arrhythmogenic; may cause hypotension.

Vasodilators: 
- Nitroglycerin 5 mcg/min IV infusion (50 mg in 250 mL D5W). Titrating in increments of 5 mcg/min to control symptoms and maintain systolic BP >90 mmHg.
- Nesiritide (Natrecor) 2 mcg/kg IV load over 1 min, then 0.010 mcg/kg/min IV infusion. Titrating in increments of 0.005 mcg/kg/min q3h to max 0.03 mcg/kg/min IV infusion.

Potassium: 
- KCL (Micro-K) 20-80 mEq PO qd if the patient is taking loop diuretics.

Pacing: 
- Synchronized biventricular pacing if ejection fraction <40% and QRS duration >150 msec.

10. Symptomatic Medications: 
- Morphine sulfate 2-4 mg IV push pm dyspnea or anxiety.
- Heparin 5000 U SQ q12h or enoxaparin (Lovenox) 1 mg/kg SC q12h.
- Docusate sodium (Colace) 100-200 mg PO qhs.
- Famotidine (Pepcid) 20 mg IV/PO q12h.

11. Extras: CXR PA and LAT, ECG now and repeat if chest pain or palpitations, impedance cardiography, echocardiogram.

12. Labs: SMA 7&12, CBC; B-type natriuretic peptide (BNP), cardiac enzymes: CPK-MB, troponin T, myoglobin STAT and q6h for 24h. Repeat SMA 7 in AM, UA.
Supraventricular Tachycardia

1. Admit to:
2. Diagnosis: PSVT
3. Condition:
4. Vital Signs: q1h. Call physician if BP >160/90, <90/60; apical pulse >130, <50; R >25, <10; T >38.5°C
5. Activity: Bedrest with bedside commode.
6. Nursing:
7. Diet: Low fat, low cholesterol, no caffeine.
8. IV Fluids: D5W at TKO.
9. Special Medications:
   Attempt vagal maneuvers (Valsalva maneuver) before drug therapy.
   Cardioversion (if unstable or refractory to drug therapy):
   1. NPO for 6h, digoxin level must be less than 2.4 and potassium and magnesium must be normal.
   2. Midazolam (Versed) 2-5 mg IV push.
   3. If stable, cardiovert with synchronized 10-50 J, and increase by 50 J increments if necessary. If unsta-
      ble, start with 75-100 J, then increase to 200 J and 360 J.
10. Symptomatic Medications:
    -Lorazepam (Ativan) 1-2 mg PO tid prn anxiety.
11. Extras: Portable CXR, ECG; repeat if chest pain.
    Cardiology consult.
12. Labs: CBC, SMA 7&12, Mg, thyroid panel. UA.

Ventricular Arrhythmias

1. Ventricular Fibrillation and Tachycardia:
   - If unstable (see ACLS protocol): Defibrillate with unsynchronized 200 J, then 300 J.
   - Oxygen 100% by mask.
   - Lidocaine (Xylocaine) loading dose 75-100 mg IV, then 2-4 mg/min IV OR
   - Amiodarone (Cordarone) 300 mg in 100 mL of D5W, IV infusion over 10 min, then 900 mg in 500 mL of D5W, at 1 mg/min for 6 hrs, then at 0.5 mg/min thereafter; or 400 mg PO q8h x 14 days, then 200-
     400 mg qd.
   - Also see "other antiarrhythmics" below.
2. Torsades De Pointes Ventricular Tachycardia:
   - Correct underlying cause and consider discontinuing quinidine, procainamide, disopyramide, moricizine, amiodarone, sotalol, ibutilide, phenothiazine, haloperidol, tricyclic and tetracyclic antidepressants, ketoconazole, itraconazole, bepridil, hypokalemia, and hypomagnesemia.
   - Magnesium sulfate 1-4 gm in IV bolus over 5-15 min or infuse 3-20 mg/min for 7-48h until QTc interval <440 msec.
   - Isoproterenol (Isuprel), 2-20 mcg/min (2 mg in 500 mL D5W, 4 mcg/mL).
   - Consider ventricular pacing and/or cardioversion.
3. Other Antiarrhythmics:
   Class I:
   - Moricizine (Ethmozine) 200-300 mg PO q8h, max 900 mg/d [200, 250, 300 mg].
   Class la:
   - Quinidine gluconate (Quinaglute) 324-648 mg PO q8-
     12h [324 mg].
   - Procainamide (Procan, Procanbid) IV: 15 mg/kg IV loading dose at 20 mg/min, followed by 2-4 mg/min continuous IV infusion.
   - PO: 500 mg (nonsustained release) PO q8h x 2 doses, then Procanbid 1-2 gm PO q12h [500, 1000 mg].
   - Disopyramide (Norpace, Norpace CR) 100-300 mg PO q8-12h [100, 150, 200 mg] or disopyramide CR 100-
     150 mg PO bid [100, 150 mg].
   Class Ib:
   - Lidocaine (Xylocaine) 75-100 mg IV, then 2-4 mg/min IV
   - Mexiletine (Mexitil) 100-200 mg PO q8h, max 1200 mg/d [150, 200, 250 mg].
   - Tocainide (Tonocard) loading 400-600 mg PO, then 400-600 mg PO q8-12h (1200-1800 mg/d) PO in divided doses q8-12h [400, 600 mg].
   - Phenytoin (Dilantin), loading dose 100-300 mg IV given as 50 mg in NS over 10 min IV q5min, then
     100 mg IV q5min pm.
   Class Ic:
   - Flecainide (Tambocor) 50-100 mg PO q12h, max 400 mg/d [50, 100, 150 mg].
   - Propafenone (Rythmol) 150-300 mg PO q8h, max 1200 mg/d [150, 225, 300 mg].
Class II:
- Propranolol (Inderal) 1-3 mg IV in NS (max 0.15 mg/kg) or 20-80 mg PO tid-qid [10, 20, 40, 60, 80 mg]; propranolol-LA (Inderal-LA), 80-120 mg PO qd [60, 80, 120, 160 mg].
- Esmolol (Brevibloc) loading dose 500 mcg/kg over 1 min, then 50-200 mcg/kg/min IV infusion.
- Atenolol (Tenormin) 50-100 mg PO [25, 50, 100 mg].
- Nadolol (Corgard) 40-100 mg PO qd-bid [20, 40, 80, 120, 160 mg].
- Metoprolol (Lopressor) 50-100 mg PO bid-tid [50, 100 mg], or metoprolol XL (Toprol-XL) 50-200 mg PO qd [50, 100, 200 mg].

Class III:
- Amiodarone (Cordarone), PO loading 400-1200 mg/d in divided doses for 2-4 weeks, then 200-400 mg PO qd (5-10 mg/kg) [200 mg] or amiodarone (Cordarone) 300 mg in 100 mL of D5W, IV infusion over 10-20 min, then 900 mg in 500 mL of D5W, at 1 mg/min for 6 hrs, then at 0.5 mg/min thereafter.
- Sotalol (Betapace) 40-80 mg PO bid, max 320 mg/d in 2-3 divided doses [80, 160 mg].

5. Labs: SMA 7&12, Mg, calcium, CBC, drug levels, UA.

Hypertensive Emergency

1. Admit to:
2. Diagnosis: Hypertensive emergency
3. Condition:
4. Vital Signs: q30min until BP controlled, then q4h.
5. Activity: Bed rest
8. IV Fluids: D5W at TKO.
9. Special Medications:
   - Nitroprusside sodium 0.25-10 mcg/kg/min IV (50 mg in 250 mL of D5W), titrate to desired BP.
   - Labetalol (Trandate, Normodyne) 20 mg IV bolus (0.25 mg/kg), then 20-80 mg boluses IV q10-15min titrate to desired BP or continuous IV infusion of 1.0-2.0 mg/min titrate to desired BP. Ideal in patients with an aortic aneurysm.
   - Fenoldopam (Corlogam) 0.01 mcg/kg/min IV infusion. Adjust dose by 0.025-0.05 mcg/kg/min q15min to max 0.3 mcg/kg/min. [10 mg in 250 mL D5W].
   - Nicardipine (Cardene IV) 15 mg/hr IV infusion, increase rate by 2.5 mg/hr every 15 min up to 15 mg/hr (25 mg in D5W 250 mL).
   - Esmolol (Brevibloc IV) 1.25-5.0 mg IV q6h. Do not use in presence of AMI.
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h pm headache.
   - Zolpidem (Ambien) 5-10 mg qhs pm insomnia.
   - Docusate sodium (Colace) 100-200 mg PO qhs.
11. Extras: Portable CXR, ECG, impedance cardiography, echocardiogram.

Hypertension

I. Initial Diagnostic Evaluation of Hypertension
A. 15 Lead electrocardiography may document evidence of ischemic heart disease, rhythm and conduction disturbances, or left ventricular hypertrophy.
B. Screening labs include a complete blood count, glucose, potassium, calcium, creatinine, BUN, uric acid, and fasting lipid panel.
C. Urinalysis. Dipstick testing should include glucose, protein, and hemoglobin.
D. Selected patients may require plasma renin activity, 24 hour urine catecholamines, or renal function testing (glomerular filtration rate and blood flow).

II. Antihypertensive Drugs
A. Thiazide Diuretics
   1. Hydrochlorothiazide (HCTZ, HydroDiuril) 12.5-25 mg qd [25 mg].
   2. Chlorothiazide (Diuril) 250 mg qd [250, 500 mg].
   3. Thiazide/Potassium Sparing Diuretic Combinations
      a. Maxzide (hydrochlorothiazide 50/triamterene 75 mg) 1 tab qd.
      b. Moduretic (hydrochlorothiazide 50 mg/amiloride 5 mg) 1 tab qd.
      c. Dyazide (hydrochlorothiazide 25 mg/triamterene 37.5) 1 cap qd.
B. Beta-Adrenergic Blockers

1. Cardioselective Beta-Blockers
   a. Atenolol (Tenormin) initial dose 50 mg qd, then 50-100 mg qd, max 200 mg/d [25, 50, 100 mg].
   b. Metoprolol XL (Toprol XL) 100-200 mg qd [50, 100, 200 mg tab ER].
   c. Bisoprolol (Zebeta) 2.5-10 mg qd; max 20 mg qd [5, 10 mg].

2. Non-Cardioselective Beta-Blockers
   a. Propranolol LA (Inderal LA), 80-160 mg qd [60, 80, 120, 160 mg].
   b. Nadolol (Corgard) 40-80 mg qd, max 320 mg/d [20, 40, 60, 120, 160 mg].
   c. Pindolol (Visken) 5-20 mg qd, max 60 mg/d [5, 10 mg].
   d. Carteolol (Cartrol) 2.5-10 mg qd [2.5, 5 mg].

C. Angiotensin-Converting Enzyme (ACE) Inhibitors

1. Ramipril (Altace) 2.5-10 mg qd, max 20 mg/day [1.25, 2.5, 5, 10 mg].
2. Quinapril (Accupril) 20-80 mg qd [5, 10, 20, 40 mg].
3. Lisinopril (Zestril, Prinivil) 10-40 mg qd [2.5, 5, 10, 20, 40 mg].
4. Benazepril (Lotensin) 10-40 mg qd, max 80 mg/day [5, 10, 20, 40 mg].
5. Fosinopril (Monopril) 10-40 mg qd [10, 20 mg].
6. Enalapril (Vasotec) 5-40 mg qd, max 40 mg/day [2.5, 5, 10, 20 mg].
7. Moexipril (Univasc) 7.5-15 mg qd [7.5 mg].

D. Angiotensin Receptor Blockers

1. Losartan (Cozaar) 25-50 mg bid [25, 50 mg].
2. Valsartan (Diovan) 80-160 mg qd [80, 160 mg].
3. Irbesartan (Avapro) 150 mg qd; max 300 mg qd [75, 150, 300 mg].
4. Candesartan (Atacand) 8-16 mg qd-bid [4, 8, 16, 32 mg].
5. Telmisartan (Micardis) 40-80 mg qd [40, 80 mg].

E. Calcium Entry Blockers

1. Diltiazem SR (Cardizem SR) 60-120 mg bid [60, 90, 120 mg] or Cardizem CD 180-360 mg qd [120, 180, 240, 300 mg].
2. Nifedipine XL (Procardia-XL, Adalat-CC) 30-90 mg qd [30, 60, 90 mg].
3. Verapamil SR (Calan SR, Covera-HS) 120-240 mg qd [120, 180, 240 mg].
4. Amlodipine (Norvasc) 2.5-10 mg qd [2.5, 5, 10 mg].
5. Felodipine (Plendil) 5-10 mg qd [2.5, 5, 10 mg].

Syncope

1. Admit to: Monitored ward
2. Diagnosis: Syncope
3. Condition:
4. Vital Signs: q1h, postural BP and pulse q12h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10
5. Activity: Bed rest.
7. Diet: Regular
8. IV Fluids: Normal saline at TKO.
9. Special medications:
   - High-grade AV Block with Syncope:
     - Atropine 1 mg IV x 2.
     - Isoproterenol 0.5-1 mcg/min initially, then slowly titrate to 10 mcg/min IV infusion (1 mg in 250 mL NS).
     - Thoracocardiographic pacing.
   - Drug-induced Syncope:
     - Discontinue vasodilators, centrally acting hypotensive agents, tranquilizers, antidepressants, and alcohol use.
   - Vasovagal Syncope:
     - Scopolamine 1.5 mg transdermal patch q3 days.
   - Postural Syncope:
     - Midodrine (ProAmatine) 2.5 mg PO tid, then increase to 5-10 mg PO tid [2.5, 5 mg]; contraindicated in coronary artery disease.
     - Fludrocortisone 0.1-1.0 mg PO qd.
   - Symptomatic Medications:
     - Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.
   - Lab Tests:
     - CBC, SMA, urinalysis, electrolytes, ECG, 24h Holter monitor, echocardiogram.
10. Extras:
    - CXR, ECG, 24h Holter monitor, electrophysiologic study, tilt test, CT/MRI, EEG, impedance cardiography, echocardiogram.
11. Labs:
    - CBC, SMA, urinalysis, calcium, drug levels, UA, urine drug screen.
Asthma

1. Admit to:
2. Diagnosis: Exacerbation of asthma
3. Condition:
4. Vital Signs: q6h. Call physician if P >140; R >30, <10; T >38.5°C; pulse oximeter <90%
5. Activity: Up as tolerated.
6. Nursing: Pulse oximeter; bedside peak flow rate before and after bronchodilator treatments.
7. Diet: Regular, no caffeine.
8. IV Fluids: D5 ½ NS at 125 cc/h.
9. Special Medications:
   - Oxygen 2 L/min by NC. Keep O₂ sat >90%.
   - Albuterol (Ventolin) 0.5 mg in 2.5 mL NS q1-2h until peak flow rate >200-250 L/min and sat >90%, then q4h OR
   - Albuterol (Ventolin) MDI 3-8 puffs, then 2 puffs q3-6h prn, or powder 200 mcg/capsule inhaled qid.
   - Albuterol/Ipratropium (Combivent) 2-4 puffs qid.

Systemic Corticosteroids:
- Methylprednisolone (Solu-Medrol) 60-125 mg IV q6h; then 30-60 mg PO qd.
- Prednisone 20-60 mg PO qAM.

Aminophylline and Theophylline (second-line therapy):
- Aminophylline load dose: 5.6 mg/kg total body weight in 100 mL D5W IV over 20min. Maintenance of 0.5-0.6 mg/kg ideal body weight/hr (500 mg in 250 mL D5W); reduce if elderly, heart/liver failure (0.2-0.4 mg/kg/hr). Reduce load 50-75% if taking theophylline (1 mg/kg of aminophylline will raise levels 2 mcg/mL). OR
- Theophylline IV solution loading dose 4.5 mg/kg total body weight, then 0.4-0.5 mg/kg ideal body weight/hr.
- Theophylline (Theo-Dur) 100-400 mg PO bid (3 mg/kg q8h); 80% of total daily IV aminophylline in 2-3 doses.

Inhaled Corticosteroids (adjunct therapy):
- Budesonide (Pulmicort) MDI 4-8 puffs bid, with spacer 5 min after bronchodilator, followed by gargling with water.
- Triamcinolone (Azmacort) MDI 2 puffs tid-qid or 4 puffs bid.
- Flunisolide (AeroBid) MDI 1-2 puffs bid.
- Fluticasone (Flovent) 2-4 puffs bid.

Prevention and Prophylaxis:
- Cromolyn (Intal) 2-4 puffs tid-qid.
- Nedocromil (Tilade) 2-4 puffs bid-qid.
- Montelukast (Singular) 10 mg PO qd.
- Zafirlukast (Accolate) 20 mg PO bid.
- Zileuton (Zyflo) 600 mg PO qid.

Chronic Obstructive Pulmonary Disease

1. Admit to:
2. Diagnosis: Exacerbation of COPD
3. Condition:
4. Vital Signs: q4h. Call physician if P >130; R >30, <10; T >38.0°C; O₂ Sat <90%
5. Activity: Up as tolerated; bedside commode.
6. Nursing: Pulse oximeter; measure peak flow with portable peak flow meter bid and chart with vital signs. No sedatives.
8. IV Fluids: D5 ½ NS at 20 mL/h.
9. Special Medications:
   - Oxygen 1-2 L/min by NC or 24-35% by Venturi mask. Keep O₂ saturation 90-91%.
Beta-Agonists, Acute Treatment:
- Albuterol (Ventolin) 0.5 mg and ipratropium (Atrovent) 0.5 mg in 2.5 mL NS q1-2h until peak flow meter $>200-250 L/min, then q4h OR
- Albuterol (Ventolin) MDI 2-4 puffs q4-6h.
- Albuterol/ipratropium (Combivent) 2-4 puffs qid.

Corticosteroids and Anticholinergics:
- Methylprednisolone (Solu-Medrol) 60-125 mg IV q6h or 30-60 mg PO qd. Followed by:
  - Prednisone 20-60 mg PO qd.
  - Triamcinolone (Azmacort) MDI 2 puffs qid or 4 puffs bid.
  - Beclomethasone (Beclovent) MDI 4-8 puffs bid with spacer, followed by gargling with water OR
  - Flunisolide (AeroBid) MDI 2-4 puffs qid OR
  - Ipratropium (Atrovent) MDI 2 puffs tid-qid OR
  - Fluticasone (Flovent) 2-4 puffs bid (44 or 110 mcg/puff).

Aminophylline and Theophylline (second line therapy):
- Aminophylline loading dose, 5.6 mg/kg total body weight over 20 min (if not already on theophylline); then 0.5-0.6 mg/kg ideal body weight/hr (500 mg in 250 mL of D5W); reduce if elderly, or heart or liver disease (0.2-0.4 mg/kg/hr). Reduce loading to 50-75% if already taking theophylline (1 mg/kg of aminophylline will raise levels by 2 mcg/mL) OR
- Theophylline IV solution loading dose, 4.5 mg/kg total body weight, then 0.4-0.5 mg/kg ideal body weight/hr.
- Theophylline long acting (Theo-Dur) 100-400 mg PO bid-tid (3 mg/kg q8h); 80% of daily IV aminophylline in 2-3 doses.

Acute Bronchitis
- Ampicillin 1 gm IV q6h or 500 mg PO qid OR
- Trimethoprim/sulfamethoxazole (Septra DS) 160/800 mg PO bid or 160/800 mg IV q12h (10-15 mL in 100 cc D5W tid) OR
- Cefuroxime (Zinacef) 750 mg IV q8h OR
- Amoxicillin/subbactam (Unasyn) 1.5 gm IV q6h OR
- Doxycycline (Vibra-tabs) 100 mg PO qid bid OR
- Azithromycin (Zithromax) 500 mg x 1, then 250 mg PO qd x 4 OR
- Clarithromycin (Biaxin) 250-500 mg PO bid OR
- Levofoxacin (Levaquin) 500 mg PO/IV qd (250, 500 mg) OR
- Sparfloxacin (Zagam) 400 mg PO x 1, then 200 mg PO qd (200 mg).

10. Symptomatic Medications:
- Docusate sodium (Colace) 100 mg PO qhs.
- Famotidine (Pepcid) 20 mg IV/PO q12h.
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.
- Zolpidem (Ambien) 5-10 mg qhs prn insomnia.

11. Extras:
- Portable CXR, PFT's with bronchodilators, ECG, impedance cardiography, echocardiogram.

Hemoptysis
1. Admit to: Intensive care unit
2. Diagnosis: Hemoptysis
3. Condition:
4. Vital Signs: q1-6h. Orthostatic BP and pulse bid. Call physician if BP >160/90, <90/60; P >130, <50; R>25, <10; T >38.5°C; O2 sat <90%.
7. Diet:
8. IV Fluids: 1 L of NS wide open (16 gauge), then transfuse PRBC, Foley to gravity.
9. Special Medications:
- Transfuse 2-4 U PRBC wide open.
- Promethazine/codeine (Phenergan with codeine) 5 cc PO q4-6h prn cough. Contraindicated in massive hemoptysis.
- Initiate empiric antibiotics if bronchitis or infection is present.
10. Extras: CXR PA, LAT, ECG, VQ scan, contrast CT, bronchoscopy. PPD, pulmonary and thoracic surgery consults.
11. Labs: Type and cross 2-4 U PRBC, ABG, CBC, platelets, SMA7 and 12, ESR. Anti-glomerular basement antibody, rheumatoid factor, complement, anti-nuclear cytoplasmic antibody. Sputum Gram stain and C&S, alpha 1 antitrypsin level.

Anaphylaxis
1. Admit to: Intensive care unit
2. Diagnosis: Anaphylaxis
3. Condition:
4. Vital Signs: q1-4h; call physician if BP >160, <90, diastolic >90, <60; P >120, <50; R>25, <10; T >38.5°C
5. Activity: Bedrest
6. Nursing: O2 at 6 L/min by NC or mask. Keep patient in Trendelenburg’s position, No. 4 or 5 endotracheal tube at bedside.
7. Diet: NPO
8. IV Fluids: 2 IV lines. Normal saline or LR 1 L over 1-2h, then D5 ½ NS at 125 cc/h. Foley to closed drainage.

9. Special Medications:
Gastrointestinal Decontamination:
- Gastric lavage if indicated for recent oral ingestion.
- Activated charcoal 50-100 gm, followed by cathartic.

Bronchodilators:
- Epinephrine (1:1000) 0.3-0.5 mL SQ or IM q10min or 1-4 mcg/min IV OR in severe life threatening reactions, give 0.5 mg (5.0 mL of 1: 10,000 sin) IV q5-10min pm. Epinephrine, 0.3 mg of 1:1000 sln may be injected SQ at site of allergen injection OR
- Albuterol (Ventolin) 0.5%, 0.5 mL in 2.5 mL NS q30min by nebulizer pm OR
- Aerosolized 2% racemic epinephrine 0.5-0.75 mL.

Corticosteroids:
- Methylprednisolone (Solu-Medrol) 250 mg IV x 1, then 125 mg IV q6h OR
- Hydrocortisone sodium succinate 200 mg IV x 1, then 100 mg q8h, followed by oral prednisone 60 mg PO qd, tapered over 5 days.

Antihistamines:
- Diphenhydramine (Benadryl) 25-50 mg IV q4-6h OR
- Hydroxyzine (Vistaril) 25-50 mg IM or PO q2-4h.
- Famotidine (Pepcid) 20 mg IV/PO bid.

Pressors and other Agents:
- Norepinephrine (Levophed) 8-12 mcg/min IV, titrate to systolic 100 mmHg (8 mg in 500 mL D5W) OR
- Dopamine (Intropin) 5-20 mcg/kg/min IV.

10. Extras:
Portable CXR, ECG, allergy consult.

11. Labs:
CBC, SMA 7&12.

Pleural Effusion

1. Admit to:
2. Diagnosis: Pleural effusion
3. Condition:
4. Vital Signs: q shift. Call physician if BP >160/90, <90/60; P>120, <50; R>25, <10; T >38.5°C
5. Activity:
7. IV Fluids: D5W at TKO
8. Extras: CXR PA and LAT, repeat after thoracentesis; left and right lateral decubitus x-rays, ECG, ultrasound, PPD; pulmonary consult.
9. Labs: CBC, SMA 7&12, protein, albumin, amylase, ANA, ESR, INR/PTT, UA. Cryptococcal antigen, histoplasma antigen, fungal culture.

Thoracentesis:
- Tube 1: LDH, protein, amylase, triglyceride, glucose (10 mL)
- Tube 2: Gram stain, C&S, AFB, fungal C&S (20-60 mL, heparinized).
- Tube 3: Cell count and differential (5-10 mL, EDTA).
- Syringe: pH (2 mL collected anaerobically, heparinized on ice).
- Bag or Bottle: Cytology.
Anticoagulant Overdose

Unfractionated Heparin Overdose:
1. Discontinue heparin infusion.
2. Protamine sulfate, 1 mg IV for every 100 units of heparin infused in preceding hour, dilute in 25 mL fluid IV over 10 min (max 50 mg in 10 min period).

Low Molecular Weight Heparin (Enoxaparin) Overdose:
- Protamine sulfate 1 mg IV for each 1 mg of enoxaparin given. Repeat protamine 0.5 mg IV for each 1 mg of enoxaparin, if bleeding continues after 2-4 hours. Measure factor Xa.

Warfarin (Coumadin) Overdose:
- Gastric lavage and activated charcoal if recent oral ingestion. Discontinue Coumadin and heparin, and monitor hematocrit q2h.

Partial Reversal:
- Vitamin K (Phytonadione), 0.5-1.0 mg IV/SQ. Check INR in 24 hours, and repeat vitamin K dose if INR remains elevated.

Minor Bleeds:
- Vitamin K (Phytonadione), 5-10 mg IV/SQ q12h, titrated to desired INR.

Serious Bleeds:
- Vitamin K (Phytonadione), 10-20 mg in 50-100 mL fluid IV over 30-60 min (check INR q6h until corrected) AND
- Fresh frozen plasma 2-4 units x 1.
- Type and cross match for 2 units of PRBC, and transfuse wide open.
- Cryoprecipitate 10 U x 1 if fibrinogen is less than 100 mg/dL.

Labs: CBC, platelets, PTT, INR.

Deep Venous Thrombosis

1. Admit to:
2. Diagnosis: Deep vein thrombosis
3. Condition:
4. Vital Signs: q shift. Call physician if BP systolic >160, <90 diastolic, >90, <60; P >120, <50; R>25, <10; T >38.5°C.
5. Activity: Bed rest with legs elevated.
6. Nursing: Guaiac stools, warm packs to leg prn; measure calf and thigh circumference qd; no intramuscular injections.
7. Diet: Regular
8. IV Fluids: D5W at TKO
9. Special Medications:
   Anticoagulation:
   - Heparin (unfractionated) IV bolus 5000-10,000 Units (100 U/kg) IVP, then 1000-1500 U/h IV infusion (20 U/kg/h) [25,000 U in 500 mL D5W (50 U/mL)]. Check PTT 6 hours after initial bolus; adjust q6h until PTT 1.5-2.0 times control (50-80 sec). Overlap heparin and warfarin (Coumadin) for at least 4 days and discontinue heparin when INR has been 2.0-3.0 for two consecutive days.
   - Enoxaparin (Lovenox) 1 mg/kg SQ q12h or 1.5 mg/kg SQ q24 h for DVT without pulmonary embolism. Overlap enoxaparin and warfarin as outlined above.
   - Warfarin (Coumadin) 5-10 mg PO qd x 2-3 d; maintain INR 2.0-3.0. Coumadin is initiated on the first or second day only if the PTT is 1.5-2.0 times control [tab 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg].
10. Symptomatic Medications:
   - Propoxyphene/acetaminophen (Darvocet N100) 1-2 tab PO q3-4h pm pain OR
   - Hydrocodone/acetaminophen (Vicodin), 1-2 tab q4-6h PO pm pain.
   - Docusate sodium (Colace) 100 mg PO qhs.
   - Famotidine (Pepcid) 20 mg IV/PO q12h.
   - Zolpidem (Ambien) 5-10 mg qhs pm insomnia.
11. Extras: CXR PA and LAT, ECG; Doppler scan of legs, V/Q scan, chest CT scan.
12. Labs: CBC, INR/PTT, SMA 7. Protein C, protein S, antithrombin III, anticoagulant antibody. UA with dipstick for blood. PTT 6h after bolus and q4-6h until PTT 1.5-2.0 x control then qd. INR at initiation of warfarin and qd.

Pulmonary Embolism

1. Admit to: Pulmonary embolism
2. Diagnosis: Pulmonary embolism
3. Condition:
4. Vital Signs: q1-4h. Call physician if BP >160/90, <90/60; P >120, <50; R >30, <10; T >38.5°C; O₂ sat < 90%.
5. Activity: Bedrest with bedside commode
7. Diet: Regular
8. IV Fluids: D5W at TKO.
9. Special Medications:

**Anticoagulation:**
- Heparin IV bolus 5000-10,000 Units (100 U/kg) IVP, then 1000-1500 U/hr IV infusion (20 U/kg/hr) [25,000 U in 500 mL D5W (50 U/mL)]. Check PTT 6 hours after initial bolus; adjust q6h until PTT 1.5-2 times control (60-80 sec). Overlap heparin and Coumadin for at least 4 days and discontinue heparin when INR has been 2.0-3.0 for two consecutive days.
- Enoxaparin (Lovenox) 1 mg/kg sq q12h for 5 days for uncomplicated pulmonary embolism. Overlap warfarin as outlined above.
- Warfarin (Coumadin) 5-10 mg PO qd for 2-3 d, then 2-5 mg PO qd. Maintain INR of 2.0-3.0. Coumadin is initiated on second day if the PTT is 1.5-2.0 times control. Check INR at initiation of warfarin and qd [tab 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg].

**Thrombolytics (indicated if hemodynamic compromise):**
- Baseline Labs: CBC, INR/PTT, fibrinogen q6h.
- Alteplase (recombinant tissue plasminogen activator, Activase): 100 mg IV infusion over 2 hours, followed by heparin infusion at 15 U/kg/h to maintain PTT 1.5-2.5 x control OR
- Streptokinase (Streptase): Pretreat with methylprednisolone 250 mg IV push and diphenhydramine (Benadryl) 50 mg IV push. Then give streptokinase, 250,000 units IV over 30 min, then 100,000 units/h for 24-72 hours. Initiate heparin infusion at 10 U/kg/hour; maintain PTT 1.5-2.5 x control.

10. Symptomatic Medications:
- Meperidine (Demerol) 25-100 mg IV pm pain.
- Docusate sodium (Colace) 100 mg PO qhs.
- Famotidine (Pepcid) 20 mg IV/PO q12h.

11. Extras:
- CXR PA and LAT, ECG, VQ scan; chest CT scan, pulmonary angiography; Doppler scan of lower extremities, impedance cardiography.
- Labs: CBC, INR/PTT, SMA 7, ABG, cardiac enzymes. Protein C, protein S, antithrombin III, anticardiolipin antibody. UA, PTT 6 hours after bolus and q4-6h. INR at initiation of warfarin and qd.

**Sickle Cell Crisis**

1. Admit to:
2. Diagnosis: Sickle Cell Crisis
3. Condition:
5. Activity: Bedrest
6. Nursing:
7. Diet: Regular diet, push oral fluids.
8. IV Fluids: D5 ½ NS at 100-125 mL/h.

9. Special Medications:
- Oxygen 2 L/min by NC or 30-100% by mask.
- Meperidine (Demerol) 50-150 mg IM/IV q4-6h pm pain.
- Hydroxyzine (Vistaril) 25-100 mg IM/IV/PO q3-4h pm pain.
- Morphine sulfate 10 mg IV/IM/SC q2-4h pm pain OR
- Ketorolac (Toradol) 30-60 mg IV/IM then 15-30 mg IV/IM q6h pm pain (maximum of 5 days).
- Acetaminophen/codeine (Tylenol 3) 1-2 tabs PO q4-6h pm.
- Folic acid 1 mg PO qd.
- Penicillin V (prophylaxis), 250 mg PO qid [tabs 125,250,500 mg].
- Ondansetron (Zofran) 4 mg PO/IV q4-6h pm nausea or vomiting.

10. Symptomatic Medications:
- Zolpidem (Ambien) 5-10 mg qhs pm insomnia.
- Docusate sodium (Colace) 100-200 mg PO qhs.

**Vaccination:**
- Pneumovax before discharge 0.5 cc IM x 1 dose.
- Influenza vaccine (Fluogen) 0.5 cc IM once a year in the Fall.

11. Extras: CXR
12. Labs: CBC, SMA 7, blood C&S, reticulocyte count, blood type and screen, parvovirus titer. UA.
Meningitis

1. Admit to: 
2. Diagnosis: Meningitis. 
3. Condition: 
4. Vital Signs: q1h. Call physician if BP systolic >160/90, <90/60; P >120, <50; R>25, <10; T >39°C or less than 36°C. 
5. Activity: Bed rest with bedside commode. 
6. Nursing: Respiratory isolation, inputs and outputs, lumbar puncture tray at bedside. 
7. Diet: NPO. 
8. IV Fluids: D5 ½ NS at 125 cc/h with KCL 20 mEq/L. 
9. Special Medications: 
   - Empiric Therapy 15-50 years old: 
     - Vancomycin 1 gm IV q12h AND EITHER 
     - Ceftriaxone (Rocephin) 2 gm IV q12h (max 4 gm/d) 
     - Ceftazidime (Fortaz) 2 gm IV q8h. 
   - Use Vancomycin 1 gm IV q12h in place of ampicillin if drug-resistant pneumococcus is suspected. 
   - Empiric Therapy >50 years old, Alcoholic, Corticosteroids or Hematologic Malignancy or other Debilitating Condition: 
     - Ampicillin 2 gm IV q4h AND EITHER 
     - Ceftriaxone (Rocephin) 2 gm IV q8h OR 
     - Cefotaxime (Claforan) 2 gm IV q12h OR 
     - Cefazidime (Fortaz) 2 gm IV q8h. 
   - Use Vancomycin 1 gm IV q12h in place of ampicillin if drug-resistant pneumococcus is suspected. 
10. Symptomatic Medications: 
   - Heparin 5000 U SC q12h or pneumatic compression stockings. 
   - Famotidine (Pepcid) 20 mg IV/PO q12h. 
   - Acetaminophen (Tylenol) 650 mg PO/PR q4-6h prn temp >39°C. 
   - Docusate sodium 100-200 mg PO qhs. 
12. Lumbar Puncture: 
   - CSF Tube 1: Gram stain, C&S for bacteria (1-4 mL). 
   - CSF Tube 2: Glucose, protein (1-2 mL). 
   - CSF Tube 3: Cell count and differential (1-2 mL). 
   - CSF Tube 4: Latex agglutination or counterimmunoelectrophoresis antigen tests for S. pneumoniae, H. influenzae (type B), N. meningitides, E. coli, group B strep, VDRL, cryptococcal antigen, toxoplasma titers. India ink, fungal cultures, AFB (8-10 mL). 

Infective Endocarditis

1. Admit to: 
2. Diagnosis: Infective endocarditis. 
3. Condition: 
4. Vital Signs: q4h. Call physician if BP systolic >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C. 
7. IV Fluids: Heparin lock with flush q shift. 
8. Special Medications: 
   - Subacute Bacterial Endocarditis Empiric Therapy: 
     - Penicillin G 3-5 million U IV q4h or ampicillin 2 gm IV q4h AND 
     - Gentamicin 1-1.5/mg/kg IV q8h. 
   - Acute Bacterial Endocarditis Empiric Therapy: 
     - Gentamicin 2 mg/kg IV; then 1-1.5 mg/kg IV q8h AND 
     - Nafcillin or Oxacillin 2 gm IV q4h OR 
     - Vancomycin 1 gm IV q12h (1 gm in 250 mL of D5W over 1h). 
   - Streptococci viridans/bovis: 
     - Penicillin G 3-5 million U IV q4h for 4 weeks OR 
     - Vancomycin 1 gm IV q12h for 4 weeks AND 
     - Gentamicin 1 mg/kg q8h for first 2 weeks. 
   - Enterococcus: 
     - Gentamicin 1 mg/kg IV q8h for 4-6 weeks AND 
     - Ampicillin 2 gm IV q4h for 4-6 weeks OR 
     - Vancomycin 1 gm IV q12h for 4-6 weeks. 
   - Staphylococcus aureus (methicillin sensitive, native valve): 
     - Nafcillin or Oxacillin 2 gm IV q4h for 4-6 weeks OR 
     - Vancomycin 1 gm IV q12h for 4-6 weeks AND 
     - Gentamicin 1 mg/kg q8h for first 3-5 days. 
   - Methicillin resistant Staphylococcus aureus (native valve): 
     - Vancomycin 1 gm IV q12h (1 gm in 250 mL D5W over 1h) for 4-6 weeks AND 
     - Gentamicin 1 mg/kg IV q8h for 3-5 days. 
   - Methicillin resistant Staph aureus or epidermidis (prosthetic valve): 
     - Vancomycin 1 gm IV q12h for 6 weeks AND 
     - Rifampin 600 mg PO q8h for 6 weeks AND 
     - Gentamicin 1 mg/kg IV q8h for 2 weeks. 
   - Culture Negative Endocarditis: 
     - Penicillin G 3-5 million U IV q4h for 4-6 weeks OR 
     - Ampicillin 2 gm IV q4h for 4-6 weeks AND 
     - Gentamicin 1.5 mg/kg q8h for 2 weeks (of nafcillin, 2 gm IV q4h, and gentamicin if Staph aureus suspected in drug abuser or prosthetic valve). 
   - Fungal Endocarditis: 
     - Amphotericin B 0.5 mg/kg/d IV plus flucytosine (5-FC) 150 mg/kg/d PO. 
9. Symptomatic Medications: 
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn temp >39°C.
Pneumonia

1. Admit to:
2. Diagnosis: Pneumonia
3. Condition:
4. Vital Signs: q4-8h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C or O₂ saturation <90%.
5. Activity:
7. Diet: Regular.
8. IV Fluids: IV D5½ NS at 125 cc/hr.
9. Special Medications:
- Oxygen by NC at 2-4 L/min, or 24-50% by Ventimask, or 100% by non-rebreather (reservoir) to maintain O₂ saturation >90%.

Moderately ill Patients Without Underlying Lung Disease from the Community:
- Cefuroxime (Zinacef) 0.75-1.5 gm IV q8h OR Ampicillin/sulbactam (Unasyn) 1.5 gm IV q6h AND EITHER
- Erythromycin 500 mg IV/PO q6h OR Clarithromycin (Biaxin) 500 mg PO bid OR Azithromycin (Zithromax) 500 mg PO x 1, then 250 mg PO qd x 4 OR Doxycycline (Vibramycin) 100 mg IV/PO q12h.

Moderately ill Patients With Recent Hospitalization or Debilitated Nursing Home Patient:
- Cefazidime (Fortaz) 1-2 gm IV q8h OR Cefepime (Maxipime) 1-2 gm IV q12h AND EITHER
  - Gentamicin 1.5-2 mg/kg IV, then 1.0-1.5 mg/kg IV q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q24h OR
  - Ciprofloxacin (Cipro) 400 mg IV q12h or 500 mg PO q12h.

Critically ill Patients:
- Initial treatment should consist of a macrolide with 2 antipseudomonal agents for synergistic activity:
  - Erythromycin 0.5-1.0 gm IV q6h AND EITHER
  - Cefazidime 1-2 gm q8h OR Piperacillin/tazobactam (Zosyn) 3.75-4.50 gm IV q8h OR
  - Ticarcillin/clavulanate (Timentin) 3.1 gm IV q6h OR Imipenem/cilastatin (Primaxin) 0.5-1.0 gm IV q6h AND EITHER
  - Levofloxacin (Levaquin) 500 mg IV q24h OR Ciprofloxacin (Cipro) 400 mg IV q12h OR Tobramycin 2.0 mg/kg IV, then 1.5 mg/kg IV q8h or 7 mg/kg IV q24h.

Aspiration Pneumonia (community acquired):
- Clindamycin (Cleocin) 600-900 mg IV q6h (with or without gentamicin or 3rd gen cephalosporin) OR
- Ampicillin/sulbactam (Unasyn) 1.5-3 gm IV q6h (with or without gentamicin or 3rd gen cephalosporin).

Aspiration Pneumonia (nosocomial):
- Tobramycin 2 mg/kg IV then 1.5 mg/kg IV q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q24h OR Cefazidime (Fortaz) 1-2 gm IV q8h AND EITHER
- Clindamycin (Cleocin) 600-900 mg IV q6h OR Ampicillin/sulbactam or ticarcillin/clavulanate, or piperacillin/tazobactam or imipenem/cilastatin (see above) OR Metronidazole (Flagyl) 500 mg IV q6h.

10. Symptomatic Medications:
- Acetaminophen (Tylenol) 650 mg 2 tab PO q4-6h prn temp >38°C or pain.
- Docusate sodium (Colace) 100 mg PO qhs.
- Famotidine (Pepcid) 20 mg IV/PO q12h.
- Heparin 5000 U SQ q12h or pneumatic compression stockings.
11. Extras: CXR PA and LAT, ECG, PPD.
12. Labs: CBC with differential, SMA 7&12, Blood C&S x 3-4 over 24h, serum cidal titers, minimum inhibitory concentration, minimum bactericidal concentration. Repeat C&S in 48h, then once a week. Antibiotic levels peak and trough at 3rd dose. UA, urine C&S.

Specific Therapy for Pneumonia

Pneumococcus:
- Ceftriaxone (Rocephin) 2 gm IV q12h OR
-cefotaxime (Claforan) 2 gm IV q6h OR
- Erythromycin 500 mg IV q6h OR
-Vancomycin 1 gm IV q12h if drug resistance.

Staphylococcus aureus:
- Nafcillin 2 gm IV q4h OR
- Oxacillin 2 gm IV q4h.

Klebsiella pneumoniae:
- Gentamicin 1.5-2 mg/kg IV, then 1.0-1.5 mg/kg IV q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q24h OR Ceftriaxone (Claforan) 1-2 gm IV q6h OR Cefotaxime (Claforan) 1-2 gm IV q6h.

Methicillin-resistant staphylococcus aureus (MRSA):
- Vancomycin 1 gm IV q12h.

Vancomycin-Resistant Enterococcus:
- Linezolid (Zyvox) 600 mg IV/PO q12h; active against MRSA as well OR
- Quinupristin/dalfopristin (Synercid) 7.5 mg/kg IV q6h; does not cover E faecalis.
**Haemophilus influenzae:**
- Ampicillin 1-2 gm IV q8h (beta-lactamase negative) OR
- Amoxicillin/sulbactam (Unasyn) 1.5-3.0 gm q8h OR
- Cefuroxime (Zinacef) 1.5 gm IV q8h (beta-lactamase pos) OR
- Cefotaxime (Cefix) 1-2 gm IV q8h OR
- Ciprofloxacin (Cipro) 400 mg IV q12h OR
- Ofloxacin (Floxin) 400 mg IV q12h.
- Levofoxacin (Levaquin) 500 mg IV q24h.

**Pseudomonas aeruginosa:**
- Tobramycin 1.5-2.0 mg/kg IV, then 1.5-2.0 mg/kg IV q8h OR
- Cefazolin (Ancef) 1-2 gm IV q8h
- Piperacillin, Ticarcillin, Mezlocillin or Azlocillin 3 gm IV q6h
- Ceftazidime 1-2 gm IV q8h
- Imipenem/cilastatin (Primaxin) 0.5-1.0 gm IV q6h.

**Enterobacter Aerogenes or Cloacae:**
- Gentamicin 2.0 mg/kg IV, then 1.5 mg/kg IV q8h AND EITHER
- Meropenem (Merrem) 1 gm IV q8h OR
- Imipenem/cilastatin (Primaxin) 0.5-1.0 gm IV q6h.

**Serratia Marcescens:**
- Ceftizoxime (Cefizox) 1-2 gm IV q8h
- Aztreonam (Azactam) 1-2 gm IV q8h OR
- Meropenem (Merrem) 1 gm IV q8h.

**Mycoplasma pneumoniae:**
- Clarithromycin (Biaxin) 500 mg PO bid OR
- Azithromycin (Zithromax) 500 mg PO qd for 5 days OR
- Erythromycin 500 mg PO or IV q6h.
- Doxycycline (Vibramycin) 100 mg PO q12h OR
- Levofoxacin (Levaquin) 500 mg PO IV q24h.

**Legionella pneumoniae:**
- Erythromycin 1.0 gm IV q6h OR
- Levofoxacin (Levaquin) 500 mg PO q24h.
- Rifampin 600 mg PO qd may be added to erythromycin or levofloxacin.

**Moraxella catarrhalis:**
- Trimethoprim/sulfamethoxazole (Bactrim, Septra) one DS tab PO bid OR
- Ampicillin/sulbactam (Unasyn) 1.5-3.0 gm IV q6h OR
- Cefuroxime (Zinacef) 0.75-1.5 gm IV q8h OR
- Erythromycin 500 mg IV q6h OR
- Levofoxacin (Levaquin) 500 mg PO IV q24h.

**Anaerobic Pneumonia:**
- Penicillin G 2 MU IV q4h OR
- Clindamycin (Cleocin) 900 mg IV q6h OR
- Metronidazole (Flagyl) 500 mg IV q8h.

**Pneumocystis Carinii Pneumonia and HIV**

1. **Admit to:**
2. **Diagnosis:** PCP pneumonia
3. **Condition:**
4. **Vital Signs:** q2-6h. Call physician if BP >160/90, <90/60; P > 120, <50; R> 25, <10; T >38.5°C; O2 sat <90%
5. **Activity:**
6. **Nursing:** Pulse oximeter.
7. **Diet:** Regular, encourage fluids.
8. **IV Fluids:** D5 ½ NS at 100 cc/h.
9. **Special Medications:**

**Pneumocystis Carinii Pneumonia:**
- Oxygen at 2-4 L/min by NC or by mask.
- Trimethoprim/sulfamethoxazole (Bactrim, Septra) 15 mg of TMP/kg/day (20 mL in 250 mL of D5W IVPB q8h) for 21 days [inj: 80/400 mg per 5 mL].
- If severe PCP (PaO2 <70 mmHg): add prednisone 40 mg PO bid for 5 days, then 40 mg qd for 5 days, then 20 mg once daily for 11 days OR Methyldprednisolone (Solu-Medrol) 30 mg IV q12h for 5 days, then 30 mg IV qd for 5 days, then 15 mg IV qd for 11 days.
- Pentamidine (Pentam) 4 mg/kg IV qd for 21 days, with prednisone as above. Pentamidine is an alternative if inadequate response or intolerant to TMP-SMX.

**Pneumocystis Carinii Prophylaxis:**
- Trimethoprim/SMX DS (160/800 mg) PO qd OR
- Pentamidine, 300 mg in 6 mL sterile water via Respirgard II nebulizer over 20-30 min q4 weeks OR
- Dapsone (DDS) 50 mg PO bid or 100 mg twice a week, contraindicated in G-6-PD deficiency.

**Antiretroviral Therapy:**
A. Combination therapy with 3 agents (two nucleoside analogs and a protease inhibitor) is recommended as initial therapy. Nucleotide analogs are similar to nucleosides and may be used interchangeably.

**B. Nucleoside Analogs**
1. Abacavir (Ziagen) 300 mg PO bid [300 mg, 20 mg/mL].
2. Didanosine (Videx, ddI) 200 mg PO bid for patients >60 kg; or 125 mg bid for patients <60 kg, chewable tab: 25, 50, 100, 150 mg, pwd 100, 167, 250 mg packets.
3. Lamivudine (Epivir, 3TC) 150 mg twice daily [150 mg].
4. Stavudine (Zerit, D4T) 40 mg bid [15-mg, 20-mg, 30-mg and 40-mg capsules].
5. Zalcitabine (Hivid, ddC) 0.15 mg tid [0.375, 0.75].
6. Zidovudine (Retrovir, AZT) 200 mg tid (100, 200 mg caps, 50 mg/5 mL syrup).

**C. Protease Inhibitors**
1. Amprenavir (Agenerase) 1200 mg bid [50, 150 mg].
2. Indinavir (Crixivan) 800 mg tid [200, 400 mg].
3. Lopinavir/ritonavir (Kaletra) 400 mg PO bid.
4. Nelfinavir (Viracept) 750 mg PO tid [250, 200 mg].
5. Ritonavir (Norvir) 600 mg bid [100 mg, 80 mg/dL].
6. Saquinavir (Invirase) 600 mg tid with a meal [200 mg].

**D. Non-Nucleoside Reverse Transcriptase Inhibitors**
1. Delavirdine (U-90) 400 mg tid.
2. Efavirenz (Sustiva) 600 mg PO qd [50, 100, 200 mg].
3. Nevirapine (Viramune) 200 mg qd for 2 weeks, then bid [200 mg].

**E. Nucleotide Analogs**
1. Tenofovir (Viread) 300 mg PO qd with food.

**Postexposure HIV Prophylaxis**
A. The injury should be immediately washed and scrubbed with soap and water.
B. Zidovudine 200 mg PO tid and lamivudine (3TC) 150 mg PO bid, plus indinavir (Crixivan) 800 mg PO tid for highest risk exposures. Treatment is continued for one month.

**Zidovudine-Induced Neutropenia/Ganciclovir-Induced Leucopenia**
- Recombinant human granulocyte colony-stimulating factor (G-CSF, Filgrastim, Neupogen) 1-2 mcg/kg SQ qd until absolute neutrophil count 500-1000; indicated only if the patient's endogenous erythropoietin level is low.

**10. Symptomatic Medications:**
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.
- Docusate sodium 100-200 mg PO qhs.

**10. Extras:**
- CXR PA and LAT.

**11. Labs:**
- Sputum for Gram stain, C&S, AFB. Giemsa immunofluorescence for Pneumocystis. CD4 count, HIV RNA, VDRL, serum cryptococcal antigen, UA.

**Opportunistic Infections in HIV-Infected Patients**

**Oral Candidiasis**
- Fluconazole (Diflucan) acute: 100-200 mg PO qd OR
- Ketoconazole (Nizoral), acute: 400 mg PO qd OR
- Itraconazole (Sporanox) 200 mg PO qd OR
- Clotrimazole (Mycelex) troches 10 mg dissolved slowly in mouth 5 times/d.

**Candida Esophagitis**
- Fluconazole (Diflucan) 200-400 mg PO qd for 14-21 days OR
- Ketoconazole (Nizoral) 200 mg PO bid.
- Itraconazole (Sporanox) 200 mg PO qd for 2 weeks.

**Primary or Recurrent Mucocutaneous HSV**
- Acyclovir (Zovirax), 200-400 mg PO 5 times a day for 10 days, or 5 mg/kg IV q8h OR in cases of acyclovir resistance, foscarnet, 40 mg/kg IV q8h for 21 days.

**Herpes Simplex Encephalitis (or visceral disease)**
- Acyclovir (Zovirax) 10 mg/kg IV q8h for 10-21 days.

**Herpes Varicella Zoster**
- Acyclovir (Zovirax) 10 mg/kg IV over 60 min q8h for 7-14 days OR 800 mg PO 5 times/d for 7-10 days OR
- Famciclovir (Famvir) 500 mg PO q8h for 7 days [500 mg] OR
- Valacyclovir (Valtrex) 1000 mg PO q8h for 7 days [500 mg] OR
- Foscarnet (Foscavir) 40 mg/kg IV q8h.

**Cytomegalovirus Retinitis**
- Ganciclovir (Cytovene) 5 mg/kg IV q12h for 14-21 days OR
- Foscarnet (Foscavir) 60 mg/kg IV q8h for 2-3 weeks OR
- Cidofovir (Vistide) 5 mg/kg IV q6h for 2 weeks. Administer probenecid, 2 g PO 3 hours prior to cidofovir, 1 g PO 2 hours after, and 1 g PO 8 hours after.

**Suppressive Treatment for Cytomegalovirus Retinitis**
- Ganciclovir (Cytovene) 5 mg/kg qd.
- Foscarnet (Foscavir) 90-120 mg IV qd OR
- Cidofovir (Vistide) 5 mg/kg IV over 60 min every 2 weeks with probenecid.

**Acute Toxoplasmosis**
- Pyrimethamine 200 mg, then 50-75 mg qd, plus sulfadiazine 1.0-1.5 gm PO q6h, plus folic acid 10 mg PO qd OR
- Atovaquone (Mepron) 750 mg PO tid.

**Suppressive Treatment for Toxoplasmosis**
- Pyrimethamine 25-50 mg PO qd plus sulfadiazine 0.5-1.0 gm PO q6h plus folic acid 5 mg PO qd OR
- Pyrimethamine 50 mg PO qd, plus clindamycin 300 mg PO qid, plus folic acid 5 mg PO qd.

**Cryptococcus Neoforans Meningitis**
- Amphotericin B 0.7-1.0 mg/kg/d IV, total dosage of 2 g, with or without 5-flucytosine 100 mg/kg PO qd in divided doses, followed by fluconazole (Diflucan) 400 mg PO qd oritraconazole (Sporanox) 200 mg PO bid 6-8 weeks OR
- Amphotericin B liposomal (Abelcet) 5 mg/kg IV q24h OR
- Fluconazole (Diflucan) 400-800 mg PO qd for 8-12 weeks

**Suppressive Treatment of Cryptococcus**
- Fluconazole (Diflucan) 200 mg PO qd indefinitely.
Active Tuberculosis:  
-Isoniazid (INH) 300 mg PO qd; and rifampin 600 mg PO qd; and pyrazinamide 15-25 mg/kg PO qd (500 mg bid-tid); and ethambutol 15-25 mg/kg PO qd (400 mg bid-tid).  
-All four drugs are continued for 2 months; isoniazid and rifampin are continued for a period of at least 9 months and at least 6 months after the last negative cultures.  
-Pyridoxine (Vitamin B6) 50 mg PO qd concurrent with INH.

Prophylaxis for Inactive Tuberculosis:  
-Isoniazid 300 mg PO qd; and pyridoxine 50 mg PO qd for 12 months.

Disseminated Mycobacterium Avium Complex (MAC):  
-Clarithromycin (Biaxin) 500 mg PO bid AND Ethambutol 800-1000 mg qd; with or without rifabutin 450 mg qd.

Prophylaxis against Mycobacterium Avium Complex:  
-Amphotericin B 0.5-0.8 mg/kg IV qd, to a total dose 2.0 gm OR -Amphotericin B liposomal (Abelcet) 5 mg/kg IV q24h OR -Fluconazole (Diflucan) 400-800 mg PO or IV qd.

Disseminated Histoplasmosis:  
-Amphotericin B (Fungizone) 0.5-0.8 mg/kg IV qd, to a total dose 15 mg/kg OR -Amphotericin B liposomal (Abelcet) 5 mg/kg IV q24h OR -Fluconazole (Diflucan) 400 mg PO qd. OR -Itraconazole (Sporanox) 300 mg PO bid for 3 days, then 200 mg PO bid.

Suppressive Treatment for Histoplasmosis:  
-Fluconazole (Diflucan) 400 mg PO qd OR -Itraconazole (Sporanox) 200 mg PO bid.

Septic Arthritis

1. Admit to:  
2. Diagnosis: Septic arthritis  
3. Condition:  
4. Vital Signs: q shift  
6. Nursing: Warm compresses pm, keep joint immobi- 
 
7. Diet: Regular diet.  
8. IV Fluids: Heparin lock  
9. Special Medications:  
- Acetaminophen and codeine (Tylenol 3) 1-2 PO q4-6h prn pain.  
- Heparin 5000 U SQ bid.  
- Famotidine (Pepcid) 20 mg IV/PO q12h.  
- Zolpidem (Ambien) 5-10 mg qhs pm insomnia.  
- Docusate sodium 100-200 mg PO qhs.  
10. Symptomatic Medications:  
- Oxygen at 2-5 L/min by NC or mask.

Antibiotic Therapy

A. Initial treatment of life-threatening sepsis should include a third-generation cephalosporin (cefotaxime, ceftriaxone, ceftizoxime or ceftriaxone), or piperacillin/tazobactam, or ticarcillin/clavulanic acid or imipenem, each with an aminoglycoside (gentamicin, tobramycin or amikacin). If Enterobacter aerogenes or cloacae is
suggested, treatment should begin with meropenem, or imipenem with an aminoglycoside.

B. Intra-abdominal or pelvic infections, likely to involve anaerobes, should be treated with ampicillin, gentamicin and metronidazole, or either ticarcillin/clavulanic acid, ampicillin/subactam, piperacillin/tazobactam, imipenem, cefoxitin or cefotetan, each with an aminoglycoside.

C. Febrile neutropenic patients with neutrophil counts <500/mm³ should be treated with vancomycin and cefazidime, or piperacillin/tazobactam and tobramycin or imipenem and tobramycin.

D. Dosages for Antibiotics Used in Sepsis

- Ampicillin 1-2 gm IV q4h.
- Cefotaxime (Cliaforan) 2 gm q4-6h.
- Ceftriaxone (Rocephin) 1-2 gm IV q12h (max 4 gm/d).
- Cefotaxin (Mefoxin) 1-2 gm q6h.
- Cefotetan (Cefotan) 1-2 gm IV q12h.
- Cefazidime (Fortaz) 1-2 g IV q8h.
- Ticarcillin/clavulanate (Timentin) 3.1 gm IV q4-6h (200-300 mg/kg/d).
- Amoxicillin/subactam (Unasyn) 1.5-3.0 gm IV q6h.
- Piperacillin/tazobactam (Unasyn) 1.5-3.0 gm IV q6h.
- Vancomycin and ceftazidime, or piperacillin/tazobactam and tobramycin or imipenem and tobramycin.

10. Symptomatic Medications:

- Acetaminophen (Tylenol) 650 mg PR q4-6h prn temp >39°C.
- Famotidine (Pepcid) 20 mg IV/PO q12h.
- Heparin 5000 U SQ q12h or pneumatic compression stockings.
- Docusate sodium 100-200 mg PO qhs.

11. Extras: CXR, KUB, ECG. Ultrasound, lumbar puncture.

12. Labs: CBC with differential, SMA 7&12, blood C&S x3, T&C for 3-6 units PRBC, INR/PTT, drug levels peak and trough at 3rd dose. UA. Cultures of urine, sputum, wound, IV catheters, decubitus ulcers, pleural fluid.
Option 2:
- Ticarcillin/clavulanate (Timentin) 3.1 gm IV q4-6h with an aminoglycoside as above OR
- Piperacillin/tazobactam (Zosyn) 3.375 gm IV q6h with an aminoglycoside as above OR
- Ampicillin/sulbactam (Unasyn) 1.5-3.0 gm IV q6h with aminoglycoside as above OR
- Imipenem/cilastatin (Primaxin) 0.5-1.0 gm IV q6-8h OR
- Meropenem (Merrem) 500-1000 mg IV q8h.

Fungal Peritonitis:
- Amphotericin B peritoneal dialysis, 2 mg/L of dialysis fluid over the first 24 hours, then 1.5 mg in each liter OR
- Fluconazole (Diflucan) 200 mg IV x 1, then 100 mg IV qd.

10. Symptomatic Medications:
- Famotidine (Pepcid) 20 mg IV/PO q12h.
- Acetaminophen (Tylenol) 325 mg PO/PR q4-6h prn temp >38.5°C.
- Heparin 5000 U SQ q12h.

11. Labs:
- CBC with differential, SMA 7&12, amylase, lactate, INR/PTT, UA with micro, C&S; drug levels peak and trough 3rd dose.

12. Paracentesis Tube 1: Cell count and differential (1-2 mL, EDTA purple top tube)
Tube 2: Gram stain of sediment; inject 10-20 mL into anaerobic and aerobic culture bottle; AFB, fungal C&S (3-4 mL).
Tube 3: Glucose, protein, albumin, LDH, triglycerides, specific gravity, bilirubin, amylase (2-3 mL, red top tube).
Syringe: pH, lactate (3 mL).

Diverticulitis
1. Admit to:
2. Diagnosis: Diverticulitis
3. Condition:
4. Vital Signs: qid. Call physician if BP systolic >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C
7. Diet: NPO. Advance to clear liquids as tolerated.
8. IV Fluids:
9. Special Medications:
Regimen 1:
- Gentamicin or tobramycin 100-120 mg IV (1.5-2 mg/kg), then 80 mg IV q8h (5 mg/kg/d) or 7 mg/kg in 50 mL of D5W over 60 min IV q4h AND EITHER
  - Cefoxitin (Mefoxin) 2 gm IV q6-8h OR
  - Clindamycin (Cleocin) 600-900 mg IV q8h.
Regimen 2:
- Metronidazole (Flagyl) 500 mg q8h AND Ciprofloxacin (Cipro) 250-500 mg PO bid or 200-300 mg IV q12h.
Output Regimen:
- Metronidazole (Flagyl) 500 mg PO q8h AND EITHER Ciprofloxacin (Cipro) 500 mg PO bid OR
-Trimethoprim/SMX (Bactrim) 1 DS tab PO bid.
10. Symptomatic Medications:
- Meperidine (Demerol) 50-100 mg IM or IV q3-4h prn pain.
- Zolpidem (Ambien) 5-10 mg qhs prn insomnia.
11. Extras: Acute abdomen series, CXR PA and LAT, ECG, CT scan of abdomen, ultrasound, surgery and GI consults.
12. Labs: CBC with differential, SMA 7&12, amylase, lipase, blood cultures x 2, drug levels peak and trough 3rd dose. UA, C&S.

Lower Urinary Tract Infection
1. Admit to:
2. Diagnosis: UTI.
3. Condition:
4. Vital Signs: q shift. Call physician if BP <90/60; >160-190, R >30, <10; P >120, <50; T >38.5°C
6. Nursing:
7. Diet: Regular
8. IV Fluids:
9. Special Medications:
Lower Urinary Tract Infection (treat for 3-7 days):
- Trimethoprim-sulfamethoxazole (Septra) 1 double strength tab (160/800 mg) PO bid.
- Norfloxacin (Noroxin) 400 mg PO bid.
- Ciprofloxacin (Cipro) 250 mg PO bid.
- Levofloxacin (Levaquin) 500 mg IV/PO q24h.
- Lomefloxacin (Maxaquin) 400 mg PO qd.
- Enoxacin (Penetrex) 200-400 mg PO q12h; 1h before or 2h after meals.
- Cefpodoxime (Vantin) 100 mg PO bid.
- Cephalexin (Keflex) 500 mg PO q6h.
- Cefixime (Suprax) 200 mg PO q12h or 400 mg PO qd.
- Cefazolin (Ancef) 1-2 gm IV q8h.

Complicated or Catheter-Associated Urinary Tract Infection:
- Ceftizoxime (Cefizox) 1 gm IV q8h.
- Gentamicin 2 mg/kg, then 1.5/kg q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q24h.
- Ticarcillin/clavulanate (Timentin) 3.1 gm IV q4-6h.
- Ciprofloxacin (Cipro) 500 mg PO bid.
- Levofloxacin (Levaquin) 500 mg IV/PO q24h.

Candida Cystitis
- Fluconazole (Diflucan) 100 mg PO or IV x 1 dose, then 50 mg PO or IV qd for 5 days OR
- Amphotericin B continuous bladder irrigation, 50 mg/1000 mL sterile water via 3-way Foley catheter at 1 L/d for 5 days.

10. Symptomatic Medications:
- Phenazopyridine (Pyridium) 100 mg PO or IV x 1 dose.
- Meperidine (Demerol) 50-100 mg IM q4-6h prn pain.
- Docusate sodium (Colace) 100 mg PO qhs.
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn temp >39°C.
- Zolpidem (Ambien) 5-10 mg qhs prn insomnia.

11. Extras:
- Renal ultrasound.

12. Labs:
- CBC, SMA 7. UA with micro, urine Gram stain, C&S.

Pyelonephritis

1. Admit to:

2. Diagnosis: Pyelonephritis

3. Condition:

4. Vital Signs: tid. Call physician if BP <90/60; >160/90; R >30; <10; P >120; <50; T >38.5°C

5. Activity:


7. Diet: Regular

8. IV Fluids: D5 ½ NS at 125 cc/h.

9. Special Medications:
- Trimethoprim-sulfamethoxazole (Septra) 160/800 mg (10 mL in 100 mL D5W IV over 2 hours) q12h or 1 double strength tab PO bid.
- Ciprofloxacin (Cipro) 500 mg PO bid or 400 mg IV q12h.
- Norfloxacin (Noroxin) 400 mg PO bid
- Ofloxacin (Flomox) 400 mg PO or IV bid.
- Levofloxacin (Levaquin) 500 mg PO/IV q24h.
- In more severely ill patients, treatment with an IV third-generation cephalosporin, or ticarcillin/clavulanic acid, or piperacillin/tazobactam or imipenem is recommended with an aminoglycoside.
- Ceftizoxime (Cefizox) 1 gm IV q8h.
- Ceftazidime (Fortaz) 1 gm IV q8h.
- Ticarcillin/clavulanate (Timentin) 3.1 gm IV q8h.
- Piperacillin/tazobactam (Zosyn) 3.375 gm IV/IVB q6h.
- Imipenem/cilastatin (Primaxin) 0.5-1.0 gm IV q6-8h.
- Gentamicin or tobramycin, 2 mg/kg IV, then 1.5 mg/kg q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q24h.

10. Symptomatic Medications:
- Phenazopyridine (Pyridium) 100 mg PO tid.
- Docusate sodium (Colace) 100 mg PO qhs.
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn temp >39°C.
- Zolpidem (Ambien) 5-10 mg qhs prn insomnia.


12. Labs: CBC with differential, SMA 7. UA with micro, urine Gram stain, C&S.

Osteomyelitis

1. Admit to:

2. Diagnosis: Osteomyelitis

3. Condition:

4. Vital Signs: qid. Call physician if BP <90/60; >160/90; R >30; <10; P >120; <50; T >38.5°C

5. Activity:


7. Diet: Regular, high fiber.

8. IV Fluids: Heparin lock with flush q shift.

9. Special Medications:
- Nafcillin or oxacillin 2 gm IV q4h OR
- Cefazolin (Ancef) 1-2 gm IV q8h OR
- Vancomycin 1 gm IV q12h (1 gm in 250 cc D5W over 1h).
- Add 3rd generation cephalosporin if gram negative bacilli on Gram stain. Treat for 4-6 weeks.

Post-Operative or Post-Trauma:
- Vancomycin 1 gm IV q12h AND ceftazidime (Fortaz) 1-2 gm IV q8h.
- Imipenem/cilastatin (Primaxin) (single-drug treatment) 0.5-1.0 gm IV q6-8h.
- Ticarcillin/clavulanate (Timentin) (single-drug treatment) 3.1 gm IV q4-6h.
- Ciprofloxacin (Cipro) 500-750 mg PO bid or 400 mg IV q12h AND Rifampin 600 mg PO qd.

Osteomyelitis with Decubitus Ulcer:
- Cefoxitin (Mefoxin), 2 gm IV q6-8h.
- Ciprofloxacin (Cipro) and metronidazole 500 mg IV q8h.
- Imipenem/cilastatin (Primaxin), see dosage above.
- Nafcillin, gentamicin and clindamycin; see dosage above.

10. Symptomatic Medications:
- Mephenesin (Demerol) 50-100 mg IM q3-4h pm pain.
- Docusate sodium (Colace) 100 mg PO qhs.
- Heparin 5000 U SQ bid.

11. Extras:
- Technetium/gallium bone scans, multiple X-ray views, CT/MRI.

12. Labs:
- CBC with differential, SMA 7, blood C&S x 3.
- MBC, UA with micro, C&S. Needle biopsy of bone for C&S. Trough antibiotic levels.

Active Pulmonary Tuberculosis

1. Admit to:
2. Diagnosis: Active Pulmonary Tuberculosis
3. Admission:
4. Vital Signs: q shift
5. Activity: Up ad lib in room.
7. Diet: Regular
8. Special Medications:
   - Isoniazid 300 mg PO qd (5 mg/kg/d, max 300 mg/d)
   - Rifampin 600 mg PO qd (10 mg/kg/d, 600 mg/d max)
   - Pyrazinamide 500 mg PO bid-tid (15-30 mg/kg/d, max 2.5 gm)
   - Ethambutol 400 mg PO bid-tid (15-25 mg/kg/d, 2.5 gm/d max).
- Empiric treatment consists of a 4-drug combination of isoniazid (INH), rifampin, pyrazinamide (PZA), and either ethambutol or streptomycin. A modified regimen is recommended for patients known to have INH-resistant TB. Treat for 8 weeks with the four-drug regimen, followed by 18 weeks of INH and rifampin.
- Pyridoxine 50 mg PO qd with INH.

Prophylaxis
- Isoniazid 300 mg PO qd (5 mg/kg/d) x 6-9 months.

9. Extras: CXR PA, LAT, ECG.

10. Labs: CBC with differential, SMA7 and 12, LFTs, HIV serology. First AM sputum for AFB x 3 samples.

Cellulitis

1. Admit to:
2. Diagnosis: Cellulitis
3. Condition:
4. Vital Signs: tid. Call physician if BP <90/60, T >38.5°C
6. Nursing: Keep affected extremity elevated; warm compresses pm.
7. Diet: Regular, encourage fluids.
8. IV Fluids: Heparin lock with flush q shift.
9. Special Medications:
   - Acetaminophen/codeine (Tylenol #3) 1-2 PO q4-6h prn pain.
   - Docusate sodium (Colace) 100 mg PO qhs.
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h pm temp >35°C.
   - Zolpidem (Ambien) 5-10 mg qhs pm insomnia.

10. Symptomatic Medications:
- Technetium/gallium bone scans, Doppler study (ankle-brachial indices).

11. Labs: CBC, SMA 7, blood C&S x 2. Leading edge aspirate for Gram stain, C&S; UA, antibiotic levels.
Pelvic Inflammatory Disease

1. Admit to:
2. Diagnosis: Pelvic Inflammatory Disease
3. Condition:
4. Vital Signs: q8h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C
5. Activity:
7. Diet: Regular
8. IV Fluids: D5 ½ NS at 100-125 cc/hr.
9. Special Medications:
   - Cefoxitin (Mefoxin) 2 gm IV q6h OR cefotetan (Cefotan) 1-2 gm IV q12h; AND doxycycline (Vibramycin) 100 mg IV q12h (IV for 4 days and 48h after afebrile, then complete 10-14 days of doxycycline 100 mg PO bid) OR
   - Clindamycin 900 mg IV q6h AND Gentamicin 2 mg/kg IV, then 1.5 mg/kg IV q8h or 7 mg/kg in 50 mL of D5W over 60 min IV q3h, then complete 10-14 d of Clindamycin 300 mg PO qid or Doxycycline 100 mg PO bid OR
   - Ceftriaxone (Rocephin) 250 mg IM x 1 and doxycycline 100 mg PO bid for 14 days OR
   - Ofloxacin (Floxin) 400 mg PO bid for 14 days.
   AND EITHER
   - Clindamycin 300 mg PO qid for 14 days OR
   - Metronidazole (Flagyl) 500 mg PO bid for 14 days.
10. Symptomatic Medications:
    - Acetaminophen (Tylenol) 1-2 tabs PO q4-6h prn pain or temperature >38.5°C.
    - Meperidine (Demerol) 25-100 mg IM q4-6h prn pain.
    - Zolpidem (Ambien) 10 mg PO qhs prn insomnia.
11. Labs: CBC, SMA 7&12, ESR. GC culture, chlamydia direct fluorescent antibody stain. UA with micro, C&S, VDRL, HIV, blood cultures x 2. Pelvic ultrasound.
Gastrointestinal Disorders

Gastroesophageal Reflux Disease

1. Admit to:
2. Diagnosis: Gastroesophageal reflux disease.
3. Condition:
4. Vital Signs: q4h. Call physician if BP >160/90, <90/60; P >120, <50; T >38.5°C
5. Activity: Up ad lib. Elevate the head of the bed by 6 to 8 inches.
7. Diet: Low-fat diet; no cola, citrus juices, or tomato products; avoid the supine position after meals; no eating within 3 hours of bedtime.
8. IV Fluids: D5 ½ NS with 20 mEq KCL at TKO.
9. Special Medications:
   - Pantoprazole (Protonix) 40 mg PO/IV q24h OR
   - Nizatidine (Axid) 300 mg PO qhs OR
   - Omeprazole (Prilosec) 20 mg PO bid (30 minutes prior to meals) OR
   - Lansoprazole (Prevacid) 15-30 mg PO qd prior to breakfast [15, 30 mg caps] OR
   - Esomeprazole (Nexum) 20 or 40 mg PO qd OR
   - Rabeprazole (Aciphex) 20 mg delayed-release tablet PO qd OR
   - Ranitidine (Zantac) 50 mg IV bolus, then continuous infusion at 12.5 mg/h (300 mg in 250 mL D5W at 11 mL/h over 24h) or 50 mg IV q8h OR
   - Cimetidine (Tagamet) 300 mg IV bolus, then continuous infusion at 50 mg/h (1200 mg in 250 mL D5W over 24h) or 300 mg IV q8-12h OR
   - Famotidine (Pepcid) 20 mg IV q12h.
10. Symptomatic Medications:
    - Trimethobenzamide (Tigan) 100-250 mg PO or 100-200 mg IM/PR q6h prn nausea OR
    - Prochlorperazine (Compazine) 5-10 mg IM/IV/PO q4-6h or 25 mg PR q4-6h prn nausea.
12. Labs: CBC, SMA 7&12, amylase, lipase, LDH. UA.

Peptic Ulcer Disease

1. Admit to:
2. Diagnosis: Peptic ulcer disease.
3. Condition:
4. Vital Signs: q4h. Call physician if BP >160/90, <90/60; P >120, <50; T >38.5°C
5. Activity: Up ad lib
7. Diet: NPO 48h, then regular, no caffeine.
8. IV Fluids: D5 ½ NS with 20 mEq KCL at 125 cc/h. NG tube at low intermittent suction (if obstructed).
9. Special Medications:
   - Ranitidine (Zantac) 50 mg IV bolus, then continuous infusion at 12.5 mg/h (300 mg in 250 mL D5W at 11 mL/h over 24h) or 50 mg IV q8h OR
   - Cimetidine (Tagamet) 300 mg IV bolus, then continuous infusion at 50 mg/h (1200 mg in 250 mL D5W over 24h) or 300 mg IV q8-12h OR
   - Famotidine (Pepcid) 20 mg IV q12h OR
   - Pantoprazole (Protonix) 40 mg PO/IV q24h OR
   - Nizatidine (Axid) 300 mg PO qhs OR
   - Omeprazole (Prilosec) 20 mg PO bid (30 minutes prior to meals) OR
   - Lansoprazole (Prevacid) 15-30 mg PO qd prior to breakfast [15, 30 mg caps].
10. Symptomatic Medications:
    - Trimethobenzamide (Tigan) 100-250 mg PO or 100-200 mg IM/PR q6h prn nausea OR
    - Prochlorperazine (Compazine) 5-10 mg IM/IV/PO q4-6h or 25 mg PR q4-6h prn nausea.
12. Labs: CBC, SMA 7&12, amylase, lipase, LDH. UA.

Eradication of Helicobacter pylori

A. Bismuth, Metronidazole, Tetracycline, Ranitidine
   1. 14 day therapy
   2. Bismuth (Pepto Bismol) 2 tablets PO qid.
   3. Metronidazole (Flagyl) 250 mg PO qid (tid if cannot tolerate the qid dosing).
   4. Tetracycline 500 mg PO qid.
   5. Ranitidine (Zantac) 150 mg PO bid.
   6. Efficacy is greater than 90%.
B. Amoxicillin, Omeprazole, Clarithromycin (AOC)
   1. 10 days of therapy
   2. Amoxicillin 1 gm PO bid.
   3. Omeprazole (Prilosec) 20 mg PO bid.
   4. Clarithromycin (Biaxin) 500 mg PO bid.
C. Metronidazole, Omeprazole, Clarithromycin (MOC)
   1. 10 days of therapy
   2. Metronidazole 500 mg PO bid.
   3. Omeprazole (Prilosec) 20 mg PO bid.
   4. Clarithromycin (Biaxin) 500 mg PO bid.
   5. Efficacy is >80%
   6. Expensive, usually well tolerated.
D. Omeprazole, Clarithromycin (OC)
   1. 14 days of therapy
   2. Omeprazole (Prilosec) 40 mg PO qd for 14 days, then 20 mg qd for an additional 14 days of therapy.
   3. Clarithromycin (Biaxin) 500 mg PO bid for 14 days.
   4. Efficacy is 70-80%; expensive.
E. Ranitidine-Bismuth-Citrate, Clarithromycin (RBC-C)
   1. 28 days of therapy
   2. Ranitidine-bismuth-citrate (Tritec) 400 mg PO bid for 28 days.
   3. Clarithromycin (Biaxin) 500 mg PO tid for 14 days.
   4. Efficacy is 70-80%; expensive.
10. **Symptomatic Medications:**
- Trimethobenzamide (Tigan) 100-250 mg PO or 100-200 mg IM/PR q6h prn nausea OR
- Prochlorperazine (Compazine) 5-10 mg IM/IV/PO q4-6h or 25 mg PR q4-6h prn nausea.

11. **Extras:** Upright abdomen, KUB, CXR, ECG, endoscopy, GI consult, surgery consult.

12. **Labs:** CBC, SMA 7&12, amylase, lipase, LDH, UA, Helicobacter pylori serology. Fasting serum gastrin qAM for 3 days. Urea breath test for H. pylori.

---

**Gastrointestinal Bleeding**

1. **Admit to:**
2. **Diagnosis:** Upper/lower GI bleed
3. **Condition:**
4. **Vital Signs:** q30min. Call physician if BP >160/90, <90/60; P >120, <50; R >25, <10; T >38.5°C; urine output <15 mL/hr for 4h.
5. **Activity:** Bed rest
6. **Nursing:** Place nasogastric tube, then lavage with 2 L of room temperature normal saline, then connect to low intermittent suction. Repeat lavage q1h. Record volume and character of lavage. Foley to closed drainage. inputs and outputs.
7. **Diet:** NPO
8. **IV Fluids:** Two 16 gauge IV lines. 1-2 L NS wide open; transfuse 2-6 units PRBC to run as fast as possible, then repeat CBC.
9. **Special Medications:**
   - Oxygen 2 L by NC.
   - Ranitidine (Zantac) 50 mg IV bolus, then continuous infusion at 12.5 mg/h [300 mg in 250 mL D5W over 24h (11 cc/h)], or 50 mg IV q6-8h OR
   - Famotidine (Pepcid) 20 mg IV q12h.
   - Vitamin K (Phytonadione) 10 mg IV/SQ qd for 3 days (if INR is elevated).

**Esophageal Variceal Bleeds:**

- Somatostatin (Octreotide) 50 mcg IV bolus, followed by 25-50 mcg/h IV infusion (1200 mcg in 250 mL of D5W at 11 mL/h).

**Vasopressin/Nitroglycerine Paste Therapy:**
- Vasopressin (Pitressin) 20 U IV over 20-30 minutes, then 0.2-0.3 U/min (100 U in 250 mL of D5W 0.4 U/mL) for 30 min, followed by increases of 0.2 U/min until bleeding stops or max of 0.9 U/min. If bleeding stops, taper over 24-48h AND
- Nitroglycerine paste 1 inch q6h OR nitroglycerin IV at 10-30 mcg/min continuous infusion (50 mcg in 250 mL of D5W).

10. **Extras:** Portable CXR, upright abdomen, ECG.

**Surgery and GI consults.**

**Upper GI Bleeds:** Esophagogastroduodenoscopy with coagulation or sclerotherapy; Linton-Nachlas tube for tamponade of esophageal varices.

**Lower GI Bleeds:** Sigmoidoscopy/colonoscopy (after a GoLytely purge 6-8 L over 4-6h), technetium 99m RBC scan, angiography with embolization.

11. **Labs:** Repeat hematocrit q2h; CBC with platelets q12-24h. Repeat INR in 6 hours. SMA 7&12, ALT, AST, alkaline phosphatase. INR/PTT, type and cross for 3-6 U PRBC and 2-4 U FFP.

---

**Cirrhotic Ascites and Edema**

1. **Admit to:**
2. **Diagnosis:** Cirrhotic ascites and edema
3. **Condition:**
4. **Vital Signs:** Vitals q4-6 hours. Call physician if BP >160/90, <90/60; P >120, <50; T >38.5°C; urine output < 25 cc/hr for 4h.
5. **Activity:** Bed rest with legs elevated.
6. **Nursing:** Inputs and outputs, daily weights, measure abdominal girth qd, guaiac all stools.
7. **Diet:** 2500 calories, 100 gm protein; 500 mg sodium restriction; fluid restriction to 1-1.5 L/d (if hyponatremia, Na <130).
8. **IV Fluids:** Heparin lock with flush q shift.
9. **Special Medications:**
   - Diurese to reduce weight by 0.5-1 kg/d (if edema) or 0.25 kg/d (if no edema).
   - Spironolactone (Aldactone) 25-50 mg PO qid or 200 mg PO qAM, increase by 100 mg/d to max of 400 mg/d.
   - Furosemide (Lasix) refractory ascites 40-120 mg PO or IV q4-bid. Add KCL 20-40 mEq PO qAM if renal function is normal OR
   - Torsemide (Demadex) 20-40 mg PO/IV qd-bid.
   - Metolazone (Zaroxolyn) 5-10 mg PO qd (max 20 mg/d).
   - Folic acid 1 mg PO qd.
   - Thiamine 100 mg PO qd.
   - Multivitamin PO qd.

**Paracentesis:** Remove up to 5 L of ascites if peripheral edema, tense ascites, or decreased diaphragmatic excursion. If large volume paracentesis without peripheral edema or with renal insufficiency, give salt-poor albumin, 12.5 gm for each 2 liters of fluid removed (50 mL of 25% solution); fuse 25 mL before paracentesis and 25 mL 6h after.

10. **Symptomatic Medications:**
   - Docusate sodium (Colace) 100 mg PO qhs.
   - Lactulose 30 mL PO bid-qid prn constipation.
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.
11. **Extras:** KUB, CXR, abdominal ultrasound, liver-spleen scan, GI consult.

12. **Labs:** Ammonia, CBC, SMA 7 & 12, LFTs, albumin, amylase, lipase, INR/PTT. Urine creatinine, Na, K, HBsAg, anti-HBs, hepatitis C virus antibody, alpha-1-antitrypsin.

**Paracentesis Ascitic Fluid**

**Tube 1:** Protein, albumin, specific gravity, glucose, bilirubin, amylase, lipase, triglyceride, LDH (3-5 mL, red top tube).

**Tube 2:** Cell count and differential (3-5 mL, purple top tube).

**Tube 3:** C&S, Gram stain, AFB, fungal (5-20 mL); inject 20 mL into bottle of blood culture at bedside.

**Tube 4:** Cytology (>20 mL).

**Syringe:** pH (2 mL).

---

**Viral Hepatitis**

1. Admit to:
2. **Diagnosis:** Hepatitis
3. **Condition:**
4. **Vital Signs:** qid. Call physician if BP <90/60; T >38.5°C
5. **Activity:**
6. **Nursing:** Stool isolation.
7. **Diet:** Clear liquid (if nausea), low fat (if diarrhea).
8. **Special Medications:**
   - Famotidine (Pepcid) 20 mg IV/PO q12h.
   - Vitamin K 10 mg SQ qd for 3d.
   - Multivitamin PO qd.
9. **Symptomatic Medications:**
   - Metoclopramide (Reglan) 10 mg PO q6-8h prn.
   - Acetaminophen (Tylenol) 650-1000 mg PO q4-6h prn.
   - Multi-nutrient formula.
   - Potassium Replacement.
10. **Extras:** Ultrasound, GI consult.
11. **Labs:** CBC, SMA 7 & 12, GGT, LDH, amylase, lipase, INR/PTT, IgM anti-HAV, IgM anti-HBc, HBsAg, anti-HCV; alpha-1-antitrypsin, ANA, ferritin, ceruloplasmin, urine copper.

---

**Cholecystitis and Cholangitis**

1. Admit to:
2. **Diagnosis:** Bacterial cholangitis
3. **Condition:**
4. **Vital Signs:** q4h. Call physician if BP systolic >160, <90; diastolic: >90, <60; P >120, <50; R>25, <10; T >38.5°C
5. **Activity:** Bed rest
6. **Nursing:** Inputs and outputs
7. **Diet:** NPO
8. **IV Fluids:** 0.5-1 L LR over 1h, then D5 ½ NS with 20 mEq KCL/L at 125 cc/h. NG tube at low constant suction. Foley to closed drainage.
9. **Special Medications:**
   - Ticarcillin or piperacillin 3 gm IV q4-6h, and either metronidazole (Flagyl) 500 mg q6h or cefoxitin (Mefoxin) 1-2 gm IV q6h.
   - Ampicillin 1-2 gm IV q4-6h and gentamicin 100 mg (1-2 mg/kg), then 80 mg IV q6h (3-5 mg/kg/d) and metronidazole 500 mg IV q6h.
   - Imipenem/cilastatin (Primaxin) 1.0 gm IV q6h (single agent).
   - Ampicillin/sulbactam (Unasyn) 1.5-3.0 gm IV q6h (single-agent).
10. **Symptomatic Medications:**
   - Meperidine (Demerol) 50-100 mg IV/IM q4-6h pm pain.
   - Hydroxyzine (Vistaril) 25-50 mg IV/IM q4-6h pm with meperidine.
   - Omeprazole (Prilosec) 20 mg PO bid.
   - Heparin 5000 U SQ q12h.
11. **Extras:** CXR, ECG, RUQ ultrasound, HIDA scan, acute abdomen series. GI consult, surgical consult.
12. **Labs:** CBC, SMA 7 & 12, GGT, amylase, lipase, blood C&S x 2. UA, INR/PTT.

---

**Acute Pancreatitis**

1. Admit to:
2. **Diagnosis:** Acute pancreatitis
3. **Condition:**
4. **Vital Signs:** q1-4h, call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C; urine output < 25 cc/hr for more than 4 hours.
5. **Activity:** Bed rest with bedside commode.
6. **Nursing:** Inputs and outputs, fingerstick glucose qid, guaiac stools. Foley to closed drainage.
7. **Diet:** NPO
8. **IV Fluids:** 1-4 L NS over 1-3h, then D5 ½ NS with 20 mEq KCL/L at 125 cc/hr. NG tube at low constant suction (if obstruction).
9. **Special Medications:**
   - Ranitidine (Zantac) 6.25 mg/h (150 mg in 250 mL D5W at 11 mL/h) IV or 50 mg IV q6-8h OR Famotidine (Pepcid) 20 mg IV q12h.
   - Ticarcillin/clavulanate (Timentin) 3.1 gm IV, or ampicillin/subactam (Unasyn) 3.0 gm IV q6h or imipenem (Primaxin) 0.5-1.0 gm IV q6h.
   - Antibiotics are indicated for infected pancreatic pseudocysts or for abscess. Uncomplicated pancre-
Acute Diarrhea

1. Admit to:
2. Diagnosis: Acute Diarrhea
3. Condition:
4. Vital Signs: q6h; call physician if BP >160/90, <80/60; P >120, R>25, T >38.5°C
5. Activity: Up ad lib
7. Diet: NPO except ice chips for 24h, then low residual elemental diet; no milk products.
8. IV Fluids: 1-2 L NS over 1-2 hours; then D5 ½ NS with 40 mEq KCL/L at 125 cc/h.
9. Special Medications: Febrile or gross blood in stool or neutrophils on microscopic exam or prior travel:
   -Ciprofloxacin (Cipro) 500 mg PO bid OR
   -Levofloxacin (Levaquin) 500 mg PO qd OR
   -Trimethoprim/SMX (Bactrim DS) (160/800 mg) one DS tab PO bid.
12. Labs: SMA7 and 12, CBC with differential, UA, blood culture x 2. Stool studies: Wright's stain for fecal leukocytes, ova and parasites x 3, clostridium difficile toxin, culture for enteric pathogens, E coli 0157:H7 culture.

Specific Treatment of Acute Diarrhea

Shigella:
- Trimethoprim/SMX, (Bactrim) one DS tab PO bid for 5 days OR
- Ciprofloxacin (Cipro) 500 mg PO bid for 5 days OR
- Azithromycin (Zithromax) 500 mg PO x 1, then 250 mg PO qd x 4.

Salmonella (bacteremia):
- Ofloxacin (Floxin) 400 mg IV/PO q12h for 14 days OR
- Ciprofloxacin (Cipro) 400 mg IV q12h or 750 mg PO q12h for 14 days OR
- Trimethoprim/SMX (Bactrim) one DS tab PO bid for 14 days OR
- Ceftriaxone (Rocephin) 2 gm IV q12h for 14 days.

Campylobacter jejuni:
- Erythromycin 250 mg PO qid for 5-10 days OR
- Azithromycin (Zithromax) 500 mg PO x 1, then 250 mg PO qd x 4 OR
- Ciprofloxacin (Cipro) 500 mg PO bid for 5 days.

Enterotoxigenic Enteroinvasive E coli (Travelers Diarrhea):
- Ciprofloxacin (Cipro) 500 mg PO bid for 5-7 days OR
- Trimethoprim/SMX (Bactrim), one DS tab PO bid for 5-7 days.

Antibiotic-Associated and Pseudomembranous Colitis (Clostridium difficile):
- Metronidazole (Flagyl) 250 mg PO or IV qd for 10-14 days OR
- Vancomycin 125 mg PO qid for 10 days (500 PO qid for 10-14 days, if recurrent).

Yersinia Enterocolitica (sepsis):
- Trimethoprim/SMX (Bactrim), one DS tab PO bid for 5-7 days OR
- Ciprofloxacin (Cipro) 500 mg PO bid for 5-7 days OR
- Ofloxacin (Floxin) 400 mg PO bid OR
- Ceftriaxone (Rocephin) 1 gm IV q12h.

Entamoeba Histolytica (AMEBIASIS):
- Mild to Moderate Intestinal Disease:
  - Metronidazole (Flagyl) 750 mg PO tid for 10 days OR
  - Tinidazole 2 gm per day PO for 3 days Followed By:
    - Iodoquinol 650 mg PO tid for 20 days OR
    - Paromomycin 25-30 mg/kg/d PO tid for 7 days.

- Severe Intestinal Disease:
  - Metronidazole (Flagyl) 750 mg PO tid for 10 days OR
  - Tinidazole 600 mg PO bid for 5 days Followed By:
    - Iodoquinol 650 mg PO tid for 20 days OR
    - Paromomycin 25-30 mg/kg/d PO tid for 7 days.

Giardia Lamblia:
- Quinacrine 100 mg PO tid for 5d OR
- Metronidazole 250 mg PO bid for 7 days.

Cryptosporidium:
- Paromomycin 500 mg PO qid for 7-10 days [250 mg].
Crohn’s Disease

1. Admit to:
2. Diagnosis: Crohn’s disease.
3. Condition:
4. Vital Signs: q8h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C
5. Activity: Up ad lib in room.
6. Nursing: Inputs and outputs. NG at low intermittent suction (if obstruction).
7. Diet: NPO except for ice chips and medications for 48h, then low residue or elemental diet, no milk products.
8. IV Fluids: 1-2 L NS over 1-3h, then D5 ½ NS with 40 mEq KCL/L at 125 cc/hr.
9. Special Medications:
   - Mesalamine (Asacol) 400-800 mg PO tid or mesalamine (Pentasa) 1000 mg (four 250 mg tabs) PO qid OR
   - Sulfasalazine (Azulfidine) 0.5-1 gm PO bid; increase over 10 days to 0.5-1 gm PO qid OR
   - Olsalazine (Dipentum) 500 mg PO bid.
   - Infliximab (Remicade) 5 mg/kg IV over 2 hours; MR at 2 and 6 weeks
   - Prednisone 40-60 mg/d PO in divided doses OR
   - Hydrocortisone 100 mg IM for 5d then 100-200 mcg IM q month.
   - Multivitamin PO qAM or 1 ampule IV qAM.
   - Folic acid 1 mg PO qd.
11. Labs: CBC, SMA 7&12, Mg, ionized calcium, blood C&S x 2; stool Wright’s stain, stool culture, C difficile antigen assay, stool ova and parasites x 3.

Ulcerative Colitis

1. Admit to:
2. Diagnosis: Ulcerative colitis
3. Condition:
4. Vital Signs: q4-6h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C
5. Activity: Up ad lib in room.
7. Diet: NPO except for ice chips for 48h, then low residue or elemental diet, no milk products.
8. IV Fluids: 1-2 L NS over 1-2h, then D5 ½ NS with 40 mEq KCL/L at 125 cc/hr.
9. Special Medications:
   - Mesalamine (Asacol) 400-800 mg PO tid OR
   - 5-aminosalicylate (Mesalamine) 400-800 mg PO tid or 1 gm PO qid or enema 4 gm/60 mL PR qhs OR
   - Sulfasalazine (Azulfidine) 0.5-1 gm PO bid, increase over 10 days as tolerated to 0.5-1.0 gm PO qid OR
   - Olsalazine (Dipentum) 500 mg PO bid OR
   - Hydrocortisone retention enema, 100 mg in 120 mL saline bid.
   - Methylprednisolone (Solu-Medrol) 10-20 mg IV qhs OR
   - Hydrocortisone 100 mg IV q6h.
   - Prednisone 40-60 mg/d PO in divided doses.
10. Symptomatic Medications:
   - Loperamide (Imodium) 2-4 mg PO tid-qid prn, max 16 mg/d OR
   - Kaopectate 60-90 mL PO qid prn.
   - Folate 1 mg PO qd.
12. Labs: CBC, SMA 7&12, Mg, ionized calcium, blood C&S x 2; stool Wright’s stain, stool culture, C difficile antigen assay, stool ova and parasites x 3, culture for enteric pathogens; Clostridium difficile antigen assay, UA.

Parenteral Nutrition

General Considerations: Daily weights, inputs and outputs. Finger stick glucose q6h.

Central Parenteral Nutrition
   - Infuse 40-50 mL/h of amino acid-dextrose solution in the first 24h; increase daily by 40 mL/hr increments until providing 1.3-2 x basal energy requirement and 1.2-1.7 gm protein/kg/d (see formula page 97).

Standard solution:
   - Amino acid sm (Aminosyn) 7-10% ............ 500 mL
   - Dextrose 40-70% ........................ 500 mL
   - Sodium .................................. 35 mEq
   - Potassium .............................. 36 mEq
   - Chloride .................................. 35 mEq
   - Calcium .................................. 4.5 mEq
   - Phosphate ................................. 9 mmol
   - Magnesium ................................ 8.0 mEq
   - Acetate ................................... 82-104 mEq
   - Multi-trace element formula ............. 1 mL/d
   - Zn, copper, manganese, chromium
   - Regular insulin (if indicated) ........... 10-60 U/L
   - Multivitamin(12)(2 amp) ................. 10 mL/d
   - Vitamin K (in solution, SQ, IM) ........... 10 mg/week
   - Vitamin B12 ............................. 1000 mcg/week
   - Selenium (after 20 days of continuous TPN) 80 mcg/d
Intralipid 20%, 500 mL/d IVPB; infuse in parallel with standard solution at 1 mL/min for 15 min. If no adverse reactions, increase to 100 mL/hr once daily or 20 mg/hr continuously. Obtain serum triglyceride 6h after end of infusion (maintain <250 mg/dL).

**Cyclic Total Parenteral Nutrition:**
- 12h night schedule; taper continuous infusion in morning by reducing rate by half of original rate for 1 hour. Further reduce rate by half for an additional hour, then discontinue. Finger stick glucose q4-6h; restart TPN in afternoon. Taper at beginning and end of cycle. Final rate of 185 mL/hr for 9-10 h and 2 hours of taper at each end for total of 2000 mL.

**Peripheral Parenteral Supplementation:**
- 3% amino acid sln (ProCalamine) up to 3 L/d at 125 cc/h
- Combine 500 mL amino acid solution 7% or 10% (Aminosyn) and 500 mL 20% dextrose and electrolyte additive. Infuse at up to 100 cc/hr in parallel with:
  - Intralipid 10% or 20% at 1 mL/min for 15 min (test dose); if no adverse reactions, infuse 500 mL/d at 21 mL/h over 24h, or up to 100 mL/h over 5 hours daily.
  - Draw triglyceride level 6h after end of Intralipid infusion.

**Special Medications:**
- Famotidine 20 mg IV q12h or 40 mg/day in TPN
- Ranitidine (Zantac) 50 mg IV q8h or 150 mg/day in TPN.

**Extras:**
- Nutrition consult.

**Labs:**
- Daily labs: SMA7, osmolality, CBC, cholesterol, triglyceride, urine glucose and specific gravity.
- Twice weekly Labs: Calcium, phosphate, SMA-12, magnesium
- Weekly Labs: Serum albumin and protein, pre-albumin, ferritin, INR/PTT, zinc, copper, B12, folate, 24h urine nitrogen and creatinine.

**Enteral Nutrition**

**General Considerations:** Daily weights, inputs and outputs, nasoduodenal feeding tube. Head-of-bed at 30” while enteral feeding and 2 hours after completion.

**Enteral Bolus Feeding:** Give 50-100 mL of enteral solution (Pulmocare, Jejivex, Vivonex, Omomalite, Vital HN) q3h. Increase amount in 50 mL steps to max of 250-300 mL q3-4h; 30 kcal of nonprotein calories/kg/d and 1.5 gm protein/kg/d. Before each feeding measure residual volume, and delay feeding by 1h if >100 mL. Flush tube with 100 cc of water after each bolus.

**Continuous enteral infusion:** Initial enteral solution (Pulmocare, Jejivex, Vivonex, Omomalite) 30 mL/hr. Measure residual volume q1h for 12h then tid; hold feeding for 1h if >100 mL. Increase rate by 25-50 mL/hr at 24 hr intervals as tolerated until final rate of 50-100 mL/hr. Three tablespoonsfuls of protein powder (Promix) may be added to each 500 cc of solution. Flush tube with 100 cc water q8h.

**Special Medications:**
- Metoclopramide (Reglan) 10-20 mg IV/NG OR
- Erythromycin 250 mg IV PO q12h OR
- Ranitidine (Zantac) 150 mg NG bid.

**Symptomatic Medications:**
- Loperamide (Imodium) 2-4 mg NG/J-tube q6h prn, max 16 mg/d
- Diphenoxylate/atropine (Lomotil) 1-2 tabs or 5-10 mL (2.5 mg/5 mL) PO/J-tube q4-6h prn, max 12 tabs/d OR
- Kaopectate 30 cc NG or in J-tube q8h.

**Labs:**
- Daily labs: SMA7, osmolality, CBC, cholesterol, triglyceride, urine glucose and specific gravity.
- Twice weekly Labs: Calcium, phosphate, SMA-12, magnesium
- Weekly labs when indicated: Protein, Mg, INR/PTT, zinc, copper, B12, folate, 24h urine nitrogen and creatinine.

**Hepatic Encephalopathy**

1. **Admit to:**
2. **Diagnosis:** Hepatic encephalopathy
3. **Condition:**
4. **Vital Signs:** q1-4h, neurochecks q4h. Call physician if BP >160/100, <90/60; P >100, <50; R >25, <10; T >38.5°C.
5. **Allergies:** Avoid sedatives, NSAIDS or hepatotoxic drugs.
6. **Activity:** Bed rest.
7. **Nursing:** Keep head-of-bed at 40 degrees, guaiac stools; turn patient q2h while awake, chart stools. Seizure precautions, egg crate mattress, soft restraints pm. Record inputs and outputs.
8. **Diet:** NPO for 8 hours, then low-protein nasogastric enteral feedings (Hepatic-Aid II) at 30 mL/hr. Increase rate by 25-50 mL/hr at 24 hr intervals as tolerated until final rate of 50-100 mL/hr as tolerated.
9. **IV Fluids:** DSW at TKO, Foley to closed drainage.
10. **Special Medications:**
    - Sorbitol 70% solution, 30-60 gm PO now.
    - Lactulose 30-45 mL PO q1h for 3 doses, then 15-45 mL PO bid-qid, titrate to produce 3 soft stools/d OR
    - Lactulose enema 300 mL added to 700 mL of tap wa-
ter; instill 200-250 mL per rectal tube bid-qid

-Neomycin 1 gm PO q6h (4-12 qd) OR
-Metronidazole (Flagyl) 250 mg PO q12h.

-Flumazenil (Romazicon) 0.2 mg (2 mL) IV over 30 seconds q1min until a total dose of 3 mg; if a partial response occurs, continue 0.5 mg doses until a total of 5 mg. Flumazenil may help reverse hepatic encephalopathy, even in the absence of benzodiazepine use.

-Multivitamin PO qAM or 1 ampule IV qAM.
-Folic acid 1 mg PO/IV qd.
-Thiamine 100 mg PO/IV qd.
-Vitamin K 10 mg SQ qd for 3 days if elevated INR.

11. Extras: CXR, ECG; GI and dietetics consults.

12. Labs: Ammonia, CBC, platelets, SMA 7&12, AST, ALT, GGT, LDH, alkaline phosphatase, protein, albumin, bilirubin, INR/PTT, ABG, blood G&G x 2, hepatitis B surface antibody, UA.

Alcohol Withdrawal

1. Admit to:

2. Diagnosis: Alcohol withdrawals/delirium tremens.

3. Condition:

4. Vital Signs: q4-6h. Call physician if BP >160/90, <90-60; P >130, <50; R>25, <10; T >38.5°C; or increase in agitation.

5. Activity:


7. Diet: Regular, push fluids.

8. IV Fluids: Heparin lock or D5 ½ NS at 100-125 cc/h.

9. Special Medications:

Withdrawal syndrome:

- Chlordiazepoxide (Librium) 50-100 mg PO/IV q6h for 3 days OR
- Lorazepam (Ativan) 1 mg PO tid-qid.

Delirium tremens:

- Chlordiazepoxide (Librium) 100 mg slow IV push or PO, repeat q4-6h pt agitation or tremor for 24h; max 500 mg/d. Then give 50-100 mg PO q6h prn agitation or tremor OR
- Diazepam (Valium) 2 mg slow IV push, repeat q6h until calm, then 5-10 mg PO q4-6h.

Seizures:

- Thiamine 100 mg IV push AND
- Dextrose water 50%, 50 mL IV push.
- Lorazepam (Ativan) 0.1 mg/kg IV at 2 mg/min; may repeat x 1 if seizures continue.

Wernicke-Korsakoff Syndrome:

- Thiamine 100 mg IV stat, then 100 mg IV qd.

10. Symptomatic Medications:

-Multivitamin 1 amp IV, then 1 tab PO qd.
-Folate 1 mg PO qd.
-Thiamine 100 mg PO qd.
-Acetaminophen (Tylenol) 1-2 PO q4-6h prn headache.

11. Extras: CXR, ECG. Alcohol rehabilitation and social work consult.

12. Labs: CBC, SMA 7&12, Mg, amylase, lipase, liver panel, urine drug screen. UA, INR/PTT.
Poisoning and Drug Overdose

Decontamination:
- **Gastric Lavage:** Place patient left side down, place nasogastric tube, and check position by injecting air and auscultating. Lavage with normal saline until clear fluid, then leave activated charcoal or other antidote. Gastric lavage is contraindicated for corrosives.
- **Cathartics:**
  - Magnesium citrate 6% sln 150-300 mL PO
  - Magnesium sulfate 10% solution 150-300 mL PO.
- **Activated Charcoal:** 50 gm PO (first dose should be given using product containing sorbitol). Repeat q2-6h for large ingestions.
- **Hemodialysis** is indicated for isopropanol, methanol, ethylene glycol, severe salicylate intoxication (>100 mg/dL), lithium, or theophylline (if neurotoxicity, seizures, or coma).

**Antidotes:**

**Narcotic Overdose:**
- Naloxone (Narcan) 0.4 mg IV/ET/IM/SC, may repeat q2min.

**Methanol Ingestion:**
- Ethanol (10% in D5W) 7.5 mL/kg load, then 1.4 mL/kg/hr IV infusion until methanol level <20 mg/dL. Maintain ethanol level of 100-150 mg/100 mL.

**Ethylene Glycol Ingestion:**
- Fomepizole (Antizol) 15 mg/kg IV over 30 min, then 10 mg/kg IV q12h x 4 doses, then 15 mg/kg IV q12h until ethylene glycol level is less than 20 mg/dL. **AND**
  - Pyridoxine 100 mg IV q6h for 2 days and thiamine 100 mg IV q6h for 2 days.

**Carbon Monoxide Intoxication:**
- Hyperbaric oxygen therapy or 100% oxygen by mask if hyperbaric oxygen not available.

**Tricyclic Antidepressants Overdose:**
- Gastric lavage
- Magnesium citrate 300 mg PO/NG x1
- Activated charcoal premixed with sorbitol 50 gm NG q4-6h until level is less than the toxic range.

**Benzodiazepine Overdose:**
- Flumazenil (Romazicon) 0.2 mg (2 mL) IV over 30 seconds q1min until a total dose of 3 mg; if a partial response occurs, repeat 0.5 mg doses until a total of 5 mg. If sedation persists, repeat the above regimen or start a continuous IV infusion of 0.1-0.5 mg/h.

**Labs:**
- Drug screen (serum, gastric, urine); blood levels, SMA 7, fingerstick glucose, CBC, LFTs, ECG.

**Acetaminophen Overdose**

1. **Admit to:** Medical intensive care unit.
2. **Diagnosis:** Acetaminophen overdose
3. **Condition:**
4. **Vital Signs:** q1h with neurochecks. Call physician if BP >160/90, <90/60; P >130, <50; R >25, <10; urine output <20 ccc for 3 hours.
5. **Activity:** Bed rest with bedside commode.
6. **Nursing:** Inputs and outputs, aspiration and seizure precautions. Place large bore (Ewald) NG tube, then lavage with 2 L of NS.
7. **Diet:** NPO
8. **IV Fluids:**
9. **Special Medications:**
  - Activated charcoal 30-100 gm doses, remove via NG suction prior to acetylcysteine.
  - Acetylcysteine (Mucomyst, NAC) 5% solution loading dose 140 mg/kg via NG tube, then 70 mg/kg via NG tube q6h x 17 doses OR acetylcysteine 150 mg/kg IV in 200 mL D5W over 15 min, followed by 50 mg/kg in 500 mL D5W, infused over 4h, followed by 100 mg/kg in 1000 mL of D5W over next 16h. Complete all NAC doses even if acetaminophen levels fall below toxic range.
  - Phytonadione 5 mg IV/IM/ SQ (if INR increased).
  - Fresh frozen plasma 2-4 U (if INR is unresponsive to phytonadione).
  - Trimethobenzamide (Tigan) 100-200 mg IM/PR q6h prn nausea
10. **Extras:** ECG. Nephrology consult for hemodialysis or charcoal hemoperfusion.
11. **Labs:** CBC, SMA 7&12, LFTs, INR/PTT, acetaminophen level now and in 4h. UA.

**Theophylline Overdose**

1. **Admit to:** Medical intensive care unit.
2. **Diagnosis:** Theophylline overdose
3. **Condition:**
4. **Vital Signs:** Neurochecks q2h. Call physician if BP >160/90, <90/60; P >130, <50; R >25, <10.
5. **Activity:** Bed rest
6. **Nursing:** ECG monitoring until level <20 mcg/mL, aspiration and seizure precautions. Insert single lumen NG tube and lavage with normal saline if recent ingestion.
7. **Diet:** NPO
8. **IV Fluids:** D5 ½ NS at 125 ccc/h
9. Special Medications:
- Activated charcoal 50 gm PO q4-6h, with sorbitol cathartic, until theophylline level <20 mcg/mL. Maintain head-of-bed at 30-45 degrees to prevent aspiration of charcoal.
- Charcoal hemoperfusion is indicated if the serum level is >60 mcg/mL or if signs of neurotoxicity, seizure, coma are present.
- Seizure: Lorazepam (Ativan) 0.1 mg/kg IV at 2 mg/min; may repeat x 1 if seizures continue.

10. Extras: ECG.

11. Labs: CBC, SMA 7&12, theophylline level now and in q6-8h; INR/PTT, liver panel, UA.

Tricyclic Antidepressant Overdose

1. Admit to: Medical intensive care unit.
2. Diagnosis: TCA Overdose
3. Condition:
4. Vital Signs: Neurochecks q1h.
5. Activity: Bedrest.
6. Nursing: Continuous suicide observation, ECG monitoring, measure QRS width hourly, inputs and outputs, aspiration and seizure precautions. Place single-lumen nasogastric tube and lavage with 2 liters of normal saline if recent ingestion.
7. Diet: NPO
8. IV Fluids: NS at 100-150 cc/hr.
9. Special Medications:
- Activated charcoal premixed with sorbitol 50 gm via NG tube q4-6h until the TCA level decreases to therapeutic range. Maintain head-of-bed at 30-45 degree angle to prevent charcoal aspiration.
- Magnesium citrate 300 mL via nasogastric tube x 1 dose.
10. Cardiac Toxicity:
- If mechanical ventilation is necessary, hyperventilate to maintain pH 7.50-7.55.
- Administer sodium bicarbonate 50-100 mEq (1-2 amps or 1-2 mEq/kg) IV over 5-10 min, followed by infusion of sodium bicarbonate (2 amps in D5W 1 L) at 100-150 cc/hr. Adjust rate to maintain pH 7.50-7.55.
11. Extras: ECG.
12. Labs: Urine toxicology screen, serum TCA levels, liver panel, CBC, SMA-7 and 12, UA.
Neurologic Disorders

Ischemic Stroke

1. Admit to:
2. Diagnosis: Ischemic stroke
3. Condition:
4. Vital Signs: Vital signs and neurochecks q30minutes for 6 hours, then q60 minutes for 12 hours. Call physician if BP >185/105, <110/60, P >120, <50; R>24, <10; T >38.5°C; or change in neurologic status.
5. Activity: Bedrest.
6. Nursing: Head-of-bed at 30 degrees, turn q2h when awake, range of motion exercises q4d. Foley catheter, eggcrate mattress. Guaiac stools, inputs and outputs's. Bleeding precautions: check puncture sites for bleeding or hematomas. Apply digital pressure or pressure dressing to active compressible bleeding sites.
7. Diet: NPO except medications for 24 hours, then dysphagia ground diet with thickened liquids.
8. IV Fluids and Oxygen: 0.45% normal saline at 100 cc/h. Oxygen at 2 L per minute by nasal cannula.
9. Special Medications: Ischemic Stroke < 3 hours:
   a. Tissue plasminogen activator (t-PA, Alteplase) is indicated if the patient presents within 3 hours of onset of symptoms and the stroke is non-hemorrhagic; 0.9 mg/kg (max 90 mg) over 60 min, with 10% of the total dose given as an initial bolus over 1 minute.
   b. Repeat CT scan or MRI 24 hours after completion of tPA. Begin heparin if results of scan are negative for hemorrhage.
   c. Heparin 12 U/kg/h continuous IV infusion, without a bolus. Check aPTT q6h to maintain 1.2-1.5 x control.
Completed Ischemic Stroke >3 hours:
   -Aspirin enteric coated 325 mg PO qd OR
   -Clopidogrel (Plavix) 75 mg PO qd OR
   -Aspirin 25 mg/dipyridamole 200 mg (Aggrenox) 1 tab PO bid.
10. Symptomatic Medications:
   -Famotidine (Pepcid) 20 mg IV/PO q12h.
   -Omeprazole (Prilosec) 20 mg PO bid or qhs.
   -Docusate sodium (Colace) 100 mg PO qhs
   -Bisacodyl (Dulcolax) 10-15 mg PO qhs or 10 mg PR prn.
   -Acetaminophen (Tylenol) 650 mg PO/PRI q4-6h pm temp >38°C or headache.
11. Extras: CXR, ECG, CT without contrast or MRI with gadolinium contrast; carotid duplex scan; echocardiogram, 24-hour Holter monitor; swallowing studies. Physical therapy consult for range of motion exercises; neurology, rehabilitation medicine consults.
12. Labs: CBC, glucose, SMA 7&12, fasting lipid profile, VDRL, ESR; drug levels, INR/PTT, UA. Lupus anticoagulant, anticardiolipin antibody.

Transient Ischemic Attack

1. Admit to:
2. Diagnosis: Transient ischemic attack
3. Condition:
4. Vital Signs: q1h with neurochecks. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C; or change in neurologic status.
5. Activity: Up as tolerated.
7. Diet: Dysphagia ground with thickened liquids or regular diet.
8. IV Fluids: Heparin lock with flush q shift.
9. Special Medications:
   -Aspirin 325 mg PO qd OR
   -Clopidogrel (Plavix) 75 mg PO qd OR
   -Aspirin 25 mg/dipyridamole 200 mg (Aggrenox) 1 tab PO bid.
   -Heparin (only if recurrent TIAs or cardiogenic or vertebrobasilar source for emboli) 700-800 U/h (12 U/kg/h) IV infusion without a bolus (25,000 U in 500 mL D5W); adjust q6-12h until PTT 1.2-1.5 x control.
   -Warfarin (Coumadin) 5.0-7.5 mg PO qd for 3d, then 2-4 mg PO qd. Titrate to INR of 2.0-2.5.
10. Symptomatic Medications:
   -Famotidine (Pepcid) 20 mg IV/PO q12h.
   -Docusate sodium (Colace) 100 mg PO qhs.
   -Milk of magnesia 30 mL PO qd prn constipation.
11. Extras: CXR, ECG, CT without contrast; carotid duplex scan, echocardiogram, 24-hour Holter monitor. Physical therapy, neurology consults.
12. Labs: CBC, glucose, SMA 7&12, fasting lipid profile, VDRL, drug levels, INR/PTT, UA.

Subarachnoid Hemorrhage

1. Admit to:
2. Diagnosis: Subarachnoid hemorrhage
3. Condition:
4. Vital Signs: Vital signs and neurochecks q1-6h. Call physician if BP >185/105, <110/60, P >120, <50; R>24, <10; T >38.5°C; or change in neurologic status.
5. Activity: Bedrest.
6. Nursing: Head-of-bed at 30 degrees, turn q2h when awake. Foley catheter, eggcrate mattress. Guaiac stools, inputs and outputs's. Bleeding precautions: check puncture sites for bleed-
ing or hematomas. Apply digital pressure or pressure dressing to active compressible bleeding sites.
7. Diet: NPO except medications.
8. IV Fluids and Oxygen: 0.45% normal saline at 100 cc/h. Oxygen at 2 L per minute by nasal cannula.
   - Keep room dark and quiet; strict bedrest. Neurologic checks q1h for 12 hours, then q2h for 12 hours, then q4h. Call physician if abrupt change in neurologic status.
   - Restrict total fluids to 1000 mL/day; diet as tolerated.
9. Special Medications:
   - Nimodipine (Nimotop) 60 mg PO or via NG tube q4h for 21d, must start within 96 hours.
   - Phenytoin (seizures) load 15 mg/kg IV in NS (infuse at max 50 mg/min), then 300 mg PO/IV qAM (4-6 mg/kg/d).
10. Hypertension:
   - Nitroprusside sodium, 0.1-0.5 mcg/kg/min (50 mg in 250 mL NS), titrate to control blood pressure.
11. Labs: CBC, SMA 7&12, VDRL, UA.

Seizure and Status Epilepticus
1. Admit to:
2. Diagnosis: Seizure
3. Condition:
4. Vital Signs: q6h with neurochecks. Call physician if BP >160/90, <80/60; P >120, <50; R>25, <10; T >38.5°C; or any change in neurological status.
5. Activity: Bed rest
6. Nursing: Finger stick glucose. Seizure precautions with bed rails up; padded tongue blade at bedside. EEG monitoring.
7. Diet: NPO for 24h, then regular diet if alert.
8. IV Fluids: D5 ½ NS at 100 cc/hr; change to heparin lock when taking PO.
9. Special Medications:
   - Status Epilepticus:
     1. Maintain airway.
     2. Position the patient laterally with the head down. The head and extremities should be cushioned to prevent injury.
     3. A bite block or other soft object may be inserted into the mouth to prevent injury to the tongue.
     4. 100% O2 by mask, obtain brief history, and a fingerstick glucose.
     5. Secure IV access and draw blood for glucose analysis. Give thiamine 100 mg IV push, then dextrose 50% 50 mL IV push.
6. Initial Control:
   - Lorazepam (Ativan) 6-8 mg (0.1 mg/kg; not to exceed 2 mg/min) IV at 1-2 mg/min. May repeat 6-8 mg q5-10min (max 80 mg/24h) OR
   - Diazepam (Valium), 5-10 mg slow IV at 1-2 mg/min. Repeat 5-10 mg q5-10 min pm (max 100 mg/24h).
   - Phenytoin (Dilantin) 15-20 mg/kg load in NS at 50 mg/min. Repeat 100-150 mg IV q30min, max 1.5 gm; monitor BP.
   - Fosphenytoin (Cerebyx) 20 mg/kg IV/IM (at 150 mg/min), then 4-6 mg/kg/day in 2 or 3 doses (150 mg IVIM q8h). Fosphenytoin is metabolized to phenytoin; fosphenytoin may be given IM.
   - If Seizures Persist, Administer Phenobarbital 20 mg/kg IV at 50 mg/min, repeat 2 mg/kg q15min; additional phenobarbital may be given, up to max of 30-60 mg/kg.
7. If Seizures Persist, Intubate the Patient and Give:
   - Midazolam (Versed) 0.2 mg/kg IV push, then 0.045 mg/kg/hr; titrate up to 0.6 mg/kg/hr OR
   - Propofol (Diprivan) 2 mg/kg IV push, then 2 mg/kg/hr; titrate up to 10 mg/kg/hr OR
   - Phenobarbital as above
   - Induction of coma with pentobarbital 10-15 mg/kg IV over 1-2h, then 1-1.5 mg/kg/hr continuous infusion. Initiate continuous EEG monitoring.
8. Consider Intubation and General Anesthesia Maintenance Therapy for Epilepsy:
   - Primary Generalized Seizures – First-Line Therapy:
     - Carbamazepine (Tegretol) 200-400 mg PO tid [100, 200 mg]. Monitor CBC.
     - Phenytoin (Dilantin) loading dose of 400 mg PO followed by 300 mg PO q4h for 2 doses (total of 1 g), then 300 mg PO qd or 100 mg tid or 200 mg bid [50, 50, 100 mg].
     - Divalproex (Depakote) 250-500 mg PO tid-qid with meals [125, 250, 500 mg].
     - Valproic acid (Depakene) 250-500 mg PO tid-qid with meals [250 mg].
   - Primary Generalized Seizures – Second Line Therapy:
     - Phenobarbital 30-120 mg PO bid [8, 16, 32, 65, 100 mg].
     - Primidone (Mysoline) 250-500 mg PO tid [50, 250 mg]; metabolized to phenobarbital.
     - Felbamate (Felbatol) 1200-2400 mg PO qd in 3-4 divided doses, max 3600 mg/d [400, 600 mg; 600 mg/5 mL susp]; adjunct therapy; aplastic anemia, hepatotoxicity.
     - Gabapentin (Neurontin), 300-400 mg PO bid-tid; max 1800 mg/day [100, 300, 400 mg]; adjunct therapy.
     - Lamotrigine (Lamictal) 50 mg PO qd; then increase to 50-250 mg PO bid [25, 100, 150, 200 mg]; adjunct therapy.
   - Partial Seizure:
     - Carbamazepine (Tegretol) 200-400 mg PO tid [100, 200 mg].
- Divalproex (Depakote) 250-500 mg PO tid with meals
  [125, 250, 500 mg].
- Valproic acid (Depakene) 250-500 mg PO tid-qid with meals [250 mg].
- Phenytoin (Dilantin) 300 mg PO qd or 200 mg PO bid [30, 50, 100].
- Phenobarbital 30-120 mg PO tid or qd [8, 16, 32, 65, 100 mg].
- Primidone (Mysoline) 250-500 mg PO tid [50, 250 mg]; metabolized to phenobarbital.
- Felbamate (Felbato) 1200-2400 mg PO qd in 3-4 divided doses, max 3600 mg/d [400,600 mg; 600 mg/5 mL susp]; adjunct therapy; aplastic anemia, hepatotoxicity.
- Gabapentin (Neurontin), 300-400 mg PO bid-tid; max 1800 mg/day [100, 300, 400 mg]; adjunct therapy.
- Lamotrigine (Lamictal) 50 mg PO qd; then increase to 50-250 mg PO bid [25, 100, 150, 200 mg]; adjunct therapy.
- Topiramate (Topamax) 25 mg PO bid; titrate to max 200 mg PO bid [tab 25, 100, 200 mg]; adjunctive therapy.

**Absence Seizure:**
- Divalproex (Depakote) 250-500 mg PO tid-qid [125, 250, 500 mg].
- Clonazepam (Klonopin) 0.5-5 mg PO bid-qid [0.5, 1, 2 mg].
- Lamotrigine (Lamictal) 50 mg PO qd; then increase to 50-250 mg PO bid [25, 100, 150, 200 mg]; adjunct therapy.

**10. Extras:** MRI with and without gadolinium or CT with contrast; EEG (with photic stimulation, hyperventilation, sleep deprivation, awake and asleep tracings); portable CXR, ECG.

**11. Labs:** CBC, SMA 7, glucose, Mg, calcium, phosphate, liver panel, VDRL, anticonvulsant levels. UA, drug screen.
**Diabetic Ketoacidosis**

1. Admit to:  
2. Diagnosis: Diabetic ketoacidosis  
3. Condition:  
4. Vital Signs: q1-4h, postural BP and pulse. Call physician if BP >160/90, <90/60; P >140; <50; R >30, <10; T >38.5°C; or urine output < 20 mL/hr for more than 2 hours.  
5. Activity: Bed rest with bedside commode.  
7. Diet: NPO for 12 hours, then clear liquids as tolerated.  
8. IV Fluids: 1-2 L NS over 1-3h (16-gauge), infuse at 400-1000 mL/h until hemodynamically stable, then change to 0.45% saline at 125-150 cc/hr; keep urine output >30-60 mL/h. Add KCL when serum potassium is <5.0 mEq/L. Concentration 20-40 mEq KCL/L.  
9. Special Medications:  
- Oxygen at 2 L/min by NC.  
- Insulin regular (Humulin) 7-10 units (0.1 U/kg) IV bolus, then 7-10 U/hr infusion (0.1 U/kg/hr); 50 U in 250 mL of 0.9% saline; flush IV tubing with 20 mL of insulin sln before starting infusion. Adjust insulin infusion to decrease serum glucose by 100 mg/dL or less per hour. When bicarbonate level is >16 mEq/L and anion gap is <16 mEq/L, decrease insulin infusion rate by half.  
- When the glucose level reaches 250 mg/dL, 5% dextrose should be added to the replacement fluids with KCL 20-40 mEq/L. Use 10% glucose at 50-100 mL/h if anion gap persists and serum glucose has decreased to less than 100 mg/dL while on insulin infusion.  
- Change to subcutaneous insulin when anion gap cleared; discontinue insulin infusion 1-2h after subcutaneous dose.  
10. Symptomatic Medications:  
- Docusate sodium (Colace) 100 mg PO qhs.  
- Acetaminophen (Tylenol) 325-650 mg PO q4-6h prn headache.  
11. Extras: Portable CXR, ECG.  
12. Labs: Fingerstick glucose q1-2h. SMA 7 q4-6h. SMA 12, pH, bicarbonate, phosphate, amylase, lipase, hemoglobin A1c; CBC, UA, serum pregnancy test.

**Nonketotic Hyperosmolar Syndrome**

1. Admit to:  
2. Diagnosis: Nonketotic hyperosmolar syndrome  
3. Condition:  
4. Vital Signs: q1h. Call physician if BP >160/90, <90/60; P >140; <50; R >25, <10; T >38.5°C; or urine output < 20 cc/hr for more than 4 hours.  
5. Activity: Bed rest with bedside commode.  
7. Diet: NPO.  
8. IV Fluids: 1-2 L NS over 1h (16-gauge IV catheter), then give 0.45% saline at 125 cc/hr. Maintain urine output >50 mL/h. Add 20-40 mEq/L KCL when urine output adequate.  
9. Special Medications:  
- Insulin regular 2-3 U/hr infusion (50 U in 250 mL of 0.9% saline).  
- Famotidine (Pepcid) 20 mg IV/PO q12h.  
- Heparin 5000 U SQ q12h.  
10. Extras: Portable CXR, ECG.  
11. Labs: Fingerstick glucose q1-2h x 6h, then q6h. SMA 7, osmolality. SMA 12, phosphate, ketones, hemoglobin A1c; CBC, UA.

**Thyroid Storm and Hyperthyroidism**

1. Admit to:  
2. Diagnosis: Thyroid Storm  
3. Condition:  
4. Vital Signs: q1-4h. Call physician if BP >160/90, <90/60; P >130; <50; R >25, <10; T >38.5°C; or urine output < 20 cc/hr for more than 4 hours.  
5. Activity: Bed rest.  
7. Diet: Regular  
8. IV Fluids: D5 ½ NS at 125 mL/h.  
9. Special Medications:  
- Methimazole (Tapazole) 30-60 mg PO, then maintenance of 15 mg PO q/Bid OR  
- Propylthiouracil (PTU) 1000 mg PO, then 50-250 mg PO q4-8h, up to 1200 mg/d; usual maintenance dose 50 mg PO tid AND  
- Iodide solution (Lugol’s solution), 3-6 drops tid; one hour after propylthiouracil AND  
- Dexamethasone (Decadron) 2 mg IV q6h AND
-Propranolol 40-160 mg PO q6h or 5-10 mg/h, max 2-5 mg IV q4h or propranolol-LA (Inderal-LA), 80-120 mg PO qd [60, 80, 120, 160 mg].
-Acetaminophen (Tylenol) 1-2 tabs PO q4-6h prn temp >38°C.
-Zolpidem (Ambien) 10 mg PO qhs prn insomnia OR
-Lorazepam (Ativan) 1-2 mg IV/IM/PO q4-8h prn anxiety.

11. Labs: CBC, SMA 7&12; sensitive TSH, free T4, UA.

**Myxedema Coma and Hypothyroidism**

1. Admit to:
2. Diagnosis: Myxedema Coma
3. Condition:
4. Vital Signs: q1h. Call physician if BP systolic >160/90, <90/60; P >130, <50; R>25, <10; T >38.5°C
5. Activity: Bed rest
7. Diet: NPO
8. IV Fluids: IV D5 NS TKO.
9. Special Medications:
   **Myxedema Coma and Hypothyroidism:**
   -Volume replacement with NS 1 L rapid IV, then 125 mL/h.
   -Levothyroxine (Synthroid, Levoxine) 300-500 mcg IV, then 100 mcg PO or IV qd.
   -Hydrocortisone 100 mg IV loading dose, then 50-100 mg IV q6h.

**Hypothyroidism in Medically Stable Patient:**
-Levothyroxine (Synthroid, T4) 50-75 mcg PO qd, increase by 25 mcg PO qd at 2-4 week intervals to 75-150 mcg qd until TSH normalized.

12. Labs: CBC, SMA 7&12; sensitive TSH, free T4, UA, rheumatoid factor, ANA.
Nephrologic Disorders

Renal Failure

1. Admit to:
2. Diagnosis: Renal failure
3. Condition:
4. Vital Signs: q8h. Call physician if QRS complex >0.14 sec; urine output <20 cc/hr; BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C
5. Allergies: Avoid magnesium containing antacids, salt substitutes, NSAIDs. Discontinue phosphate or potassium supplements.
8. Diet: Renal diet of high biologic value protein of 0.6-0.8 g/kg, sodium 2 g, potassium 1 mEq/kg, and at least 35 kcal/kg of nonprotein calories. In oliguric patients, daily fluid intake should be restricted to less than 1 L after volume has been normalized.
9. IV Fluids: D5W at TKO.
10. Special Medications:
   - Consider fluid challenge (to rule out pre-renal azotemia if not fluid overloaded) with 500-1000 mL NS IV over 30 min. In acute renal failure, in-and-out catheterize and check postvoid residual to rule out obstruction.
   - Furosemide (Lasix) 80-320 mg IV bolus over 10-60 min, double the dose if no response after 2 hours to total max 1000 mg/24h, or furosemide 1000 mg in 250 mL D5W at 20-40 mg/hr continuous IV infusion OR
   - Torsemide (Demadex) 20-40 mg IV bolus over 5-10 min, double the dose up to max 200 mg/day OR
   - Bumetanide (Bumex) 1-2 mg IV bolus over 1-20 min; double the dose if no response in 1-2 h to total max 10 mg/day.
   - Metolazone (Zaroxolyn) 5-10 mg PO (max 20 mg/24h) 30 min before a loop diuretic.
   - Dopamine (Intropin) 1-3 mcg/kg per minute IV.
   - Hyperkalemia is treated with sodium polystyrene sulfonate (Kayexalate), 15-30 gm PO/NG/PR q4-6h.
   - Hyperphosphatemia is controlled with calcium acetate (PhosLo), 2-3 tabs with meals.
   - Metabolic acidosis is treated with sodium bicarbonate to maintain the serum pH >7.2 and the bicarbonate level >20 mEq/L. 1-2 amps (50-100 mEq) IV push, followed by infusion of 2-3 amps in 1000 mL of D5W at 150 mL/hr.
   - Adjust all medications to creatinine clearance, and remove potassium phosphate and magnesium from IV. Avoid NSAIDs and nephrotoxic drugs.
12. Labs: CBC, platelets, SMA 7&12, creatinine, BUN, potassium, magnesium, phosphate, calcium, uric acid, osmolality, ESR, INR/PTT, ANA. Urine specific gravity, UA with micro, urine C&S; 1st AM spot urine electrolytes, eosinophils, creatinine, pH, osmolality; Wright's stain, urine electrophoresis. 24h urine protein, creatinine, sodium.

Nephrolithiasis

1. Admit to:
2. Diagnosis: Nephrolithiasis
3. Condition:
4. Vital Signs: q8h. Call physician if urine output <30 cc/hr; BP >160/90, <90/60; T >38.5°C
6. Nursing: Strain urine, measure inputs and outputs. Place Foley if no urine for 4 hours.
7. Diet: Regular, push oral fluids.
8. IV Fluids: IV D5 ½ NS at 100-125 cc/hr (maintain urine output of 80 mL/h)
9. Special Medications:
   - Cefazolin (Ancef) 1-2 gm IV q8h
   - Mephenidine (Demerol) 75-100 mg and hydroxyzine 25 mg IM/IV q2-4h pm pain OR
   - Butorphanol (Stadol) 0.5-2 mg IV q3-4h.
   - Hydromorphone (Dilaudid) 0.05-0.2 mg PO q3-4h.
   - Oxycodone/acetaminophen (Percocet) 1 tab q6h pm pain
   - Acetaminophen with codeine (Tylenol 3) 1-2 tabs PO q3-4h pm pain
   - Ketorolac (Toradol) 10 mg PO q4-6h pm pain, or 30-60 mg IV/IM then 15-30 mg IV/IM q6h (max 5 days).
   - Zolpidem (Ambien) 10 mg PO qhs pm insomnia.
10. Extras: Intravenous pyelogram, KUB, CXR, ECG.

Hypercalcemia

1. Admit to:
2. Diagnosis: Hypercalcemia
3. Condition:
4. Vital Signs: q4h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C; or tetany or any
abnormal mental status.
5. **Activity:** Encourage ambulation; up in chair at other times.
6. **Nursing:** Seizure precautions, measure inputs and outputs.
7. **Diet:** Restrict dietary calcium to 400 mg/d, push PO fluids.
8. **Special Medications:**
   - 1-2 L of 0.9% saline over 1-4 hours until no longer hypotensive, then saline diuresis with 0.9% saline infused at 125 cc/h **AND**
   - Furosemide (Lasix) 20-80 mg IV q4-12h. Maintain urine output of 200 mL/h, monitor serum sodium, potassium, magnesium.
   - Calcitonin (Calcimar) 4-8 IV kg IM q12h or SQ q8-12h.
   - Etodronate (Didronel) 7.5 mg/kg/day in 250 mL of normal saline IV infusion over 2 hours. Repeat on 3 days.
   - Pamidronate (Aredia) 60 mg in 1 liter of NS infused over 4 hours or 90 mg in 1 liter of NS infused over 24 hours x one dose.
9. **Extras:** CXR, ECG, mammogram.
10. **Labs:** Total and ionized calcium, parathyroid hormone, SMA 7&12, phosphate, Mg, alkaline phosphatase, prostate specific antigen and carcinoembryonic antigen. 24h urine calcium, phosphate.

**Hypocalcemia**
1. **Admit to:**
2. **Diagnosis:** Hypocalcemia
3. **Condition:**
4. **Vital Signs:** q4h. Call physician if BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C; or any abnormal mental status.
5. **Activity:** Up ad lib
6. **Nursing:** I and O.
7. **Diet:** No added salt diet.
8. **Special Medications:**
   - Symptomatic Hypocalcemia:
     - Calcium chloride, 10% (270 mg calcium/10 mL vial) give 5-10 mL slowly over 10 min or dilute in 50-100 mL of D5W and infuse over 20 min, repeat q20-30 min if symptomatic, or hourly if asymptomatic. Correct hyperphosphatemia before hypocalcemia **OR**
     - Calcium gluconate, 20 mL of 10% solution IV (2 vials)/90 mg elemental calcium/10 mL vial) infused over 10-15 min, followed by infusion of 60 mL of calcium gluconate in 500 cc of D5W (1 mg/mL) at 0.5-2.0 mg/kg/h.
   - Chronic Hypocalcemia:
     - Calcium carbonate with vitamin D (Oscal-D) 1-2 tab PO tid **OR**
     - Calcium carbonate (Oscal) 1-2 tab PO tid **OR**
     - Calcium citrate (Citracal) 1 tab PO q8h or Extra strength Tums 1-2 PO with meals.
     - Vitamin D2 (Ergocalciferol) 1 tab PO qd.
     - Calcitriol (Rocaltril) 0.25 mcg PO qd, titrate up to 0.5-2.0 mcg qd.
     - Docusate sodium (Colace) 1 tab PO bid.
9. **Extras:** CXR, ECG.
10. **Labs:** SMA 7&12, phosphate, Mg. 24h urine calcium, potassium, phosphate, magnesium.

**Hyperkalemia**
1. **Admit to:**
2. **Diagnosis:** Hyperkalemia
3. **Condition:**
4. **Vital Signs:** q4h. Call physician if QRS complex >0.14 sec or BP >160/90, <90/60; P >120, <50; R>25, <10; T >38.5°C.
5. **Activity:** Bed rest; up in chair as tolerated.
6. **Nursing:** Inputs and outputs. Chart QRS complex width q1h.
7. **Diet:** Regular, no salt substitutes.
8. **IV Fluids:** D5NS at 125 cc/h
9. **Special Medications:**
   - Consider discontinuing ACE inhibitors, angiotensin II receptor blockers, beta-blockers, potassium sparing diuretics.
   - Sodium bicarbonate 1 amp (50 mEq) IV over 5 min (give after calcium in separate IV).
   - Regular insulin 10 units IV push with 1 ampule of 50% glucose IV push.
   - Kayexalate 30-45 gm premixed in sorbitol solution PO/NG/PR now and in q3-4h prn.
   - Furosemide 40-80 mg IV, repeat prn.
   - Consider emergent dialysis if cardiac complications or renal failure.
10. **Extras:** ECG.
11. **Labs:** CBC, platelets, SMA7, magnesium, calcium, SMA-12, UA, urine specific gravity, urine sodium, pH, 24h urine potassium, creatinine.
**Hypokalemia**

1. **Admit to:**
2. **Diagnosis:** Hypokalemia
3. **Condition:**
4. **Vital Signs:** Vitals, urine output q4h. Call physician if BP >160/90, <90/60; P>120, <50; R>25, <10; T >38.5°C.
5. **Activity:** Bed rest; up in chair as tolerated.
6. **Nursing:** Inputs and outputs
7. **Diet:** Regular
8. **Special Medications:**
   - **Acute Therapy:**
     - KCL 20-40 mEq in 100 cc saline infused IVPB over 2 hours; or add 40-80 mEq to 1 liter of IV fluid and infuse over 4-8 hours.
     - KCL elixir 40 mEq PO tid (in addition to IV); max total dose 100-200 mEq/d (3 mEq/kg/d).
   - **Chronic Therapy:**
     - Micro-K 10 mEq tabs 2-3 tabs PO tid after meals (40-100 mEq/d) OR
     - K-Dur 20 mEq tabs 1 PO bid-tid.

**Hypokalemia with metabolic acidosis:**
- Potassium citrate 15-30 mL in juice PO qid after meals (1 mEq/mL).
- Potassium gluconate 15 mL in juice PO qid after meals (20 mEq/15 mL).

9. **Extras:** ECG, dietetics consult.
10. **Labs:** CBC, magnesium, SMA 7&12, UA, urine Na, pH, 24h urine for K, creatinine.

**Hypermagnesemia**

1. **Admit to:**
2. **Diagnosis:** Hypermagnesemia
3. **Condition:**
4. **Vital Signs:** q6h. Call physician if QRS >0.14 sec.
5. **Activity:** Up ad lib
6. **Nursing:** Inputs and outputs, daily weights.
7. **Diet:** Regular
8. **Special Medications:**
   - Saline diuresis 0.9% saline infused at 100-200 cc/h to replace urine loss AND
   - Calcium chloride, 1-3 gm added to saline (10% sln; 1 gm per 10 mL amp) to run at 1 gm/hr AND
   - Furosemide (Lasix) 20-40 mg IV q4-6h as needed.
   - Magnesium of >9.0 requires stat hemodialysis because of risk of respiratory failure.
9. **Extras:** ECG
10. **Labs:** Magnesium, calcium, SMA 7&12, creatinine. 24 hour urine magnesium, creatinine.

**Hypomagnesemia**

1. **Admit to:**
2. **Diagnosis:** Hypomagnesemia
3. **Condition:**
4. **Vital Signs:** q6h
5. **Activity:** Up ad lib
6. **Diet:** Regular
7. **Special Medications:**
   - Magnesium sulfate 4-6 gm in 500 mL D5W IV at 1 gm/hr. Hold if no patellar reflex. (Estimation of Mg deficit = 0.2 x kg weight x desired increase in Mg concentration; give deficit over 2-3d) OR
   - Magnesium sulfate (severe hypomagnesemia <1.0) 1-2 gm (2-4 mL of 50% sln) IV over 15 min, OR
   - Magnesium chloride (Slow-Mag) 65-130 mg (1-2 tabs) PO tid-qid (64 mg or 5.3 mEq/tab) OR
   - Milk of magnesia 5 mL PO qid-qid.
8. **Extras:** ECG
9. **Labs:** Magnesium, calcium, SMA 7&12, creatinine. 24h urine magnesium, creatinine.

**Hypernatremia**

1. **Admit to:**
2. **Diagnosis:** Hypernatremia
3. **Condition:**
4. **Vital Signs:** q2-8h. Call physician if BP >160/90, <70/50; P >140, <50; R>25, <10; T >38.5°C.
5. **Activity:** Bed rest; up in chair as tolerated.
6. **Nursing:** Inputs and outputs, daily weights.
7. **Diet:** No added salt.
8. **Special Medications:**
   - **Hypernatremia with Hypovolemia:**
     - If volume depleted, give 1-2 L NS IV over 1-3 hours until not orthostatic, then give DSW IV or PO to replace half of body water deficit over first 24 hours (attempt to correct sodium at 1 mEq/L/h), then remaining deficit over next 1-2 days.
     - Body water deficit (L) = \( \frac{0.6(\text{weight kg})(\text{Na serum}-140)}{140} \)

9. **Extras:** CXR, ECG.
10. **Labs:** SMA 7&12, serum osmolality, liver panel, ADH, plasma renin activity. UA, urine specific gravity. Urine
Hyponatremia

1. Admit to:
2. Diagnosis: Hyponatremia
3. Condition:
4. Vital Signs: q4h. Call physician if BP >160/90, <70/50; P >140, <50; R >25, <10; T >38.5°C.
5. Activity: Up in chair as tolerated.
7. Diet: Regular diet.
8. Special Medications:
   - Hyponatremia with Hypervolemia and Edema (low osmolality <280, UNa <10 mmol/L; nephrosis, heart failure, cirrhosis):
     - Water restrict to 0.5-1.0 L/d.
     - Furosemide 40-80 mg IV or PO qd-bid.
   - Hyponatremia with Normal Volume Status (low osmolality <280, UNa <10 mmol: water intoxication; UNa >20: SIADH, diuretic-induced):
     - Water restrict to 0.5-1.5 L/d.
   - Hyponatremia with Hypovolemia (low osmolality <280
     UNa <10 mmol/L: vomiting, diarrhea, third space/respiratory/skin loss; UNa >20 mmol/L: diuretics, renal injury, RTA, adrenal insufficiency, partial obstruction, salt wasting:
      - If volume depleted, give 0.5-2 L of 0.9% saline over 1-2 hours until no longer hypotensive, then 0.9% saline at 125 mL/h or 100-500 mL 3% hypertonic saline over 4h.

Severe Symptomatic Hyponatremia:
   - If volume depleted, give 1-2 L of 0.9% saline (154 mEq/L) over 1-2 hours until no longer orthostatic.
   - Determine volume of 3% hypertonic saline (513 mEq/L) to be infused:
     \[ \text{Na (mEq) deficit} = 0.6 \times (\text{wt kg}) \times (\text{desired [Na]} - \text{actual [Na]}) \]
     \[ \text{Volume of sln (L)} = \frac{\text{Sodium to be infused (mEq)}}{\text{Number of hrs} \times (\text{mEq/L in sln}) \times \text{Number of hrs}} \]
   - Correct half of sodium deficit intravenously over 24 hours until serum sodium is 120 mEq/L; increase sodium by 12-20 mEq/L over 24 hours (1 mEq/L/h).
   - Alternate Method: 3% saline 100-300 mL over 4-6h, repeated as needed.

9. Extras: CXR, ECG, head/chest CT scan.
10. Labs: SMA 7&12, osmolality, triglyceride, liver panel.

Hyperphosphatemia

1. Admit to:
2. Diagnosis: Hyperphosphatemia
3. Condition:
4. Vital Signs: qid
5. Activity: Up ad lib
6. Nursing: Inputs and outputs
7. Diet: Low phosphorus diet with 0.7-1 gm/d
8. Special Medications:
   - Moderate Hyperphosphatemia:
     - Restrict dietary phosphate to 0.7-1.0 gm/d.
     - Calcium acetate (PhosLo) 1-3 tabs PO tid with meals, OR
     - Aluminum hydroxide (Amphojel) 5-10 mL or 1-2 tablets PO before meals tid.
   - Severe Hyperphosphatemia:
     - Volume expansion with 0.9% saline 1-2 L over 1-2h.
     - Acetazolamide (Diamox) 500 mg PO or IV q6h.
     - Consider dialysis.

9. Extras: CXR PA and LAT, ECG.
10. Labs: Phosphate, SMA 7&12, magnesium, calcium.

Hypophosphatemia

1. Admit to:
2. Diagnosis: Hypophosphatemia
3. Condition:
4. Vital Signs: qid
5. Activity: Up ad lib
6. Nursing: Inputs and outputs
7. Diet: Regular diet.
8. Special Medications:
   - Mild to Moderate Hypophosphatemia (1.0-2.2 mg/dL):
     - Sodium or potassium phosphate 0.25 mmoles/kg in 150-250 mL of NS or D5W at 10 mmoles/h.
     - Neutral phosphate (Nutra-Phos), 2 tab PO bid (250 mg elemental phosphorus/tab) OR
     - Phospho-Soda 5 mL (129 mg phosphorus) PO bid-tid.
   - Severe Hypophosphatemia (<1.0 mg/dL):
     - Na or K phosphate 0.5 mmoles/kg in 250 mL D5W or NS, IV infusion at 10 mmoles/hr OR
     - Add potassium phosphate to IV solution in place of maintenance KCL; max IV dose 7.5 mg phosphorus/kg/h.

9. Extras: CXR PA and LAT, ECG.
10. Labs: Phosphate, SMA 7&12, Mg, calcium, UA.
Rheumatologic Disorders

Systemic Lupus Erythematosus

1. Admit to:
2. Diagnosis: Systemic Lupus Erythematosus
3. Condition:
4. Vital Signs: tid
5. Allergies:
6. Activity: As tolerated with bathroom privileges
7. Nursing:
8. Diet: No added salt, low psoralen diet.
9. Special Medications:
   - Ibuprofen (Motrin) 400 mg PO qid (max 2.4 g/d) OR
   - Indomethacin (Indocin) 25-50 mg tid-qid.
   - Hydroxychloroquine (Plaquenil) 200-600 mg/d PO
   - Prednisone 60-100 mg PO qd, may increase to 200-300 mg/d. Maintenance 10-20 mg PO qd or 20-40 mg PO QOD OR
   - Methylprednisolone (pulse therapy) 500 mg IV over 30 min q12h for 3-5d, then prednisone 50 mg PO qd.
   - Betamethasone dipropionate (Diprolene) 0.05% ointment applied bid.
10. Extra:
11. Labs: CBC, platelets, SMA 7&12, INR/PTT, ESR, complement CH-50, C3, C4, C-reactive protein, LE prep, Coombs test, VDRL, rheumatoid factor, ANA, DNA binding, lupus anticoagulant, anticardiolipin, antinuclear cytoplasmic antibody, UA.

Acute Gout Attack

1. Admit to:
2. Diagnosis: Acute gout attack
3. Condition:
4. Vital Signs: tid
5. Activity: Bed rest with bedside commode
6. Nursing: Keep foot elevated; support sheets over foot; guaiac stools.
7. Diet: Low purine diet.
8. Special Medications:
   - Ibuprofen (Motrin) 800 mg, then 400-800 mg PO q4-6h OR
   - Diclofenac (Voltaren) 25-75 mg tid-qid with food OR
   - Indomethacin (Indocin) 25-50 mg PO qid for 2d, then 50 mg tid for 2 days, then 25 mg PO tid OR
   - Ketorolac (Toradol) 30-60 mg IVIM, then 15-30 mg IVIM q4h or 10 mg PO tid-qid OR
   - Naproxen sodium (Anaprox, Anaprox-DS) 550 mg PO bid OR
   - Methylprednisolone (SoluMedrol) 125 mg IV x 1 dose THEN
   - Prednisone 60 mg PO qd for 5 days, followed by tapering.
   - Colchicine 2 tablets (0.5 mg or 0.6 mg), followed by 1 tablet q1h until relief, max dose of 9.6 mg/24h.
   - Hypouricemic Therapy:
   - Probenecid (Benemid), 250 mg bid. Increase the dosage to 500 mg bid after 1 week, then increase by 500-mg increments every 4 weeks until the uric acid level is below 6.5 mg/dL. Max dose 2 g/d. Contraindicated during acute attack.
   - Allopurinol (Zyloprim) 300 mg PO qd, may increase by 100-300 mg q2weeks. Usually initiated after the acute attack.
9. Symptomatic Medications:
   - Famotidine (Pepcid) 20 mg IV/PO q12h.
   - Metoprolol (Demerol) 50-100 mg IM/IV q4-6h pm pain OR
   - Acetaminophen (Tylenol) 325-650 mg PO q4-6h pm pain.
   - Zolpidem (Ambien) 5-10 mg qhs pm insomnia.
General Pediatrics

Pediatric History and Physical Examination

History

Identifying Data: Patient's name; age, sex. List the patient's significant medical problems. Name and relationship to child of informant (patient, parent).

Chief Complaint: Reason given for seeking medical care and the duration of the symptom(s).

History of Present Illness (HPI): Describe the course of the patient's illness, including when it began, character of the symptom(s); aggravating or alleviating factors; pertinent positives and negatives. Past diagnostic testing.

Past Medical History (PMH): Past diseases, surgeries, hospitalizations; medical problems; history of asthma.

Birth History: Gestational age at birth, preterm, obstetrical problems.

Developmental History: Motor skills, language development, self-care skills.

Medications: Include prescription and OTC drugs, vitamins, herbal products, natural remedies, nutritional supplements.

Feeding: Diet, volume of formula per day.

Immunizations: Up-to-date?

Drug Allergies: Penicillin, codeine?

Food Allergies:

Family History: Medical problems in family, including the patient's disorder. Asthma, cancer, tuberculosis, allergies.

Social History: Family situation, alcohol, smoking, drugs. Level of education.

Review of Systems (ROS):

General: Weight loss, fever, chills, fatigue, night sweats.

Skin: Rashes, skin discolorations.

Head: Headaches, dizziness, seizures.

Eyes: Visual changes.

Ears: Tinnitus, vertigo, hearing loss.

Nose: Nose bleeds, discharge.

Mouth and Throat: Dental disease, hoarseness, throat pain.

Respiratory: Cough, shortness of breath, sputum (color and consistency).

Cardiovascular: Dyspnea on exertion, edema, valvular disease.

Gastrointestinal: Abdominal pain, vomiting, diarrhea, constipation.

Genitourinary: Dysuria, frequency, hematuria.

Gynecological: Last menstrual period (frequency, duration), age of menarche; dysmenorrhea, contraception, vaginal bleeding, breast masses.

Endocrine: Polyuria, polydipsia.

Musculoskeletal: Joint pain or swelling, arthritis, myalgias.

Skin and Lymphatics: Easy bruising, lymphadenopathy.

Neuropsychiatric: Weakness, seizures.

Pain: quality (sharp/stabbing, aching, pressure), location, duration

Physical Examination

General appearance: Note whether the patient looks “ill,” well, or malnourished.

Physical Measurements: weight, height, head circumference (plot on growth charts).

Vital Signs: Temperature, heart rate, respiratory rate, blood pressure.

Skin: Rashes, scars, moles, skin turgor, capillary refill (in seconds).

Lymph Nodes: Cervical, axillary, inguinal nodes: size, tenderness.

Head: Bruising, masses, fontanels.

Eyes: Pupils: equal, round, and reactive to light and accommodation (PERRLA); extra ocular movements intact (EOMI). Funduscopy (papilledema, hemorrhages, exudates).

Ears: Acuity, tympanic membranes (dull, shiny, intact, infected, bulging).

Mouth and Throat: Mucus membrane color and moisture; oral lesions, dentition, pharynx, tonsils.

Neck: Thyromegaly, lymphadenopathy, masses.

Chest: Equal expansion, rhonchi, crackles, rubs, breath sounds.

Heart: Regular rate and rhythm (RRR), first and second heart sounds (S1, S2); gallops (S3, S4), murmurs (grade 1-6), pulses (graded 0-2+).

Breast: Discharge, masses; axillary masses.

Abdomen: Bowel sounds, bruits, tenderness, masses; hepatomegaly, splenomegaly; guarding, rebound, percussion note ( tympanic), suprapubic tenderness.

Genitourinary: Inginal masses, hernias, scrotum, testicles.

Pelvic Examination: Vaginal mucosa, cervical discharge, uterine size, masses, adnexal masses, ovaries.

Extremities: Joint swelling, range of motion, edema (grade 1-4+); cyanosis, clubbing, edema (CCE); pulses.

Rectal Examination: Sphincter tone, masses, fissures; test for occult blood

Neurological: Mental status and affect; gait, strength
Sensation, deep tendon reflexes (biceps, triceps, patellar, ankle; graded 0-4+).

Labs: Electrolytes (sodium, potassium, bicarbonate, chloride, BUN, creatinine), CBC (hemoglobin, hematocrit, WBC count, platelets, differential), x-rays, ECG, urine analysis (UA), liver function tests (LFTs).

Assessment (Impression): Assign a number to each problem and discuss separately. Discuss differential diagnosis and give reasons that support the working diagnosis; give reasons for excluding other diagnoses.

Plan: Describe therapeutic plan for each numbered problem, including testing, laboratory studies, medications.

Progress Notes

Daily progress notes should summarize developments in a patient’s hospital course, problems that remain active, plans to treat those problems, and arrangements for discharge. Progress notes should address every element of the problem list.

<table>
<thead>
<tr>
<th>Example Progress Note</th>
</tr>
</thead>
</table>
| Date/time: Identify Discipline and Level of Education: e.g. Pediatric resident PL-3
| Subjective: Any problems and symptoms of the patient should be charted. Appetite, pain, or fussiness may be included.
| Objective: General appearance, Vitals, including highest temperature (Tmax) over past 24 hours. Feedings, fluid inputs and outputs (I/O), including oral and parenteral intake and urine and stool volume output. Physical exam, including chest and abdomen, with particular attention to active problems. Emphasize changes from previous physical exams.
| Labs: Include new test results and flag abnormal values.
| Current Medications: List all medications and dosages.
| Assessment and Plan: This section should be organized by problem. A separate assessment and plan should be written for each problem.

Discharge Note

The discharge note should be written in the patient’s chart prior to discharge.

<table>
<thead>
<tr>
<th>Discharge Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date/time: Diagnoses: Treatment: Briefly describe treatment provided during hospitalization, including surgical procedures and antibiotic therapy. Studies Performed: Electrocardiograms, CT scans. Discharge Medications: Follow-up Arrangements:</td>
</tr>
</tbody>
</table>

Prescription Writing

- Patient’s name:
- Date:
- Drug name, dosage form, dose, route, frequency (include concentration for oral liquids or mg strength for oral solids): Amoxicillin 125mg/5mL 5 mL PO tid
- Quantity to dispense: mL for oral liquids, # of oral solids
- Refills: If appropriate
- Signature
Procedure Note

A procedure note should be written in the chart after a procedure is performed (e.g. lumbar puncture).

<table>
<thead>
<tr>
<th>Procedure Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date and time:</td>
</tr>
<tr>
<td>Procedure:</td>
</tr>
<tr>
<td>Indications:</td>
</tr>
<tr>
<td>Patient Consent: Document that the indications, risks and alternatives to the procedure were explained to the parents and patient. Note that the parents and the patient were given the opportunity to ask questions and that the parents consented to the procedure in writing.</td>
</tr>
<tr>
<td>Lab tests: Relevant labs, such as the CBC</td>
</tr>
<tr>
<td>Anesthesia: Local with 2% lidocaine</td>
</tr>
<tr>
<td>Description of Procedure: Briefly describe the procedure, including sterile prep, anesthesia method, patient position, devices used, anatomic location of procedure, and outcome.</td>
</tr>
<tr>
<td>Complications and Estimated Blood Loss (EBL):</td>
</tr>
<tr>
<td>Disposition: Describe how the patient tolerated the procedure.</td>
</tr>
<tr>
<td>Specimens: Describe any specimens obtained and labs tests which were ordered.</td>
</tr>
</tbody>
</table>

Developmental Milestones

<table>
<thead>
<tr>
<th>Age</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month</td>
<td>Raises head slightly when prone; alerts to sound; regards face, moves extremities equally.</td>
</tr>
<tr>
<td>2-3 months</td>
<td>Smiles, holds head up, coos, reaches for familiar objects, recognizes parent.</td>
</tr>
<tr>
<td>4-5 months</td>
<td>Rolls front to back and back to front; sits well when propped; laughs, orients to voice; enjoys looking around; grasps rattle, bears some weight on legs.</td>
</tr>
<tr>
<td>6 months</td>
<td>Sits unsupported; passes cube hand to hand; babbles; uses raking grasp; feeds self crackers.</td>
</tr>
<tr>
<td>8-9 months</td>
<td>Crawls, cruises; pulls to stand; pincer grasp; plays pat-a-cake; feeds self with bottle; sits without support; explores environment.</td>
</tr>
<tr>
<td>12 months</td>
<td>Walking, talking a few words; understands &quot;no&quot;; says &quot;mama/dada&quot; discriminantly; throws objects; imitates actions, marks with crayon, drinks from a cup.</td>
</tr>
<tr>
<td>15-18 months</td>
<td>Comes when called; scribbles; walks backward; uses 4-20 words; builds tower of 2 blocks.</td>
</tr>
<tr>
<td>24-30 months</td>
<td>Removes shoes; follows 2 step command; jumps with both feet; holds pencil, knows first and last name; knows pronouns. Parallel play; points to body parts, runs, spoon feeds self, copies parents.</td>
</tr>
<tr>
<td>3 years</td>
<td>Dresses and undresses; walks up and down steps; draws a circle; uses 3-4 word sentences; takes turns; shares. Group play.</td>
</tr>
<tr>
<td>4 years</td>
<td>Hops, skips, catches ball; memorizes songs; plays cooperatively; knows colors; copies a circle; uses plurals.</td>
</tr>
<tr>
<td>5 years</td>
<td>Jumps over objects; prints first name; knows address and mother’s name; follows game rules; draws three part man; hops on one foot.</td>
</tr>
</tbody>
</table>

Immunizations

<table>
<thead>
<tr>
<th>Immunization Schedule for Infants and Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>Birth - 2 mo</td>
</tr>
<tr>
<td>1-4 mo</td>
</tr>
<tr>
<td>2 mo</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>4 mo</td>
</tr>
</tbody>
</table>
| 6 mo      | DTaP, (Hib), PCV | Dose 3 of Hib is not indicated if the product for doses 1 and 2 was PevaxHIB.
| 6-18 mo   | HBV, IPV       | The third HBV dose should be administered at least 4 months after the first dose and at least 2 months after the second dose. For infants of HbsAg positive or unknown status mothers, the third dose should be given at 6 months of age. |
| 12-15 mo  | Hib, PCV, MMR, VAR | Tuberculin testing may be done at the same visit if indicated. Varicella vaccine is recommended in children who do not have a reliable history of having had the clinical disease. |
| 15-18 mo  | DTaP           | The 4th dose of DTaP should be given 6-12 mo after the third dose of DTaP and may be given as early as 12 mo, provided that the interval between doses 3 and 4 is at least 6 mo. |
| 4-6 yr    | DTaP, IPV, MMR | DTaP and IPV should be given at or before school entry. DTaP should not be given after the 7th birthday. |
| 11-12 yr  | MMR           | Omit if MMR dose was given at age 4-6 years. |
| 14-16 yr  | Td            | Repeat every 10 yrs throughout life |

HBV = Hepatitis B virus vaccine; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; IPV = inactivated polio vaccine; MMR = live measles, mumps, and rubella viruses vaccine; PCV = pneumococcal conjugate vaccine (Prevnar); Td = adult tetanus toxoid (full dose) and diphtheria toxoid (reduced dose), for children >7 yr and adults; VAR = varicella virus vaccine

Recommended Schedule for Children Younger than 7 Years Not Immunized in the First Year of Life

<table>
<thead>
<tr>
<th>Age</th>
<th>Immunizations</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>First visit</td>
<td>DTaP, (Hib), HBV, MMR, IPV (PCV), VAR</td>
<td>If indicated, tuberculin testing may be done at the same visit. If child is &gt;6 yrs, Hib is not indicated. PCV recommended for all children &lt;2 yrs or 24-59 months of age and at high risk for invasive pneumococcal disease (e.g. sickle cell anemia, HIV, immunocompromised). Varicella vaccine if child has not had varicella disease.</td>
</tr>
<tr>
<td>Interval after 1st visit</td>
<td>DTaP, HBV</td>
<td>Second dose of Hib is indicated only if first dose was received when &lt;15 months. Second dose of PCV 6-8 weeks after first dose (if criteria met above).</td>
</tr>
<tr>
<td>1 month</td>
<td>DTaP, Hib, IPV (PCV)</td>
<td>DTaP, HBV, IPV</td>
</tr>
<tr>
<td>2 months</td>
<td>DTaP, IPV, MMR</td>
<td>DTaP is not necessary if the fourth dose was given after the fourth birthday. IPV is not necessary if the third dose was given after the fourth birthday.</td>
</tr>
<tr>
<td>4-6 years (at or before school entry)</td>
<td>DTaP, IPV, MMR</td>
<td>MMR should be given at entry to middle school or junior high school if it wasn’t given at age 4-6 years.</td>
</tr>
</tbody>
</table>
| 11-12 yr | MMR | Td | Repeat every 10 yrs
HBV = Hepatitis B virus vaccine; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; IPV = inactivated polio vaccine; MMR = live measles, mumps, and rubella viruses vaccine; PCV = pneumococcal conjugate vaccine (Prevnar); Td = adult tetanus toxoid (full dose) and diphtheria toxoid (reduced dose), for children >7 yr and adults; VAR = varicella virus vaccine

**Recommended Schedule for Children >7 Years Who Were Not Immunized Previously**

<table>
<thead>
<tr>
<th>Age</th>
<th>Immunizations</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>First visit</td>
<td>HBV, IPV, MMR, Td, VAR</td>
<td>Varicella vaccine if child has not had varicella disease.</td>
</tr>
<tr>
<td>Interval after First visit 2 months</td>
<td>HBV, IPV, Td, VAR, MMR</td>
<td>If child is &gt;13 years old, a second varicella vaccine dose is needed 4-8 weeks after the first dose.</td>
</tr>
<tr>
<td>8-14 months</td>
<td>HBV, Td, IPV</td>
<td>If child is &gt;13 years old, a second varicella vaccine dose is needed 4-8 weeks after the first dose.</td>
</tr>
<tr>
<td>11-12 yrs old</td>
<td>MMR</td>
<td>Omit if MMR dose was given at age 4-6 years.</td>
</tr>
<tr>
<td>10 yr later</td>
<td>Td</td>
<td>Repeat every 10 years</td>
</tr>
</tbody>
</table>

HBV = Hepatitis B virus vaccine; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; IPV = inactivated polio vaccine; MMR = live measles, mumps, and rubella viruses vaccine; PCV = pneumococcal conjugate vaccine (Prevnar); Td = adult tetanus toxoid (full dose) and diphtheria toxoid (reduced dose), for children >7 yr and adults; VAR = varicella virus vaccine

**Haemophilus Immunization**

**H influenzae type b Vaccination in Children Immunized Beginning at 2 to 6 Months of Age**

<table>
<thead>
<tr>
<th>Vaccine Product</th>
<th>Total Number of Doses</th>
<th>Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>PedvaxHIB (PRP-OMP)</td>
<td>3</td>
<td>2 doses two months apart plus booster at 12-15 months which must be at least two months after previous dose. Any vaccine may be used for the booster.</td>
</tr>
<tr>
<td>HibTITER (HbOC), ActHIB (PRP-T), OmniHIB (PRP-T)</td>
<td>4</td>
<td>3 doses two months apart plus booster at 12-15 months which must be at least two months after previous dose. Any vaccine may be used for the booster.</td>
</tr>
</tbody>
</table>

**H influenzae type b Vaccination When the Initial Vaccination was Delayed Until 7 Months of Age or Older**

<table>
<thead>
<tr>
<th>Age at Initiation</th>
<th>Vaccine Product</th>
<th>Total Doses</th>
<th>Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-11 mo</td>
<td>any vaccine (PedvaxHIB or HibTITER or ActHIB or OmniHIB)</td>
<td>3</td>
<td>2 doses at 2-month intervals plus booster at 12-18 months (at least 2 months after previous dose)</td>
</tr>
<tr>
<td>12-14 mo</td>
<td>any vaccine</td>
<td>2</td>
<td>2 doses 2 months apart</td>
</tr>
<tr>
<td>15-59 mo</td>
<td>any vaccine</td>
<td>1</td>
<td>Single dose of any product</td>
</tr>
<tr>
<td>&gt;5 years</td>
<td>Any vaccine</td>
<td>1</td>
<td>Only recommended for children with chronic illness known to be associated with an increased risk for H flu disease.</td>
</tr>
</tbody>
</table>
Varicella Immunization

Indications for Varicella Immunization:

A. Age 12 to 18 months: One dose of varicella vaccine is recommended for universal immunization for all healthy children who lack a reliable history of varicella.

B. Age 19 months to the 13th birthday: Vaccination of susceptible children is recommended and may be given any time during childhood but before the 13th birthday because of the potential increased severity of natural varicella after this age. Susceptible is defined by either lack of proof of either varicella vaccination or a reliable history of varicella. One dose is recommended.

C. Healthy adolescents and young adults: Healthy adolescents past their 13th birthday who have not been immunized previously and have no history of varicella infection should be immunized against varicella by administration of two doses of vaccine 4 to 8 weeks apart. Longer intervals between doses do not necessitate a third dose, but may leave the individual unprotected during the intervening months.

D. All susceptible children aged 1 year to 18 years old who are in direct contact with people at high risk for varicella related complications (eg, immunocompromised individuals) and who have not had a documented case of varicella.

Influenza Immunization

Indications for Influenza Vaccination

A. Targeted high-risk children and adolescents (eg, chronic pulmonary disease including asthma, sickle cell anemia, HIV infection).

B. Other high-risk children and adolescents (eg, diabetes mellitus, chronic renal disease, chronic metabolic disease).

C. Close contacts of high risk patients.

D. Foreign travel if exposure is likely.

Vaccine Administration. Administer in the Fall, usually October 1 - November 15, before the start of the influenza season.

<table>
<thead>
<tr>
<th>Age</th>
<th>Vaccine Type</th>
<th>Dosage (mL)</th>
<th>Number of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-35 months</td>
<td>Split virus only</td>
<td>0.25</td>
<td>1-2*</td>
</tr>
<tr>
<td>3-8 yrs</td>
<td>Split virus only</td>
<td>0.5</td>
<td>1-2*</td>
</tr>
<tr>
<td>9-12 yrs</td>
<td>Split virus only</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>&gt; 12 yrs</td>
<td>Whole or split virus</td>
<td>0.5</td>
<td>1</td>
</tr>
</tbody>
</table>

*Two doses administered at least one month apart are recommended for children who are receiving influenza vaccine for the first time.
Pediatric Symptomatic Care

**Antipyretics**

Analgesics/Antipyretics:
- Acetaminophen (Tylenol) 10-20 mg/kg/dose PO/PR q4-6h, max 5 doses/day or 80 mg/kg/day or 4 gm/day (whichever is smaller) OR
- Acetaminophen dose by age (if weight appropriate for age):
  
<table>
<thead>
<tr>
<th>Age</th>
<th>mg/dose PO/PR q4-6h prn:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3 mo</td>
<td>40 mg/dose</td>
</tr>
<tr>
<td>4-11 mo</td>
<td>80 mg/dose</td>
</tr>
<tr>
<td>1-2 yr</td>
<td>120 mg/dose</td>
</tr>
<tr>
<td>2-3 yr</td>
<td>160 mg/dose</td>
</tr>
<tr>
<td>4-5 yr</td>
<td>240 mg/dose</td>
</tr>
<tr>
<td>6-8 yr</td>
<td>320 mg/dose</td>
</tr>
<tr>
<td>9-10 yr</td>
<td>400 mg/dose</td>
</tr>
<tr>
<td>11-12 yr</td>
<td>480 mg/dose</td>
</tr>
<tr>
<td>&gt;12 yr</td>
<td>325-650 mg/dose</td>
</tr>
</tbody>
</table>

- Preparations: caplets: 160, 500 mg; caplet, ER: 650 mg; drops: 80 mg/0.8 mL; elixir: 80 mg/2.5 mL, 80 mg/5 mL, 120 mg/5 mL, 160 mg/5 mL, 325 mg/5 mL, 500 mg/15 mL; suppositories: 80, 120, 325, 650 mg; tabs: 325, 500 mg; tabs, chewable: 80, 120, 160 mg.

- Ibuprofen (Motrin, Advil, Nuprin, Medipren, Children's Motrin)
  
  - Analgesic: 4-10 mg/kg/dose PO q6-8h prn
  - Antipyretic: 5-10 mg/kg/dose PO q6-8h.

  - Preparations: cap: 200 mg; caplet: 100 mg; oral drops: 40 mg/mL; sus: 100 mg/5 mL; tabs: 100, 200, 300, 400, 600, 800 mg; tabs, chewable: 50, 100 mg.

May cause GI distress, bleeding.

**Antitussives, Decongestants, Expectorants, and Antihistamines**

Antihistamines:
- Brompheniramine (Dimetane) [elixir: 2 mg/5 mL; tab: 4, 8, 12 mg; tab, SR: 8, 12 mg] < 6 yr: 0.5 mg/kg/day PO q6h prn (max 8 mg/day)
  
<table>
<thead>
<tr>
<th>Age</th>
<th>mg/dose PO q12h (max 24 mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;6 yr</td>
<td></td>
</tr>
</tbody>
</table>

  - Chlorpheniramine (Chlor-Trimeton) [cap: SR: 8, 12 mg; syrup 2mg/mL; tabs: 4, 8, 12 mg; tab, chew: 2 mg; tab, SR: 8, 12 mg] 2-5 yr: 1 mg PO q4-6h prn
  
<table>
<thead>
<tr>
<th>Age</th>
<th>mg/dose PO q4-6h prn or 8-12 mg SR PO q8-12h</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 yr</td>
<td></td>
</tr>
</tbody>
</table>

- Pseudoephedrine (Sudafed, Novafed): [cap: 60 mg; cap: SR: 120, 240 mg; drops: 7.5 mg/0.8 mL; syrup: 15 mg/5 mL, 30 mg/5 mL, tabs: 30, 60 mg; <2 yr: 4 mg/kg/day PO q6h. 2-5 yr: 15 mg po q6h 6-11 yr: 30 mg po q6h
  
<table>
<thead>
<tr>
<th>Age</th>
<th>mg/dose PO q4-6h prn or sustained release 120 mg PO q12h or sustained release 240 mg PO q24h.</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 yr</td>
<td></td>
</tr>
</tbody>
</table>

- Phenylephrine (Neo-synephrine) [nasal drops: 1/4, 1/2, 1%; nasal spray: 1/4, 1/2, 1%]. Children: Use 1/4 % spray or drops, 1-2 drops/spray in each nostril q3-4h. Adults: Use 1/4-1/2% drops/spray, 1-2 drops/sprays in each nostril q3-4h. Discontinue use after 3 days to avoid rebound congestion.

**Combination Products**

- Actifed [per cap or tab or 10 mL syrup: Triprolidine 2.5 mg, Pseudoephedrine 60 mg]. 4 mth-2 yr: 1.25 mL PO q6-8h 2-4 yr: 2.5 mL PO q6-8h 4-6 yr: 3.75 mL PO q6-8h 6-11 yr: 5 mL or ½ tab PO q6-8h
  
<table>
<thead>
<tr>
<th>Age</th>
<th>mg pseudoephedrine/kg/day PO tid-qid</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 yr</td>
<td></td>
</tr>
</tbody>
</table>

- Actifed with Codeine cough syrup [syrup/5 mL: Codeine 10 mg, Triprolidine 1.25 mg, Pseudoephedrine 30 mg]. 4 mth-2 yr: 1.25 mL PO q6-8h 2-4 yr: 2.5 mL PO q6-8h 2-4 yr: 2.5 mL PO q6-8h
4-6 yr: 3.75 mL PO q6-8h
6-11 yr: 5 mL PO q6-8h
>12 yr: 10 mL PO q6-8h OR
4 mg pseudoephedrine/kg/day PO tid-qid.

-Dimetane Decongestant [cap/cpl or 10 mL: Brompheniramine 4 mg, Phenylephrine 5 mg].
6-11 yr: 5 mL or ½ cap/caplet PO q4-6h pm
>12 yr: 10 mL or 1 cap/caplet PO q4-6h pm

-Dimetane DX [syrup per 5 mL: Brompheniramine 2 mg, Dextromethorphan 10 mg, Pseudoephedrine 30 mg].
2-5 yrs: 2.5 mL PO q4-6h pm
6-11 yr: 5 mL PO q4-6h pm
>12 yrs: 10 mL PO q4-6h pm

-PediaCare Cough-Cold Chewable Tablets: [tab, chew: Pseudoephedrine 15 mg, Chlorpheniramine 1 mg, Dextromethorphan 5 mg].
3-5 yr: 1 tab PO q4-6h prn
6-11 yr: 2 tabs PO q4-6h prn
>12 yr: 4 tabs PO q4-6h prn

-PediaCare Cough-Cold Liquid [liquid per 5 mL: Pseudoephedrine 15 mg, Chlorpheniramine 1 mg, Dextromethorphan 5 mg].
2-5 yr: 2.5 mL PO q4-6h prn
6-11 yr: 5 mL PO q4-6h prn
>12 yr: 10 mL PO q4-6h prn

-Phenergan VC [syrup per 5 mL: Phenylephrine 5 mg, Promethazine 6.25 mg].
2-5 yr: 1.25 mL PO q4-6h pm
6-11 yr: 2.5 mL PO q4-6h pm
>12 yr: 5 mL PO q4-6h pm

-Phenergan with Codeine [syrup per 5 mL: Promethazine 6.25 mg, Codeine 10 mg, Phenylephrine 5 mg].
2-5 yr: 1.25 mL PO q4-6h pm
6-11 yr: 2.5 mL PO q4-6h pm
>12 yr: 5 mL PO q4-6h pm

-Phenergan with Dextromethorphan [syrup per 5 mL: Promethazine 6.25 mg, Dextromethorphan 15 mg].
2-5 yr: 1.25 mL PO q4-6h pm
6-11 yr: 2.5 mL PO q4-6h pm
>12 yr: 5 mL PO q4-6h pm

-Rondec drops [drops per 1 mL: Carbinoxamine maleate 2 mg, Pseudoephedrine 25 mg].
4-5 mg pseudoephedrine/kg/day PO q6h pm OR
1-3 m: 1/4 dropperful (1/4 mL) PO q6h pm
3-6 m: 1/2 dropperful (1/2 mL) PO q6h pm
6-9 m: 3/4 dropperful (0.75 mL) PO q6h pm
9-18 m: 1 dropperful (1 mL) PO q6h pm.

-Rondec syrup [syrup per 5 mL: Pseudoephedrine 60 mg, Carbinoxamine maleate 4 mg].
4-5 mg pseudoephedrine/kg/day PO q6h pm.

- Tylenol Cold Multi-Symptom Plus Cough Liquid, Children’s [liquid per 5 mL: Acetaminophen 160 mg, Chlorpheniramine 1 mg, Pseudoephedrine 15 mg].
2-5 yr: 5 mL PO q4h pm
Analgesia and Sedation

Analgesics/Anesthetic Agents:
- Acetaminophen (Tylenol) 16-15 mg/kg PO/PR q4-6h prn (see page 92 for detailed list of available products)
- Acetaminophen/Codeine [per 5 mL: Acetaminophen 120 mg, Codeine 12 mg; tabs: Tylenol #2: 15 mg codeine/300 mg acetaminophen; #3: 30 mg codeine/300 mg acetaminophen; #4: 60 mg codeine/300 mg acetaminophen]
  - 0.5–1.0 mg codeine/kg/dose PO q4h prn.
- Acetaminophen/Hydrocodone [elixir per 5 mL: hydrocodone 2.5 mg, acetaminophen 187 mg]
  - Ages: 2-5 yr: 2 tabs PO q4h prn
  - Ages: 6-11 yr: 4 tabs PO q4h prn
  - Ages: 12 yr: 4 tabs PO q4h prn
  - Maximum four doses daily.

Sedation:
- Fentanyl and Midazolam Sedation:
  - Fentanyl 1 mcg/kg IV q1-2h prn or 1-3 mcg/kg/hr continuous IV infusion.
  - Hydromorphone (Dilaudid) 0.015 mg/kg IV/IM/SC q3-4h or 0.0075 mg/kg/hr continuous IV infusion titrated as necessary for pain relief or 0.03-0.08 mg/kg PO q6–8h prn.
- Ketamine 4 mg/kg IM or 0.5-1 mg/kg IV. Onset for IV administration is 30 seconds, duration is 5-15 minutes.
- Lidocaine, buffered: Add sodium bicarbonate 1 mEq/mL 1 part to 9 parts lidocaine 1% for local infiltration (eg. 2 mL lidocaine 1% and 0.22 mL sodium bicarbonate 1 mEq/mL) to raise the pH of the lidocaine to neutral and decrease the “sting” of subcutaneous lidocaine.
- Meperidine (Demerol) 1 mg/kg IV q2-3h prn for pain.
- Morphine 0.05–0.1 mg/kg IV q2-4h prn or 0.02–0.06 mg/kg/hr continuous IV infusion or 0.1–0.15 mg/kg IM/SC q3-4h or 0.2–0.5 mg/kg PO q4-6h.

Phenothiazines:
- Promethazine (Phenergan) 0.5-1 mg/kg/dose IM or slow IV over 20 min, max 50 mg/dose.
- Chlorpromazine (Thorazine) 0.5-1 mg/kg/dose IM or slow IV over 20min, max 50 mg/dose.

Antihistamines:
- Diphenhydramine (Benadryl) 1 mg/kg/dose IV/IM/PO, max 50 mg.
- Hydroxyzine (Vistaril) 0.5-1 mg/kg/dose IM/PO, max 50 mg.

Barbiturates:
- Methohexital (Brevital)
  - IM: 5-10 mg/kg
  - IV: 1-2 mg/kg
PR: 25 mg/kg (max 500 mg/dose)
- Thiopental (Pentothal): Sedation, rectal: 5-10 mg/kg; seizures, IV: 2-3 mg/kg

Other Sedatives:
- Chloral hydrate 25-100 mg/kg/dose PO/PR (max 1.5 gm/dose), allow 30 min for absorption.

Nonsteroidal Anti-inflammatory Drugs:
- Ibuprofen (Motrin, Advil, Nuprin, Medipren, Children's Motrin)
  Anti-inflammatory: 30-50 mg/kg/day PO q6h, max 2400 mg/day.
  [cap: 200 mg; caplet: 100 mg; oral drops: 40 mg/mL; susp: 100 mg/5 mL; tabs: 100, 200, 300, 400, 600, 800 mg; tabs, chewable: 50, 100 mg].
- Ketorolac (Toradol)
  Single dose: 0.4-1 mg/kg IV/IM (max 30 mg/dose IV, 60 mg/dose IM)
  Multiple doses: 0.4-0.5 mg/kg IV/IM q6h pm (max 30 mg/dose).
  [inj: 15 mg/mL, 30 mg/mL].
  Do not use for more than three days because of risk of GI bleed.
- Naproxen (Naprosyn)
  Analgesia: 5-7 mg/kg/dose PO q8-12h
  Inflammatory disease: 10-15 mg/kg/day PO q12h, max 1000 mg/day
  [susp: 125 mg/5 mL; tab: 250, 375, 500 mg; tab, DR: 375, 500 mg].
- Naproxen sodium (Aleve, Anaprox, Naprelan)
  Analgesia: 5-7 mg/kg/dose PO q8-12h
  Inflammatory disease: 10-15 mg/kg/day PO q12h, max 1000 mg/day
  [tab: 220, 275, 550 mg; tab, ER: 375, 500, 750 mg]. Naproxen sodium 220 mg = 200 mg base.

Antiemetics
- Chlorpromazine (Thorazine)
  0.25-1 mg/kg/dose slow IV over 20 min/IM/PO q4-8h prn, max 50 mg/dose
  [inj: 25 mg/mL; oral concentrate 30 mg/mL; susp: 25, 50 mg; syrup: 10 mg/5 mL; tabs: 10, 25, 50, 100, 200 mg].
- Diphenhydramine (Benadryl)
  1 mg/kg/dose IM/IV/PO q6h pm, max 50 mg/dose
  [caps: 25, 50 mg; inj: 10 mg/mL, 50 mg/mL; liquid: 12.5 mg/5 mL; tabs: 25, 50 mg].
- Dimenhydrinate (Dramamine)
  >12 yrs: 5 mg/kg/day IM/IV/PO q6h pm, max 300 mg/day
  Not recommended in <12y due to high incidence of extrapyramidal side effects.
  [cap: 50 mg; inj: 50 mg/mL; liquid 12.5 mg/4 mL; tab: 50 mg; tab, chew: 50mg].
- Prochlorperazine (Compazine)
  >12 yrs: 0.1-0.15 mg/kg/dose IM, max 10 mg/dose OR 5-10 mg PO q6-8h, max 40 mg/day OR 5-25 mg PR q12h, max 50 mg/day
  Not recommended in <12y due to high incidence of extrapyramidal side effects
  [caps, SR: 10, 15, 30 mg; inj: 5 mg/mL; susp: 2.5, 5, 25 mg; syrup: 5 mg/5 mL; tabs: 5, 10, 25 mg].
- Promethazine (Phenergan)
  0.25-1 mg/kg/dose PO/IM/IV over 20 min or PR q4-6h pm, max 50 mg/dose
  [inj: 25, 50 mg/mL; susp: 12.5, 25, 50 mg; syrup: 6.25 mg/5 mL; tabs: 12.5, 25, 50 mg].
- Trimethobenzamide (Tigan)
  15 mg/kg/day IM/IV/PO q6-8h, max 100 mg/dose if <13.6 kg or 200 mg/dose if 13.6-41kg.
  [caps: 100, 250 mg; inj: 100 mg/mL; susp: 100, 200 mg].

Post-Operative Nausea and Vomiting:
- Ondansetron (Zofran) 0.1 mg/kg IV x 1, max 4 mg.
- Droperidol (Inapsine) 0.01-0.05 mg/kg IV/IM q4-6h pm, max 5 mg [inj: 2.5 mg/mL].

Chemotherapy-Induced Nausea:
- Dexamethasone
  10 mg/m²/dose IV x 1, then 5 mg/m²/dose (max 10 mg) IV q6h pm
  [inj: 4 mg/mL, 10 mg/mL]
- Droperidol (Marinol)
  5 mg/m²/dose PO 1-3 hrs prior to chemotherapy, then q4h pm afterwards. May titrate up in 2.5 mg/m²/dose increments to max of 15 mg/m²/dose.
  [cap: 2.5, 5, 10 mg].
- Granisetron (Kytril)
  10-20 mcg/kg IV given just prior to chemotherapy (single dose) [inj: 1 mg/mL] adults (oral): 1 mg PO bid or 2 mg PO qd [tab: 1 mg]
- Metoclopramide (Reglan)
  0.5-1 mg/kg/dose IV q6h pm.
  Pretreatment with diphenhydramine 1 mg/kg IV is recommended to decrease the risk of extrapyramidal reactions.
  [inj: 5 mg/mL]
- Ondansetron (Zofran)
  0.15 mg/kg/dose IV 30 minutes before chemotherapy and repeated 4 hr and 8 hr later (total of 3 doses) OR
  0.3 mg/kg/dose IV x 1 30 minutes before chemotherapy OR
  0.45 mg/kg/day as a continuous IV infusion OR
  Oral:
  <0.3 m²: 1 mg PO three times daily
  0.3-0.6 m²: 2 mg PO three times daily
  0.6-1 m²: 3 mg PO three times daily
  >1 m²: 4 mg PO three times daily OR
4-11 yr: 4 mg PO three times daily
>11 yr: 8 mg PO three times daily
(inj: 2 mg/mL; oral soln: 4 mg/5 mL; tab: 4, 8, 24 mg; tab, orally disintegrating: 4, 8 mg)
Pediatric Advanced Life Support

I. Cardiopulmonary assessment

A. Airway (A) assessment. The airway should be assessed and cleared.

B. Breathing (B) assessment determines the respiratory rate, respiratory effort, breath sounds (air entry) and skin color. A respiratory rate of less than 10 or greater than 60 is a sign of impending respiratory failure.

C. Circulation (C) assessment should quantify the heart rate and pulse. In infants, chest compressions should be initiated if the heart rate is less than 80 beats/minute (bpm). In children, chest compressions should be initiated if the heart rate is less than 60 bpm.

II. Respiratory failure

A. An open airway should be established. Bag-valve-mask ventilation should be initiated if the respiratory rate is less than 10. Intubation is performed if prolonged ventilation is required. Matching the endotracheal tube to the size of the nares or fifth finger provides an estimate of tube size.

<table>
<thead>
<tr>
<th>Intubation</th>
<th>ETT Size</th>
<th>Laryngoscope Blade Size</th>
<th>NG Tube Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature</td>
<td>2.0-2.5</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Newborn &gt; 2 kg</td>
<td>3.0-3.5</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Infant</td>
<td>3.5-4.0</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>12 mo</td>
<td>4.0-4.5</td>
<td>1.5</td>
<td>12</td>
</tr>
<tr>
<td>36 mo</td>
<td>4.5-5.0</td>
<td>2</td>
<td>12-14</td>
</tr>
<tr>
<td>6 yr</td>
<td>5.0-5.5</td>
<td>2</td>
<td>14-16</td>
</tr>
<tr>
<td>10 yr</td>
<td>5.5-6.0</td>
<td>2</td>
<td>16-18</td>
</tr>
<tr>
<td>Adolescent</td>
<td>6.0-6.5</td>
<td>3</td>
<td>18-20</td>
</tr>
<tr>
<td>Adult</td>
<td>7.5-8.0</td>
<td>3</td>
<td>20</td>
</tr>
</tbody>
</table>

Uncuffed ET tube in children <8 yrs. Straight laryngoscope blade if <6-10 yrs; curved blade if older.

B. Vascular access should be obtained. Gastric decompression with a nasogastric or oral gastric tube is necessary in endotracheally intubated children and in children receiving bag-valve-mask ventilation.

III. Shock

A. If the child is in shock, oxygen administration and monitoring are followed by initiation of vascular access. Crystalloid (normal saline or lactated Ringer’s) solutions are used for rapid fluid boluses of 20 mL/kg over less than 20 minutes until the shock is resolved.

B. Shock secondary to traumatic blood loss may require blood replacement if perfusion parameters have not normalized after a total of 40 to 60 mL/kg of crystalloid has been administered.

C. Children in septic shock and cardiogenic shock should initially receive crystalloid solution (boluses of 20 mL/kg). Epinephrine should be considered if septic or cardiogenic shock persists after intravenous volume has been repleted (repletion requires 40 to 60 mL/kg of crystalloid).

IV. Cardiopulmonary failure

A. Oxygen is delivered at a concentration of 100%.

B. Intubation and foreign body removal are completed. If signs of shock persist, crystalloid replacement is initiated with boluses of 20 mL/kg over less than 20 minutes. Inotropic agents are added if indicated.

<table>
<thead>
<tr>
<th>Inotropic Agents Used in Resuscitation of Children</th>
<th>Intravenous dosage</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td>0.1 to 1.0 µg/kg/minute (continuous infusion)</td>
<td>Symptomatic bradycardia, shock (cardiogenic, septic, anaphylactic), hypotension</td>
</tr>
<tr>
<td>Dopamine</td>
<td>2 to 5 µg/kg/minute (continuous infusion)</td>
<td>Low dose: improve renal and splanchnic blood flow</td>
</tr>
<tr>
<td></td>
<td>10 to 20 µg/kg/minute (continuous infusion)</td>
<td>High dose: useful in the treatment of hypotension and shock in the presence of adequate intravascular volume</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>2 to 20 µg/kg/minute (continuous infusion)</td>
<td>Normotensive cardiogenic shock</td>
</tr>
</tbody>
</table>

V. Dysrhythmias

A. Bradycardia

1. Bradycardia is the most common dysrhythmia in children. Initial management is ventilation and oxygenation. Chest compressions should be
initiated if the heart rate is <60 bpm in a child or
<80 bpm in an infant.
2. If these measures do not restore the heart rate, epinephrine is administered. Intravenous or intraosseous epinephrine is given in a dose of 0.1 mL/kg of the 1:10,000 concentration (0.01 mg/kg). Endotracheal tube epinephrine is given as a dose of 0.1 mL/kg of the 1:1,000 concentration (0.1 mg/kg) diluted to a final volume of 3-5 mL in normal saline. This dose may be repeated every three to five minutes.
3. Atropine may be tried if multiple doses of epinephrine are unsuccessful. Atropine is given in a dose of 0.2 mL/kg IV/IO/ET of the 1:10,000 concentration (0.02 mg/kg). The minimum dose is 0.1 mg; the maximum single dose is 0.5 mg for a child and 1 mg for an adolescent. Endotracheal tube administration of atropine should be further diluted to a final volume of 3-5 mL in normal saline.
4. Pacing may be attempted if drug therapy has failed.

B. Asystole
1. Epinephrine is the drug of choice for asystole. The initial dose of intravenous or intraosseous epinephrine is given in a dose of 0.1 mL/kg of the 1:10,000 concentration of epinephrine (0.01 mg/kg). Endotracheal tube administration of epinephrine is given as a dose of 0.1 mL/kg of the 1:1,000 concentration of epinephrine (0.1 mg/kg), further diluted to a final volume of 3-5 mL in normal saline.
2. Subsequent doses of epinephrine are administered every three to five minutes at 0.1 mL/kg IV/IO/ET of the 1:1,000 concentration (0.1 mg/kg).

C. Supraventricular tachycardia
1. Supraventricular tachycardia presents with a heart rate >220 beats/minute in infants and >180 beats/minute in children. Supraventricular tachycardia is the most common dysrhythmia in the first year of life.
2. Stable children with no signs of respiratory compromise or shock and a normal blood pressure
   a. Initiate 100% oxygen and cardiac monitoring, and obtain pediatric cardiology consultation.
   b. Administer adenosine 0.1 mg/kg (max 6 mg) by rapid intravenous push. The dose of adenosine may be doubled to 0.2 mg/kg (max 12 mg) and repeated if supraventricular tachycardia is not converted.
   c. Verapamil (Calan) may be used; however, it is contraindicated under one year; in congestive heart failure or myocardial depression; in children receiving beta-adrenergic blockers; and in the presence of a possible bypass tract (ie, Wolff-Parkinson-White syndrome). Dose is 0.1-0.3 mg/kg/dose (max 5 mg) IV; may repeat dose in 30 minutes prn (max 10 mg).
3. Supraventricular tachycardia in unstable child with signs of shock: Administer synchronized cardioversion at 0.5 joules (J)/kg. If supraventricular tachycardia persists, cardioversion is repeated at double the dose: 1.0 J/kg.

D. Ventricular tachycardia with palpable pulse
1. A palpable pulse with heart rate >120 bpm with a wide QRS (>0.08 seconds) is present. Initiate cardiac monitoring, administer oxygen and ventilate.
2. If vascular access is available, administer a lidocaine bolus of 1 mg/kg; if successful, begin lidocaine infusion at 20-50 µg/kg/minute.
3. If ventricular tachycardia persists, perform synchronized cardioversion using 0.5 J/kg.
4. If ventricular tachycardia persists, repeat synchronized cardioversion using 1.0 J/kg.
5. If ventricular tachycardia persists, administer a lidocaine bolus of 1.0 mg/kg, and begin lidocaine infusion at 20-50 µg/kg/min.
6. Repeat synchronized cardioversion as indicated.

E. Ventricular fibrillation and pulseless ventricular tachycardia
1. Apply cardiac monitor, administer oxygen, and ventilate.
2. Perform defibrillation using 2 J/kg. Do not delay defibrillation.
3. If ventricular fibrillation persists, perform defibrillation using 4 J/kg.
4. If ventricular fibrillation persists, perform intubation, continue CPR, and obtain vascular access. Administer epinephrine, 0.1 mL/kg of 1:10,000 IV or IO (0.01 mg/kg); or 0.1 mL/kg of 1:1000 ET (0.1 mg/kg).
5. If ventricular fibrillation persists, perform defibrillation using 4 J/kg.
6. If ventricular fibrillation persists, perform defibrillation using 4 J/kg.
7. If ventricular fibrillation persists, administer lidocaine 1 mg/kg IV or IO, or 2 mg/kg ET.
8. If ventricular fibrillation persists, perform defibrillation using 4 J/kg.
9. If ventricular fibrillation persists, continue epinephrine, 0.1 mg/kg IV/IO/ET, 0.1 mL/kg of 1:1,000; administer every 3 to 5 minutes.
10. If ventricular fibrillation persists, alternate defibrillation (4 J/kg) with lidocaine and epinephrine. Consider bretylium 5 mg/kg IV first
dose, 10 mg/kg IV second dose.

**F. Pulseless electrical activity** is uncommon in children. It usually occurs secondary to hypoxemia, hypovolemia, hypothermia, hypoglycemia, hyperkalemia, cardiac tamponade, tension pneumothorax, severe acidosis or drug overdose. Successful resuscitation depends on treatment of the underlying etiology.

1. The initial dose of IV or IO epinephrine is given in a dose of 0.1 mL/kg of the 1:10,000 concentration (0.01 mg/kg). Endotracheal epinephrine is given as a dose of 0.1 mL/kg of the 1:10,000 concentration (0.1 mg/kg) diluted to a final volume of 3-5 mL in normal saline.

2. Subsequent doses are administered every three to five minutes as 0.1 mL/kg of the 1:1000 concentration IV/IO/ET (0.1 mg/kg).

**VI. Serum glucose concentration** should be determined in all children undergoing resuscitation. Glucose replacement is provided with 25% dextrose in water, 2 to 4 mL/kg (0.5 to 1 g/kg) IV over 20 to 30 minutes for hypoglycemia. In neonates, 10% dextrose in water, 5 to 10 mL/kg (0.5 to 1 g/kg), is recommended.

**Congestive Heart Failure**

1. Admit to:  
2. Diagnosis: Congestive Heart Failure  
3. Condition:  
4. Vital signs: Call MD if:  
5. Activity:  
6. Nursing: Daily weights, inputs and outputs  
7. Diet: Low salt diet  
8. IV Fluids:  
9. Special Medications:  

   - Oxygen 2-4 L/min by NC.  
   - Furosemide (Lasix) 1 mg/kg/dose IV/IM/PO q6-12h prn, max 80 mg PO, 40 mg IV; may increase to 2 mg/kg/dose IV/IM/PO [inj: 10 mg/mL; oral liquid: 10 mg/mL, 40 mg/5 mL; tabs: 20, 40, 80 mg] OR  
   - Bumetanide (Bumex) 0.015-0.1 mg/kg PO/IV/M q12-24h, max 10 mg/day [inj: 0.25 mg/mL; tabs: 0.5, 1, 2 mg].  

**Digoxin:**  

   - Obtain a baseline ECG, serum electrolytes (potassium), and serum creatinine before administration. Initial digitalization is given over 24 hours in three divided doses: ½ total digitalizing dose (TDD) at time 0 hours, 1/4 TDD at 8-12 hours, and 1/4 TDD 8-12 hours later.

   Maintenance therapy is then started.

**Total Digitalizing Dose**

<table>
<thead>
<tr>
<th></th>
<th>PO</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature infant</td>
<td>70-30 mcg/kg</td>
<td>10-30 mcg/kg</td>
</tr>
<tr>
<td>Full term newborn (0-2 weeks)</td>
<td>30 mcg/kg, 20-25 mcg/kg</td>
<td>40-50 mcg/kg, 30-40 mcg/kg</td>
</tr>
<tr>
<td>2-10 yr</td>
<td>30-40 mcg/kg</td>
<td>25-30 mcg/kg</td>
</tr>
<tr>
<td>&gt;10 yr</td>
<td>0.75-1.5 mg, 10 mcg/kg</td>
<td>(max 1 mg)</td>
</tr>
</tbody>
</table>

**Maintenance digoxin dose**

<table>
<thead>
<tr>
<th></th>
<th>PO</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm neonate</td>
<td>4-10 mcg/kg/day</td>
<td>4-9 mcg/kg/day</td>
</tr>
<tr>
<td>Term neonate (0-2 wks)</td>
<td>6-10 mcg/kg/day</td>
<td>6-8 mcg/kg/day</td>
</tr>
<tr>
<td>2 weeks - 2 yr</td>
<td>10-12 mcg/kg/day</td>
<td>8-10 mcg/kg/day</td>
</tr>
<tr>
<td>2-10 yr</td>
<td>8-10 mcg/kg/day</td>
<td>6-8 mcg/kg/day</td>
</tr>
<tr>
<td>&gt;10 yr</td>
<td>5 mcg/kg/day</td>
<td>2-3 mcg/kg/day</td>
</tr>
</tbody>
</table>

Adult 0.125-0.5 mg/day  
Divide bid if <10 yrs or qd if >10 yrs.  
[caps: 50, 100, 200 mcg; elixir: 50 mcg/mL; inj: 100 mcg/mL, 250 mcg/mL; tabs: 0.125, 0.25, 0.5 mg].

**Other Agents:**  

   - Dopamine (Intropin) 2-20 mcg/kg/min continuous IV infusion, titrate cardiac output and BP.  
   - Dobutamine (Dobutrex) 2-20 mcg/kg/min continuous IV infusion, max of 40 mcg/kg/min.  
   - Nitroglycerin 0.5 mcg/kg/min continuous IV infusion, may increase by 1 mcg/kg q20min; usual max 5 mcg/kg/min.  
   - Captopril (Capoten)  

Neonates: 0.05-0.1 mg/kg/dose PO q6-8h  
Infants: 0.15-0.3 mg/kg/dose PO q8h.  
Children: 0.5 mg/kg/dose PO q6-12h. Titrate as needed up to max of 6 mg/kg/day [tabs: 12.5, 25, 50, 100 mg]. Tablets can be crushed and made into extemporaneous suspension.  
-KCl 1-4 mEq/kg/day PO q6-24h.  

**10. Extras and X-rays:** CXR PA and LAT, ECG, echocardiogram.  

**11. Labs:** ABG, SMA 7, Mg, Ca, CBC, iron studies, digoxin level, UA.
Hypertensive Emergencies

1. Admit to:
2. Diagnosis: Hypertensive Emergency
3. Condition: Call MD if systolic BP >150 mmHg, diastolic BP >90 mmHg, MAP > 120 mmHg.
4. Vital signs: Call MD if systolic BP >150 mmHg, diastolic BP >90 mmHg, MAP > 120 mmHg.
5. Activity:
6. Nursing: BP q1h, ECG, daily weights, inputs and outputs.
7. Diet:
8. IV Fluids:

9. Special Medications:
   - Nitroprusside (Nipride) 0.5-10 mcg/kg/min continuous IV infusion. Titrate to desired blood pressure.
     Cyanide and thiocyanate toxicity may develop with prolonged use or in renal impairment.
   - Labetalol (Trandate) 0.2 mg/kg (max 20 mg) IV over 2 min or 0.4-1 mg/kg/hr continuous infusion.
   - Enalaprilat (Vasotec IV) 5-10 mcg/kg/dose IV q8-24h prn.
   - Nifedipine (Adalat, Procardia): 0.25-0.5 mg/kg/dose PO (max 10 mg/dose) q4h prn [trade name capsules: 10 mg/0.34 mL, 20 mg/0.45 mL; may puncture capsule with tuberculin syringe and draw up partial oral dosages].

11. Labs: CBC, SMA 7, BUN, creatinine, UA with micro. Urine specific gravity, thyroid panel, 24H urine for metanephrines; ANA, complement, ASO titer; toxicology screen.
Asthma

1. Admit to:
2. Diagnosis: Exacerbation of asthma
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids: D5 1/4 NS or D5 ½ NS at maintenance rate.
9. Special Medications:
   - Oxygen humidified prn, 1-6 L/min by NC or 25-80% by mask, keep sat >92%
   - Aerosolized and Nebulized Beta 2 Agonists:
     - Albuterol (Ventolin) using 0.5% = 5 mg/mL soln nebulized 0.2-0.5 mL in 2 mL NS q1-4h and prn; may also be given by continuous aerosol. [soln for inhalation: 0.83 mg/3 mL, unit dose; 5 mg/mL 20 mL multidose bulk bottle]
     - Albuterol (Ventolin, Proventil) 2 puffs q1-6h pm with spacer and mask. [capsule for inhalation (Rotacaps) using Rotahaler inhalation device: 200 mcg, MDI: 90 mcg/puff, 200 puffs/17 gm]
     - Levalbuterol (Xopenex) 2-11 yrs: 0.16-1.25 mg nebulized >12 yrs: 0.63-1.25mg nebulized q6-8h
       [soln for inhalation: 0.63 mg/3 mL, 1.25 mg/3 mL]. Levalbuterol 0.63 mg is comparable to albuterol 2.5 mg.
     - Salmeterol (Serevent) > 4 yrs: 2 puffs bid. Not indicated for acute treatment. [Serevent Diskus: 50 mcg/puff, MDI: 21 mcg/puff, 60 puffs/6.5gm or 120 puffs/13 gm]
     - Formoterol (Foradil): >5 yrs: 12 mcg capsule aerosolized using dry powder inhaler bid. [capsule for aerosolization: 12 mcg]
   - Metaproterenol (Alupent, Metaprel) > 12 yrs: 2-3 puffs q3-4h pm, max 12 puffs/24 hrs.
     [MDI: 0.65 mg/puff] Racemic epinephrine (2.25% sln) 0.05 mL/kg/dose (max 0.5 mL) in 2-3 mL saline nebulized q1-6h.
   - Intravenous Beta-2 Agonist: Terbutaline (Brethaire, Brethine, Bricanyl)
     Loading dose: 2-10 mcg/kg IV Maintenance continuous IV infusion: 0.08-6 mcg/kg/min
     Monitor heart rate and blood pressure closely. [inj: 1 mg/mL]
   - Corticosteroid (systemic) Pulse Therapy:
     - Prednisolone 1-2 mg/kg/day PO q12-24h x 3-5 days [syrup: 5 mg/5 mL; Orapred 20.2 mg/5mL; Prelone 15 mg/5 mL] OR
     - Prednisone 1-2 mg/kg/day PO q12-24h x 3-5 days [oral solution: 1 mg/mL, 5 mg/mL; tabs: 1, 2, 5, 10, 20, 50 mg] OR
     - Methylprednisolone (Solu-Medrol) 2 mg/kg/dose IV/IM q6h x 1-4 doses, then 0.5-1 mg/kg/dose IV/IM q8h x 3-5 days.
   - Aminophylline and theophylline:
     - Therapeutic range 10-20 mcg/mL. Concomitant drugs (e.g. erythromycin or carbamazepine) may increase serum theophylline levels by decreasing drug metabolism.
     - Aminophylline loading dose 5-6 mg/kg total body weight IV over 20-30 min [1 mg/kg of aminophylline will raise serum level by 2 mcg/mL].
     - Aminophylline maintenance as continuous IV infusion (based on ideal body weight)
       1-6 mth: 0.5 mg/kg/hr
       6-12 mth: 0.6-0.75 mg/kg/hr
       1-10 yr: 1.0 mg/kg/hr
       10-16 yr: 0.75-0.9 mg/kg/hr
       >16 yr: 0.7 mg/kg/hr OR
     - Theophylline PO maintenance 80% of total daily maintenance IV aminophylline dose in 2-4 doses/day OR
       1-6 mth: 9.6 mg/kg/day.
       6-12 mth: 11.5-14.4 mg/kg/day.
       1-10 yr: 19.2 mg/kg/day.
       10-16 yr: 14.4-17.3 mg/kg/day.
       >16 yr: 10 mg/kg/day.
     - Give theophylline as sustained release theophylline preparation: q8-12h or liquid immediate release: q6h.
     - Slo-Phyllin Gyrocaps, may open caps and sprinkle on food [60, 125, 200 mg caps] q8-12h
     - Slobid Gyrocaps, may open caps and sprinkle on food [50, 75, 100, 125, 200, 300 mg caps] q8-12h
     - Theophylline oral liquid: 80 mg/15 mL, 10 mg/mL q8-12h
     - Theo-Dur [100, 200, 300, 450 mg tabs; scored, may be cut in half, but do not crush] q8-12h.
     - Theophylline Products Cap: 100, 200 mg
       Cap, SR: 50, 60, 65, 75, 100, 125, 130, 200, 250, 260, 300 mg
       Liquid: 80 mg/15 mL, 10 mg/mL
       Tab: 100, 125, 200, 250, 300 mg
       Tab, SR: 50, 75, 100, 125, 130, 200, 250, 260, 300, 400, 450, 500 mg
Corticosteroid metered dose inhalers or nebulized solution:
- Beclomethasone (Beclovent, Vanceril) MDI 1-4 puffs bid-qid with spacer and mask, followed by gargling with water [42 mcg/puff]
- Beclomethasone (Vanceril Double Strength) MDI 2 puffs bid [84 mcg/puff]
- Budesonide (Pulmicort Turbohaler) MDI 1-2 puffs bid [200 mcg/puff]
- Budesonide (Pulmicort) 0.25-0.5 mg nebulized bid [0.25 mg/2mL, 0.5 mg/2mL]
- Flunisolide (AeroBid) MDI 2-4 puffs bid [250 mcg/puff]
- Fluticasone (Flovent) MDI 1-2 puffs bid [44, 110, 220 mcg/actuation]
- Triamcinolone (Azmacort) MDI 1-4 puffs bid-qid [100 mcg/puff]

Cromolyn/nedocromil:
- Cromolyn sodium (Intal) MDI 2-4 puffs qid [800 mcg/puff] or nebulized 20 mg bid-qid [10 mg/mL 2 mL unit dose ampules]
- Nedocromil (Tilade) MDI 2 puffs bid-qid [1.75 mg/puff]

Oral beta-2 agonists:
- Albuterol (Proventil) 2-6 years: 0.1-0.2 mg/kg/dose PO q6-8h
  6-12 years: 2 mg PO tid-qid
  >12 years: 2-4 mg PO tid-qid or 4-8 mg ER tab PO bid
  [soln: 2 mg/5 mL; tab: 2, 4 mg; tab, ER: 4, 8 mg]
- Metaproterenol (Alupent, Metaprel) < 2 yrs: 0.4 mg/kg/dose PO tid-qid
  2-6 yrs: 1.3-2.6 mg PO q6-8h
  6-9 yrs: 10 mg PO q6-8h
  [syrup: 10 mg/5 mL; tabs: 10, 20 mg]

Leukotriene receptor antagonists:
- Montelukast (Singulair) 2-5 yr: 4 mg PO qPM
  6-14 yr: 5 mg PO qPM
  >14 yr: 10 mg PO qPM
  [tab: 10 mg]
- Zafirlukast (Accolate) 7-11 yr: 10 mg PO bid
  >12 yr: 20 mg PO bid
  [tabs: 10, 20 mg]
- Zileuton (Zyflo) >12 yr: 600 mg PO qid (with meals and at bedtime)
  [tab: 600 mg]

10. Extras and X-rays: CXR, pulmonary function test, peak flow rates.
11. Labs: CBC, CBG/ABG. Urine antigen screen, UA, theophylline level.

Allergic Rhinitis and Conjunctivitis

Antihistamines:
- Astemizole (Hismanal):
  6-12 yr: 5 mg/day PO qd
  >12 yr: 10 mg PO qd
  [tab: 10 mg]
- Loratadine (Claritin)
  >3 yrs and < 30 kg: 5 mg PO qd
  >30 kg: 10 mg PO qd.
  [syrup: 1 mg/mL; tab: 10 mg; tab, rapidly disintegrating: 10 mg]
- cetirizine (Zyrtec)
  12 y: 5-10 mg qd
  6-11 y: 5-10 mg qd
  [tabs: 5, 10 mg Syrup: 5 mg/5 mL]
- Fexofenadine (Allegra), 12 y: 60 mg bid [60 mg]
  6-11 y: 5-10 mg bid
  [tabs: 5, 10 mg Syrup: 5 mg/5 mL]
- Acetaminophen (Per cap or tab or 10 mL syrup: triprolidine 2.5 mg, pseudoephedrine 60 mg)
  4 mg pseudoephedrine/kg/day PO tid-qid OR
  4 m-2 yr: 1.25 mL PO q6-8h
  2-4 yr: 2.5 mL PO q6-8h
  4-6 yr: 3.75 mL PO q6-8h
  6-11 y: 5 mL or ½ tab PO q6-8h
  >12 yr: 10 mL or 1 cap/tab PO q6-8h.
- Chlorpheniramine maleate (Chlor-Trimeton):
  0.35 mg/kg/day PO q4-6h OR
  2-5 yr: 1 mg PO q4-6h (max 4 mg/day)
  6-11y: 2 mg PO q4-6h (max 12 mg/day)
  >12y: 4 mg PO q4-6h or 8-12 mg SR q6-12h (max 24 mg/day).
  [cap, SR: 8, 12 mg; soln: 2 mg/5 mL; tab: 4, 8, 12 mg;
  chew: 2 mg; tab: SR: 8, 12 mg]
- Diphenhydramine (Benadryl)
  1 mg/kg/dose PO q6h pm, max 50 mg/dose
  [elixir/liquid: 12.5 mg/5 mL; tab: cap: 25, 50 mg].

Intrasal Therapy:
- Azelastine (Astralin)
  3-12 yr: 1 spray in each nostril bid
  >12 yr: 2 sprays in each nostril bid [nasal soln: 1 mg/mL, 17 mL (137 mcg/spray)]
- Beclomethasone (Beconase, Vancenase)
  6-11 yrs: 1 spray into each nostril tid
  >12 yrs: 1 spray into each nostril bid-qid [2 mcg/actuation]
- Beclomethasone aqueous (Beconase AQ)
  6-11 yrs: 1-2 sprays into each nostril bid
  >12 yrs: 1-2 sprays into each nostril bid [4 mcg/actuation]
- Beclomethasone Double Strength (Vancenase AQ)
  6-11 yrs: 1-2 puffs into each nostril qd
  >12 yrs: 1-2 sprays into each nostril bid-qid [4 mcg/actuation]
- Budesonide (Rhinocort)
  6-11 yrs: 2 sprays into each nostril bid or 4 sprays into each nostril qAM
- **Budesonide aqueous (Rhinocort AQ)**
  6-11 yrs: 1-2 sprays into each nostril bid or 2 sprays into each nostril qAM
  >12 yrs: 1 sprays into each nostril qd, may increase up to 4 sprays into each nostril qAM
  [32 mcg/actuation]

- **Cromolyn (Nasalcrom)**
  1 puff into each nostril q3-4h
  [40 mg/mL 13 mL]

- **Flunisolide (Nasalide, Nasarel)**
  6-11 yrs: 1 spray into each nostril tid or 2 sprays into each nostril bid
  >12 yrs: 2 sprays into each nostril bid-tid
  [25 mcg/actuation]

- **Fluticasone (Flonase)**
  4-6 yrs: 1-2 sprays into each nostril qd
  6-11 yrs: 1 spray into each nostril bid or 2 sprays into each nostril bid
  >12 yrs: 2 sprays into each nostril qd-tid
  [50 mcg/actuation]

- **Mometasone (Nasonex)**
  4-6 yrs: 1 spray into each nostril qd
  6-11 yrs: 1 spray into each nostril qd
  >12 yrs: 2 sprays into each nostril qd
  [55 mcg/actuation]

- **Triamcinolone (Nasacort)**
  6-11 yr: 2 sprays into each nostril qd
  >12 yr: 2 sprays into each nostril qd.
  [55 mcg/actuation]

- **Triamcinolone aqueous (Nasacort AQ)**
  6-11 yr: 2 spray into each nostril qd
  >12 yr: 2 sprays into each nostril qd.
  [55 mcg/actuation]

**Allergic Conjunctivitis Therapy:**
- **Azelastine (Optivar)**
  >3 yr: instill 1 drop into affected eye(s) bid
  [ophth soln: 0.05% 6 mL]

- **Cromolyn ophthalmic (Crolom, Opticrom)**
  Instill 2 drops into each affected eye(s) q4-6h
  [ophth soln: 4% 2.5, 10 mL]

**Decongestants:**
- **Pseudoephedrine (Sudafed, Novafed)**
  <12 yr: 4 mg/kg/day PO q6h.
  >12 yr and adults: 30-60 mg/dose PO q6-8h or sustained release 120 mg PO q12h or sustained release 240 mg PO q24h
  [cap/cplt, SR: 120, 240 mg; drops: 7.5 mg/0.8mL; syrup: 15 mg/5mL, 30 mg/5mL; tabs: 30, 60 mg]

**Anaphylaxis**
1. Admit to: 
2. Diagnosis: Anaphylaxis
3. Condition: 
4. Vital signs: Call MD if: 
5. Activity: 
7. Diet: 
8. IV Fluids: 2 IV lines. Normal saline or LR 10-20 mL/kg rapidly over 1h, then D5 ½ NS at 1-1.5 times maintenance.
9. Special Medications: 
   - Saline (0.9% or 0.45%)
   - Epinephrine, 0.01 mg/kg [0.01 mL/kg of 1 mg/mL = 1:1000] (maximum 0.5 mL) subcutaneously, repeat every 15-20 minutes pm.
   - Nebulized epinephrine (2.25%): 0.25-0.5 mL in 2.5 mL NS over 15 min q30 min-4hr.
   - Albuterol (Ventolin) (0.5%, 5 mg/mL sln) nebulized 0.01-0.03 mL/kg (max 1 mL) in 2 mL NS q1-2h.
   - Hydroxyzine (Vistaril) 0.5-1 mg/kg/dose IM/IV/PO q4-6h, max 50 mg/dose.
10. Antihistamines: 
   - Diphenhydramine (Benadryl) 1 mg/kg/dose IV/IM/IO/PO q6h, max 50 mg/dose; antihistamines are not a substitute for epinephrine OR
   - Hydroxyzine (Vistaril) 0.5-1 mg/kg/dose IM/IV/PO q4-6h, max 50 mg/dose.
11. Labs: CBC, SMA 7, ABG.

**Pleural Effusion**
1. Admit to: 
2. Diagnosis: Pleural effusion
3. Condition: 
4. Vital signs: Call MD if: 
5. Activity: 
6. Diet: 
7. IV Fluids: 
8. Extras and X-rays: Portable CXR.
9. Labs: CBC with differential, SMA 7, protein, albumin,
Pleural fluid:

**Tube 1** - LDH, protein, amylase, triglycerides, glucose, specific gravity (10 mL red top).

**Tube 2** - Gram stain, culture and sensitivity, AFB, fungal culture (20-60 mL).

**Tube 3** - Cell count and differential (5-10 mL, EDTA purple top).

**Tube 4** - Cytology (25-50 mL, heparinized).

**Syringe** - pH (2 mL, heparinized).

<table>
<thead>
<tr>
<th>Evaluation of Thoracentesis Fluid</th>
<th>Transude</th>
<th>Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific gravity</td>
<td>&lt;1.016</td>
<td>&gt;1.016</td>
</tr>
<tr>
<td>Protein ratio pleural fluid/serum</td>
<td>&lt;0.5</td>
<td>&gt;0.5</td>
</tr>
<tr>
<td>Protein (gm/100 mL)</td>
<td>&lt;3.0</td>
<td>&gt;3.0</td>
</tr>
<tr>
<td>LDH ratio pleural fluid/serum</td>
<td>&lt;0.6</td>
<td>&gt;0.6</td>
</tr>
<tr>
<td>WBC</td>
<td>&lt;1,000/mm³</td>
<td>&gt;1,000/mm³</td>
</tr>
<tr>
<td>Glucose</td>
<td>Equivalent to serum</td>
<td>Less than serum</td>
</tr>
</tbody>
</table>
**Suspected Sepsis**

1. **Admit to:**
2. **Diagnosis:** Suspected sepsis
3. **Condition:**
4. **Vital signs:** Call MD if:
5. **Activity:**
6. **Nursing:** Inputs and outputs, daily weights, cooling measures prn temp >38°C, consent for lumbar puncture.
7. **Diet:**
8. **IV Fluids:** Correct hypovolemia if present; NS 10-20 mL/kg IV bolus, then IV fluids at 1-1.5 times maintenance.
9. **Special Medications:**
   - **Term newborns <1 month old (Group B strep, E. coli, Group D strep, gram negatives, Listeria monocytogenes):** Ampicillin and gentamicin or cefotaxime.
     - Ampicillin IV/IM: <7d: 150 mg/kg/day q8h; >7d: 200 mg/kg/day q8h.
     - Cefotaxime (Clavirarin) IV/IM: <7 days: 100 mg/kg/day q12h; >7 days: 150 mg/kg/day q8h.
     - Gentamicin (Garamycin) IV/IM: 5 mg/kg/day q12h.
   - Also see page 155.
10. **Infant 1-2 months old (H. flu, strep pneumonia, N meningitidis, Group B strep):**
    - Ampicillin 100 mg/kg/day IV/IM q6h AND EITHER
    - Cefotaxime (Clavirarin) 100 mg/kg/day IV/IM q6h OR
    - Ceftriaxone (Rocephin) 50-75 mg/kg/day IV/IM q12- 24h OR
    - Gentamicin (Garamycin) 7.5 mg/kg/day IV/IM q8h
11. **Children 2 months to 18 years old (S pneumonia, H. flu, N. meningitidis):**
    - Cefotaxime (Clavirarin) 100 mg/kg/day IV/IM q6h, max 12 gm/day OR
    - Ceftriaxone (Rocephin) 50-75 mg/kg/day IV/IM q12-24h, max 4 gm/day.
12. **Immunocompromised Patients (Gram negative bacilli, Pseudomonas, Staph, Strept viridans):**
    - Ticarcillin (Ticar) 200-300 mg/kg/day IV/IM q6h, max 24 gm/day
    - Ticarcillin/clavulanate (Timentin) 200-300 mg/kg/day of ticarcillin IV/IM q6-8h, max 24 gm/day OR
    - Piperacillin (Pipracil) 200-300 mg/kg/day IV/IM q6h, max 24 gm/day OR
    - Piperacillin/tazobactam (Zosyn) 240 mg/kg/day of piperacillin IV/IM q6-8h, max 12 gm/day OR
    - Cefazidime (Fortaz) 100-150 mg/kg/day IV/IM q8h, max 12 gm/day AND
    - Tobramycin (Nebcin) or Gentamicin (Garamycin) (normal renal function):
      - <5 yr (except neonates): 7.5 mg/kg/day IV/IM q8h.
      - 5-10 yr: 6.0 mg/kg/day IV/IM q8h.
      - >10 yr: 5.0 mg/kg/day IV/IM q8h AND (if gram positive infection strongly suspected)
    - Vancomycin (Vancocin) (central line infection) 40-60 mg/kg/day IV q6-8h, max 4 gm/day
13. **Symptomatic Medications:**
    - Ibuprofen (Advil) 5-10 mg/kg/dose PO q6h-8h prn temp >38°C OR
    - Acetaminophen (Tylenol) 10-15 mg/kg PO/PR q4-6h prn temp >38°C or pain.
14. **Extras and X-rays:** CXR.
15. **Labs:** CBC, SMA 7. Blood culture and sensitivity x 2.
16. **CSF Tube 1** - Gram stain, culture and sensitivity for bacteria, antigen screen (1-2 mL).
17. **CSF Tube 2** - Glucose, protein (1-2 mL).
18. **CSF Tube 3** - Cell count and differential (1-2 mL).
Children 3 months to 18 years old (S pneumonia, H flu, N. meningitidis):
- Cefotaxime (Claforan) 200 mg/kg/day IV/IM q6h, max 12 gm/day or ceftriaxone (Rocephin) 100 mg/kg/day IV/IM q12-24h, max 4 gm/day AND
- Vancomycin (Vancocin) 60 mg/kg/day IV q6h, max 4 gm/day.
- Dexamethasone 0.6 mg/kg/day IV q6h x 4 days. Initiate before or with the first dose of parenteral antibiotic.

10. Symptomatic Medications:
- Ibuprofen (Advil) 5-10 mg/kg/dose PO q6-8h prn
- Acetaminophen (Tylenol) 15 mg/kg PO/PR q4h prn temp >38°C or pain.

11. Extras and X-rays:
- CXR, MRI.

12. Labs:

Luumber Puncture:
- CSF Tube 1 - Gram stain, culture and sensitivity, bacterial antigen screen (1-2 mL).
- CSF Tube 2 - Glucose, protein (1-2 mL).
- CSF Tube 3 - Cell count and differential (1-2 mL).

Specific Treatment of Meningitis and Encephalitis

Dexamethasone (0.6 mg/kg/day IV q6h x 4 days) given before the first dose of antibiotics decreases hearing deficits and possibly other neurologic sequelae in Haemophilus influenzae meningitis.

Streptococcus pneumoniae:
Until sensitivities are available, combination therapy with vancomycin and cefotaxime/ceftriaxone is recommended. For children with severe hypersensitivity to beta-lactams, the combination of vancomycin and rifampin is recommended.
- Penicillin G 250,000-400,000 U/kg/day IV/IM q4-6h, max 24 MU/day
- Cefotaxime (Claforan) 200-300 mg/kg/day IV/IM q6h, max 12 gm/day
- Ceftriaxone (Rocephin) 100 mg/kg/day IV/IM q12-24h, max 4 gm/day
- Vancomycin (Vancocin) 60 mg/kg/day IV q6h, max 4 gm/day
- Rifampin 20 mg/kg/day IV q12h, max 600 mg/day
- Meropenem (Merrem) 120 mg/kg/day IV q6h, max 6 gm/day
- Chloramphenicol (Chloromycetin) 75-100 mg/kg/day IV q6h, max 4 gm/day

Neisseria meningitidis:
Penicillin is the drug of choice. Cefotaxime and ceftriaxone are acceptable alternatives.
- Penicillin G 250,000-400,000 U/kg/day IV/IM q4h x 7-10d, max 24 MU/day.
- Cefotaxime (Claforan) 200-300 mg/kg/day IV/IM q6h, max 12 gm/day
- Ceftriaxone (Rocephin) 100 mg/kg/day IV/IM q12-24h, max 4 gm/day

Meningococcal exposure prophylaxis (see H flu prophylaxis below):
- Ceftriaxone (Rocephin) IM x 1 dose; <12y: 125 mg; >12y: 250 mg OR
- Rifampin, <1 mth: 5 mg/kg/dose PO bid x 2 days; >1 mth: 10 mg/kg/dose (max 600 mg/dose) PO q12h x 2 days [caps: 150 mg, 300 mg; extemporaneous suspension] OR
- Ciprofloxacin (Cipro) 500 mg PO x 1 for adults (>18 yr).

Haemophilus influenzae
Ampicillin should not be used alone as initial therapy until sensitivities are available as 10-40% of isolates are ampicillin-resistant.
- Cefotaxime (Claforan) 200-300 mg/kg/day IV/IM q6h, max 12 gm/day OR
- Ceftriaxone (Rocephin) 100 mg/kg/day IV/IM q12-24h, max 4 gm/day OR
- Ampicillin (beta-lactamase negative) 200-400 mg/kg/day IV/IM q4-6h, max 12 gm/day.

H influenzae type B exposure prophylaxis and eradication of nasopharyngeal carriage:
- Rifampin <1 month: 10 mg/kg/day PO q24h x 4 days; >1 month: 20 mg/kg/day PO q4x 4 doses (max 600 mg/dose). [caps: 150, 300 mg; extemporaneous suspension]

Group A or non-enterococcal Group D Streptococcus:
- Penicillin G 250,000 U/kg/day IV/IM q4-6h, max 24 MU/day.

Listeria monocytogenes or Group B Streptococcus:
- Ampicillin 200 mg/kg/day IV/IM q8h, max 12 gm/day AND
- Gentamicin (Garamycin) or Tobramycin (Nebcin) (normal renal function):
- <5 yr (except neonates): 7.5 mg/kg/day IV/IM q8h, 5-10 yr: 6.0 mg/kg/day IV/IM q8h.
- >10 yr: 5.0 mg/kg/day IV/IM q8h.

Staphylococcus aureus:
- Nafcillin (Naftil) or Oxacillin (Bactocill, Prostaphilin) 150-200 mg/kg/day IV/IM q4-6h, max 12 gm/day OR
- Vancomycin (Vancocin) 40-60 mg/kg/day IV q6h, max 4 gm/day (may require concomitant intrathecal therapy).

Herpes Simplex Encephalitis:
- Acyclovir (Zovirax) 1500 mg/m²/day or 30 mg/kg/day IV over 1h q8h x 14-21 days
Infective Endocarditis

1. Admit to:
2. Diagnosis: Infective endocarditis
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Diet:
7. IV Fluids:
8. Special Medications:
   Subacute Bacterial Endocarditis Empiric Therapy:
   - Penicillin G 250,000 U/kg/day IVIM q4-6, max 24 MU/day AND
   - Gentamicin (Garamycin) or Tobramycin (Nebcin) (normal renal function):
     <5 yr (except neonates): 7.5 mg/kg/day IVIM q8h. 5-10 yr: 8.0 mg/kg/day IVIM q8h. >10 yr: 5.0 mg/kg/day IVIM q8h.
   Acute Bacterial Endocarditis Empiric Therapy (including IV drug user):
   - Gentamicin (Garamycin) or Tobramycin (Nebcin), see above for dose AND EITHER
   - Nafcillin (Nafcil) or oxacillin (Bactocill, Prostaphlin)
     150 mg/kg/day IVIM q6h, max 12 gm/day OR
   - Vancomycin (Vancocin) 40-60 mg/kg/day IV q6-8h, max 4 gm/day.
   Streptococci viridans/bovis:
   - Penicillin G 150,000 U/kg/day IVIM q4-6h, max 24 MU/day OR
   - Vancomycin (Vancocin) 40-60 mg/kg/day IV q6-8h, max 4 gm/day.
   Staphylococcus aureus (methicillin sensitive):
   - Nafcillin (Nafcil) or oxacillin (Bactocill, Prostaphlin)
     150 mg/kg/day IVIM q6h, max 12 gm/day AND
   - Gentamicin (Garamycin) or Tobramycin (Nebcin), see above for dose.
   Methicillin-resistant Staphylococcus aureus:
   - Vancomycin (Vancocin) 40-60 mg/kg/day IV q6h, max 4 gm/day.
   Staphylococcus epidermidis:
   - Vancomycin (Vancocin) 40-60 mg/kg/day IV q6h max 4 gm/day AND
   - Gentamicin (Garamycin) or Tobramycin (Nebcin), see above for dose.
10. Labs: CBC, ESR. Bacterial culture and sensitivity x 3-4 over 24h, MBC. Antibiotic levels. UA, urine culture and sensitivity.

Endocarditis Prophylaxis

<table>
<thead>
<tr>
<th>Situation</th>
<th>Drug</th>
<th>Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard general prophylaxis</td>
<td>Amoxicillin</td>
<td>50 mg/kg PO as a single dose 1 hr before procedure</td>
<td>2000 mg</td>
</tr>
<tr>
<td>Unable to take oral medication</td>
<td>Ampicillin</td>
<td>50 mg/kg IVIM within 30 minutes before procedure</td>
<td>2000 mg</td>
</tr>
<tr>
<td>Allergic to penicillin</td>
<td>Clindamycin or</td>
<td>20 mg/kg PO as a single dose 1 hour before procedure</td>
<td>600 mg</td>
</tr>
<tr>
<td></td>
<td>Cephalexin (Keflex) or cepodoxin (Duricef) or Azithromycin (Zithromax) or clarithromycin (Biaxin)</td>
<td>50 mg/kg PO as a single dose 1 hour before procedure</td>
<td>2000 mg</td>
</tr>
<tr>
<td>Allergic to penicillin and unable to take oral medications</td>
<td>Clindamycin or</td>
<td>20 mg/kg IV 30 minutes before procedure</td>
<td>600 mg</td>
</tr>
<tr>
<td></td>
<td>Cefazolin (Ancef)</td>
<td>25 mg/kg IVIM within 30 minutes before procedure</td>
<td>1000 mg</td>
</tr>
<tr>
<td>Situation</td>
<td>Drug</td>
<td>Regimen</td>
<td>Maximum Dose</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>High-risk patients</td>
<td>Ampicillin plus</td>
<td>50 mg/kg IV/IM</td>
<td>2000 mg</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
<td>1.5 mg/kg IV/IM within 30 minutes before starting procedure</td>
<td>120 mg</td>
</tr>
<tr>
<td></td>
<td>Ampicillin or Amoxicillin</td>
<td>25 mg/kg IV/IM</td>
<td>1000 mg</td>
</tr>
<tr>
<td></td>
<td>25 mg/kg PO six hours later</td>
<td>1000 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vancomycin plus</td>
<td>20 mg/kg IV over 1-2 hours</td>
<td>1000 mg</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
<td>1.5 mg/kg IV/IM to be completed within 30 minutes before starting procedure</td>
<td>120 mg</td>
</tr>
<tr>
<td>Moderate-risk Patients</td>
<td>Amoxicillin or</td>
<td>50 mg/kg PO one hour before procedure</td>
<td>2000 mg</td>
</tr>
<tr>
<td></td>
<td>Vancomycin</td>
<td>20 mg/kg IV over 1-2 hours, completed within 30 minutes of starting procedure</td>
<td>1000 mg</td>
</tr>
</tbody>
</table>

Pneumonia

1. Admit to:
2. Diagnosis: Pneumonia
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   - Humidified O₂ by NC at 2-4 L/min or 25-100% by mask, adjust to keep saturation >92%
   - Term Neonates <1 month:
     - Ampicillin 100 mg/kg/day IV/IM q6h AND
     - Cefotaxime (Claforan) <1 wk: 100 mg/kg/day IV/IM q12h; >1 wk: 150 mg/kg/day IV/IM q8h OR
     - Gentamicin (Garamycin) 3 mg/kg/day IV/IM q12h.
   - Children 1 month-5 years old:
     - Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h OR
     - Ampicillin 100 mg/kg/day IV/IM q8h AND
     - Gentamicin (Garamycin) or Tobramycin (Nebcin): 7.5 mg/kg/day IV/IM q8h (normal renal function).
     - If chlamydia is strongly suspected, add erythromycin 30 mg/kg/day IV q8h.
   - Oral Therapy:
     - Cefuroxime axetil (Ceftin)
       - tab: child: 125-250 mg PO bid; adult: 250-500 mg PO bid
       - susp: 30 mg/kg/day PO q12h, max 1000 mg/day [susp: 125 mg/5 mL; tabs: 125, 250, 500 mg] OR
       - Loracarbef (Lorabid)
         - 30 mg/kg/day PO q12h, max 800 mg/day [cap: 200, 400 mg, susp: 100 mg/5 mL, 200 mg/5 mL]
       - Cefpodoxime (Vantin)
         - 10 mg/kg/day PO q12h, max 800 mg/day [susp: 50 mg/5 mL, 100 mg/5 mL; tabs: 100, 200 mg]
     - Cefprozil (Cefzil)
       - 30 mg/kg/day PO q12h, max 1000 mg/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]
     - Ceftxime (Suprax)
       - 8 mg/kg/day PO qd-bid, max 400 mg/day [susp: 100 mg/5 mL; tabs: 200, 400 mg]
     - Clarithromycin (Biaxin)
       - 15-30 mg/kg/day PO bid, max 1000 mg/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]
     - Azithromycin (Zithromax)
       - Children ≥2 yrs: 12 mg/kg/day PO qd x 5 days, max 500 mg/day
       - ≥18 yrs: 500 mg PO on day 1, 250 mg PO on day 2
days 2-5
[cap: 250 mg; susp: 100 mg/5mL, 200 mg/5mL; tabs: 250, 600 mg]
-Amoxicillin/clavulanate (Augmentin)
-30-40 mg/kg/day of amoxicillin PO q8h, max 500 mg/dose
[elixir: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg; tabs, chew: 125, 250 mg]
-Amoxicillin/clavulanate (Augmentin Bid)
-30-40 mg/kg/day PO q12h, max 875 mg (amoxicillin)/dose
[elixir: 200 mg/5 mL, 400 mg/5 mL; tabs: 875 mg; tabs, chew: 200, 400 mg]

Community Acquired Pneumonia 5-18 years old (viral, Mycoplasma pneumoniae, chlamydia pneumoniae, pneumococcus, legionella):
-Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h, max 9 gm/day OR
-Erythromycin estolate (Ilosone) 30-50 mg/kg/day PO q8h-12h, max 2 gm/day
[caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tab: 500 mg, tabs, chew: 125, 250 mg]
-Erythromycin ethylsuccinate (EryPed, EES) 30-50 mg/kg/day PO q6-8h, max 2 gm/day
[susp: 200 mg/5 mL, 400 mg/5 mL; tab: 400 mg; tab, chew: 200 mg]
-Erythromycin base (E-mycin, Ery-Tab, Eryc)
-50-50 mg/kg/day PO q6-8h, max 2 gm/day
[cap, DR: 250 mg; tabs: 250, 333, 500 mg]
-Erythromycin lactobionate 20-40 mg/kg/day IV q6h, max 4 gm/day
[inj: 500 mg, 1 gm]
-Clarithromycin (Biaxin) 15-30 mg/kg/day PO bid, max 1000 mg/day
[susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]

Immunosuppressed, Neutropenic Pneumonia (S. pneumoniae, group A strep, H flu, gram neg enterics, Klebsiella, Mycoplasma Pneumonia, Legionella, Chlamydia pneumoniae, S aureus):
-Tobramycin (Nebcin) (normal renal function):<5 yr (except neonates): 7.5 mg/kg/day IV/IM q8h, 5-10 yr: 6.0 mg/kg/day IV/IM q8h
>10 yr: 5.0 mg/kg/day IV/IM q8h OR
-Ceftazidine (Fortaz) 150 mg/kg/day IV/IM q8h, max 12 gm/day AND
-Ticarcillin/clavulanate (Timentin) 200-300 mg/kg/day of ticarcillin IV q6-8h, max 24 gm/day OR
-Nafcillin (Nafcil) or oxacillin (Bactocill, Prostaphlin) 150 mg/kg/day IV/IM q6h, max 12 gm/day OR
-Vancomycin (Vancocin) 40 mg/kg/day IV q6h, max 4 gm/day

Cystic Fibrosis Exacerbation (Pseudomonas aeruginosa):
-Ticarcillin/clavulanate (Timentin) 200-300 mg/kg/day of ticarcillin IV q6-8h, max 24 gm/day OR
-Piperacillin/tazobactam (Zosyn) 300 mg/kg/day of piperacillin IV q6-8h, max 12 gm/day OR
-Piperacillin (Pipracil) 200-300 mg/kg/day IV/IM q4-6h, max 24 gm/day AND
-Tobramycin (Nebcin):<5 yr (except neonates): 7.5 mg/kg/day IV/IM q8h, 5-10 yr: 6.0 mg/kg/day IV/IM q8h
>10 yr: 5.0 mg/kg/day IV/IM q8h OR
-Ceftazidine (Fortaz) 150 mg/kg/day IV/IM q8h, max 12 gm/day OR
-Aztreonam (Azactam) 150-200 mg/kg/day IV/IM q6-8h, max 8 gm/day OR
-Imipenem/Cilastatin (Primaxin) 60-100 mg/kg/day imipenem component IV q6-8h, max 4 gm/day OR
-Meropenem (Merrem) 60-120 mg/kg/day IV q6h, max 6 gm/day.

10. Symptomatic Medications:
-Acetaminophen (Tylenol) 10-15 mg/kg PO/PR q4h prn temp >38°C or pain.

11. Extras and X-rays:
-CXR PA and LAT, PPD.

12. Labs:
-CBC, ABG, blood culture and sensitivity x 2. Sputum gram stain, culture and sensitivity, AFB. Antibiotic levels. Nasopharyngeal washings for direct fluorescent antibody (RSV, adenovirus, parainfluenza, influenza virus, chlamydia) and cultures for respiratory viruses. UA.
Specific Therapy for Pneumonia

Pneumococcal pneumonia:
- Erythromycin estolate (Ilosone) 30-50 mg/kg/day PO q8-12h, max 2 gm/day [caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tab: 500 mg; tabs, chew: 125,250 mg]
- Erythromycin ethylsuccinate (EryPed, EES) 30-50 mg/kg/day PO q6-8h, max 2gm/day [susp: 200 mg/5 mL, 400 mg/5 mL; tab: 400 mg; tab, chew: 200 mg]
- Erythromycin base (E-Mycin, Ery-Tab, Eryc) 30-50 mg/kg/day PO q6-8h, max 2gm/day [tab: 250, 333, 500 mg]
- Erythromycin lactobionate 20-40 mg/kg/day IV q6h, max 4 gm/day [inj: 500 mg, 1 g mL OR]
- Vancomycin (Vancocin) 40 mg/kg/day IV q6h, max 4 gm/day OR
  - Cefotaxime (Claforan) 100-150 mg/kg/day IVIM q6h, max 12 gm/day OR
  - Penicillin G 150,000 UI/kg/day IVIM q4-6h, max 24 MU/day.

Staphylococcus aureus:
- Oxacillin (Bactocill, Prostaphlin) or Nafcillin (Naftcil) 150-200 mg/kg/day IVIM q4-6h, max 12 gm/day OR
- Vancomycin (Vancocin) 40 mg/kg/day IV q6h, max 4 gm/day

Haemophilus influenzae (<5 yr of age):
- Cefotaxime (Claforan) 100-150 mg/kg/day IVIM q8h, max 12 gm/day OR
  - Cefuroxime (Zinacef) 100-150 mg/kg/day IVIM q8h (beta-lactamase pos), max 9 gm/day OR
  - Ampicillin 100-200 mg/kg/day IVIM q6h (beta-lactamase negative), max 12 gm/day

Pseudomonas aeruginosa:
- Tobramycin (Neobcin):<5 yr (except neonates): 7.5 mg/kg/day IVIM q8h. 5-10 yr: 6.0 mg/kg/day IVIM q8h. >10 yr: 5.0 mg/kg/day IVIM q8h AND
- Piperacillin (Pipracil) or ticarcillin (Ticar) 200-300 mg/kg/day IVIM q4-6h, max 24 gm/day OR
  - Ceftazidime (Fortaz) 150 mg/kg/day IVIM q4h, max 12 gm/day

Mycoplasma pneumoniae:
- Clarithromycin (Biaxin) 15-30 mg/kg/day PO q12h, max 1 gm/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]
- Erythromycin estolate (Ilosone) 30-50 mg/kg/day PO q8-12h, max 2 gm/day [caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tab: 500 mg; tabs, chew: 125,250 mg]
- Erythromycin ethylsuccinate (EryPed, EES) 30-50 mg/kg/day PO q6-8h, max 2gm/day [susp: 200 mg/5 mL, 400 mg/5 mL; tab: 400 mg; tab, chew: 200 mg]
- Erythromycin base (E-Mycin, Ery-Tab, Eryc) 30-50 mg/kg/day PO q6-8h, max 2gm/day [cap, DR: 250 mg; tabs: 250, 333, 500 mg]
- Erythromycin lactobionate (Erythrocin) 20-40 mg/kg/day IV q6h, max 4 gm/day [inj: 500 mg, 1 gm]
- Tetracycline (Achromycin) >8 yrs only 25-50 mg/kg/day PO q6h, max 2 gm/day [caps: 100, 250, 500 mg; susp: 125 mg/5 mL; tabs: 250, 500 mg]

Mycoplasma pneumoniae:
- Clarithromycin (Biaxin) 15-30 mg/kg/day PO q12h, max 1 gm/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg] OR
- Cefuroxime (Zinacef) 100-150 mg/kg/day IVIM q8h, max 9 gm/day OR
  - Erythromycin estolate (Ilosone) 30-50 mg/kg/day PO q8-12h, max 2 gm/day [caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tab: 500 mg; tabs, chew: 125,250 mg]
- Erythromycin ethylsuccinate (EryPed, EES) 30-50 mg/kg/day PO q6-8h, max 2gm/day [susp: 200 mg/5 mL, 400 mg/5 mL; tab: 400 mg; tab, chew: 200 mg]
- Erythromycin base (E-Mycin, Ery-Tab, Eryc) 30-50 mg/kg/day PO q6-8h, max 2gm/day [cap, DR: 250 mg; tabs: 250, 333, 500 mg]
- Erythromycin lactobionate (Erythrocin) 20-40 mg/kg/day IV q6h, max 4 gm/day [inj: 500 mg, 1 gm] OR
  - Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 6-12 mg, TMP/kg/day PO/IV q12h, max 320 mg TMP/day [inj per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg]
Chlamydia pneumoniae (TWAR), psittaci, trachomatous:
- Erythromycin estolate (Ilosone)
  30-50 mg/kg/day PO q8-12h, max 2 gm/day
  [caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/6 mL; tab: 500 mg; tabs, chew: 125,250 mg]
- Erythromycin ethylsuccinate (EryPed, EES)
  30-50 mg/kg/day PO q6-8h, max 2gm/day
  [susp: 200 mg/5 mL, 400 mg/5 mL; tab, chew: 200 mg]
- Erythromycin base (E-Mycin, Ery-Tab, Eryc)
  30-50 mg/kg/day PO q6-8h, max 2gm/day
  [cap, DR: 250 mg; tabs: 250, 333, 500 mg]
- Erythromycin lactobionate (Erythrocin)
  20-40 mg/kg/day IV q6h, max 4 gm/day
  [inj: 500 mg, 1 gm ] OR
- Azithromycin (Zithromax)
  children >2 yrs: 12 mg/kg/day PO qd x 5 days, max 500 mg/day
  >16 yrs: 500 mg PO on day one, then 250 mg PO qd on days 2-5
  [cap: 250 mg; susp: 100 mg/5mL, 200 mg/5mL; tabs: 250, 600 mg]

Influenza Virus:
- Oseltamivir (Tamiflu)
  >1 yr and <15 kg: 30 mg PO bid
  T5-23 kg: 45 mg PO bid
  >23 - 40 kg: 60 mg PO bid
  >40 kg: 75 mg PO bid
  >18 yr: 75 mg PO bid
  [cap: 75 mg; susp: 12 mg/mL]
  Approved for treatment of uncomplicated influenza A or B when patient has been symptomatic no longer than 48 hrs. OR
- Rimantadine (Flumadine)
  <10 yr: 5 mg/kg/day PO qd, max 150 mg/day
  >10 yr: 100 mg PO bid
  [syrup: 50 mg/5 mL; tab: 100 mg].
  Approved for treatment or prophylaxis of Influenza A. Not effective against Influenza B. OR
- Amantadine (Symmetrel)
  1-9 yr: 5 mg/kg/day PO qd-bid, max 150 mg/day
  >9 yr: 5 mg/kg/day PO qd-bid, max 200 mg/day
  [cap: 100 mg; syr: 50 mg/5 mL].
  Approved for treatment or prophylaxis of Influenza A. Not effective against Influenza B.

Bronchiolitis

1. Admit to:
2. Diagnosis: Bronchiolitis
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   - Oxygen, humidified 1-4 L/min by NC or 40-60% by mask, keep sat >92%.
   - Nebulized Beta 2 Agonists:
     - Albuterol (Ventolin, Proventil) (5 mg/mL sln) nebulized 0.2-0.5 mL in 2 mL NS (0.10-0.15 mg/kg) q1-4h pm.
   - Treatment of Respiratory Syncytial Virus (severe lung disease or underlying cardiopulmonary disease):
     - Ribavirin (Virazole) therapy should be considered in high risk children <2 yrs with bronchopulmonary dysplasia or with history of premature birth less than 35 weeks gestational age. Ribavirin is administered as a 6 gm vial, aerosolized by SPAG nebulizer over 18-20h qd x 3-5 days or 2 gm over 2 hrs q6h x 3-5 days.
   - Prophylaxis Against Respiratory Syncytial Virus:
     - Recommended use in high risk children <2 yrs with BPD who required medical management within the past six months, or with history of premature birth less than or equal to 28 weeks gestational age who are less than one year of age at start of RSV season, or with history of premature birth 29-32 weeks gestational age who are less than six months of age at start of RSV season.
     - Palivizumab (Synagis) 15 mg/kg IM once a month throughout RSV season (usually October-March).
     - RSV-IVIG (RespiGam) 750 mg/kg IV once a month throughout RSV season (usually from October to March).

Influenza A:
- Oseltamivir (Tamiflu)
  >1 yr and <15 kg: 30 mg PO bid
  T5-23 kg: 45 mg PO bid
  >23 - 40 kg: 60 mg PO bid
  >40 kg: 75 mg PO bid
  >18 yr: 75 mg PO bid
  [cap: 75 mg; susp: 12 mg/mL]
  Approved for treatment of uncomplicated influenza A or B when patient has been symptomatic no longer than 48 hrs. OR
- Rimantadine (Flumadine)
  <10 yr: 5 mg/kg/day PO qd, max 150 mg/day
  >10 yr: 100 mg PO bid
  [syrup: 50 mg/5 mL; tab: 100 mg].
  Approved for treatment or prophylaxis of Influenza A. Not effective against Influenza B. OR
- Amantadine (Symmetrel)
  1-9 yr: 5 mg/kg/day PO qd-bid, max 150 mg/day
>9 yr: 5 mg/kg/day PO qd-bid, max 200 mg/day [cap: 100 mg; syr: 50 mg/5 mL]. Approved for treatment or prophylaxis of Influenza A. Not effective against Influenza B.

**Pertussis:**

The estolate salt is preferred due to greater penetration.

- Erythromycin estolate 50 mg/kg/day PO q8-12h, max 2 gm/day [caps: 125, 250 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tab: 500 mg; tabs, chew: 125, 250 mg]

- Erythromycin lactobionate (Erythrocin) 20-40 mg/kg/day IV q6h, max 4 gm/day [inj: 500 mg, 1 gm].

**Oral Beta 2 Agonists and Acetaminophen:**

- Albuterol liquid (Proventil, Ventolin) 2-6 years: 0.1-0.2 mg/kg/dose PO q6-8h
  6-12 years: 2 mg PO bd-qid
  >12 years: 2-4 mg PO bd-qid [soln: 2 mg/5 mL; tabs: 2.4 mg; tabs, SR: 4, 8 mg]

- Acetaminophen (Tylenol) 10-15 mg/kg PO/PR q4-6h prn temp >38°.

**Viral Laryngotracheitis (Croup):**

1. Admit to:
2. Diagnosis: Croup
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   - Oxygen, cool mist, 1-2 L/min by NC or 40-60% by mask, keep sat >92%.
   - Racemic epinephrine (2.25% sln) 0.05 mL/kg/dose max 0.5 mL in 2-3 mL saline nebulized q1-6h.
   - Dexamethasone (Decadron) 0.25-0.5 mg/kg/dose IM/IV q6h prn, max dose 10 mg OR
   - Prednisone 1-2 mg/kg/day PO QD for 5 days, max 30 mg/day [syr: 1 mg/mL, 5 mg/mL; tabs: 1, 2.5, 5, 10, 20, 50 mg]
   - Prednisolone 1-2 mg/kg/day PO QD 5-7 days [5 mg/5 mL, 10 mg/5 mL, 20 mg/5 mL, 25 mg/5 mL]
10. Extras and X-rays: CXR PA and LAT, posteroanterior x-ray of neck.

**Varicella Zoster Infections**

**Immunocompetent Patient**

A. Therapy with oral acyclovir is not recommended routinely for the treatment of uncomplicated varicella in the otherwise healthy child <12 years of age.

B. Oral acyclovir may be given within 24 hours of the onset of rash. Administration results in a modest decrease in the duration and magnitude of fever and a decrease in the number and duration of skin lesions.

C. Acyclovir (Zovirax) 80 mg/kg/day PO q6h for five days, max 3200 mg/day [cap: 200 mg; susp: 200 mg/5 mL, tabs: 400, 800 mg]

**Immunocompromised Patient**

A. Intravenous acyclovir should be initiated early in the course of the illness. Therapy within 24 hours of rash onset maximizes efficacy. Oral acyclovir should not be used because of unreliable oral bioavailability.

Dose: 500 mg/m²/dose IV q8h x 7-10 days

B. Varicella zoster immune globulin (VZIG) may be given shortly after exposure to prevent or modify the course of the disease. It is not effective once disease is established.

Dose: 125 U per 10 kg body weight, round up to nearest vial size to max of 625 U [vial: 125 U/1.25ml]. Must be administered IM.

**Pneumocystis Carinii Pneumonia**

1. Admit to:
2. Diagnosis:
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   - Oxygen pm for hypoxia.
   - Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 15-20 mg TMP/kg/day IV/PO q6h x 14-21 days [inj per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg] x 14-21
Oral therapy is reserved for patients with mild disease who do not have malabsorption or diarrhea

OR

-Pentamidine isethionate (Pentam) 4 mg/kg/day IV over 1-2h for 14-21 days

-Prednisone:
<13 yrs: 2 mg/kg/day PO qd x 7-10 days, then taper over the next 10-14 days.
>13 yrs old with hypoxia: 40 mg PO bid x 5 days, then 40 mg PO qd x 5 days, then 20 mg PO qd x 11 days.

**Pneumocystis Carinii Pneumonia Prophylaxis:**

-Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 150 mg/m² trimethoprim/kg/day PO bid three days per week. (in) per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80/SMX 400 mg [inj per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80/SMX 400 mg]

- Dapsone (Avlosulfon) (>1 mo) 2 mg/kg/day PO q24h, max 100 mg/day or 4 mg/kg/dose PO q week, max 200 mg/dose [tabs: 25, 100 mg]

-Aerosolized Pentamidine (NebuPent) (if >5 yrs): 300 mg nebulized monthly

-Alovaquine (Mepron)
1-3 months and >24 months: 45 mg/kg/day PO qd 4-24 months: 30 mg/kg/day PO qd

**Septic Arthritis**

1. Admit to:
2. Diagnosis: Septic arthritis
3. Condition:
4. Vital signs: Call MD if:
5. Activity: No weight bearing on infected joint.
7. Diet:
8. IV Fluids:
9. Special Medications:
   **Empiric Therapy for Infants 1-6 months (strep, staph, gram neg, gonococcus):**
   -Nafcillin (Nafcil) or oxacillin (Bactocill, Prostaphlin) 100 mg/kg/day IV/IM q6h AND
   -Cefotaxime (Claforan) 100 mg/kg/day IV/IM q8h OR
   -Gentamicin (Garamycin) or tobramycin (Nebcin) (normal renal function): 7.5 mg/kg/day IV/IM q8h
   **Empiric Therapy for Patients Age 6 months-4 yr (H influenae, strep, staphylococcus):**
   -Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h (preferred for H flu coverage until culture results available) AND/OR
   -Nafcillin (Nafcil) or oxacillin (Bactocill) 100-200 mg/kg/day IV/IM q6h
   **Empiric Therapy for Children Older than 4 Years (staph, strep):**
   -Nafcillin (Nafcil) or oxacillin (Bactocill, Prostaphlin) 150 mg/kg/day IV/IM q6h, max 12 gm/day OR
   -Vancomycin (Vancocin) (MRSA) 40-60 mg/kg/day IV q6-8 h, max 4 gm/day.
10. **Symptomatic Medications:**
   -Acetaminophen and codeine 0.5-1 mg codeine/kg/dose PO q4-6h prn pain [elixir per 5 mL: codeine 12 mg, acetaminophen 120 mg]
   -Ibuprofen (Children’s Advil) 5-10 mg/kg/dose PO q6-8 hrs pm fever.
11. **Extravas and X-rays:** X-ray views of joint, CXR. Orthopedics and infectious disease consults. CT scan.

**Lower Urinary Tract Infection**

1. Admit to:
2. Diagnosis: UTI
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: Inputs and outputs
7. Diet:
8. IV Fluids:
9. Special Medications:
   **Lower Urinary Tract Infection:**
   -Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 6-10 mg/kg/day TMP PO q12h, max 320 mg TMP/day [susp per 5 mL: TMP 40 mg, SMX 200 mg; tab SS: 80 mg/400 mg; tab DS: 160 mg/600 mg] OR
   -Cefpodoxime (Vantin) 10 mg/kg/day PO q12h, max 800 mg/day [susp: 50 mg/5 mL, 100 mg/5 mL; tabs: 100, 200 mg] OR
   -Cefprozil (Ceftizox) 30 mg/kg/day PO q12h, max 1 gm/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg] OR
   **Prophylactic Therapy:**
   -Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 2
mg TMP/kg/day and 10 mg SMX/kg/day PO qhs (susp per 5 mL; TMP 40 mg/SMX 200 mg, tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80 mg/SMX 400 mg) OR
-Sulfisoxazole (Gantrisin) 10-20 mg/kg/day PO q12h (sr: 500 mg/5 mL; tab: 500 mg)

10. Symptomatic Medications:
-Phenazopyridine (Pyridium), children 6-12 yrs: 12 mg/kg/day PO tid (max 200 mg/dose); >12 yrs: 100-200 mg PO tid x 2 days prn dysuria [tabs: 100, 200 mg]. Does not treat infection; acts only as an analgesic.

11. Extras and X-rays: Renal ultrasound. Voiding cystourethrogram 3 weeks after infection. Radiological work up on all children <1 year of age.

12. Labs: CBC, SMA 7. UA with micro, urine Gram stain, culture and sensitivity. Repeat urine culture and sensitivity 24-48 hours after therapy; blood culture and sensitivity.

Pyelonephritis

1. Admit to:
2. Diagnosis: Pyelonephritis
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: inputs and outputs, daily weights
7. Diet:
8. IV Fluids:
9. Special Medications:
   -If less than 1 week old, see suspected sepsis, pages 108, 155.
   -Ampicillin 100 mg/kg/day IV/MM q6h, max 12 gm/day 
   AND
   -Gentamicin (Garamycin) or Tobramycin (Nebcin): 30 days-5 yr: 7.5 mg/kg/day IV/MM q8h.
   -10 yr: 5.0 mg/kg/day IV/MM q8h OR
   -Cefotaxime (Claforan) 100 mg/kg/day IV/MM q6-8h, max 12 gm/day.
10. Symptomatic Medications:
   -Acetaminophen (Tylenol) 10-15 mg/kg PO/PR q4-6h prn temp >38° ... 
11. Extras and X-rays: Renal ultrasound.
12. Labs: CBC, SMA-7, UA with micro, urine culture and sensitivity. Repeat urine culture and sensitivity 24-48 hours after initiation of therapy; blood culture and sensitivity x 2; drug levels.

Osteomyelitis

1. Admit to:
2. Diagnosis: Osteomyelitis
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   -Children <3 yrs (H flu, strep, staph): -Cefuroxime (Zinacef) 100-150 mg/kg/day IV/MM q8h, max 9 gm/day.
   -Children >3 yrs (staph, strep, H flu): -Nafcillin (Nafcil) or oxacillin (Bactocill) 100-150 mg/kg/day IV/MM q6h, max 12 gm/day OR
   -Cefotaxime (Claforan) 100-150 mg/kg/day IV/MM q8h, max 12 gm/day OR
   -Cefazolin (Ancef) 100 mg/kg/day IV/MM q6-8h, max 6 gm/day OR
   -Cefuroxime (Zinacef) 100-150 mg/kg/day IV/MM q8h, max 9 gm/day.
   -Postoperative or Traumatic (staph, gram neg, Pseudomonas):
     -Ticarcillin/clavulanate (Timentin) 200-300 mg/kg/day IV/MM q6-8h, max 24 gm/day OR
     -Vancomycin (Vancocin) 40-60 mg/kg/day IV q6-8h, max 4 gm/day AND
     -Cefazidine (Fortaz) 150 mg/kg/day IV/MM q6h, max 12 gm/day OR
     -Nafcillin (Nafcil) or oxacillin (Bactocill) 150 mg/kg/day IV/MM q6h, max 12 gm/day AND
     -Tobramycin (Nebcin) 30 days-5 yr: 7.5 mg/kg/day IV/MM q8h.
     -10 yr: 6.0 mg/kg/day IV/MM q8h.
   >10 yr: 5.0 mg/kg/day IV/MM q6h.
10. Symptomatic Medications:
   -Acetaminophen (Tylenol) 10-15 mg/kg PO/PR q4-6h prn temp >38° ... 
12. Labs: CBC, SMA 7, blood culture and sensitivity x 3, ESR, sickle prep, UA, culture and sensitivity, antibiotic levels, serum bacteriocidal titers.
Otitis Media

Acute Otitis Media (S pneumoniae, non-typable H flu, M catarrhalis, Staph aureus, group A streptococcus):
- Amoxicillin (Amoxil) 25-50 mg/kg/day PO q8h, max 3 gm/day
  [caps: 250, 500 mg; drops: 50 mg/mL; susp: 125 mg/5mL, 200 mg/5mL, 250 mg/5mL, 400 mg/5mL; tabs: 500, 875 mg; tabs, chew: 125, 200, 250, 400 mg] OR
- Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 6-8 mg/kg/day of TMP PO bid, max 320 mg TMP/day
  [susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg] OR
- Erythromycin/sulfisoxazole (Pediazole) 1 mL/kg/day PO qd or 40 mg/kg/day of erythromycin PO qd, max 50 mL/day
  [susp per 5 mL: erythromycin 200 mg/sulfisoxazole 600 mg] OR
- Amoxicillin/clavulanate (Augmentin) 40 mg/kg/day of amoxicillin PO q12h, max 875 mg of amoxicillin/dose
  [susp: 200 mg/5mL, 400 mg/5mL; tabs: 200, 400 mg]
- Azithromycin (Zithromax)
  Children >2 yrs: 12 mg/kg/day PO qd x 5 days, max 50 mL/day
  >16 yrs: 500 mg PO on day 1, 250 mg PO qd on days 2-5
  [cap: 250 mg; susp: 100 mg/5mL, 200 mg/5mL; tabs: 250, 500 mg]

Acute Otitis Media (resistant strains of Strep pneumoniae):
- Amoxicillin (Amoxil) 80-90 mg/kg/day PO q12h, max 3 gm/day
  [caps: 250, 500 mg; drops: 50 mg/mL; susp: 125 mg/5mL, 200 mg/5mL, 250 mg/5mL, 400 mg/5mL; tabs: 500, 875 mg; tabs, chew: 125, 200, 250, 400mg] OR
- Amoxicillin/clavulanate (Augmentin BID) 80-90 mg/kg/day PO q12h.
  [susp 200 mg/5 mL, 400 mg/5 mL; tab: 875 mg; tab, chew: 200, 400 mg]

Prophylactic Therapy (>3 episodes in 6 months):
Therapy reserved for control of recurrent acute otitis media, defined as three or more episodes per 6 months or 4 or more episodes per 12 months.
- Sulfisoxazole (Gantrisin) 50 mg/kg/day PO qhs [tab 500 mg; susp 500 mg/5 mL] OR
- Amoxicillin (Amoxil) 20 mg/kg/day PO qhs
  [caps: 250, 500 mg; drops: 50 mg/mL; susp: 125 mg/5mL, 200 mg/5mL, 250 mg/5mL, 400 mg/5mL; tabs: 500, 875 mg; tabs, chew: 125, 200, 250, 400mg] OR
- Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 4 mg/kg/day of TMP PO qhs
  [susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg]

Symptomatic Therapy:
- Ibuprofen (Advil) 5-10 mg/kg/dose PO q6-8 hrs prn fever
  [suspension: 100 mg/5 mL, tabs: 200, 300, 400, 600, 800 mg] AND/OR
- Acetaminophen (Tylenol) 10-15 mg/kg/dose PO/PR q4-6h prn fever
  [tabs: 325, 500 mg; chewable tabs: 80 mg; caplets: 160 mg, 500 mg; drops: 80 mg/0.8 mL; elixir: 120 mg/5 mL, 130 mg/5 mL, 160 mg/5 mL, 325 mg/5 mL; caplet, ER: 650 mg; suppositories: 120, 325, 650 mg].
- Benzocaine/antipyrine (Auralgan otic) fill ear canal with 2-4 drops, moisten cotton pledget and place in external ear; repeat every 1-2 hours prn pain [soln, otic: Antipyrine 5.4%, benzocaine 1.4% in 10 mL and 15 mL bottles]

Extras and X rays:
- Aspiration tympanocentesis, tympanogram; audiometry.
Otitis Externa

Otitis Externa (Pseudomonas, gram negatives, proteus):
- Polymyxin B/neomycin/hydrocortisone (Cortisporin otic susp or solution) 2-4 drops in ear canal tid-qid x 5-7 days.
  [otic soln or susp per mL: neomycin sulfate 5 mg; polymyxin B sulfate 10,000 units; hydrocortisone 10 mg in 10 mL bottles].
  The suspension is preferred. The solution should not be used if the eardrum is perforated.

Malignant Otitis Externa in Diabetes (Pseudomonas):
- Ceftazidime (Fortaz) 100-150 mg/kg/day IV/IM q8h, max 12 gm/day OR
- Piperacillin (Pipracil) or ticarcillin (Ticar) 200-300 mg/kg/day IV/IM q4-6h, max 24 gm/day OR
- Tobramycin (Nebcin) 30 days-5 yr: 7.5 mg/kg/day IV/IM q8h. 5-10 yr: 6.0 mg/kg/day IV/IM q8h. >10 yr: 5.0 mg/kg/day IV q8h.

Tonsillopharyngitis

Streptococcal Pharyngitis:
- Penicillin V (Pen Vee K) 25-50 mg/kg/day PO qid x 10 days, max 3 gm/day [susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 125, 250, 500 mg] OR
- Penicillin G benzathine (Bicillin LA) 25,000-50,000 U/kg (max 1.2 MU) IM x 1 dose OR
- Azithromycin (Zithromax) 12 mg/kg/day PO qd x 5 days, max 500 mg/day [cap: 250 mg; susp: 100 mg/5 mL, 200 mg/5 mL; tabs: 250, 600 mg] OR
- Clarithromycin (Biaxin) 15 mg/kg/day PO bid, max 1 gm/day [susp 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg] OR
- Erythromycin (penicillin allergic patients) 40 mg/kg/day PO qd x 10 days, max 2 gm/day [susp: 100 mg/5 mL, 200 mg/5 mL; tabs: 250, 500 mg; cap: 250 mg; susp: 100 mg/5 mL, 200 mg; tab, chew: 200 mg]

Prophylaxis (5 strep infections in 6 months):
- Penicillin V Potassium (Pen Vee K) 40 mg/kg/day PO bid, max 3 gm/day [susp 125 mg/5 mL, 250 mg/5 mL; tabs: 125, 250, 500 mg].

Retropharyngeal Abscess (strep, anaerobes, E corrodens):
- Ceftriaxone (Rocephin) 50 mg/kg/day IV/IM qd, max 2 gm/day OR
- Cefuroxime (Zinacef) 75-100 mg/kg/day IV/IM q8h, max 9 gm/day OR
- Cefotaxime (Claforan) 100-150 mg/kg/day IV/IM q6h, max 12 gm/day AND
- Latex agglutination; UA, urine antigen screen.

Epiglottitis

1. Admit to: Pediatric intensive care unit.
2. Diagnosis: Epiglottitis
3. Condition:
4. Vital Signs: Call MD if:
5. Activity:
7. Diet: NPO
8. IV Fluids:
9. Special Medications:
   - Oxygen, humidified, blow-by; keep sat >92%.
   - Antibiotics:
     Most common causative organism is Haemophilus influenzae.
     - Ceftriaxone (Rocephin) 50 mg/kg/day IV/IM qd, max 2 gm/day OR
     - Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q6h, max 9 gm/day OR
     - Cefotaxime (Claforan) 100-150 mg/kg/day IV/IM q6-8h, max 12 gm/day
10. Extras and X-rays: CXR PA and LAT, lateral neck. Otolaryngology consult for incision and drainage.
11. Labs: CBC, CBG/ABG. Blood culture and sensitivity, latex agglutination; UA, urine antigen screen.
Sinusitis

Treatment of Sinusitis (S. pneumoniae, H flu, M catarrhalis, group A strep, anaerobes):
- Treat for 14-21 days.
- Amoxicillin (Amoxil) 40 mg/kg/day PO tid, max 500 mg/day
  [caps: 250, 500 mg; drops: 50 mg/mL; sus: 500, 875 mg; tabs: 125, 200, 250 , 400mg]
  OR
- Azithromycin (Zithromax)
  Children >2 yrs: 12 mg/kg/day PO qd x 5 days, max 500 mg/day
  >16 yrs: 500 mg PO on day 1, 250 mg PO qd on Days 2-5
  [cap: 250 mg; susp: 100 mg/5mL, 200 mg/5mL; tab: 250, 500 mg]
  OR
- Trimethoprim/sulfamethoxazole (Bactrim, Septra) 6-8 mg/kg/day of TMP PO bid, max 320 mg TMP/day
  [susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg]
  OR
- Erythromycin/sulfisoxazole (Pediazole) 1 mL/kg/day PO qid or 40-50 mg/kg/day of erythromycin PO qid, max 2 gm erythromycin/day
  [sus: 125 mg/5 mL; erythromycin 200 mg, sulfisoxazole 600 mg]
  OR
- Amoxicillin/clavulanate (Augmentin) 40 mg/kg/day of amoxicillin PO bid, max 500 mg/dose
  [elixir 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg; tabs, chew: 125, 250 mg]
  OR
- Cefuroxime axetil (Ceftin)
  tab: child: 125-250 mg PO bid; adult: 250-500 mg PO bid
  susp: 30 mg/kg/day PO qid, max 500 mg/day
  [sus: 125 mg/5 mL; tabs: 125, 250, 500 mg]
  Labs: Sinus x-rays, MRI scan.

Active Pulmonary Tuberculosis

1. Admit to:
2. Diagnosis: Active Pulmonary Tuberculosis
3. Condition:
4. Vital signs:
5. Activity:
7. Diet:
8. Special Medications:

Pulmonary Infection:
Six Month Regimen: Two months of isoniazid, rifampin and pyrazinamide daily, followed by 4 months of isoniazid and rifampin daily OR
Two months of isoniazid, rifampin and pyrazinamide daily, followed by 4 months of isoniazid and rifampin twice weekly.

Nine Month Regimen (for hilar adenopathy only): Nine months of isoniazid and rifampin daily OR one month of isoniazid and rifampin daily, followed by 8 months of isoniazid and rifampin twice weekly.

Anti-tuberculosis Agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Daily Dose</th>
<th>Twice Weekly Dose</th>
<th>Dosage Forms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (Lanazid)</td>
<td>10-15 mg/kg/day PO qd, max 300 mg</td>
<td>20-30 mg/kg PO, max 900 mg</td>
<td>Tab: 50, 100, 300 mg, Syr: 10 mg/mL</td>
</tr>
<tr>
<td>Rifampin (Rifadin)</td>
<td>10-20 mg/kg/day PO qd, max 600 mg</td>
<td>10-20 mg/kg, max 600 mg</td>
<td>Cap: 150, 300 mg Extemporaneous suspension</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>20-40 mg/kg PO qd, max 2000 mg</td>
<td>50 mg/kg PO, max 2000 mg</td>
<td>Tab: 500 mg Extemporaneous suspension</td>
</tr>
<tr>
<td>Ethambutol (Myambutol)</td>
<td>15-25 mg/kg/day PO qd, max 2500 mg</td>
<td>50 mg/kg PO, max 2500 mg</td>
<td>Tab: 100, 400 mg</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>20-40 mg/kg IM qd, max 1 gm</td>
<td>20-40 mg IM, max 1 gm</td>
<td>Inj: 400 mg/mL, IM only</td>
</tr>
</tbody>
</table>

- Directly observed therapy should be considered for all patients. All household contacts should be tested.

Tuberculosis Prophylaxis for Skin Test Conversion:
- Isoniazid-susceptible: Isoniazid (Lanazid) 10 mg/kg/day (max 300 mg) PO qd x 6-9 months.
- Isoniazid-resistant: Rifampin (Rifadin) 10 mg/kg/day (max 600 mg) PO qd for 9 months.

10. Labs: CBC, SMA7, liver panel, HIV antibody, ABG. First AM sputum for AFB x 3 (drug sensitivity tests on
Cellulitis

1. Admit to:
2. Diagnosis: Cellulitis
3. Condition:
4. Vital signs: Call MD if:
5. Activity: Keep affected extremity elevated; warm compresses tid prn. Monitor area of infection.
7. Diet:
8. IV Fluids:
9. Special Medications: Empiric Therapy for Extremity Cellulitis:
   - Nafcillin (Natcil) or oxacillin (Bactocill, Prostaphlin) 100-200 mg/kg/day/IV/IM q4-6h, max 12 gm/day OR
   - Ceftazolin (Ancef) 75-100 mg/kg/day/IV/IM q8-12h, max 6 gm/day OR
   - Cefoxitin (Mefoxin) 100-160 mg/kg/day IV/IM q6h, max 12 gm/day OR
   - Ticarcillin/clavulanate (Timentin) 200-300 mg/kg/day IV/IM q6-8h, max 24 gm/day OR
   - Dicloxacillin (Dynicil, Dynapen, Pathocil) 50-100 mg/kg/day PO qid, max 2 gm/day [caps: 125, 250, 500 mg; susp: 62.5 mg/5 mL]
   
   OR
   - Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h, max 9 gm/day OR
   - Cefotaxime (Claforan) 100-150 mg/kg/day IV/IM q6-8h, max 12 gm/day OR

Periorbital Cellulitis (H. flu, pneumococcus):
   - Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h, max 9 gm/day OR
   - Cefotaxime (Claforan) 100-150 mg/kg/day IV/IM q6-8h, max 12 gm/day OR

Cheek/Buccal Cellulitis (Hflu):
   - Cefuroxime (Zinacef) 100-150 mg/kg/day IV/IM q8h, max 9 gm/day OR
   - Cefotaxime (Claforan) 100-150 mg/kg/day IV/IM q6-8h, max 12 gm/day OR

Impetigo, Scalded Skin Syndrome, and Staphylococcal Scarlet Fever

1. Admit to:
2. Diagnosis: Impetigo, scalded skin syndrome or staphylococcal scarlet fever
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
9. Special Medications:
   - Nafcillin (Natcil) or oxacillin (Bactocill, Prostaphlin) 100-200 mg/kg/day/IV/IM q4-6h, max 12 gm/day OR
   - Dicloxacillin (Dynicil, Dynapen, Pathocil) 25-50 mg/kg/day PO qid x 5-7 days, max 2 gm/day [caps: 125, 250, 500 mg; susp: 30 mg/kg/day PO qid, max 500 mg/day [susps: 125 mg/5 mL; tabs: 125, 250, 500 mg]
   - Cephalexin (Keflex) 25-50 mg/kg/day PO qid, max 4 gm/day [caps: 250, 500 mg; drops 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL; tabs: 125, 250, 500 mg]
   
   OR
   - Loracarbef (Lorabid) 30 mg/kg/day PO bid, max 800 mg/day [caps: 200, 400 mg; susp: 100 mg/5 mL, 200 mg/5 mL]
   - Cefpodoxime (Vantin) 10 mg/kg/day PO bid, max 800 mg/day [susps: 50 mg/5 mL, 100 mg/5 mL; tab: 100 mg, 200 mg]
   - Cefprozil (Cefzil) 30 mg/kg/day PO bid, max 1 gm/day [susps: 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]
   - Vancomycin (Vancocin) 40 mg/kg/day IV q6-8h, max 4 gm/day
   - Mupirocin (Bactroban) ointment or cream, apply topically tid (cream/ointment: 2% 15 gm). Extensive involvement requires systemic antibiotics.

10. Symptomatic Medications:
   - Acetaminophen and codeine, 0.5-1 mg codeine/kg/dose PO q4-6h pm pain [elixir per 5 mL: codeine 12 mg, acetaminophen 120 mg]
   
11. Labs: CBC, SMA 7, blood culture and sensitivity. Leading edge aspirate, Gram stain, culture and sensitivity; UA, urine culture.

Tetanus

History of One or Two Primary Immunizations or Unknown:

Low risk wound - Tetanus toxoid 0.5 mL IM.
Tetanus prone - Tetanus toxoid 0.5 mL IM, plus tetanus immunoglobulin (TIG) 250 U IM.

Three Primary Immunizations and 10 yrs or more Since Last Booster:

Low risk wound - Tetanus toxoid, 0.5 mL IM.
Tetanus prone - Tetanus toxoid, 0.5 mL IM.
Three Primary Immunizations and 5-10 yrs Since Last Booster:
- Low risk wound - None
- Tetanus prone - Tetanus toxoid 0.5 mL IM

Three Primary Immunizations and <5 yrs Since Last Booster:
- Low risk wound - None
- Tetanus prone - None

Treatment of Clostridium Tetani Infection:
- Tetanus immune globulin (TIG): single dose of 3,000 to 6,000 U IM (consider immune globulin intravenous if TIG is not available). Part of the TIG dose may be infiltrated locally around the wound. Keep wound clean and débrided.
- Penicillin G 100,000 UI/kg/day IV q4-6h, max 24 MI/day x 10-14 days OR
- Metronidazole (Flagyl) 30 mg/kg/day PO/IV q6h, max 4 gm/day x 10-14 days.

Pediculosis

Pediculosis Capitis (head lice):
- Permethrin (Nix) is the preferred treatment. Available in a 1% cream rinse that is applied to the scalp and hair for 10 minutes. A single treatment is adequate, but a second treatment may be applied 7-10 days after the first treatment [cream rinse: 1% 60 mL].
- Pyrethrin (Rid, A-2000, R&C). Available as a shampoo that is applied to the scalp and hair for 10 minutes. A repeat application 7-10 days later may sometimes be necessary [shampoo (0.3% pyrethrins, 3% piperonyl butoxide): 60, 120, 240 mL].
- For infestation of eyelashes, apply petrolatum ointment tid-qid for 8-10 days and mechanically remove the lice.

Pediculosis Corporis (body lice):
- Treatment consists of improving hygiene and cleaning clothes. Infested clothing should be washed and dried at hot temperatures to kill the lice. Pediculicides are not necessary.

Pediculosis Pubis (pubic lice, “crabs”): Permethrin (Nix) or pyrethrin-based products may be used as described above for pediculosis capitis. Retreatment is recommended 7-10 days later.

Scabies

Treatment:
- Bathe with soap and water; scrub and remove scaling or crusted detritus; towel dry. All clothing and bed linen contaminated within past 2 days should be washed in hot water for 20 min.
- Permethrin (Elimite) - 5% cream: Adults and children: Massage cream into skin from head to soles of feet. Remove by washing after 8 to 14 hours. Treat infants on scalp, temple and forehead. One application is curative. [cream: 5% 60 gm]
- Lindane (Kwell, Gamma benzene) - available as 1% cream or lotion: Use 1% lindane for adults and older children; not recommended in pregnancy, infants, or on excoriated skin. 1-2 treatments are effective. Massage a thin layer from neck to toes (including soles). In adults, 20-30 gm of cream or lotion is sufficient for 1 application. Bathe after 8 hours. May be repeated in one week if mites remain or if new lesions appear. Contraindicated in children <2 years of age. [lotion: 1% 60, 473 mL; shampoo:1% 60, 473 mL].

Dermatophytoses

Diagnostic procedures:
1. KOH prep of scales and skin scrapings for hyphae.
2. Fungal cultures are used for uncertain cases.

Treat for at least 4 weeks.

Tinea corporis (ringworm), cruris (jock itch), pedis (athlete’s foot):
- Ketoconazole (Nizoral) cream qd [2%: 15, 30, 60 gm].
- Clotrimazole (Lotrimin) cream bid [1%: 15, 30, 45 gm].
- Miconazole (Micatin) cream bid [2%: 15, 30 gm].
- Econazole (Spectazole) cream bid [1%: 15, 30, 85 gm].
- Oxiconazole (Oxistat) cream or lotion qd-bid [1% cream: 15, 30, 60 gm; 1% lotion: 30 mL].
- Sulconazole (Exelderm) cream or lotion qd-bid [1% cream: 15, 30, 60 gm; 1% lotion: 30 mL].
- Naftifine (Naftin) cream or gel applied bid [1% cream: 15, 30 gm; 1% gel: 5, 15, 30 gm].

Tinea capitis:
- Griseofulvin Microsize (Grisactin, Grifulvin V) 15-20 mg/kg/day PO qd, max 1000 mg/day [caps: 125, 250 mg; susp: 125 mg/5 mL; tabs: 250, 500 mg].
- Griseofulvin Ultramicrosize (Fulvicin P/G, Grisactin Ultra, Gris-PEG) 5-10 mg/kg/day PO qd, max 750 mg/day [tabs: 125, 165, 250, 330 mg].
- Give griseofulvin with whole-milk or fatty foods to increase absorption. May require 4-6 weeks of therapy and should be continued for two weeks beyond clinical resolution.

Tinea Unguium (Fungal Nail Infection):
- Griseofulvin (see dosage above) is effective, but may require up to 4 months of therapy.

Tinea Versicolor:
- Cover body surface from face to knees with selenium
sulfide 2.5% lotion or selenium sulfide 1% shampoo daily for 30 minutes for 1 week, then monthly x 3 to help prevent recurrences.

**Bite Wounds**

1. **Admit to:**
2. **Diagnosis:** Bite Wound.
3. **Condition:** Guarded.
4. **Vital signs:** Call MD if:
5. **Activity:**
6. **Nursing:** Cooling measures prn temp >38°C, age appropriate pain scale.
7. **Diet:**
8. **IV Fluids:** D5 NS at maintenance rate.
9. **Special Medications:**
   - Initiate antimicrobial therapy for: moderate/severe bite wounds, especially if edema or crush injury is present; puncture wounds, especially if bone, tendon sheath, or joint penetration may have occurred; facial bites; hand and foot bites; genital area bites; wounds in immunocompromised or asplenic patients.

**Dog Bites and Cat Bites:**
- Oral: amoxicillin/clavulanate
- Oral, penicillin allergic: extended-spectrum cephalosporins or trimethoprim-sulfamethoxazole PLUS clindamycin
- IV: ampicillin-sulbactam
- IV, penicillin allergic: extended spectrum cephalosporins or trimethoprim-sulfamethoxazole PLUS clindamycin

**Reptile Bites:**
- Oral: amoxicillin-clavulanate
- Oral, penicillin allergic: extended-spectrum cephalosporins or trimethoprim-sulfamethoxazole PLUS clindamycin
- IV: ampicillin-sulbactam PLUS gentamicin
- IV, penicillin allergic: clindamycin PLUS gentamicin

**Human Bites:**
- Oral: amoxicillin-clavulanate
- Oral, penicillin allergic: trimethoprim-sulfamethoxazole PLUS clindamycin
- IV: ampicillin-sulbactam
- IV, penicillin allergic: extended-spectrum cephalosporins or trimethoprim-sulfamethoxazole PLUS clindamycin

**Antibiotic Dosages:**
- **Amoxicillin/clavulanate (Augmentin):**
  - 40 mg/kg/day of amoxicillin PO tid, max 500 mg/dose
  - [elixir 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg; tabs, chew: 125, 250 mg OR]
  - Amoxicillin/clavulanate (Augmentin BID)
  - 40 mg/kg/day PO bid, max 875 mg (amoxicillin)/dose
  - [susp: 200 mg/5 mL, 400 mg/5 mL; tab: 875 mg; tabs, chew: 200, 400 mg]
- **Cefpodoxime (Vantin):**
  - 10 mg/kg/day PO bid, max 800 mg/day
  - [susp: 50 mg/5 mL, 100 mg/5 mL; tabs: 100 mg, 200 mg]
- **Cefprozil (Cefzil):**
  - 30 mg/kg/day PO bid, max 1 gm/day
  - [susp 125 mg/5 mL, 250 mg/5 mL; tabs: 250, 500 mg]
- **Cefixime (Suprax):**
  - 8 mg/kg/day PO bid-qd, max 400 mg/day
  - [susp: 100 mg/5 mL; tabs: 200, 400 mg]
- **Trimethoprim/Sulfamethoxazole (Bactrim, Septra):**
  - 6-8 mg/kg/day of TMP PO/I V bid, max 320 mg TMP/day
  - [inj per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg]
- **Clindamycin (Cleocin):**
  - 6-30 mg/kg/day PO q6-8h, max 1600 mg/day or 25-40 mg/kg/day IVIM q6-8h, max 4.8 gm/day [caps: 75, 150, 300 mg; soln: 75 mg/5 mL]
  - Ampicillin-sulbactam (Unasyn) 100-200 mg/kg/day ampicillin IV/IM q8h, max 12 gm ampicillin/day
  - [1.5 gm (ampicillin 1 gm and sulbactam 0.5 gm; 3 gm (ampicillin 2 gm and sulbactam 1 gm)]
  - Cefotaxime (Claforan) 100-150 mg/kg/day IVIM q6-8h, max 12 gm/day
  - Ceftriaxone (Rocephin) 50 mg/kg/day IVIM qd, max 2 gm/day
  - Gentamicin (Garamycin) (normal renal function):
    - <5 yr (except neonates): 7.5 mg/kg/day IVIM q8h.
    - 5-10 yr: 6.0 mg/kg/day IVIM q8h.
    - >10 yr: 5.0 mg/kg/day IVIM q8h.

**Additional Considerations:**
- Sponge away visible dirt. Irrigate with a copious volume of sterile saline by high-pressure syringe irrigation. Debride any devitalized tissue.
- Tetanus immunization if not up-to-date.
- Assess risk of rabies from animal bites and risk of hepatitis and HIV from human bites.

10. **Symptomatic Medications:**
- **Ibuprofen (Motrin):** 5-10 mg/kg/dose PO q6-8h prn OR
- **Acetaminophen (Tylenol):** 15 mg/kg PO/PR q4h prn temp >38°C or pain.

11. **Extras and X-rays:** X-ray views of site of injury.
12. **Labs:** CBC, SMA 7, wound culture.
Lyme Disease

1. Admit to:
2. Diagnosis: Lyme disease.
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing:
7. Diet:
8. IV Fluids: Isotonic fluids at maintenance rate.
9. Special Medications:
   Early Localized Disease:
   Age >6 yrs: doxycycline 100 mg PO bid x 14-21 days
   [caps: 50, 100 mg; susp: 25 mg/5mL; syrup: 50 mg/5mL; tabs 50, 100 mg]
   All ages: amoxicillin 25-50 mg/kg/day PO bid (max 3 gm/day) x 14-21 days
   [caps: 250,500 mg; drops: 50 mg/mL; susp: 125 mg/5mL, 200 mg/5mL, 250 mg/5mL, 400 mg/5mL;
   tabs: 500, 875 mg; tabs, chew: 125, 200, 250 , 400mg]

   Early Disseminated and Late Disease:
   Multiple Erythema Migrans: Take same oral regimen as for early disease but for 21 days.
   Isolated Facial Palsy: Take same oral regimen as for early disease but for 21-28 days.
   Arthritis: Take same oral regimen as for early disease but for 28 days.
   Persistent or Recurrent Arthritis:
   - Ceftriaxone (Rocephin) 75-100 mg/kg/day IM/IV q12-24h (max 2 gm/dose) for 14-21 days OR
   - Penicillin G 300,000 U/kg/day IV q4h (max 20 million units/day) x 14-21 days.
   Carditis or Meningitis or Encephalitis:
   - Ceftriaxone (Rocephin) 75-100 mg/kg/day IM/IV q12-24h (max 2 gm/dose) for 14-21 days OR
   - Penicillin G 300,000 U/kg/day IV q4h (max 20 million units/day) x 14-21 days.

   Lyme disease vaccine is available for children >15 years of age.
10. Symptomatic Medications:
    - Ibuprofen (Advil) 5-10 mg/kg/dose PO q6-8h prn temp >38° C OR
    - Acetaminophen (Tylenol) 15 mg/kg PO/PR q4h prn temp >38° C.
11. Extras and X-rays: CXR, MRI.
12. Labs: IgM-specific antibody titer usually peaks between weeks 3 and 6 after the onset of infection.
    Enzyme immunoassay (EIA) is the most commonly used test for detection of antibodies. The Western immunoblot test is the most useful for corroborating a positive or equivocal EIA test.
Gastroenteritis

1. Admit to:
2. Diagnosis: Acute Gastroenteritis
3. Condition:
4. Vital signs: Call MD if:
5. Activity: Inputs and outputs, daily weights, urine specific gravity.
6. Nursing: Diet:
7. Activity:
8. IV Fluids: See Dehydration, page 147.
9. Special Medications:
   Severe Gastroenteritis with Fever, Gross Blood and Neutrophils in Stool (E coli, Shigella, Salmonella):
   - Ceftriaxone (Rocephin) 50-75 mg/kg/day IV/IM q 12-24h, max 4 gm/day OR
   - Cefixime (Suprax) 8 mg/kg/day PO bid-qd, max 400 mg/day [susps: 100 mg/5 mL; tabs: 200, 400 mg]
   - Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 10 mg of TMP component/kg/day PO bid x 5-7d, max 320 mg TMP/day [susps per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg].

Salmonella (treat infants and patients with septicemia):
   - Ceftriaxone (Rocephin) 50-75 mg/kg/day IV/IM q12-24h, max 4 gm/day OR
   - Cefixime (Suprax) 8 mg/kg/day PO bid-qd, max 400 mg/day [susps: 100 mg/5 mL; tabs: 200, 400 mg]
   - Ampicillin 100-200 mg/kg/day IV q6h, max 12 gm/day or 50-100 mg/kg/day PO qid x 5-7d, max 4 gm/day [caps: 250, 500 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL] OR
   - Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 10 mg TMP/kg/day PO bid x 5-7d, max 320 mg TMP/day [susps per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg] OR
   - If >18 yrs: Ciprofloxacin (Cipro) 250-750 mg PO q12h or 200-400 mg IV q12h [inj: 200, 400 mg; susp: 100 mg/mL; tabs: 100, 250, 500, 750 mg]

Antibiotic Associated Diarrhea and Pseudomembranous Colitis (Clostridium difficile):
   - Treat for 7-10 days. Do not give antidiarrheal drugs.
   - Metronidazole (Flagyl) 30 mg/kg/day PO/IV (PO preferred) q8h x 7 days, max 4 gm/day, [inj: 500 mg; tabs: 250, 500 mg; extemporaneous suspension] OR
   - Vancomycin (Vancocin) 40 mg/kg/day PO qid x 7 days, max 2 gm/day [caps: 125, 250 mg; oral soln: 250 mg/5 mL, 500 mg/6 mL] Vancomycin therapy is reserved for patients who are allergic to metronidazole or who have not responded to metronidazole therapy.

Rotavirus supportive treatment, see Dehydration page 147.

10. Extras and X-rays: Upright abdomen
11. Labs: SMA7, CBC, stool Wright stain for leukocytes, Rotazyme. Stool culture and sensitivity for enteric pathogens; C difficile toxin and culture, ova and parasites; occult blood. Urine specific gravity, UA, blood culture and sensitivity.

Specific Therapy for Gastroenteritis

Shigella Sonnei:
   - Treat x 5 days. Oral therapy is acceptable except for seriously ill patients. For resistant strains, ciprofloxacin should be considered but is not recommended for use for persons younger than 18 years of age except in exceptional circumstances.
   - Ampicillin (preferred over amoxicillin) 50-100 mg/kg/day PO q6h, max 3 gm/day [caps: 250, 500 mg; drops: 100 mg/mL; susp: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL] OR
   - Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 10 mg TMP/kg/day PO/IV q12h x 5 days [inj per mL: TMP 16mg/SMX 80mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg] OR
   - Ampicillin 50-80 mg/kg/day PO q6h, max 4 gm/day; or 100 mg/kg/day IV/M q6h for 5-7 days, max 12 gm/day [caps: 250, 500 mg; susp: 125 mg/5 mL, 250 mg/5 mL] OR
   - Ceftriaxone (Rocephin) 50-75 mg/kg/day IV/IM q 12-24h, max 4 gm/day OR
   - Cefixime (Suprax) 8 mg/kg/day PO bid-qd, max 400 mg/day [susps: 100 mg/5 mL; tabs: 200, 400 mg]

Yersinia (sepsis):
   - Most isolates are resistant to first-generation cephalosporins and penicillins.
   - Trimethoprim/sulfamethoxazole (Bactrim, Septra) 10 mg/kg/day TMP PO q12h x 5-7 days [susps per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg]

Campylobacter jejuni:
   - Erythromycin 40 mg/kg/day PO q6h x 5-7 days, max 2 gm/day
   - Erythromycin ethylsuccinate (EryPed, EES) [susps: 200 mg/5 mL, 400 mg/5 mL; tab: 400 mg; tab, chew: 200 mg]
Erythromycin base (E-Mycin, Ery-Tab, Eryc)
[cap, DR: 250 mg; tabs: 250, 333, 500 mg] OR
-Azithromycin (Zithromax)
10 mg/kg PO x 1 on day 1 (max 500 mg) followed by 5 mg/kg/day PO qd on days 2-5 (max 250 mg)
[cap: 250 mg; susp: 100 mg/5mL, 200 mg/5mL; tabs: 250, 600 mg]

Enteropathogenic E coli (Travelers Diarrhea):
-Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 10 mg/kg/day TMP PO/IV bid [inj per mL: TMP 16 mg/SMX 80 mg; susp per 5 mL: TMP 40 mg/SMX 200 mg; tab DS: TMP 160 mg/SMX 800 mg; tab SS: TMP 80mg/SMX 400 mg].

Enteroinvasive E coli:
-Antibiotic selection should be based on susceptibility testing of the isolate. If systemic infection is suspected, parenteral antimicrobial therapy should be given.

Giardia Lamblia:
-Metronidazole is the drug of choice. A 5-7 day course of therapy has a cure rate of 80-95%. Furazolidone is 72-100% effective when given for 7-10 days. Albendazole is also an acceptable alternative when given for 5 days.
-Metronidazole (Flagyl) 15 mg/kg/day PO q8h x 5-7 days (max 4 gm/day) [tabs: 250, 500 mg; extemporaneous suspension] OR
-Furazolidone (Furoxone) 5-8.8 mg/kg/day PO qid for 7-10 days, max 400 mg/day [caps: 50, 100 mg; susp: 50 mg/5mL; syrup: 50 mg/5mL; tabs 50, 100 mg]

Entamoeba Histolytica:
-Asymptomatic cyst carriers:
-Metronidazole (Flagyl) 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; extemporaneous suspension] followed by:
-Metronidazole (Flagyl) 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; powder for reconstitution] OR
-Paromomycin (Humatin) 25-35 mg/kg/day PO q8h x 7 days [caps: 250 mg] OR
-Diloxanide: 20 mg/kg/day PO q8h x 10 days, max 1500 mg/day. (Available only through CDC).

Mild-to-moderate intestinal symptoms with no dysentery:
-Metronidazole (Flagyl): 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; extemporaneous suspension] followed by:
-Metronidazole (Flagyl) 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; powder for reconstitution] OR
-Paromomycin (Humatin) 25-35 mg/kg/day PO q8h x 7 days [caps: 250 mg] OR
-Diloxanide: 20 mg/kg/day PO q8h x 10 days, max 1500 mg/day. (Available only through CDC).

Dysentery or extraintestinal disease (including liver abscess):
-Metronidazole (Flagyl): 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; extemporaneous suspension] followed by:
-Metronidazole (Flagyl) 35-50 mg/kg/day PO q8h x 10 days, max 2250 mg/day [tabs: 250, 500 mg; powder for reconstitution] OR
-Paromomycin (Humatin) 25-35 mg/kg/day PO q8h x 7 days [caps: 250 mg] OR
-Diloxanide: 20 mg/kg/day PO q8h x 10 days, max 1500 mg/day. (Available only through CDC).

Hepatitis A
1. Admit to:
2. Diagnosis: Hepatitis A
3. Condition:
4. Vital signs: Call MD if:
5. Activity: Up ad lib
6. Nursing: Contact precautions.
7. Diet:
8. IV Fluids: D5NS IV at maintenance rate.
9. Symptomatic Medications:
   -Trime-tho
   -nida-zole (Tigan) 15 mg/kg/day PO or PR q6-8h, max 100 mg/dose if <13.6 kg or 200 mg/dose if 13.6-41 kg [caps: 100, 250 mg; inj: 100 mg/mL; susp: 100, 200 mg].
   -Acetaminophen (Tylenol) 15 mg/kg PO/PR q4h pm temp >38° C or pain.
   -Meperidine (Demerol) 1 mg/kg IV/IM q2-3h pm pain.
10. Special Medications:
   -Hepatitis A immune globulin, 0.02 mL/kg IM (usually requires multiple injections at different sites), when given within 2 weeks after exposure to HAV, is 65% effective in preventing symptomatic infection.
   -Hepatitis A vaccine (Havrix) if >2 yrs: 0.5 mL IM, repeat in 6-12 months.
12. Labs: IgM anti-HAV antibody, HAV IgG, liver function tests, INR, PTT, stool culture for enteric pathogens.

Hepatitis B
1. Admit to:
2. Diagnosis: Hepatitis B.
3. Condition: Guarded.
4. Vital signs: Call MD if:
5. Activity:
7. Diet: Low fat diet.
8. IV Fluids: Isotonic fluids at maintenance rate.
9. Symptomatic Medications:
   - Trimethobenzamide (Tigan) 15 mg/kg/day IM/PO/PR q8-12h, max 100 mg/dose if <13.6 kg or 200 mg/dose if 13.6-41 kg. [caps: 100, 250 mg; inj: 100 mg/mL; supp: 100, 200 mg].
   - Diphenhydramine (Benadryl) 1 mg/kg/dose IV/IM/IO/PO q6h prn pruritus or nausea, max 50 mg/dose OR
   - Acetaminophen (Tylenol) 15 mg/kg PO/PR q4h pm temp >38°C or pain.
   - Meperidine (Demerol) 1 mg/kg IV/IM q2-3h prn pain.
   - Hepatitis B immune globulin 0.06 mL/kg (minimum 0.5 mL) IM x1 AND
   - Hepatitis B vaccine 0.5 mL IM (complete three dose series with second dose in one month and third dose in six months)
10. Extravasation for previously unimmunized persons:
11. Labs: IgM anti-HAV, IgM anti-HBc, HBsAg, anti-HCV, alpha-1-antitrypsin, ANA, ferritin, ceruloplasmin, urine copper, liver function tests, INR, PTT.

Ulcerative Colitis

1. Admit to:
2. Diagnosis: Ulcerative colitis.
3. Condition:
4. Vital signs:
5. Activity:
8. IV Fluids:
9. Special Medications:
   - Mesalamine (Asacol): 50 mg/kg/day PO q8-12h, max 800 mg PO TID [tab, EC: 400 mg] OR
   - Mesalamine (Pentasa) 50 mg/kg/day PO q6-12h, max 1000 mg PO qid [cap, CR: 250 mg] OR
   - Mesalamine (Rowasa) >12 yrs: 60 mL (4 gm) retention enema at bedtime retained overnight for approximately 8 hrs [4 gm/60 mL] OR > 12 yrs: mesalamine (Rowasa) 1 suppository PR bid [supp: 500 mg] OR
   - Olsalazine sodium (Dipentum) >12 yrs: 500 mg PO with food bid [cap: 250 mg] OR
   - Sulfasalazine (Azulfidine), children >2 yrs: Mild exacerbation: 40-50 mg/kg/day PO q6h Moderate to severe exacerbation: 50-75 mg/kg/day PO q4-6h, max 6 gm/day.
   - Maintenance therapy: 30-50 mg/kg/day PO q4-8h, max 2 gm/day [susp: 50 mg/mL; tab, EC: 500 mg] OR
   - Hydrocortisone retention enema 100 mg PR qhs OR
   - Hydrocortisone acetate 90 mg aerosol foam PR qid or 25 mg supp PR bid.
   - Prednisone 1-2 mg/kg/day PO qAM or bid (max 40-60 mg/day).
Other Medications:
   - Vitamin B12 100 mcg IM qd x 5 days, then 100-200 mcg IM q month.
   - Multivitamin PO qAM or 1 ampule IV qAM.
   - Folic acid 1 mg PO qd.
11. Labs: CBC, platelets, SMA 7, Mg, ionized calcium; liver panel, blood culture and sensitivity x 2. Stool culture and sensitivity for enteric pathogens, ova and parasites, C. difficile toxin and culture, Wright's stain.

Gastroesophageal Reflux

A. Treatment:
   - Thicken feedings; give small volume feedings; keep head of bed elevated 30 degrees.
   - Metoclopramide (Reglan) 0.1-0.2 mg/kg/dose PO qid 20-30 minutes prior to feedings, max 1 mg/kg/day [concentrated soln: 10 mg/mL; syrup: 1 mg/mL; tab: 10 mg].
   - Cimetidine (Tagamet) 20-40 mg/kg/day IV/PO q6h (20-30 min before feeding) [inj: 150 mg/mL oral: 60 mg/mL, tabs: 200, 300, 400, 800 mg] OR
   - Ranitidine (Zantac) 2-4 mg/kg/day IV q8h or 4-6 mg/kg/day PO q12h [inj: 25 mg/mL; liquid: 15 mg/mL; tabs: 75, 150, 300 mg] OR
   - Erythromycin (used as a prokinetic agent not as an antibiotic) 2-3 mg/kg/dose PO q6-8h. [ethylsuccinate susp: 200 mg/5mL, 400 mg/5mL] Comitant cisapride is contraindicated due to potentially fatal drug interaction.
   - Cisapride (Propulsid) 0.15-0.3 mg/kg/dose PO tid-qid [susp: 1 mg/mL; tab, scored: 10 mg]. Available via limited-access protocol only (Janssen, 1-800-Janssen) due to risk of serious cardiac arrhythmias.
B. Extras and X-rays: Upper GI series, pH probe, gastroesophageal nuclear scintigraphy (milk scan), endoscopy.
Constipation

I. Management of Constipation in Infants
A. Glycerin suppositories are effective up to 6 months of age; 1 suppository rectally prn. Barley malt extract, 1-2 teaspoons, can be added to a feeding two to three times daily. Four to six ounces prune juice are often effective. After 6 months of age, lactulose 1 to 2 mL/kg/day is useful.
B. Infants that do not respond may be treated with emulsified mineral oil (Haley’s MO) 2 mL/kg/dose PO bid, increasing as needed to 6-8 oz per day.

II. Management of Constipation in Children >2 years of Age
A. The distal impaction should be removed with hypertonic phosphate enemas (Fleet enema). Usually three enemas are administered during a 36 to 48 hour period.
B. Lactulose may also be used at 5 to 10 mL PO bid, increasing as required up to 45 mL PO bid.
C. Emulsified mineral oil (Haley’s MO) may be begun at 2 mL/kg/dose PO bid and increased as needed up to 6 to 8 oz per day. Concerns about mineral oil interfering with absorption of fat-soluble vitamins have not been substantiated.
D. Milk of magnesia: Preschoolers are begun at 2 tsp PO bid, with adjustments made to reach a goal of one to three substantial stools a day over 1 to 2 weeks. Older children: 1-3 tablets (31 mg magnesium hydroxide/chewable tablet) PO bid prn.
E. A bulk-type stool softener (e.g., Metamucil) should be initiated. Increase intake of high-residue foods (e.g., fruits, vegetables), bran, and whole grain products. Water intake should be increased.

III. Stool Softeners and Laxatives:
A. Docusate sodium (Colace):
   <3y 20-40 mg/day PO q6-24h
   3-6y 20-60 mg/day PO q6-24h
   6-12y 40-150 mg/day PO q6-24h
   >12y 50-400 mg/day PO q6-24h
   [caps: 50, 100, 250 mg; oral soln: 10 mg/mL; 50 mg/mL]
B. Magnesium hydroxide (Milk of Magnesia) 0.5 mL/kg/dose or 2-5 yr: 5-15 mL; 6-12y: 15-30 mL; >12y: 30-60 mL PO prn.
C. Hyperosmotic soln (CoLyte or GoLytely) 15-20 mL/kg/hr PO/NG.
D. Polyethylene glycol (MiraLax)
   3-6 yr: 1 tsp powder dissolved in 3 ounces fluid PO qd-tid
   6-12 yr: ½ tablespoon powder dissolved in 4 ounces fluid PO qd-tid
   >12 yr: one tablespoon powder dissolved in 8 ounces fluid PO qd-tid
E. Senna (Senokot, Senna-Gen) 10-20 mg/kg POPR qhs prn (max 872 mg/day) [granules: 362 mg/teaspoon; supp: 652 mg; syrup: 218 mg/5mL; tabs: 187, 217, 600 mg]
F. Sennosides (Agoral, Senokot, Senna-Gen), 2-6 yrs: 3-8.6 mg/dose PO qd-bid; 6-12 yrs: 7.15-15 mg/dose PO qd-bid; > 12 yrs: 12-25 mg/dose PO qd-bid [granules per 5 mL: 8.3, 15, 20 mg; liquid: 33 mg/mL; syrup: 8.8 mg/5 mL; tabs: 6, 8.6, 15, 17, 25 mg]

IV. Diagnostic Evaluation: Anorectal manometry, anteroposterior and lateral abdominal radiographs, lower GI study of unprepared colon.
Toxicology

Poisonings

Gastric Decontamination:

Ipecac Syrup:
- <6 mos: not recommended
- 6-12 mos: 5-10 mL PO followed by 10-20 mL/kg of water
- >12 yrs: 30 mL PO followed by 240 mL of water
  May repeat dose one time if vomiting does not occur within 20-30 minutes. Syrup of ipecac is contraindicated in corrosive or hydrocarbon ingestions or in patients without or soon to lose gag reflex.

Activated Charcoal:
- 1 gm/kg/dose (max 50 gm) PO/NG; the first dose should be given using product containing sorbitol as a cathartic. Repeat ½ of initial dose q4h if indicated.

Gastric Lavage:
- Left side down, with head slightly lower than body; place large-bore orogastric tube and check position by injecting air and auscultating. Normal saline lavage: 15 mL/kg boluses until clear (max 400 mL), then give activated charcoal or other antidote.
- Save initial aspirate for toxicological exam. Gastric lavage is contraindicated if corrosives, hydrocarbons, or sharp objects were ingested.

Cathartics:
- Magnesium citrate 6% sln:
  - <6 yrs: 2-4 mL/kg/dose PO/NG
  - 6-12 yrs: 100-150 mL PO/NG
  - >12 yrs: 150-300 mL PO/NG

Antidotes to Common Poisonings

Narcotic or Propoxyphene Overdose:
- Naloxone (Narcan) 0.1 mg/kg/dose (max 4 mg) IV/IO/ET/IM, may repeat q2min.

Methanol or Ethylene Glycol Overdose:
- Ethanol 8-10 mL/kg (10% inj soln) IV in D5W over 30min, then 0.8-1.4 mL/kg/hr. Maintain ethanol level at 100-130 mg/dL.

Carbon Monoxide Inhalation:
- Oxygen 100% or hyperbaric oxygen.

Cyanide Ingestion:
- Amyl nitrite, break ampule and inhale ampule contents for 30 seconds q1min until sodium nitrite is administered. Use new amp q3min AND
- Sodium nitrite 0.33 mL/kg of 3% inj soln (max 10 mL) IV over 5 minutes. Repeat ½ dose 30 min later if inadequate clinical response.

Followed By:
- Sodium thiosulfate 1.65 mL/kg of 25% soln (max 50 mL) IV.

Phenothiazine Reaction (Extrapyramidal Reaction):
- Diphenhydramine (Benadryl) 1 mg/kg IV/IM q6h for 4 doses (max 50 mg/dose) followed by 5 mg/kg/day PO q6h for 2-3 days.

Digoxin Overdose:
- Digibind (Digoxin immune Fab). Dose (# vials) = digoxin level in ng/mL x body wt (kg)/100 OR
  Dose (# of vials) = mg of digoxin ingested divided by 0.6

Benzodiazepine Overdose:
- Flumazenil (Romazicon) 0.01 mg/kg IV (max 0.5 mg).
  Repeat dose if symptoms return.

Alcohol Overdose: Cardiorespiratory support
- Labs: Blood glucose; CBC, ABG, rapid toxicology screen.
- Treatment: Dextrose 0.5-1 gm/kg (2-4 mL/Kg D25W or 5-10 mL/Kg D10W), max 25 gm.
- Naloxone (Narcan) 0.1 mg/kg (max 2 mg) IV, repeat q2min prn to max dose 0-10 mg if drug overdose suspected. For extreme agitation, give diazepam 0.1-0.5 mg/kg IV (max 5 mg if < 5 yrs, 10 mg if >5 yrs).

Anticholinergic Toxicity
- Physostigmine (Antilirium): 0.01-0.03 mg/kg/dose IV; may repeat after 15-20 minutes to a maximum total dose of 2 mg.

Heparin Overdose
- Protamine sulfate dosage is determined by the most recent dosage of heparin and the time elapsed since the overdose.

<table>
<thead>
<tr>
<th>Dosage of Protamine Sulfate</th>
<th>Time Elapsed</th>
<th>IV Dose of Protamine (mg) to Neutralize 100 units of Heparin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Immediate</td>
<td>1-1.5</td>
</tr>
<tr>
<td></td>
<td>30-60 minutes</td>
<td>0.5-0.75</td>
</tr>
<tr>
<td></td>
<td>&gt; 2 hrs</td>
<td>0.25-0.375</td>
</tr>
</tbody>
</table>

Warfarin Overdose
- Phytonadione (Vitamin K1)
  - If no bleeding and rapid reversal needed and patient will require further oral anticoagulation therapy, give 0.5-2 mg IV/SC.
  - If no bleeding and rapid reversal needed and patient...
will not require further oral anticoagulation therapy, give 2.5 mg IV/SC
- If significant bleeding but not life-threatening, give 0.5-2 mg IV/SC
- If significant bleeding and life-threatening, give 5 mg IV [inj: 2 mg/mL, 10 mg/mL]

**Acetaminophen Overdose**

1. Admit to:
2. Diagnosis: Acetaminophen overdose
3. Condition:
4. Vital signs: Call MD if
5. Nursing: ECG monitoring, inputs and outputs, pulse oximeter, aspiration precautions.

6. Diet:
7. IV Fluids:
8. Special Medications:
9. Gastric lavage with 10 mL/kg (if >5 yrs, use 150-200 mL) of normal saline by nasogastric tube if < 60 minutes after ingestion.
- Activated charcoal (if recent ingestion) 1 gm/kg PO/NG q2-4h, remove via suction prior to acetylecysteine.
- N-Acetylcysteine (Mucomyst, NAC) loading dose 140 mg/kg PO/NG, then 70 mg/kg PO/NG q4h x 17 doses (20% sln diluted 1:4 in carbonated beverage); follow acetaminophen levels. Continue for full treatment course even if serum levels fall below nomogram.
- Phytodetoxine (Vitamin K) 1-5 mg PO/IVIM/SQ (if INR >1.5).
- Fresh frozen plasma should be administered if INR >3.
10. Extras and X-rays: Portable CXR. Nephrology consult for charcoal hemoperfusion.

**Lead Toxicity**

1. Admit to:
2. Diagnosis: Lead toxicity
3. Condition:
4. Vital signs: Call MD if
5. Nursing: ECG monitoring, inputs and outputs, pulse oximeter
6. Diet:
7. IV Fluids:
8. Special Medications:
9. Symptoms of lead encephalopathy and/or blood level >70 mcg/dL:
- Treat for five days with edetate calcium disodium and dimercaprol.
  - Edetate calcium disodium 250 mg/m2/dose IM q4h or 50 mg/kg/day continuous IV infusion or 1-1.5 g/m2 IV as either an 8hr or 24 hr infusion.
  - Dimercaprol (BAL): 4 mg/kg/dose IM q4h
- Symptomatic lead poisoning without encephalopathy or asymptomatic with blood level >70 mcg/dL:
  - Treat for 3–5 days with edetate calcium disodium and dimercaprol until blood lead level < 50 mcg/dL.
  - Edetate calcium disodium 167 mg/m2 IM q4h or 1 g/m2 as a 8-24 hr continuous IV infusion.
  - Dimercaprol (BAL): 4 mg/kg IM x 1 then 3 mg/kg/dose IM q4h
- Asymptomatic children with blood lead level 45-69 mcg/dL:
  - Edetate calcium disodium 25 mg/kg/day as a 8-24 hr IV infusion or IV q12h OR
  - Succimer (Chemet): 10 mg/kg/dose (or 350 mg/m2/dose) PO q8h x 5 days followed by 10 mg/kg/dose (or 350 mg/m2/dose) PO q12h x 14 days [cap: 100 mg].
11. Labs: CBC, SMA 7, blood lead level, serum iron level.

**Theophylline Overdose**

1. Admit to:
2. Diagnosis: Theophylline overdose
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: ECG monitoring until serum level is less than 20 mcg/mL; inputs and outputs, aspiration and seizure precautions.

7. Diet:
8. IV Fluids: Give IV fluids at rate to treat dehydration.
9. Special Medications:
- No specific antidote is available.
- Activated charcoal 1 gm/kg PO/NG (max 50 gm) q2-4h, followed by cathartic, regardless of time of ingestion. Multiple dose charcoal has been shown to be effective in enhancing elimination.
- Gastric lavage if greater than 20 mg/kg was ingested or if unknown amount ingested or if symptomatic.
- Charcoal hemoperfusion (if serum level >60 mcg/mL or signs of neurotoxicity, seizure, coma).
Iron Overdose

1. Admit to:
2. Diagnosis: Iron overdose
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: Inputs and outputs
7. Diet:
8. IV Fluids: Maintenance IV fluids
9. Special Medications:
   Toxicity likely if >60 mg/kg elemental iron ingested. Possibly toxic if 20-60 mg/kg elemental iron ingested. Induce emesis with ipecac if recent ingestion (<1 hour ago). Charcoal is not effective. Gastric lavage if greater than 20 mg/kg of elemental iron ingested or if unknown amount ingested.
   If hypotensive, give IV fluids (10-20 mL/kg normal saline) and place the patient in Trendelenburg’s position.
   Maintain urine output of >2 mL/kg/h.
   If peak serum iron is greater than 350 mcg/dL or if patient is symptomatic, begin chelation therapy.
   -Deferoxamine (Desferal) 15 mg/kg/hr continuous IV infusion. Continue until serum iron is within normal range.
   Exchange transfusion is recommended in severely symptomatic patients with serum iron >1,000 mcg/dL.
10. Extras and X-rays: KUB to determine if tablets are present in intestine.
11. Labs: Type and cross, CBC, electrolytes, serum iron, TIBC, INR/PTT, blood glucose, liver function tests, calcium.
Neurologic and Endocrinologic Disorders

Seizure and Status Epilepticus

1. Admit to: Pediatric intensive care unit.
2. Diagnosis: Seizure
3. Condition:
4. Vital signs: Neurochecks q2-6h; call MD if:
5. Activity:
7. Diet: NPO
8. IV Fluids:
9. Special Medications:
   - Febrile Seizures: Control fever with antipyretics and cooling measures. Anticonvulsive therapy is usually not required.
   - Status Epilepticus:
     1. Maintain airway, 100% O₂ by mask; obtain brief history, fingerstick glucose.
     2. Start IV NS. If hypoglycemic, give 1-2 mL/kg D25W IV/IO (0.25-0.5 gm/kg).
     3. Lorazepam (Ativan) 0.1 mg/kg (max 4 mg) IV/IM. Repeat q15-20 min x 3 pm.
     4. Phenytoin (Dilantin) 15-18 mg/kg in normal saline at <1 mg/kg/min (max 50 mg/min) IV/IO. Monitor BP and ECG (QT interval).
     5. If seizures continue, intubate and give phenobarbital loading dose of 15-20 mg/kg IV or 5 mg/kg IV every 15 minutes until seizures are controlled or 30 mg/kg is reached.
     6. If seizures are refractory, consider midazolam (Versed) infusion (0.1 mg/kg/hr) or general anesthesia with EEG monitoring.
   - Diet: NPO
   - IV Fluids:
   - Special Medications:
   - Febrile Seizures:
   - Status Epilepticus:
   - Generalized Seizures Maintenance Therapy:
     - Carbamazepine (Tegretol): <6 yr: initially 10-20 mg/kg/day PO bid, then may increase in 5-7 day intervals by 5 mg/kg/day; usual max dose 35 mg/kg/day PO q6-8h
     - Valproic acid (Depacon, Depakote, Depakene), see above
   - Partial Seizures and Secondary Generalized Seizures:

Partial Seizures and Secondary Generalized Seizures:

- Carbamazepine (Tegretol), see above OR
- Phenytoin (Dilantin), see above OR
- Valproic acid (Depacon, Depakote, Depakene), see above OR
Lamotrigine (Lamictal):

**Adding to regimen containing valproic acid:**
- 2-12 yrs: 0.15 mg/kg/day PO qd-bid weeks 1-2, then increase to 0.3 mg/kg/day PO qd-bid weeks 3-4, then increase q1-2 weeks by 0.3 mg/kg/day to maintenance dose 1-5 mg/kg/day (max 200 mg/day)
- >12 yrs: 25 mg PO qOD weeks 1-2, then increase to 25 mg PO qd weeks 3-4, then increase q1-2 weeks by 25-50 mg/day to maintenance dose 100-400 mg/day PO qd-bid

**Adding to regimen without valproic acid:**
- 2-12 yrs: 0.6 mg/kg/day PO bid weeks 1-2, then increase to 1.2 mg/kg/day PO bid weeks 3-4, then increase q1-2 weeks by 1.2 mg/kg/day to maintenance dose 5-15 mg/kg/day PO bid (max 400 mg/day)
- >12 yrs: 50 mg PO qd weeks 1-2, then increase to 50 mg PO bid weeks 3-4, then increase q1-2 weeks by 100 mg/day to maintenance dose 300-500 mg/day PO bid.

-Primidone (Mysoline) PO: 8 yrs: 50-125 mg/day qhs, increase by 50-125 mg/day q3-7d; usual dose 10-25 mg/kg/day tid-qid
>
16 yrs: 125-250 mg qhs; increase by 125-250 mg/day q3-7d, usual dose 750-1500 mg/day tid-qid (max 2 gm/day).

<table>
<thead>
<tr>
<th>Adjunctive Anticonvulsants</th>
</tr>
</thead>
</table>

**Carbamazepine** 4-12 mcg/mL

**Clonazepam** 20-80 ng/mL

**Ethosuximide** 40-100 mcg/mL

**Phenobarbital** 15-40 mcg/mL

**Phenytoin** 10-20 mcg/mL

**Primidone** 5-12 mcg/mL

**Valproic acid** 50-100 mcg/mL

**Felbamate (Felbatol)**
- 2-14 yrs: 15 mg/kg/day PO tid-qid, increase weekly by 15 mg/kg/day if needed to maximum of 45 mg/kg/day or 3600 mg/day (whichever is smaller)
- >14 yrs: 1200 mg/day PO tid-qid, increase weekly by 1200 mg/day if needed to maximum of 3600 mg/day (sus: 600 mg/5 mL; tabs: 400, 600 mg)

**Gabapentin (Neurontin)**
- 2-12 yrs: 5-35 mg/kg/day PO q8h
- >12 yrs: initially 300 mg PO tid, titrate dose upward if needed; usual dose 900-1800 mg/day, maximum 3600 mg/day (caps: 100, 300, 400 mg; soln: 250 mg/5 mL; tabs: 600, 800 mg)

**Levetiracetam (Keppra)**
- >16 yrs: 500 mg PO bid, may increase by 1000 mg/day q2 weeks to maximum of 3000 mg/day [tabs: 250, 500, 750 mg]

**Tiagabine (Gabitril)**
- <12 yrs: dosing guidelines not established
- 12-16 yrs: 4 mg PO qd x 1 week, then 4 mg bid x 1 week, then increase weekly by 4-8 mg/day and titrate to response; maximum dose 32 mg/day bid-qid. [tabs: 2, 4, 12, 20 mg]. Lower doses may be effective in patients not receiving enzyme-inducing drugs.

**Topiramate (Topamax)**
- 2-16 yrs with partial onset seizures: 1-3 mg/kg/day PO qhs x 1 week (max 25 mg/day), may increase q1-2 weeks by 1-3 mg/kg/day bid to usual maintenance dose 5-9 mg/kg/day bid
- 2-16 yrs with primary generalized tonic clonic seizures: use slower initial titration rate to max of 6 mg/kg/day PO by the end of eight weeks
- >16 yrs with partial onset seizures: 50 mg/day qhs x 1 week, then 100 mg/day bid x 1 week, then increase by 50 mg/day q week; usual maintenance dose 200 mg bid, max 1600 mg/day
- >16 yrs with generalized tonic clonic seizures: use slower initial titration rate to usual maintenance dose 200 mg bid, max 1600 mg/day [caps, sprinkles: 15, 25, 50 mg; tabs: 25, 100, 200 mg]
Vigabatrin (Sabril) PO
3-9 yrs: 500 mg bid
> 9 yrs: 1000 mg bid, may increase if needed to max 4000 mg/day
(tab: 500 mg). Most effective in complex partial seizures, with or without generalization. Should be used as add-on therapy in patients with drug-resistant seizures, not as monotherapy. Do not abruptly discontinue therapy; gradually taper off to avoid rebound increase in seizure frequency and possible psychotic-like episodes.

New Onset Diabetes
1. Admit to:
2. Diagnosis: New Onset Diabetes Mellitus
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet: Diabetic diet with 1000 kcal + 100 kcal/year of age. 3 meals and 3 snacks (between each meal and qhs.)
8. IV Fluids: Hep-lock with flush q shift.
9. Special Medications:
   - Goal is preprandial glucose of 100-200 mg/dL

<table>
<thead>
<tr>
<th>Total Daily Insulin Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5 Years (U/kg)</td>
</tr>
<tr>
<td>5-11 Years (U/kg)</td>
</tr>
<tr>
<td>12-18 Years (U/kg)</td>
</tr>
<tr>
<td>0.6-0.8</td>
</tr>
<tr>
<td>0.75-0.9</td>
</tr>
<tr>
<td>0.8-1.5</td>
</tr>
</tbody>
</table>

-Divide 2/3 before breakfast and 1/3 before dinner. Give 2/3 of total insulin requirement as NPH and give 1/3 as lispro or regular insulin.
10. Extras and X-rays: CXR. Endocrine and dietary consult.
11. Labs: CBC, ketones; SMA 7 and 12, antithyroglobulin, antithyroid microsomal, anti-insulin, anti-islet cell antibodies. UA, urine culture and sensitivity; urine pregnancy test; urines ketones.

Diabetic Ketoacidosis
1. Admit to: Pediatric intensive care unit.
2. Diagnosis: Diabetic ketoacidosis
3. Condition: Critical
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: ECG monitoring; capillary glucose checks q1-2h until glucose level is <200 mg/dL, daily weights, inputs and outputs. O₂ at 2-4 L/min by NC. Record labs on flow sheet.
7. Diet: NPO
8. IV Fluids: 0.9% saline 10-20 mL/kg over 1h, then repeat until hemodynamically stable. Then give 0.45% saline and replace ½ of calculated deficit plus insensible loss over 24h, replace remaining ½ of deficit plus insensible losses over 16-24h. Keep urine output >1.0 mL/kg/hour.
   Add KCL when potassium is <6.0 mEq/dL
   Serum K+ Infuse KCL
   <3 40-60 mEq/L
   3-4 30
   4-5 20
   5-6 10
   >6 0
   Rate: 0.25-1 mEq KCL/kg/hr, maximum 1 mEq/kg/h or 20 mEq/h.
9. Special Medications:
   -Insulin Regular (Humulin) 0.05-0.1 U/kg/hr (50 U in 500 mL NS) continuous IV infusion. Adjust to decrease glucose by 50-100 mg/dL/hr.
   -If glucose decreases at less than 50 mg/dL/hr, increase insulin to 0.14-0.2 U/kg/hr. If glucose decreases faster than 100 mg/dL/hr, continue insulin at 0.05-0.1 U/kg/h and add D5W to IV fluids.
   -When glucose approaches 250-300 mg/dL, add D5W to IV. Change to subcutaneous insulin (lispro or regular) when bicarbonate is >15, and patient is tolerating PO food; do not discontinue insulin drip until one hour after subcutaneous dose of insulin.
10. Extras and X-rays: Portable CXR, ECG. Endocrine and dietary consultation.
11. Labs: Dextrostix q1-2h until glucose <200, then q3-6h. Glucose, potassium, phosphate, bicarbonate q3-4h; serum acetone, CBC, UA, urine ketones, culture and sensitivity.
Hematologic and Inflammatory Disorders

**Sickle Cell Crisis**

1. Admit to:
2. Diagnosis: Sickle Cell Anemia, Sickle Cell Crisis
3. Condition:
4. Vital signs: Call MD if
5. Activity:
6. Nursing: Age appropriate pain scale.
7. Diet:
8. IV Fluids: D5 ½ NS at 1.5-2.0 x maintenance.

**Special Medications:**
- Oxygen 2-4 L/min by NC.
- Morphine sulfate 0.1 mg/kg/dose (max 10-15 mg) IV/IM/SC q2-4h prn or follow bolus with infusion of 0.05-0.1 mg/kg/hr prn or 0.3-0.5 mg/kg PO q4h prn OR
- Acetaminophen/codeine 0.5-1 mg/kg/dose (max 60 mg/dose) of codeine PO q4-6h prn [elixir: 12 mg codeine/5 mL; tabs: 15, 30, 60 mg codeine component] OR
- Acetaminophen and hydrocodone [elixir per 5 mL: hydrocodone 2.5 mg, acetaminophen] 167 mg; tabs: Hydrocodone 2.5 mg, acetaminophen 500 mg; Hydrocodone 5 mg, acetaminophen 500 mg; Hydrocodone 7.5 mg, acetaminophen 500 mg; Hydrocodone 7.5 mg, acetaminophen 650 mg; Hydrocodone 10 mg, acetaminophen 500 mg; Hydrocodone 10 mg, acetaminophen 650 mg Children: 0.6 mg hydrocodone/kg/day PO q6-8h prn <2 yr: do not exceed 1.25 mg/dose 2-12 yr: do not exceed 5 mg/dose >12 yr: do not exceed 10 mg/dose

**Patient Controlled Analgesia**
- Morphine
  - Basal rate 0.01-0.02 mg/kg/hr
  - Intermittent bolus dose 0.01-0.03 mg/kg
  - Bolus frequency (‘lockout interval’) every 6-15 minutes
- Hydromorphone (Dilaudid)
  - Basal rate 0.0015-0.003 mg/kg/hr
  - Intermittent bolus dose 0.0015-0.0045 mg/kg
  - Bolus frequency (‘lockout interval’) every 6-15 min

**Adjunctive Therapy:**
- Hydroxyzine (Vistaril) 0.5-1 mg/kg/dose PO q6h (max 50 mg/dose)
- Ibuprofen (Motrin) 10 mg/kg/dose PO q6h (max 800 mg/dose) OR
- Ketorolac (Toradol) 0.4 mg/kg/dose IV/IM q8h (max 30 mg/dose); maximum 3 days, then switch to oral ibuprofen

**Maintenance Therapy:**
- Hydroxyurea (Hydrea): 15 mg/kg/day PO qd, may increase by 5 mg/kg/day q12 weeks to a maximum dose of 35 mg/kg/day. Monitor for myelotoxicity. [caps: 200, 300, 400, 500 mg]
- Folic acid 1 mg PO qd (if >1 yr).
- Transfusion PRBC 5 mL/kg over 2h, then 10 mL/kg over 2h, then check hemoglobin. If hemoglobin is less than 6-8 g/dL, give additional 10 mL/kg.
- Deferoxamine (Desferal) 15 mg/kg/hr x 48 hours (max 12 gm/day) concomitantly with transfusion or 1-2 gm/day SQ over 8-24 hrs
- Vitamin C 100 mg PO qd while receiving deferoxamine
- Vitamin E PO qd while receiving deferoxamine
- Penicillin VK (Pen Vee K) (prophylaxis for pneumococcal infections): <3 yrs: 125 mg PO bid; >3 yrs: 250 mg PO bid [elixir: 125 mg/mL, 250 mg/5 mL; tabs: 125, 250, 500 mg]. If compliance with oral antibiotics is poor, use penicillin G benzathine 50,000 U/kg (max 1.2 million units) IM every 3 weeks. Erythromycin is used if penicillin allergic.

10. **Extras and X-rays:** CXR.

11. **Labs:** CBC, blood culture and sensitivity, reticulocyte count, type and cross, SMA 7, parvovirus titers, UA, urine culture and sensitivity.

**Kawasaki Syndrome**

1. Admit to:
2. Diagnosis:
3. Condition:
4. Vital signs:
5. Activity: Bedrest
6. Nursing: Temperature at least q4h
7. Diet:
8. Special Medications:
- Immunoglobulin (IVIG) 2 gm/kg/dose IV x 1 dose. Administer dose at 0.02 mL/kg/min over 30 min; if no adverse reaction, increase to 0.04 mL/kg/min over 30 min; if no adverse reaction, increase to 0.08 mL/kg/min for remainder of infusion. Defer measles vaccination for 11 months after receiving high dose IVIG. [inj: 50 mg/mL, 100 mg/mL]
- Aspirin 100 mg/kg/day PO or PR q6h until fever resolves, then 8-10 mg/kg/day PO/PR qd (supp: 60, 120, 125, 130, 195, 200, 300, 325, 600, 650 mg; tabs: 325, 500, 650 mg; tab, chew: 81 mg).
-Ambubag, epinephrine (0.1 mL/kg of 1:10,000), and diphenhydramine 1 mg/kg (max 50 mg) should be available for IV use if an anaphylactic reaction to immunoglobulin occurs.

9. **Extras and X-rays:** ECG, echocardiogram, chest X-ray. Rheumatology consult.

10. **Labs:** CBC with differential and platelet count. ESR. CBC, liver function tests, rheumatoid factor, salicylate levels, blood culture and sensitivity x 2. SMA 7.
**Dehydration**

1. Admit to:
2. Diagnosis: Dehydration
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:

### Maintenance Fluids:

<table>
<thead>
<tr>
<th>Weight Range</th>
<th>Fluid Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10 kg</td>
<td>100 mL/kg/24h</td>
</tr>
<tr>
<td>10-20 kg</td>
<td>1000 mL plus 50 mL/kg/24h for each kg over 10 kg</td>
</tr>
<tr>
<td>&gt;20 kg</td>
<td>1500 mL plus 20 mL/kg/24h for each kg over 20 kg</td>
</tr>
</tbody>
</table>

### Electrolyte Requirements:

- Sodium: 3-5 mEq/kg/day
- Potassium: 2-3 mEq/kg/day
- Chloride: 3 mEq/kg/day
- Glucose: 5-10 gm/100 mL water required (D5W - D10W)

### Estimation of Dehydration

<table>
<thead>
<tr>
<th>Degree of Dehydration</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight Loss--Infants</td>
<td>5%</td>
<td>10%</td>
<td>15%</td>
</tr>
<tr>
<td>Weight Loss--Children</td>
<td>3%–4%</td>
<td>6%-8%</td>
<td>10%</td>
</tr>
<tr>
<td>Pulse</td>
<td>Normal</td>
<td>Slightly increased</td>
<td>Very increased</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>Normal</td>
<td>Normal to orthostatic, &gt;10 mm Hg change</td>
<td>Orthostatic to shock</td>
</tr>
<tr>
<td>Behavior</td>
<td>Normal</td>
<td>Irritable</td>
<td>Hyperirritable to lethargic</td>
</tr>
<tr>
<td>Thirst</td>
<td>Slight</td>
<td>Normal to sunken</td>
<td>Sunken</td>
</tr>
<tr>
<td>Mucous Membranes</td>
<td>Normal</td>
<td>Dry</td>
<td>Parched</td>
</tr>
<tr>
<td>Tears</td>
<td>Present</td>
<td>Decreased</td>
<td>Absent, sunken eyes</td>
</tr>
<tr>
<td>Anterior Fontanelle</td>
<td>Normal</td>
<td>Normal to sunken</td>
<td>Sunken</td>
</tr>
<tr>
<td>External Jugular Vein</td>
<td>Visible when supine</td>
<td>Not visible except with supravacular pressure</td>
<td>Not visible even with supravacular pressure</td>
</tr>
<tr>
<td>Skin</td>
<td>Capillary refill &lt;2 sec</td>
<td>Delayed capillary refills, 2-4 sec (decreased turgor)</td>
<td>Very delayed capillary refill (&gt;4 sec), tenting; cool skin, acrocyanotic, or mottled</td>
</tr>
<tr>
<td>Urine Specific Gravity (SG)</td>
<td>&gt;1.020</td>
<td>&gt;1.020; oliguria</td>
<td>Oliguria or anuria</td>
</tr>
<tr>
<td>Approximate Fluid Deficit</td>
<td>&lt;50 mL/kg</td>
<td>50-100 mL/kg</td>
<td>&gt;100 mL/kg</td>
</tr>
</tbody>
</table>

### Electrolyte Deficit Calculation:

- Na\(^+\) deficit = (desired Na - measured Na in mEq/L) x 0.6 x weight in kg
- K\(^+\) deficit = (desired K - measured K in mEq/L) x 0.25 x weight in kg
- Cl\(^-\) deficit= (desired Cl - measured Cl in mEq/L) x 0.45 x weight in kg
- Free H\(_2\)O deficit in hyponatremic dehydration = 4 mL/kg for every mEq that serum Na >145 mEq/L.

### Phase 1, Acute Fluid Resuscitation (Symptomatic Dehydration):

- Give NS 20-30 mL/kg IV at maximum rate; repeat fluid boluses of NS 20-30 mL/kg until adequate circulation.

### Phase 2, Deficit and Maintenance Therapy (Asymptomatic dehydration):

#### Hypotonic Dehydration (Na\(^+\) <125 mEq/L):

- Calculate total maintenance and deficit fluids and sodium deficit for 24h (minus fluids and electrolytes given in phase 1). If isotonic or hyponatremic dehydration, replace 50% over 8h and 50% over next 16h.
- Estimate and replace ongoing losses q6-8h.
- Add potassium to IV solution after first void.
- Usually D5 ½ NS or D5 1/4 NS saline with 10-40 mEq KCl/liter 60 mL/kg over 2 hours. Then infuse at 6-8 mL/kg/h for 12h.
- See hyponatremia, page 150.
Isotonic Dehydration (Na+ 130-150 mEq/L):
- Calculate total maintenance and replacement fluids for 24h (minus fluids and electrolytes given in phase 1) and give half over first 8h, then remaining half over next 16 hours.
- Add potassium to IV solution after first void.
- Estimate and replace ongoing losses.
- Usually D5 ½ NS or D5 1/4 NS with 10-40 mEq KCL/L.

Hypertonic Dehydration (Na+ >150 mEq/L):
- Calculate and correct free water deficit and correct slowly. Lower sodium by 10 mEq/L/day; do not reduce sodium by more than 15 mEq/L/24h or by >0.5 mEq/L/hr.
- If volume depleted, give NS 20-40 mL/kg IV until adequate circulation, then give ½-1/4 NS in 5% dextrose to replace half of free water deficit over first 24h. Follow serial serum sodium levels and correct deficit over 48-72h.
- Free water deficit: 4 mL/kg x (serum Na+ -145)
- Also see "hypernatremia" page 150.
- Add potassium to IV solution after first void as KCL.
- Usually D5 1/4 NS or D5W with 10-40 mEq/L KCL. Estimate and replace ongoing losses and maintenance.

Replacement of ongoing losses (usual fluids):
- Nasogastric suction: D5 ½ NS with 20 mEq KCL/L or ½ NS with KCL 20 mEq/L.
- Diarrhea: D5 1/4 NS with 40 mEq KCl/L.

Oral Rehydration Therapy (mild-moderate dehydration <10%):
- Oral rehydration electrolyte solution (Rehydralyte, Pedialyte, Ricelyte, Revital Ice) deficit replacement of 60-80 mL/kg PO or via NG tube over 2h. Provide additional fluid requirement over remaining 18-20 hours; add anticipated fluid losses from stools of 10 mL/kg for each diarrheal stool.

<table>
<thead>
<tr>
<th>Oral Electrolyte Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Rehydralyte</td>
</tr>
<tr>
<td>Ricelyte</td>
</tr>
<tr>
<td>Pedialyte</td>
</tr>
</tbody>
</table>

Hyperkalemia
1. Admit to: Pediatric ICU
2. Diagnosis: Hyperkalemia
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:

Hyperkalemia (K+ >7 or EKG Changes)
- Calcium gluconate 50-100 mg/kg (max 1 gm) IV over 5-10 minutes or calcium chloride 10-20 mg/kg (max 1 gm) IV over 10 minutes.
- Regular insulin 0.1 U/kg plus glucose 0.5 gm/kg IV bolus (as 10% dextrose).
- Sodium bicarbonate 1-2 mEq/kg IV over 3-5 min (give after calcium in separate IV), repeat in 10-15 min if necessary.
- Furosemide (Lasix) 1 mg/kg/dose (max 40 mg IV) IV q6-12h pm, may increase to 2 mg/kg/dose IV [inj: 10 mg/mL].
- Kayexalate resin 0.5-1 gm/kg PO/PR. 1 gm resin binds 1 mEq of potassium.
9. Labs: SMA7, Mg, calcium, CBC, platelets, UA; urine potassium.
10. Extras and X-rays: ECG, dietetics, nephrology consults.

Hypokalemia
1. Admit to: Pediatric ICU
2. Diagnosis: Hypokalemia
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
If serum K <2.5 mEq/L and ECG changes are absent:
- Add 20-40 mEq KCL/L to maintenance IV fluids. May give 1-4 mEq/kg/day to maintain normal serum potassium. May supplement with oral potassium.
K <2.5 mEq/L and ECG abnormalities:
- Give KCL 1-2 mEq/kg IV at 0.5 mEq/kg/hr; max rate 1 mEq/kg/hr or 20 mEq/kg/hr in life-threatening situations ( whichever is smaller). Recheck serum potassium, and repeat IV boluses pm; ECG monitoring required.

Oral Potassium Therapy:
- Potassium chloride (KCl) elixir 1-3 mEq/kg/day PO q8-24h [10% soln = 1.33 mEq/mL].
Hyponatremia

1. Admit to:
2. Diagnosis: Hyponatremia
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
7. Diet:
8. IV Fluids:
   - If volume depleted or hypotensive, give NS 20-40 mL/kg IV until adequate circulation. Determine volume deficit clinically, and determine sodium deficit as below.
   - Calculate 24 hour fluid and sodium requirement and give half over first 9 hours, then give remainder over 16 hours. 0.9% saline = 154 mEq/L
   - Usually D5NS 60 mL/kg IV over 2h (this will increase extracellular sodium by 10 mEq/L), then infuse at 6-8 mL/kg/hr x 12h.

Hyponatremia with Hypovolemia (low osmolality <280; urine sodium <10 mM/L; vomiting, diarrhea, 3rd space/respiratory/skin loss; urine sodium >20 mM/L: diuretics, renal injury, renal tubular acidosis, adrenal insufficiency, partial obstruction, salt wasting):
   - If volume depleted, give NS 20-40 mL/kg IV until adequate circulation.
   - Correct half of sodium deficit slowly over 24h. Determine volume of 3% hypertonic saline (513 mEq/L) to be infused as follows:
     - Correct half of sodium deficit slowly over 24h.
     - For acute correction, the serum sodium goal is 125 mEq/L; max rate for acute replacement is 1 mEq/kg/hr. Serum Na should be adjusted in increments of 5 mEq/L to reach 125 mEq/L. The first dose is given over 4 hrs. For further correction for serum sodium to above 125 mEq/L, calculate mEq dose of sodium and administer over 24-48h.

Severe Symptomatic Hyponatremia:
   - If volume depleted, give NS 20-40 mL/kg IV until adequate circulation.
   - Calculate volume of 3% hypertonic saline (513 mEq/L) to be infused as follows:
     - Volume of soln (L) = Sodium to be infused (mEq) ÷ mEq/L in solution
     - For acute correction, the serum sodium goal is 125 mEq/L; max rate for acute replacement is 1 mEq/kg/hr. Serum Na should be adjusted in increments of 5 mEq/L to reach 125 mEq/L. The first dose is given over 4 hrs. For further correction for serum sodium to above 125 mEq/L, calculate mEq dose of sodium and administer over 24-48h.

9. Extras and X-rays: CXR, ECG.

Hypophosphatemia

Indications for Intermittent IV Administration:
1. Serum phosphate <1.0 mg/dL or
2. Serum phosphate <2.0 mg/dL and patient symptomatic or
3. Serum phosphate <2.5 mg/dL and patient on ventilator
### Treatment of Hypophosphatemia

<table>
<thead>
<tr>
<th>Dosage of IV Phosphate</th>
<th>Serum Phosphate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low dose</td>
<td></td>
</tr>
<tr>
<td>0.08 mM/kg IV over 6 hrs</td>
<td>&gt;1 mg/dL</td>
</tr>
<tr>
<td>Intermediate dose</td>
<td></td>
</tr>
<tr>
<td>0.16 mM/kg IV over 6 hrs</td>
<td>0.5-1 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.24 mM/kg IV over 6 hrs</td>
</tr>
<tr>
<td>High Dose</td>
<td></td>
</tr>
<tr>
<td>0.36 mM/kg IV over 6 hrs</td>
<td>&lt;0.5 mg/dL</td>
</tr>
</tbody>
</table>

**IV Phosphate Cations:**
- Sodium phosphate: Contains sodium 4 mEq/mL, phosphate 3 mM/mL
- Potassium phosphate: Contains potassium 4.4 mEq/mL, phosphate 3 mM/mL
- Max rate 0.06 mM/kg/hr

**Oral Phosphate Replacement**
- 1-3 mM/kg/day PO bid-qid

**Potassium Phosphate:**
- Powder (Neutra-Phos-K): phosphorus 250 mg [8 mM] and potassium 556 mg [14.25 mEq] per packet; Tab (K-Phos Original): phosphorus 114 mg [3.7 mM], potassium 144 mg [4.3 mEq]
- Sodium Phosphate: Phosphosoda Soln per 100 mL: sodium phosphate 10 gm and sodium biphosphate 48 gm (contains phosphate 4 mM/mL)
- Sodium and Potassium Phosphate: Powd Packet: phosphorus 250 mg [8 mM], potassium 278 mg [7.125 mEq], sodium 164 mg [7.125 mEq]; Tabs:
  - K-Phos MF: phosphorus 125.6 mg [4 mM], potassium 44.5 mg [1.1 mEq], sodium 67 mg [2.9 mEq]
  - K-Phos Neutral: phosphorus 250 mg [8 mM], potassium 226 mg [13 mEq]
  - K-Phos No 2: phosphorus 250 mg [8 mM], potassium 88 mg [2.3 mEq]
- Uro-KP-Neutral: phosphorus 250 mg [8 mM], potassium 49.4 mg [1.27 mEq], sodium 250.5 mg [10.9 mEq]

**Hypomagnesemia**

**Indications for Intermittent IV Administration:**
1. Serum magnesium <1.2 mg/dL
2. Serum magnesium <1.6 mg/dL and patient symptomatic
3. Calcium resistant tetany

**Magnesium Sulfate, Acute Treatment:**
- 25-50 mg/kg/dose (0.2-0.4 mEq/kg/dose) IV every 4-6 hrs x 3-4 doses as needed (max 2000 mg = 16 mEq/dose); max rate 1 mEq/kg/hr (125 mg/Kg/hr).

**Magnesium sulfate IV maintenance dose:** 1-2 mEq/kg/day (125-250 mg/kg/day) in maintenance IV solution.

**Magnesium PO Maintenance Dose:** 10-20 mg/kg/dose elemental magnesium PO qid.

**Magnesium Chloride (Slow-Mag):** mg salt (mEq elemental magnesium; mg elemental magnesium)
- Tab, SR: 535 mg (5.2 mEq; 53 mg).
- Magnesium Gluconate (Magonate): mg salt (mEq elemental magnesium; mg elemental magnesium)
- Liq: 1000 mg/5mL (4.8 mEq/5mL; 54 mg).
- Tab: 500 mg (2.4 mEq; 27 mg).

**Magnesium Oxide:** mg salt (mEq elemental magnesium; mg elemental magnesium)
- Tabs: 400 mg (20 mEq; 242 mg), 420 mg (21 mEq; 254 mg), 500 mg (25 mEq; 302 mg).
- Caps: 140 mg (7 mEq; 84 mg).

**Magnesium Sulfate:** mg salt (mEq elemental magnesium; mg elemental magnesium)
- Soln: 500 mg/mL (4.1 mEq/mL; 49.3 mg/mL).
## Newborn Care

### Neonatal Resuscitation

<table>
<thead>
<tr>
<th>APGAR Score</th>
<th>Sign</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate per minute</td>
<td>Absent</td>
<td>Slow (&lt;100)</td>
<td>&gt;100</td>
<td></td>
</tr>
<tr>
<td>Respiration</td>
<td>Absent</td>
<td>Slow, irregular</td>
<td>Good, crying</td>
<td></td>
</tr>
<tr>
<td>Muscle tone</td>
<td>Limp</td>
<td>Some flexion</td>
<td>Active motion</td>
<td></td>
</tr>
<tr>
<td>Reflex irritability</td>
<td>No response</td>
<td>Grimace</td>
<td>Cough or sneeze</td>
<td></td>
</tr>
<tr>
<td>Color</td>
<td>Blue or pale</td>
<td>Pink body with blue extremities</td>
<td>Completely pink</td>
<td></td>
</tr>
</tbody>
</table>

Assess APGAR score at 1 minute and 5 minutes, then continue assessment at 5 minute intervals until APGAR is greater than 7.

**General Measures:**
1. Review history, check equipment, oxygen, masks, laryngoscope, ET tubes, medications.

**Vigorous, Crying Infant:** Provide routine delivery room care for infants with heart rate >100 beats per minute, spontaneous respirations, and good color and tone: warmth, clearing the airway, and drying.

**Meconium in Amniotic Fluid:**
1. Deliver the head and suction meconium from the hypopharynx on delivery of the head. If the newly born infant has absent or depressed respirations, heart rate <100 bpm, or poor muscle tone, perform direct tracheal suctioning to remove meconium from the airway.
2. If no improvement occurs or if the clinical condition deteriorates, bag and mask ventilate with intermittent positive pressure using 100% FiO₂; stimulate vigorously by drying. Initial breath pressure: 30-40 cm H₂O for term infants, 20-30 cm H₂O for preterm infants. Ventilate at 15-20 cm H₂O at 30-40 breaths per minute. Monitor bilateral breath sounds and expansion.
3. If spontaneous respirations develop and heart rate is normal, gradually reduce ventilation rate until using only continuous positive airway pressure (CPAP). Wean to blow-by oxygen, but continue blow-by oxygen if the baby remains dusky.
4. Consider intubation if the heart rate remains <100 beats per minute and is not rising, or if respirations are poor and weak.

**Resuscitation:**
1. Provide assisted ventilation with attention to oxygen delivery, inspiratory time, and effectiveness as judged by chest rise if stimulation does not achieve prompt onset of spontaneous respirations or the heart rate is <100 bpm.
2. Provide chest compressions if the heart rate is absent or remains <60 bpm despite adequate assisted ventilation for 30 seconds. Coordinate chest compressions with ventilations at a ratio of 3:1 and a rate of 120 events per minute to achieve approximately 90 compressions and 30 breaths per minute.
3. Chest compressions should be done by two thumb-encircling hands in newly born infants and older infants. The depth of chest compression should be one third of the anterior-posterior diameter of the chest. Chest compressions should be sufficiently deep to generate a palpable pulse.
4. If condition worsens or if there is no change after 30 seconds, or if mask ventilation is difficult: use laryngoscope to suction oropharynx and trachea and intubate. Apply positive pressure ventilation. Check bilateral breath sounds and chest expansion. Check and adjust ET tube position if necessary. Continue cardiac compressions if heart rate remains depressed. Check CXR for tube placement.

**Hypotension or Bradycardia or Asystole:** Epinephrine 0.1-0.3 mL/kg [0.01-0.03 mg/kg (0.1 mg/mL = 1:10,000)] IV or ET q3-5min. Dilute ET dose to 2-3 mL in NS. If infant fails to respond, consider increasing dose to 0.1 mg/kg (0.1 mL/kg of 1 mg/mL = 1:1000).

**Hypovolemia:** Insert umbilical vein catheter and give O negative blood, plasma, 5% albumin, Ringer’s lactate, or normal saline 10 mL/kg IV over 5-10 minutes. Repeat as necessary to correct hypovolemia.

**Severe Birth Asphyxia, Mixed Respiratory/Metabolic Acidosis (not responding to ventilatory support; pH <7.2):** Give sodium Bicarbonate 1 mEq/kg, dilute 1:1 in sterile water IV q5-10min as indicated.
Narcotic-Related Depression:
1. Naloxone (Narcan) 0.1 mg/kg = 0.25 mL/kg (0.4 mg/mL concentration) or 0.1 mL/kg (1 mg/mL concentration) ET/IV/IM/SC, may repeat q2-3 min. May cause drug withdrawal and seizures in the infant if the mother is a drug abuser. 
2. Repeat administration may be necessary since the duration of action of naloxone may be shorter than the duration of action of the narcotic.

<table>
<thead>
<tr>
<th>Weight (gm)</th>
<th>Gestational Age (weeks)</th>
<th>Tube Size (mm)</th>
<th>Depth of Insertion from Upper Lip (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1000</td>
<td>&lt;28</td>
<td>2.5</td>
<td>6.5-7</td>
</tr>
<tr>
<td>1000-2000</td>
<td>28-34</td>
<td>3.0</td>
<td>7-8</td>
</tr>
<tr>
<td>2000-3000</td>
<td>34-38</td>
<td>3.5</td>
<td>8-9</td>
</tr>
<tr>
<td>&gt;3000</td>
<td>&gt;38</td>
<td>3.5-4.0</td>
<td>&gt;9</td>
</tr>
</tbody>
</table>

Suspected Neonatal Sepsis

1. Admit to: 
2. Diagnosis: Suspected sepsis 
3. Condition: 
4. Vital signs: Call MD if: 
5. Activity: 
7. Diet: 
8. IV Fluids: IV fluids at 1-1.5 times maintenance. 
9. Special Medications: Newborn Infants <1 month old (group B strep, E coli, or group B strep, gram negatives, Listeria monocytogenes):
   - Ampicillin and gentamicin OR ampicillin and cefotaxime as below. 
   - Add vancomycin as below if >7 days old and a central line is present.

Neonatal Dosage of Ampicillin:
- <1200 gm 0-4 weeks: 100 mg/kg/day IV/IM q12h
- 1200-2000 gm:
  - <7d: 100 mg/kg/day IV/IM q12h
  - >7d: 150 mg/kg/day IV/IM q12h
- >2000 gm:
  - <7d: 150 mg/kg/day IV/IM q12h
  - >7d: 200 mg/kg/day IV/IM q12h

Cefotaxime (Clavulanate):
- <1200 grams: 0-4 wks: 100 mg/kg/day IV/IM q12h
- >1200 grams: 0-7 days: 100 mg/kg/day IV/IM q12h
- >7 days: 150 mg/kg/day IV/IM q12h

Gentamicin (Garamycin)/Tobramycin (Nebcin):
- <1200 gm 0-4 weeks: 2.5 mg/kg/dose IV/IM q24h
- 1200-2000 gm:
  - <7d: 2.5 mg/kg/dose IV/IM q12-24h
  - >7d: 2.5 mg/kg/dose IV/IM q24h
- >2000 gm:
  - <7d: 2.5 mg/kg/dose IV/IM q24h
  - >7d: 2.5 mg/kg/dose IV/IM q12h

Neonatal Vancomycin (Vancocin) Dosage:
- <1200 gm 0-4 weeks: 15 mg/kg/dose IV q24h
- 1200-2000 gm:
  - <7d: 10 mg/kg/dose IV q12-18h
  - >7d: 10 mg/kg/dose IV q8-12h
- >2000 gm:
  - <7d: 10 mg/kg/dose IV q12h
  - >7d: 10 mg/kg/dose IV q8-12h

Nafcillin (Naclicl):
- <1200 gm:
  - 0-4 weeks 50 mg/kg/day IV/IM q12h
  - 1200-2000 gm:
    - <7 days: 50 mg/kg/day IV/IM q12h
    - >7 days: 75 mg/kg/day IV/IM q8h
  - >2000 gm:
    - <7 days: 75 mg/kg/day IV/IM q8h
    - >7 days: 100 mg/kg/day IV/IM q6h

Mezlocillin (Mezin):
- <1200 gm:
  - 0-4 weeks 150 mg/kg/day IV/IM q12h
  - 1200-2000 gm:
    - <7 days: 150 mg/kg/day IV/IM q12h
    - >7 days: 225 mg/kg/day IV/IM q8h
  - >2000 gm:
    - <7 days: 150 mg/kg/day IV/IM q12h
    - >7 days: 225 mg/kg/day IV/IM q8h

Amikacin:
- <1200 gm 0-4 weeks: 10 mg/kg/dose IV/IM q24h
  - 1200-2000 gm:
    - <7d: 10 mg/kg/dose IV/IM q12-24h
    - >7d: 10 mg/kg/dose IV/IM q12-24h
  - >2000 gm:
    - <7d: 10 mg/kg/dose IV/IM q12-24h
    - >7d: 10 mg/kg/dose IV/IM q12h

10. Extras and X-rays: CXR
11. Laboratory Studies: CBC, SMA 7, blood culture and sensitivity; UA, culture and sensitivity, antibiotic levels.
CSF Tube 1 - Gram stain, bacterial culture and sensitivity, antigen screen (1-2 mL).
CSF Tube 2 - Glucose protein (1-2 mL).
CSF Tube 3 - Cell count and differential (1-2 mL).

Respiratory Distress Syndrome

1. Provide mechanical ventilation as indicated.
2. Exogenous surfactant:
   - Prophylactic Therapy: Infants at risk for developing RDS with a birth weight <1250gm.
   - Rescue Therapy: Treatment of infants with RDS based on respiratory distress not attributable to any other causes and chest radiographic findings consistent with RDS.
   - Beractant (Survanta): 4 mL/kg of birth weight via endotracheal tube then q6h up to 4 doses total [100 mg (4 mL), 200 mg (8 mL)]
   - Colfosceril (Exosurf): 5 mL/kg of birth weight via endotracheal tube then q12h for 2-3 doses total [108 mg (10 mL)]
   - Poractant alfa (Curosurf): first dose 2.5 mL/kg (200 mg/kg/dose) of birthweight via endotracheal tube, may repeat with 1.25 mL/kg/dose (100 mg/kg/dose) at 12-hour intervals for up to two additional doses [120 mg (1.5 mL), 240 mg (3 mL)].
   - Calfactant (Infasurf): 3 mL/kg via endotracheal tube, may repeat q12h up to a total of 3 doses [6 mL]

Apnea

1. Admit to:
2. Diagnosis: Apnea
3. Condition:
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: Heart rate monitor, impedance apnea monitor, pulse oximeter. Keep bag and mask resuscitation equipment at bedside. Rocker bed or oscillating water bed.
7. Diet: Infant formula ad lib
8. IV Fluids:
9. Special Medications:
   - Apnea of Prematurity/Central Apnea:
     - Aminophylline: loading dose 5 mg/kg IV, then maintenance 5 mg/kg/day IV q12h (inj: 25 mg/mL) OR
     - Theophylline: loading dose 5 mg/kg PO, then 5 mg/kg/day PO q12h. (elixir: 80 mg/15mL).
     - Caffeine citrate: Loading dose 10-20 mg/kg IV/PO, then 5 mg/kg/day PO IV q12-24h (inj: 20 mg/mL, oral soln: 20 mg/mL, extemporaneously prepared oral suspension: 10 mg/mL).
10. Extras and X-rays: Pneumogram, cranial ultrasound. Upper GI (rule out reflux), EEG.
11. Labs: CBC, SMA 7, glucose, calcium, theophylline level (therapeutic range 6-14 mcg/mL), caffeine level (therapeutic range 10-20 mcg/mL).

Chronic Lung Disease

1. Admit to:
2. Diagnosis: Chronic lung disease.
4. Vital signs: Call MD if:
5. Activity:
6. Nursing: Inputs and outputs, daily weights
7. Diet:
8. IV Fluids: Isotonic fluids at maintenance rate.
9. Special Medications:
   - Diuretics:
     - Furosemide (Lasix) 1 mg/kg/dose PO/IVIM q6-24h
     - Chlorothiazide (Diuril) 2-8 mg/kg/day IV q12-24h or 20-40 mg/kg/day PO q12h [inj: 500 mg; susp: 250 mg/5mL]
     - Spironolactone (Aldactone) 2-3 mg/kg/day PO q12-24h [tabs: 25, 50, 100 mg; extemporaneous suspension]
   - Steroids:
     - Dexamethasone (Decadron) 0.5-1 mg/kg/day IV/IM q6-12h
     - Prednisone 1-2 mg/kg/day PO q12-24h [soln: 1 mg/mL, 5 mg/mL]
11. Extras and X-rays: CXR

Hyperbilirubinemia

1. Admit to:
2. Diagnosis: Hyperbilirubinemia.
3. Condition: Guarded.
4. Vital signs: Call MD if:
5. Activity:
   - Nursing: Inputs and outputs, daily weights, monitor skin color, monitor for lethargy and hypotonia
7. Diet:
8. IV Fluids: Isotonic fluids at maintenance rate (100-150 mL/kg/day). Encourage enteral feedings if possible.
9. Special Medications:
   - Phenobarbital 5 mg/kg/day PO/IV q12-24h [elixir: 15 mg/5mL, 20 mg/5mL; inj: 30 mg/mL, 60 mg/mL, 130 mg/mL]
   - Phototherapy
   - Exchange transfusion for severely elevated bilirubin
10. Symptomatic Medications:
11. Extras and X-rays:
12. Labs: Total bilirubin, indirect bilirubin, albumin, SMA

7. Blood group typing of mother and infant, a direct Coombs’ test. Complete blood cell count, reticulocyte count, blood smear. In infants of Asian or Greek descent, glucose-6-phosphate dehydrogenase (G6PD) should be measured.

Congenital Herpes Simplex Infection

- Acyclovir (Zovirax) 60 mg/kg/day IV q8h. Infuse each dose over 1 hr x 14 days (if disease is limited to skin, eye, and mouth) or 21 days (if disease is disseminated or involves the CNS). Infants with ocular involvement should also receive topical ophthalmic trifluridine.
- Trifluridine ophthalmic solution (Viroptic) 1 drop in each affected eye q2h while awake [ophth soln 1%: 7.5 mL bottle].

Hepatitis Prophylaxis

Infant born to HBs-Ag Positive Mother or Unknown Status Mother:
- Hepatitis B immune globulin (HBIG) 0.5 mL IM x 1 within 12 hours of birth
- Hepatitis B vaccine 0.5 mL IM (at separate site) within 12 hours of birth, second dose at age 1-2 months, third dose at age 6 months.

Neonatal HIV Prophylaxis

1. Pregnant women with HIV should be given oral zidovudine (200 mg PO q8h or 300 mg PO q12h) beginning at 14 weeks gestation and continuing throughout the pregnancy.
2. Intravenous zidovudine should be given to the mother during labor until delivery (2 mg/kg during the first hour and then 1 mg/kg/hr until delivery).
3. Oral administration of zidovudine to the newborn should be instituted immediately after birth and continued for at least six weeks (start at 8mg/kg/day PO q6h for the first two weeks, and then follow the dosing regimens for zidovudine. The mother should not breast feed the infant.
GYNECOLOGY

Surgical Documentation for Gynecology

Gynecologic Surgical History

Identifying Data. Age, gravida (number of pregnancies), para (number of deliveries).

Chief Complaint. Reason given by patient for seeking surgical care.

History of Present Illness (HPI). Describe the course of the patient’s illness, including when it began, character of the symptoms; pain onset (gradual or rapid); character of pain (constant, intermittent, cramping, radiating); other factors associated with pain (urination, eating, strenuous activities); aggravating or relieving factors. Other related diseases; past diagnostic testing.

Obstetrical History. Past pregnancies, durations and outcomes, preterm deliveries, operative deliveries.

Gynecologic History: Last menstrual period, length of regular cycle.

Past Medical History (PMH). Past medical problems, previous surgeries, hospitalizations, diabetes, hypertension, asthma, heart disease.

Medications. Cardiac medications, oral contraceptives, estrogen.

Allergies. Penicillin, codeine.

Family History. Medical problems in relatives.

Social History. Alcohol, smoking, drug usage, occupation.

Review of Systems (ROS):

- General: Fever, fatigue, night sweats.
- HEENT: Headaches, masses, dizziness.
- Respiratory: Cough, sputum, dyspnea.
- Cardiovascular: Chest pain, extremity edema.
- Gastrointestinal: Vomiting, abdominal pain, melena (black tarry stools), hematochezia (bright red blood per rectum).
- Genitourinary: Dysuria, hematuria, discharge.
- Skin: Easy bruising, bleeding tendencies.

Gynecologic Physical Examination

General:

Vital Signs: Temperature, respirations, heart rate, blood pressure.

Eyes: Pupils equally round and react to light and accommodation (PERRLA); extraocular movements intact (EOMI).

Neck: Jugular venous distention (JVD), thyromegaly, masses, lymphadenopathy.

Chest: Equal expansion, rales, breath sounds.

Heart: Regular rate and rhythm (RRR), first and second heart sounds, murmurs.

Breast: Skin retractions, masses (mobile, fixed), erythema, axillary or supraclavicular node enlargement.

Abdomen: Scars, bowel sounds, masses, hepatosplenomegaly, guarding, rebound, costovertebral angle tenderness, hernias.

Genitourinary: Urethral discharge, uterus, adnexa, ovaries, cervix.

Extremities: Cyanosis, clubbing, edema.

Neurological: Mental status, strength, tendon reflexes, sensory testing.

Laboratory Evaluation: Electrolytes, glucose, liver function tests, INR/PTT, CBC with differential; X-rays, ECG (if >35 yrs or cardiovascular disease), urinalysis.

Assessment and Plan: Assign a number to each problem. Discuss each problem, and describe surgical plans for each numbered problem, including preoperative
Discharge Summary

Patient's Name: 
Chart Number: 
Date of Admission: 
Date of Discharge: 
Admitting Diagnosis: 
Discharge Diagnosis: 
Name of Attending or Ward Service: 
Surgical Procedures: 

History and Physical Examination and Laboratory Data: Describe the course of the disease up to the time the patient came to the hospital, and describe the physical exam and laboratory data on admission.

Hospital Course: Describe the course of the patient's illness while in the hospital, including evaluation, treatment, outcome of treatment, and medications given.

Discharged Condition: Describe improvement or deterioration in condition.

Disposition: Describe the situation to which the patient will be discharged (home, nursing home).

Discharged Medications: List medications and instructions.

Discharged Instructions and Follow-up Care: Date of return for follow-up care at clinic; diet, exercise instructions.

Problem List: List all active and past problems.

Copies: Send copies to attending physician, clinic, consultants and referring physician.

Surgical Progress Note

Surgical progress notes are written in “SOAP” format.

| Date/Time: | Post-operative Day Number: |
| Problem List: Antibiotic day number and hyperalimentation day number if applicable. List each surgical problem separately (e.g., status-post appendectomy, hypokalemia).
| Subjective: Describe how the patient feels in the patient's own words, and give observations about the patient. Indicate any new patient complaints, note the adequacy of pain relief, and passing of flatus or bowel movements. Type of food the patient is tolerating (e.g., nothing, clear liquids, regular diet).
| Objective: |
| Vital Signs: Maximum temperature \( (T_{max}) \) over the past 24 hours. Current temperature, vital signs. |
| Intake and Output: Volume of oral and intravenous fluids, volume of urine, stools, drains, and nasogastric output. |
| Physical Exam: |
| General appearance: Alert, ambulating. |
| Heart: Regular rate and rhythm, no murmurs. |
| Chest: Clear to auscultation. |
| Abdomen: Bowel sounds present, soft, nontender. |
| Wound Condition: Comment on the wound condition (e.g., clean and dry, good granulation, serosanguinous drainage). Condition of dressings, purulent drainage, granulation tissue, erythema; condition of sutures, dehiscence. Amount and color of drainage. |
| Lab results: White count, hematocrit, and electrolytes, chest x-ray. |
| Assessment and Plan: Evaluate each numbered problem separately. Note the patient's general condition (e.g., improving), pertinent developments, and plans (e.g., advance diet to regular, chest x-ray). For each numbered problem, discuss any additional orders and plans for discharge or transfer. |

Procedure Note

A procedure note should be written in the chart when a procedure is performed. Procedure notes are brief operative notes.

| Date and time: | Procedure: |
| Indications: |
| Patient Consent: Document that the indications, risks and alternatives to the procedure were explained to the patient. Note that the patient was given the opportunity to ask questions and that the patient consented to the procedure in writing. |
| Lab tests: Electrolytes, INR, CBC |
| Anesthesia: Local with 2% lidocaine |
| Description of Procedure: Briefly describe the procedure, including sterile prep, anesthesia method, patient position, devices used, anatomic location of procedure, and outcome. |
| Complications and Estimated Blood Loss (EBL): |
| Disposition: Describe how the patient tolerated the procedure. |
| Specimens: Describe any specimens obtained and laboratory tests which were ordered. |
Discharge Note
The discharge note should be written in the patient’s chart prior to discharge.

Discharge Note

Date/time:  
Diagnoses:  
Treatment: Briefly describe treatment provided during hospitalization, including surgical procedures and antibiotic therapy.  
Studies Performed: Electrocardiograms, CT scans.  
Discharge Medications:  
Follow-up Arrangements:

Postoperative Check
A postoperative check should be completed on the evening after surgery. This check is similar to a daily progress note.

Example Postoperative Check

Date/time:  
Postoperative Check:  
Subjective: Note any patient complaints, and note the adequacy of pain relief.  
Objective:  
General appearance:  
Vitals: Maximum temperature in the last 24 hours (Tmax), current temperature, pulse, respiratory rate, blood pressure.  
Urine Output: If urine output is less than 30 cc per hour, more fluids should be infused if the patient is hypovolemic.  
Physical Exam:  
Chest and lungs:  
Abdomen:  
Wound Examination: The wound should be examined for excessive drainage or bleeding, skin necrosis, condition of drains.  
Drainage Volume: Note the volume and characteristics of drainage from Jackson-Pratt drain or other drains.  
Labs: Post-operative hematocrit value and other labs.  
Assessment and Plan: Assess the patient’s overall condition and status of wound. Comment on abnormal labs, and discuss treatment and discharge plans.

Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy Operative Report

Preoperative Diagnosis: 45 year old female, gravida 3 para 3, with menometrorrhagia unresponsive to medical therapy.  
Postoperative Diagnosis: Same as above  
Operation: Total abdominal hysterectomy and bilateral salpingo-oophorectomy  
Surgeon:  
Assistant:  
Anesthesia: General endotracheal  
Findings At Surgery: Enlarged 10 x 12 cm uterus with multiple fibroids. Normal tubes and ovaries bilaterally. Frozen section revealed benign tissue. All specimens sent to pathology.  
Description of Operative Procedure: After obtaining informed consent, the patient was taken to the operating room and placed in the supine position, given general anesthesia, and prepped and draped in sterile fashion.  
A Pfannenstiel incision was made 2 cm above the symphysis pubis and extended sharply to the rectus fascia. The fascial incision was bilaterally incised with curved Mayo scissors, and the rectus sheath was separated superiorly and inferiorly by sharp and blunt dissection. The peritoneum was grasped between two Kelly clamps, elevated, and incised with a scalpel. The pelvis was examined with the findings noted above. A Balfour retractor was placed into the incision, and the bowel was packed away with moist laparotomy sponges. Two Kocher clamps were placed on the cornua of the uterus and used for retraction.  
The round ligaments on both sides were clamped, sutured with #0 Vicryl, and transected. The anterior leaf of the broad ligament was incised along the bladder reflection to the midline from both sides, and the bladder was gently dissected off the lower uterine segment and cervix with a sponge stick.  
The retroperitoneal space was opened and the ureters were identified bilaterally. The infundibulopelvic ligaments on both sides were then doubly clamped, transected, and doubly ligated with #0 Vicryl. Excellent hemostasis was observed. The uterine arteries were skeletonized bilaterally, clamped with Heaney clamps, transected, and suture ligated in a similar fashion.  
The cervix and uterus was amputated, and the vaginal
cuff angles were closed with figure-of-eight stitches of #0 Vicryl, and then were transfixed to the ipsilateral cardinal and uterosacral ligament. The vaginal cuff was closed with a series of Interrupted #0 Vicryl, figure-of-eight sutures. Excellent hemostasis was obtained. The pelvis was copiously irrigated with warm normal saline, and all sponges and instruments were removed. The parietal peritoneum was closed with running #2-0 Vicryl. The fascia was closed with running #0 Vicryl. The skin was closed with staples. Sponge, lap, needle, and instrument counts were correct times two. The patient was taken to the recovery room, awake and in stable condition.

Estimated Blood Loss (EBL): 150 cc
Specimens: Uterus, tubes, and ovaries
Drains: Foley to gravity
Fluids: Urine output - 100 cc of clear urine
Complications: None
Disposition: The patient was taken to the recovery room in stable condition.

Endometrial Sampling and Dilation and Curettage

The endometrial cavity is frequently evaluated because of abnormal uterine bleeding, pelvic pain, infertility, or pregnancy complications. The most common diagnostic indications for obtaining endometrial tissue include abnormal uterine bleeding, postmenopausal bleeding, endometrial dating, endometrial cells on Papanicolaou smear, and follow-up of women undergoing medical therapy for endometrial hyperplasia.

I. Endometrial biopsy
A. The office endometrial biopsy offers a number of advantages to D&C because it can be done with minimal to no cervical dilation, anesthesia is not required, and the cost is approximately one-tenth of a hospital D&C.
B. Numerous studies have shown that the endometrium is adequately sampled with these techniques.
C. Pipelle endometrial sampling device is the most popular method for sampling the endometrial lining. The device is constructed of flexible polypropylene with an outer sheath measuring 3.1 mm in diameter.
D. The device is placed in the uterus through an undilated cervix. The piston is fully withdrawn to create suction and, while the device is rotated 360 degrees, the distal port is brought from the fundus to the internal os to withdraw a sample. The device is removed and the distal aspect of the instrument is severed, allowing for the expulsion of the sample into formalin.
E. The detection rates for endometrial cancer by Pipelle in postmenopausal and premenopausal women are 99.6 and 91 percent, respectively.
F. D&C should be considered when the endometrial biopsy is nondiagnostic, but a high suspicion of cancer remains (eg, hyperplasia with atypia, presence of necrosis, or pyometra).

II. Dilation and curettage
A. Dilation and curettage is performed as either a diagnostic or therapeutic procedure. Indications for diagnostic D&C include:
1. A nondiagnostic office biopsy in women who are at high risk of endometrial carcinoma.
2. Insufficient tissue for analysis on office biopsy.
3. Cervical stenosis prevents the completion of an office biopsy.
B. Diagnostic D&Cs are usually performed with hysteroscopy to obtain a visual image of the endometrial cavity, exclude focal disease, and prevent missing unsuspected polyps.
C. Examination under anesthesia. After anesthesia has been administered, the size, shape, and position of the uterus are noted, with particular attention to the axis of the cervix and flexion of the fundus. The size, shape, and consistency of the adnexa are determined. The perineum, vagina, and cervix are then prepared with an aseptic solution and vaginal retractors are inserted into the vagina.
D. Operative technique. A D&C is performed with the woman in the dorsal lithotomy position.
1. Endocervical curettage (ECC) is performed before dilation of the cervix. A Kevorkian-Younge curette is introduced into the cervical canal up to the internal os. Curetting of all four quadrants of the canal should be conducted and the specimen placed on a Telfa pad.
2. Sounding and dilation. Traction is applied to align the axis of the cervix and the uterine canal. The uterus should be sounded to document the size and confirm the position. The sound should be held between the thumb and the index finger to avoid excessive pressure.
3. Cervical dilation is then performed. The dilator is grasped in the middle of the instrument with the thumb and index finger. The cervix is gradually dilated beginning with the #13 French Pratt dilator. The dilator should be inserted through the internal os, without excessively entering the uterine cavity.
4. Sharp curettage is performed systematically beginning at the fundus and applying even pressure on the endometrial surface along the entire length of the uterus to the internal cervical os. The endometrial tissue is placed on a Telfa pad placed in the vagina. Moving around the uterus in a systematic fashion, the entire surface of the
endometrium is sampled. The curettage procedure is completed when the "uterine cry" (gritiness to palpation) is appreciated on all surfaces of the uterus. Curettage is followed by blind extraction with Randall polyp forceps to improve the rate of detection of polyps.
Management of the Abnormal Papanicolaou Smear

The Papanicolaou smear is a screening test for abnormalities that increases the risk of cervical cancer. Treatment decisions are based upon the results of colposcopically directed biopsies of the cervix. Papanicolaou smear reports are classified using the Bethesda System, which was revised in 2001.

I. Bethesda 2001 Pap Smear Report

<table>
<thead>
<tr>
<th>Interpretation Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative for intraepithelial lesion or malignancy (when there is no cellular evidence of neoplasia, state this in the General Categorization above and/or in the Interpretation/Result section of the report, whether there are organisms or other non-neoplastic findings)</td>
</tr>
<tr>
<td>Infection (Trichomonas vaginalis, Candida spp., shift in flora suggestive of bacterial vaginosis, Actinomyces spp., cellular changes consistent with Herpes simplex virus)</td>
</tr>
<tr>
<td>Other Non-neoplastic Findings (Optional to report; list not inclusive):</td>
</tr>
<tr>
<td>Reactive cellular changes associated with inflammation (includes typical repair) radiation, intrauterine contraceptive device (IUD)</td>
</tr>
<tr>
<td>Glandular cells status post-hysterectomy</td>
</tr>
<tr>
<td>Atrophy</td>
</tr>
<tr>
<td>Other Endometrial cells (in a woman &gt;40 years of age) (specify if &quot;negative for squamous intraepithelial lesion&quot;)</td>
</tr>
</tbody>
</table>

II. Squamous Cell Abnormalities

- Atypical squamous cells - of undetermined significance (ASC-US)
  - cannot exclude HSIL (ASC-H)
- Low-grade squamous intraepithelial lesion (LSIL) encompassing: HPV/mild dysplasia/CIN 1
- High-grade squamous intraepithelial lesion (HSIL) encompassing: moderate and severe dysplasia, CIS/CIN 2 and CIN 3 with features suspicious for invasion (if invasion is suspected)

III. Glandular Cell Abnormalities

- Atypical Endocervical cells (not otherwise specified or specify in comments)
- Glandular Cell (not otherwise specified or specify in comments)
- Endometrial cells (not otherwise specified or specify in comments)
- Glandular cells (not otherwise specified or specify in comments)

IV. Other Malignant Neoplasms (specify)

II. Screening for cervical cancer

A. Regular Pap smears are recommended for all women who are or have been sexually active and who have a cervix.

B. Testing should begin when the woman first engages in sexual intercourse. Adolescents whose sexual history is thought to be unreliable should be presumed to be sexually active at age 18.

C. Pap smears should be performed at least every 1 to 3 years. Testing is usually discontinued after age 65 in women who have had regular normal screening tests. Women who have had a hysterectomy, including removal of the cervix for reasons other than cervical cancer or its precursors, do not require Pap testing.

III. Techniques used in evaluation of the abnormal pap smear

A. Colposcopy allows examination of the lower genital tract to identify epithelial changes. Abnormal areas should be targeted for biopsy to determine a pathologic diagnosis.

B. Human papillomavirus testing

1. HPV infection is the leading etiologic agent in the development of premalignant and malignant lower genital tract disease. Premenopausal women who test positive for certain types of HPV are at higher risk of cervical dysplasia (HPV positive), while those who are HPV negative or have types of HPV DNA of low oncogenic potential are at low risk.

2. The most commonly used HPV test is the Hybrid Capture II HPV DNA Assay (HC II), which tests for high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. High-risk HPV types 16 and 18 are the viruses most frequently isolated in cervical cancer tissue.

IV. Atypical squamous cells

A. Atypical squamous cells of undetermined significance (ASC-US) is further divided into ASC-US, which are qualified as "of undetermined significance," and ASC-H, in which a high-grade squamous intraepithelial lesion (HSIL) cannot be excluded.

B. ASC requires further evaluation. This cytologic diagnosis is common and frequently associated with spontaneously resolving, self-limited disease.
However, 5 to 17 percent of patients with ASC and 24 to 94 percent of those with ASC-H will have CIN II or III at biopsy.

C. Women with ASC-US
   a. If liquid-based cytology is used, reflex testing for HPV should be performed, alternatively cocollection for HPV DNA testing can be done at the time of a conventional cervical cytology smear.
   b. Colposcopy should performed if human papillomavirus testing is positive. Thirty to 60 percent of women with ASC will test positive for high-risk HPV types and require immediate colposcopy.
2. Patients with a positive high-risk type HPV DNA test should be evaluated by colposcopy; those with a negative test may be triaged to repeat cytologic evaluation in 12 months. Management of women who test positive for high-risk HPV types, but have no CIN consists of either 1) cytological testing repeated in six and 12 months with colposcopic evaluation of ASC-US or greater or 2) HPV testing repeated in 12 months with colposcopy if HPV results are positive.

V. Special circumstances
A. When an infectious organism is identified, the patient should be contacted to determine if she is symptomatic. Antibiotic therapy is indicated for symptomatic infection.
B. Reactive changes due to inflammation are usually not associated with an organism on the Pap smear. The Pap smear does not need to be repeated unless the patient is HIV positive, in which case it should be repeated in four to six months.
C. Atrophic epithelium is a normal finding in postmenopausal women.
   1. Administration of estrogen causes atypical atrophic, but not dysplastic, epithelium to mature into normal squamous epithelium.
   2. Hormonal therapy given for vaginal atrophy should be followed by repeat cervical cytology one week after completing treatment. If negative, cytology should be repeated again in four to six months. If both tests are negative, the woman can return to routine screening intervals, but if either test is positive for ASC-US or greater, she should be evaluated with colposcopy.
D. Immunosuppressed women, including all women who are HIV positive, with ASC-US should be referred for immediate colposcopy, instead of HPV testing.
E. ASC-US with absence of CIN on biopsy. If colposcopic examination does not show CIN, then follow-up cytological testing should be performed in 12 months.
F. ASC-US with biopsy proven CIN. Since spontaneous regression is observed in approximately 60 percent of CIN I, expectant management with serial cytologic smears at three to four month intervals is reasonable for the reliable patient.
G. Women with ASC-H. All women with ASC-H on cytological examination should receive colposcopy. If repeat of cytology confirms ASC-H but biopsy is negative for CIN, follow-up cytology in six and 12 months or HPV DNA testing in 12 months is recommended. Colposcopy should be repeated for ASC or greater on cytology or a positive test for high risk HPV DNA. Biopsy proven CIN is treated, as appropriate.

VI. Low- and high-grade intraepithelial neoplasia
A. Low-grade squamous intraepithelial lesions (LSIL) may also be referred to as CIN I or mild dysplasia. Immediate referral for colposcopy is the recommended management for LSIL. Endocervical sampling should be done in nonpregnant women in whom the transformation zone cannot be fully visualized or a lesion extends into the endocervical canal. Endocervical sampling also should be done in nonpregnant women when no lesion is identified on colposcopy.
   1. If no CIN is identified following satisfactory or unsatisfactory colposcopy and biopsies, then options for follow-up include either:
      a. Repeat cytology testing at six and 12 months, or
      b. HPV DNA testing at 12 months
   2. Referral for repeat colposcopy is required if cytology yields ASC or greater or HPV DNA is positive for a high-risk type.
   3. Women with histologically confirmed CIN I LSIL may be treated with ablation or excision or followed with serial cytologic smears every three to six months if the entire lesion and limits of the transformation zone are completely visualized. LSIL confined to the endocervical canal may be followed with repeat smears obtained with a cytobrush and with ECC.
   4. Postmenopausal women. Postmenopausal women may be managed by serial cytology at six and 12 months or HPV DNA testing at 12 months with referral to colposcopy for positive results. Women with atrophy are treated with intravaginal estrogen followed by repeat cytology seven days after completion of therapy, with referral to colposcopy if an abnormality persists. If repeat cytology is normal, then another cytology test should be obtained in four to six months. The
A woman can return to routine surveillance if both tests are normal, but should be referred for colposcopy if either test is positive.

5. Adolescents. Initial colposcopy may be deferred in adolescents. Instead, they may be managed with serial cytology at six and 12 months or HPV DNA testing at 12 months with referral to colposcopy for positive results.

6. Pregnant women. Colposcopy should be performed, with biopsy and endocervical curettage performed for any lesion suspicious for HSIL or more severe disease.

B. High-grade squamous intraepithelial lesions

1. A high-grade squamous intraepithelial lesion (HSIL) may also be referred to as CIN II or III, severe dysplasia, or carcinoma in situ (CIS). One to two percent of women with HSIL on a cytologic smear have invasive cancer at the time of further evaluation and 20 percent of women with biopsy-proven CIS will develop an invasive cancer if left untreated. All women with HSIL should be referred for colposcopy and endocervical sampling.

C. Follow-up evaluation. Pap smears are recommended every three to four months for the first year after treatment for dysplasia. Women with cervical dysplasia present at the LEEP or cone margin or in the concomitant ECC also need a follow-up colposcopy with endocervical curettage every six months for one year. Routine surveillance can be resumed if there is no recurrence after the first year. Surveillance consists of Pap smears on a yearly basis for most women, and on a twice-yearly basis for high-risk women (ie, HIV positive).

VII. Abnormal glandular cells

A. A report of atypical glandular cells (AGC) indicates the presence of glandular cells that could be coming from the endocervical or endometrial region. The Bethesda 2001 system classifies AGC into two subcategories:

1. AGC endocervical, endometrial, or not otherwise specified (NOS)
2. AGC favor neoplasia, endocervical or NOS

B. Additional categories for glandular cell abnormalities are:

1. Endocervical adenocarcinoma in situ (AIS)
2. Adenocarcinoma

C. Evaluation of AGC or AIS on cervical cytology: These women should be referred for colposcopy and sampling of the endocervical canal. Women over age 35 and younger women with AGC and unexplained vaginal bleeding also need an endometrial biopsy. Women with only atypical endometrial cells on cytology can be initially evaluated with endometrial biopsy.

D. Endometrial cells in women >40 years of age: Endometrial biopsy should be performed.

References: See page 282.

Contraception

Approximately 31 percent of births are unintended; about 22 percent were “mistimed,” while 9 percent were “unwanted.”

I. Sterilization

A. Sterilization is the most common and effective form of contraception. While tubal ligation and vasectomy may be reversible, these procedures should be considered permanent.

B. Essure microinsert sterilization device is a permanent, hysteroscopic, tubal sterilization device which is 99.9 percent effective. The coil-like device is inserted in the office under local anesthesia into the fallopian tubes where it is incorporated by tissue. After placement, women use alternative contraception for three months, after which hysterosalpingography is performed to assure correct placement. Postoperative discomfort is minimal.

C. Tubal ligation is usually performed as a laparoscopic procedure in outpatients or in postpartum women in the hospital. The techniques used are unipolar or bipolar coagulation, silicone rubber band or spring clip application, and partial salpingectomy.

D. Vasectomy (ligation of the vas deferens) can be performed in the office under local anesthesia. A semen analysis should be done three to six months after the procedure to confirm azoospermia.

II. Oral contraceptives

A. Combined (estrogen-progestin) oral contraceptives are reliable, and they have noncontraceptive benefits, which include reduction in dysmenorrhea, iron deficiency, ovarian cancer, endometrial cancer.

<p>| Combination Oral Contraceptives |
|-----------------|-----------------|
| Drug Progestin, mg Estrogen |
| Monophasic combinations |
| Ortho-Novum 1 /35 21, 28 | Norethindrone (1) Ethinyl estradiol (35) |
| Ovcon 35 21, 28 | Norethindrone (0.4) Ethinyl estradiol (35) |
| Brevicon 21, 28 | Norethindrone Ethinyl estradiol |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Progestin, mg</th>
<th>Estrogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modicon 28</td>
<td>Norethindrone (0.5)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Necon 0.5/35E 21, 28</td>
<td>Norethindrone (0.5)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Nortrel 0.5/35 28</td>
<td>Norethindrone (0.5)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Necon 1/35 21, 28</td>
<td>Norethindrone (1)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Norinyl 1/35 21, 28</td>
<td>Norethindrone (1)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Nortrel 1/35 21, 28</td>
<td>Norethindrone (1)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Loestrin 1.20 21, 28</td>
<td>Norethindrone acetate (1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Microgestin 1.20 28</td>
<td>Norethindrone acetate (1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Loestrin 1.5/30 21, 28</td>
<td>Norethindrone acetate (1.5)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Microgestin 1.5/36 28</td>
<td>Norethindrone acetate (1.5)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Alesse 21, 28</td>
<td>Levonorgestrel (0.1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Aviane 21, 28</td>
<td>Levonorgestrel (0.1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Lessina 28</td>
<td>Levonorgestrel (0.1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Levitate 28</td>
<td>Levonorgestrel (0.1)</td>
<td>Ethinyl estradiol (20)</td>
</tr>
<tr>
<td>Necon 1/50 21, 28</td>
<td>Norethindrone (1)</td>
<td>Mestranol (50)</td>
</tr>
<tr>
<td>Norinyl 1150 21, 28</td>
<td>Norethindrone (1)</td>
<td>Mestranol (50)</td>
</tr>
<tr>
<td>Ortho-Novum 1/50 28</td>
<td>Norethindrone (1)</td>
<td>Mestranol (50)</td>
</tr>
<tr>
<td>Ovcon 50 28</td>
<td>Norethindrone (1)</td>
<td>Ethinyl estradiol (50)</td>
</tr>
<tr>
<td>Cyclessa 28</td>
<td>Desogestrel (0.1)</td>
<td>Ethinyl estradiol (25)</td>
</tr>
<tr>
<td>April 28</td>
<td>Desogestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Desogen 28</td>
<td>Desogestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Ortho-Cept 21, 28</td>
<td>Desogestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Yasmin 28</td>
<td>Drospirenone (3)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Demulen 1/35 21, 28</td>
<td>Ethynodiol diacetate (1)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Zovia 1/35 21, 28</td>
<td>Ethynodiol diacetate (1)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Demulen 1/50 21, 28</td>
<td>Ethynodiol diacetate (1)</td>
<td>Ethinyl estradiol (50)</td>
</tr>
<tr>
<td>Zovia 1/50 21, 28</td>
<td>Ethynodiol diacetate (1)</td>
<td>Ethinyl estradiol (50)</td>
</tr>
<tr>
<td>Levlen 21, 28</td>
<td>Levonorgestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Levora 21, 28</td>
<td>Levonorgestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Nordette 21, 28</td>
<td>Levonorgestrel (0.15)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Ortho-Cyclen 21, 28</td>
<td>Norgestimate (0.25)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Lo/Ovral 21, 28</td>
<td>Norgestrel (0.3)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Locelest 21, 28</td>
<td>Norgestrel (0.3)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Ogestrel 28</td>
<td>Norgestrel (0.5)</td>
<td>Ethinyl estradiol (50)</td>
</tr>
<tr>
<td>Ovral 21, 28</td>
<td>Norgestrel (0.5)</td>
<td>Ethinyl estradiol (50)</td>
</tr>
</tbody>
</table>

### Multiphasic Combinations
<table>
<thead>
<tr>
<th>Drug</th>
<th>Progestin, mg</th>
<th>Estrogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kariva 28</td>
<td>Desogestrel  (0.15)</td>
<td>Ethinyl estradiol  (20, 0, 10)</td>
</tr>
<tr>
<td>Micette 28</td>
<td>Desogestrel  (0.15)</td>
<td>Ethinyl estradiol  (20, 0, 10)</td>
</tr>
<tr>
<td>Tri-Levlen 21, 28</td>
<td>Levonorgestrel (0.05, 0.075, 0.125)</td>
<td>Ethinyl estradiol  (30, 40, 30)</td>
</tr>
<tr>
<td>Triphasil 21, 28</td>
<td>Levonorgestrel (0.05, 0.075, 0.125)</td>
<td>Ethinyl estradiol  (30, 40, 30)</td>
</tr>
<tr>
<td>Trivora 28</td>
<td>Levonorgestrel (0.05, 0.075, 0.125)</td>
<td>Ethinyl estradiol (30, 40, 30)</td>
</tr>
<tr>
<td>Necon 10/11 21, 28</td>
<td>Norethindrone (0.5, 1)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Ortho-Novum 10/11 28</td>
<td>Norethindrone (0.5, 1)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
<tr>
<td>Ortho-Novum 7/7 21, 28</td>
<td>Norethindrone (0.5, 0.75, 1)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Tri-Norinyl 21, 28</td>
<td>Norethindrone (0.5, 1, 0.5)</td>
<td>Ethinyl estradiol (30)</td>
</tr>
<tr>
<td>Estrostep 28</td>
<td>Norgestimate acetate (1)</td>
<td>Ethinyl estradiol (20, 30, 35)</td>
</tr>
<tr>
<td>Ortho Tri-Cyclen 21, 28</td>
<td>Norgestimate (0.18, 0.215, 0.25)</td>
<td>Ethinyl estradiol (35)</td>
</tr>
</tbody>
</table>

B. Pharmacology
1. Ethinyl estradiol is the estrogen in virtually all OCs.
2. Commonly used progestins include norethindrone, norethindrone acetate, and levonorgestrel. Ethynodiol diacetate is a progestin, which also has significant estrogenic activity. New progestins have been developed with less androgenic activity; however, these agents may be associated with deep vein thrombosis.

C. Mechanisms of action
1. The most important mechanism of action is estrogen-induced inhibition of the midcycle surge of gonadotropin secretion, so that ovulation does not occur.
2. Another potential mechanism of contraceptive action is suppression of gonadotropin secretion during the follicular phase of the cycle, thereby preventing follicular maturation.
3. Progestin-related mechanisms also may contribute to the contraceptive effect. These include rendering the endometrium less suitable for implantation and making the cervical mucus less permeable to penetration by sperm.

D. Contraindications
1. Absolute contraindications to OCs:
   a. Previous thromboembolic event or stroke
   b. History of an estrogen-dependent tumor
   c. Active liver disease
   d. Pregnancy
   e. Undiagnosed abnormal uterine bleeding
   f. Hypertriglyceridemia
   g. Women over age 35 years who smoke heavily (greater than 15 cigarettes per day)
2. Screening requirements. Hormonal contraception can be safely provided after a careful medical history and blood pressure measurement. Pap smears are not required before a prescription for OCs.

E. Efficacy. When taken properly, OCs are a very effective form of contraception. The actual failure rate is 2 to 3 percent due primarily to missed pills or failure to resume therapy after the seven-day pill-free interval.

Noncontraceptive Benefits of Oral Contraceptive Pills

<table>
<thead>
<tr>
<th>Dysmenorrhea</th>
<th>Functional ovarian cysts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miteischemnez</td>
<td>Benign breast cysts</td>
</tr>
<tr>
<td>Metrorrhagia</td>
<td>Ectopic pregnancy</td>
</tr>
<tr>
<td>Premenstrual syndrome</td>
<td>Acne</td>
</tr>
<tr>
<td>Hirsutism</td>
<td>Endometriosis</td>
</tr>
<tr>
<td>Ovarian and endometrial cancer</td>
<td></td>
</tr>
</tbody>
</table>

F. Drug interactions. The metabolism of OCs is accelerated by phenobarbital, phenytoin and rifampin. The contraceptive efficacy of an OC is likely to be decreased in women taking these drugs. Other antibiotics (with the exception of rifampin) do not affect the pharmacokinetics of ethinyl estradiol.

G. Preparations
1. There are two types of oral contraceptive pills: combination pills that contain both estrogen and progestin, and the progestin-only pill (“mini-pill”). Progestin-only pills, which are associated with more breakthrough bleeding than combination pills, are rarely prescribed except in lactating
women. Combination pills are packaged in 21-day or 28-day cycles. The last seven pills of a 28-day pack are placebo pills.

2. Monophasic combination pills contain the same dose of estrogen and progestin in each of the 21 hormonally active pills. Current pills contain on average 30 to 35 µg of ethinyl estradiol. Pills containing less than 50 µg of ethinyl estradiol are “low-dose” pills.

3. **20 µg preparations.** Several preparations containing only 20 µg of ethinyl estradiol are now available (Lo-Estrin 1/20, Micette, Alesse, Aviane). These are often used for perimenopausal women who want contraception with the lowest estrogen dose possible. These preparations provide enough estrogen to relieve vasomotor flashes. Perimenopausal women often experience hot flashes and premenstrual mood disturbances during the seven-day pill-free interval. Micette, contains 10 µg of ethinyl estradiol on five of the seven “placebo” days, which reduces flashes and mood symptoms.

4. **Yasmin** contains 30 mcg of ethinyl estradiol and drospirenone. Drospirenone has antimineralocorticoid activity. It can help prevent bloating, weight gain, and hypertension, but it can increase serum potassium. Yasmin is contraindicated in patients at risk for hyperkalemia due to renal, hepatic, or adrenal disease. Yasmin should not be combined with other drugs that can increase potassium, such as ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, potassium supplements, NSAIDs, or salt substitutes.

5. **Third-generation progestins**
   a. More selective progestins include norgestimate, desogestrel, and gestodene. They have some structural modifications that lower their androgen activity. Norgestimate (eg, Ortho-Cyclen or Tri-Cyclen) and desogestrel (eg, Desogen or Ortho-Cept) are the least androgenic compounds in this class. The new progestins are not much less androgenic than norethindrone.
   b. The newer OCs are more effective in reducing acne and hirsutism in hyperandrogenic women. They are therefore an option for women who have difficulty tolerating older OCs. There is an increased risk of deep venous thrombosis with the use of these agents, and they should not be routinely used.

H. **Recommendations**

1. Monophasic OCs containing the second generation progestin, norethindrone (Ovcon 35, Ortho-Novum 1/35) are recommended when starting a patient on OCs for the first time. This progestin has very low androgenicity when compared to other second generation progestins, and also compares favorably to the third generation progestins in androgenicity.

2. The pill should be started on the first day of the period to provide the maximum contraceptive effect in the first cycle. However, most women start their pill on the first Sunday after the period starts. Some form of back-up contraception is needed for the first month if one chooses the Sunday start, because the full contraceptive effect might not be provided in the first pill pack.

<table>
<thead>
<tr>
<th>Factors to Consider in Starting or Switching Oral Contraceptive Pills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective</td>
</tr>
<tr>
<td>To minimize high risk of thrombosis</td>
</tr>
<tr>
<td>To minimize nausea, breast tenderness or vascular headaches</td>
</tr>
<tr>
<td>To minimize spotting or breakthrough bleeding</td>
</tr>
<tr>
<td>To minimize androgenic effects</td>
</tr>
<tr>
<td>To avoid dyslipidemia</td>
</tr>
</tbody>
</table>
III. Injectable contraceptives

A. Depot medroxyprogesterone acetate (DMPA, Depo-Provera) is an injectable contraceptive. Deep intramuscular injection of 150 mg results in effective contraception for three to four months. Effectiveness is 99.7 percent.

B. Women who receive the first injection after the seventh day of the menstrual cycle should use a second method of contraception for seven days. The first injection should be administered within five days after the onset of menses, in which case alternative contraception is not necessary.

C. Ovulation is suppressed for at least 14 weeks after injection of a 150 mg dose of DMPA. Therefore, injections should be repeated every three months. A pregnancy test must be administered to women who are more than two weeks late for an injection.

D. Return of fertility can be delayed for up to 18 months after cessation of DMPA. DMPA is not ideal for women who may wish to become pregnant soon after cessation of contraception.

E. Amenorrhea, irregular bleeding, and weight gain (typically 1 to 3 kg) are the most common adverse effects of DMPA. Adverse effects also include acne, headache, and depression. Fifty percent of women report amenorrhea by one year. Persistent bleeding may be treated with 50 µg of ethinyl estradiol for 14 days.

F. Medroxyprogesterone acetate/estradiol cypionate (MPA/E2C, Lunelle) is a combined (25 mg MPA and 5 mg E2C) injectable contraceptive.

1. Although monthly IM injections are required, MPA/E2C has several desirable features:
   a. It has nearly 100 percent effectiveness in preventing pregnancy.
   b. Fertility returns within three to four months after it is discontinued.
   c. Irregular bleeding is less common than in women given MPA alone.

2. Weight gain, hypertension, headache, mastalgia, or other nonmenstrual complaints are common.

3. Lunelle should be considered for women who forget to take their birth control pills or those who want a discreet method of contraception. The initial injection should be given during the first 5 days of the menstrual cycle or within 7 days of stopping oral contraceptives. Lunelle injections should be given every 28 to 30 days; 33 days at the most.

G. Transdermal contraceptive patch

1. Ortho Evra is a transdermal contraceptive patch, which is as effective as oral contraceptives. Ortho Evra delivers 20 µg of ethinyl estradiol and 150 µg of norelgestromin daily for 6 to 13 months. Compliance is better with the patch. The patch is applied at the beginning of the menstrual cycle. A new patch is applied each week for 3 weeks; week 4 is patch-free. It is sold in packages of 3 patches. Effectiveness is similar to oral contraceptives.

2. Breakthrough bleeding during the first two cycles, dysmenorrhea, and breast discomfort are more common in women using the patch. A reaction at the site of application of the patch occurs in 1.9 percent of the women. Contraceptive efficacy may be slightly lower in women weighing more than 90 kg.

H. Contraceptive vaginal ring (NuvaRing) delivers 15 µg ethinyl estradiol and 120 µg of etonogestrel daily and is worn intravaginally for three weeks of each four week cycle. Advantages of this method include avoidance of gastrointestinal metabolism, rapid return to ovulation after discontinuation, lower doses of hormones, ease and convenience, and improved cycle control.

IV. Barrier methods

A. Barrier methods of contraception, such as the condom, diaphragm, cervical cap, and sperm-
cides, have fewer side effects than hormonal contraception.

B. The diaphragm and cervical cap require fitting by a clinician and are only effective when used with a spermicide. They must be left in the vagina for six to eight hours after intercourse; the diaphragm needs to be removed after this period of time, while the cervical cap can be left in place for up to 24 hours. These considerations have caused them to be less desirable methods of contraception. A major advantage of barrier contraceptives is their efficacy in protecting against sexually transmitted diseases and HIV infection.

V. Intrauterine devices

A. The currently available intrauterine devices (IUDs) are safe and effective methods of contraception:

1. Copper T380 IUD induces a foreign body reaction in the endometrium. It is effective for 8 to 10 years.
2. Progesterone-releasing IUDs inhibit sperm survival and implantation. They also decrease menstrual blood loss and relieve dysmenorrhea. Paragard is replaced every 10 years. Progestasert IUDs must be replaced after one year.
3. Levonorgestrel IUD (Mirena) provides effective contraception for five years.

B. Infection

1. Women who are at low risk for sexually transmitted diseases do not have a higher incidence of pelvic inflammatory disease with use of an IUD. An IUD should not be inserted in women at high risk for sexually transmitted infections, and women should be screened for the presence of sexually transmitted diseases before insertion.
2. Contraindications to IUDs:
   a. Women at high risk for bacterial endocarditis (e.g., rheumatic heart disease, prosthetic valves, or a history of endocarditis).
   b. Women at high risk for infections, including those with AIDS and a history of intravenous drug use.
   c. Women with uterine leiomyomas which alter the size or shape of the uterine cavity.

VI. Lactation

A. Women who breast-feed have a delay in resumption of ovulation postpartum. It is probably safest to resume contraceptive use in the third postpartum month for those who breast-feed full time, and in the third postpartum week for those who do not breast-feed.

B. A nonhormonal contraceptive or progesterone-containing hormonal contraceptive can be started at any time; an estrogen-containing oral contraceptive should not be started before the third week postpartum because women are still at increased risk of thromboembolism prior to this time. Oral contraceptive pills can decrease breast milk, while progesterone-containing contraceptives may increase breast milk.

VII. Progestin-only agents

A. Progestin-only agents are slightly less effective than combination oral contraceptives. They have failure rates of 0.5 percent compared with the 0.1 percent rate with combination oral contraceptives.

B. Progestin-only oral contraceptives (Micronor, Nor-QD, Ovrette) provide a useful alternative in women who cannot take estrogen. Progestin-only contraception is recommended for nursing mothers. Milk production is unaffected by use of progestin-only agents.

C. If the usual time of ingestion is delayed for more than three hours, an alternative form of birth control should be used for the following 48 hours. Because progestin-only agents are taken continuously, without hormone-free periods, menses may be irregular, infrequent or absent.

VIII. Postcoital contraception

A. Emergency postcoital contraception consists of administration of drugs within 72 hours to women who have had unprotected intercourse (including sexual assault), or to those who have had a failure of another method of contraception (e.g., broken condom).

B. Preparations

1. Menstrual bleeding typically occurs within three days after administration of most forms of hormonal postcoital contraception. A pregnancy test should be performed if bleeding has not occurred within four weeks.
2. Preven Emergency Contraceptive Kit includes four combination tablets, each containing 50 μg of ethinyl estradiol and 0.25 mg of levonorgestrel, and a pregnancy test to rule out pregnancy before taking the tablets. Instructions are to take two of the tablets as soon as possible within 72 hours of coitus, and the other two tablets twelve hours later.
3. An oral contraceptive such as Ovral (two tablets twelve hours apart) or Lo/Ovral (4 tablets twelve hours apart) can also be used.
4. Nausea and vomiting are the major side effects. Meclizine 50 mg, taken one hour before the first dose, reduces nausea and vomiting but can cause some sedation.
5. Plan B is a pill pack that contains two 0.75 mg tablets of levonorgestrel to be taken twelve hours apart. The cost is comparable to the Preven kit ($20). This regimen may be more effective and better tolerated than an estrogen-progestin regimen.
6. Copper T380 IUD. A copper intrauterine device (IUD) placed within 120 hours of unprotected intercourse can also be used as a form of emergency contraception. An advantage of this method is that it provides continuing contraception after the initial event.

### Emergency Contraception

| 1. Consider pretreatment one hour before each oral contraceptive pill dose, using one of the following orally administered antiemetic agents: Prochlorperazine (Compazine), 5 to 10 mg Promethazine (Phenergan), 12.5 to 25 mg Trimethobenzamide (Tigan), 250 mg Meclizine (Antivert) 50 mg |
| 2. Administer the first dose of oral contraceptive pill within 72 hours of unprotected coitus, and administer the second dose 12 hours after the first dose. Brand name options for emergency contraception include the following: Preven Kit – two pills per dose (0.5 mg of levonorgestrel and 100 µg of ethinyl estradiol per dose) Plan B – one pill per dose (0.75 mg of levonorgestrel per dose) Ovral – two pills per dose (0.5 mg of levonorgestrel and 100 µg of ethinyl estradiol per dose) Nordette – four pills per dose (0.8 mg of levonorgestrel and 120 µg of ethinyl estradiol per dose) Triphasil – four pills per dose (0.5 mg of levonorgestrel and 120 µg of ethinyl estradiol per dose) |

### References:
See page 282.

### Acute Pelvic Pain

I. Clinical evaluation
A. Assessment of acute pelvic pain should determine the patient’s age, obstetrical history, menstrual history, characteristics of pain onset, duration, and palliative or aggravating factors.
B. Associated symptoms may include urinary or gastrointestinal symptoms, fever, abnormal bleeding, or vaginal discharge.
C. Past medical history. Contraceptive history, surgical history, gynecologic history, history of pelvic inflammatory disease, ectopic pregnancy, sexually transmitted diseases should be determined. Current sexual activity and practices should be assessed.
D. Method of contraception
1. Sexual abstinence in the months preceding the onset of pain lessens the likelihood of pregnancy-related etiologies.
2. The risk of acute PID is reduced by 50% in patients taking oral contraceptives or using a barrier method of contraception. Patients taking oral contraceptives are at decreased risk for an ectopic pregnancy or ovarian cysts.
E. Risk factors for acute pelvic inflammatory disease. Age between 15-25 years, sexual partner with symptoms of urethritis, prior history of PID.

II. Physical examination
A. Fever, abdominal or pelvic tenderness, and peritoneal signs should be sought.
B. Vaginal discharge, cervical erythema and discharge, cervical and uterine motion tenderness, or adnexal masses or tenderness should be noted.

III. Laboratory tests
A. Pregnancy testing will identify pregnancy-related causes of pelvic pain. Serum beta-HCG becomes positive 7 days after conception. A negative test virtually excludes ectopic pregnancy.
B. Complete blood count. Leukocytosis suggest an inflammatory process; however, a normal white blood count occurs in 56% of patients with PID and 37% of patients with appendicitis.
C. Urinalysis. The finding of pyuria suggests urinary tract infection. Pyuria can also occur with an inflamed appendix or from contamination of the urine by vaginal discharge.
D. Testing for Neisseria gonorrhoeae and Chlamydia trachomatis are necessary if PID is a possibility.
E. Pelvic ultrasonography is of value in excluding the diagnosis of an ectopic pregnancy by demonstrating an intrauterine gestation. Sonography may reveal acute PID, torsion of the adnexa, or acute appendicitis.
F. Diagnostic laparoscopy is indicated when acute pelvic pain has an unclear diagnosis despite comprehensive evaluation.

III. Differential diagnosis of acute pelvic pain
A. Pregnancy-related causes. Ectopic pregnancy, spontaneous, threatened or incomplete abortion, intrauterine pregnancy with corpus luteum bleeding.
B. Gynecologic disorders. PID, endometriosis, ovarian cyst hemorrhage or rupture, adnexal torsion, Mittelschmerz, uterine leiomyoma torsion, primary dysmenorrhea, tumor.
C. Nonreproductive tract causes
2. Urinary tract. Urinary tract infection, renal calculus.

IV. Approach to acute pelvic pain with a positive pregnancy test
A. In a female patient of reproductive age, presenting with acute pelvic pain, the first distinction is whether the pain is pregnancy-related or non-pregnancy-related on the basis of a serum pregnancy test.

B. In the patient with acute pelvic pain associated with pregnancy, the next step is localization of the tissue responsible for the hCG production. Transvaginal ultrasound should be performed to identify an intrauterine gestation. Ectopic pregnancy is characterized by a noncystic adnexal mass and fluid in the cul-de-sac.

V. Approach to acute pelvic pain in non-pregnant patients with a negative hCG

A. Acute PID is the leading diagnostic consideration in patients with acute pelvic pain unrelated to pregnancy. The pain is usually bilateral, but may be unilateral in 10%. Cervical motion tenderness, fever, and cervical discharge are common findings.

B. Acute appendicitis should be considered in all patients presenting with acute pelvic pain and a negative pregnancy test. Appendicitis is characterized by leukocytosis and a history of a few hours of periumbilical pain followed by migration of the pain to the right lower quadrant. Neutrophilia occurs in 75%. A slight fever exceeding 37.3°C, nausea, vomiting, anorexia, and rebound tenderness may be present.

C. Torsion of the adnexa usually causes unilateral pain, but pain can be bilateral in 25%. Intense, progressive pain combined with a tense, tender adnexal mass is characteristic. There is often a history of repetitive, transitory pain. Pelvic sonography often confirms the diagnosis. Laparoscopic diagnosis and surgical intervention are indicated.

D. Ruptured or hemorrhagic corpus luteal cyst usually causes bilateral pain, but it can cause unilateral tenderness in 35%. Ultrasound aids in diagnosis.

E. Endometriosis usually causes chronic or recurrent pain, but it can occasionally cause acute pelvic pain. There usually is a history of dysmenorrhea and deep dyspareunia. Pelvic exam reveals fixed uterine retrodisplacement and tender uterosacral and cul-de-sac nodularity. Laparoscopy confirms the diagnosis.

References: See page 282.

Chronic Pelvic Pain

Chronic pelvic pain (CPP) affects approximately one in seven women in the United States (14 percent). Chronic pelvic pain (>6 months in duration) is less likely to be associated with a readily identifiable cause than is acute pain.

I. Etiology of chronic pelvic pain

A. Physical and sexual abuse. Numerous studies have demonstrated a higher frequency of physical and/or sexual abuse in women with CPP. Between 30 and 50 percent of women with CPP have a history of abuse (physical or sexual, childhood or adult).

B. Gynecologic problems

1. Endometriosis is present in approximately one-third of women undergoing laparoscopy for CPP and is the most frequent finding in these women. Typically, endometriosis pain is a sharp or “crampy” pain. It starts at the onset of menses, becoming more severe and prolonged over several menstrual cycles. It is frequently accompanied by deep dyspareunia. Uterosacral ligament nodularity is highly specific for endometriosis. Examining the woman during her menstruation may make the nodularity easier to palpate. A more common, but less specific, finding is tenderness in the cul-de-sac or uterosacral ligaments that reproduces the pain of deep dyspareunia.

2. Pelvic adhesions are found in approximately one-fourth of women undergoing laparoscopy for CPP. Adhesions form after intra-abdominal inflammation; they should be suspected if the woman has a history of surgery or pelvic inflammatory disease (PID). The pain may be a dull or sharp pulling sensation that occurs at any time during the month. Physical examination is usually nondiagnostic.

3. Dysmenorrhea (painful menstruation) and mittelschmerz (midcycle pain) without other organic pathology are seen frequently and may contribute to CPP in more than half of all cases.

4. Chronic pelvic inflammatory disease may cause CPP. Therefore, culturing for sexually transmitted agents should be a routine part of the evaluation.
Medical Diagnoses and Chronic Pelvic Pain

<table>
<thead>
<tr>
<th>Medical diagnosis/symptom source</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowel dysmotility disorders</td>
<td>50 to 80%</td>
</tr>
<tr>
<td>Musculoskeletal disorders</td>
<td>30 to 70%</td>
</tr>
<tr>
<td>Cyclic gynecologic pain</td>
<td>20 to 50%</td>
</tr>
<tr>
<td>Urologic diagnoses</td>
<td>5 to 10%</td>
</tr>
<tr>
<td>Endometriosis, advanced and/or with dense bowel adhesions</td>
<td>Less than 5%</td>
</tr>
<tr>
<td>Unusual medical diagnoses</td>
<td>Less than 2%</td>
</tr>
<tr>
<td>Multiple medical diagnoses</td>
<td>30 to 50%</td>
</tr>
<tr>
<td>No identifiable medical diagnosis</td>
<td>Less than 5%</td>
</tr>
</tbody>
</table>

C. Nongynecologic medical problems
1. **Bowel dysmotility** (eg, irritable bowel syndrome and constipation) may be the primary symptom source in 50 percent of all cases of CPP and may be a contributing factor in up to 80 percent of cases. Pain from irritable bowel syndrome is typically described as a crampy, recurrent pain accompanied by abdominal distention and bloating, alternating diarrhea and constipation, and passage of mucus. The pain is often worse during or near the menstrual period. A highly suggestive sign is exquisite tenderness to palpation which improves with continued pressure.

2. **Musculoskeletal dysfunction**, including abdominal myofascial pain syndromes, can cause or contribute to CPP.

D. Psychologic problems
1. **Depressive disorders** contribute to more than half of all cases of CPP. Frequently, the pain becomes part of a cycle of pain, disability, and mood disturbance. The diagnostic criteria for depression include depressed mood, diminished interest in daily activities, weight loss or gain, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness, loss of concentration, and recurrent thoughts of death.

2. **Somatoform disorders**, including somatization disorder, contribute to 10 to 20 percent of cases of CPP. The essential feature of somatization disorder is a pattern of recurring, multiple, clinically significant somatic complaints.

II. Clinical evaluation of chronic pelvic pain
A. History
1. The character, intensity, distribution, and location of pain are important. Radiation of pain or should be assessed. The temporal pattern of the pain (onset, duration, changes, cyclicity) and aggravating or relieving factors (eg, posture, meals, bowel movements, voiding, menstruation, intercourse, medications) should be documented.

2. Associated symptoms. Anorexia, constipation, or fatigue are often present.

3. Previous surgeries, pelvic infections, infertility, or obstetric experiences may provide additional clues.

4. For patients of reproductive age, the timing and characteristics of their last menstrual period, the presence of non-menstrual vaginal bleeding or discharge, and the method of contraception used should be determined.

5. Life situations and events that affect the pain should be sought.

6. Gastrointestinal and urologic symptoms, including the relationship between these systems to the pain should be reviewed.

7. The patient's affect may suggest depression or other mood disorders.

B. Physical examination
1. If the woman indicates the location of her pain with a single finger, the pain is more likely caused by a discrete source than if she uses a sweeping motion of her hand.

2. A pelvic examination should be performed. Special attention should be given to the bladder, urethra.

3. The piriformis muscles should be palpated; piriformis spasm can cause pain when climbing stairs, driving a car, or when first arising in the morning. This muscle is responsible for external rotation of the hip and can be palpated posterolaterally, cephalic to the ischial spine. This examination is most easily performed if the woman externally rotates her hip against the resistance of the examiner’s other hand. Piriformis spasm is treated with physical therapy.

4. Abdominal deformity, erythema, edema, scars, hemias, or distension should be noted. Abnormal bowel sounds may suggest a gastrointestinal process.

5. Palpation should include the epigastrium, flanks, and low back, and inguinal areas.

C. Special tests
1. Initial laboratory tests should include cervical cytology, endocervical cultures for Neisseria gonorrhoeae and Chlamydia, stool Hemoccult, and urinalysis. Other tests may be suggested by the history and examination.

2. Laparoscopy is helpful when the pelvic examination is abnormal or when initial therapy fails.
III. Management
A. Myofascial pain syndrome may be treated by a variety of physical therapy techniques. Trigger points can often be treated with injections of a local anesthetic (e.g., bupivacaine [Marcaine]), with or without the addition of a corticosteroid.

B. If the pain is related to the menstrual cycle, treatment aimed at suppressing the cycle may help. Common methods to accomplish this include administration of depot medroxyprogesterone (Depo-Provera) and continuously dosed oral contraceptives.

C. Cognitive-behavioral therapy is appropriate for all women with CPP. Relaxation and distraction techniques are often helpful.

D. When endometriosis or pelvic adhesions are discovered on diagnostic laparoscopy, they are usually treated during the procedure. Hysterectomy may be warranted if the pain has persisted for more than six months, does not respond to analgesics (including anti-inflammatory agents), and impairs the woman's normal function.

E. Antidepressants or sleeping aids are useful adjunctive therapies. Amitriptyline (Elavil), in low doses of 25-50 mg qhs, may be of help in improving sleep and reducing the severity of chronic pain complaints.

F. Muscle relaxants may prove useful in patients with guarding, splinting, or reactive muscle spasms.

References: See page 282.

Endometriosis

Endometriosis is characterized by the presence of endometrial tissue on the ovaries, fallopian tubes or other abnormal sites, causing pain or infertility. Women are usually 25 to 29 years old at the time of diagnosis. Approximately 24 percent of women who complain of pelvic pain are subsequently found to have endometriosis. The overall prevalence of endometriosis is estimated to be 5 to 10 percent.

I. Clinical evaluation
A. Endometriosis should be considered in any woman of reproductive age who has pelvic pain. The most common symptoms are dysmenorrhea, dyspareunia, and low back pain that worsens during menses. Rectal pain and painful defecation may also occur. Other causes of secondary dysmenorrhea and chronic pelvic pain (e.g., upper genital tract infections, adenomyosis, adhesions) may produce similar symptoms.

B. Infertility may be the presenting complaint for endometriosis. Infertile patients often have no painful symptoms.

C. Physical examination. The physician should palpate for a fixed, retroverted uterus, adnexal and uterine tenderness, pelvic masses or nodularity along the uterosacral ligaments. A rectovaginal examination should identify uterosacral, cul-de-sac or septal nodules. Most women with endometriosis have normal pelvic findings.

II. Treatment
A. Confirmatory laparoscopy is usually required before treatment is instituted. In women with few symptoms, an empiric trial of oral contraceptives or progestins may be warranted to assess pain relief.

B. Medical treatment
1. Initial therapy also should include a nonsteroidal anti-inflammatory drug.
   a. Naproxen (Naprosyn) 500 mg followed by 250 mg PO tid-qid pm [250, 375, 500 mg].
   b. Naproxen sodium (Aleve) 200 mg PO tid pm.
   c. Naproxen sodium (Anaprox) 550 mg, followed by 275 mg PO tid-qid pm.
   d. Ibuprofen (Motrin) 800 mg, then 400 mg PO q4-6h pm.
   e. Mefenamic acid (Ponstel) 500 mg PO followed by 250 mg q8h pm.

2. Progestational agents. Progestins are similar to combination OCPs in their effects on FSH, LH and endometrial tissue. They may be associated with more bothersome adverse effects than OCPs. Progestins are effective in reducing the symptoms of endometriosis. Oral progestin
regimens may include once-daily administration of medroxyprogesterone at the lowest effective dosage (5 to 20 mg). Depot medroxyprogesterone may be given intramuscularly every two weeks for two months at 100 mg per dose and then once a month for four months at 200 mg per dose.

3. Oral contraceptive pills (OCPs) suppress LH and FSH and prevent ovulation. Combination OCPs alleviate symptoms in about three quarters of patients. Oral contraceptives can be taken continuously (with no placebos) or cyclically, with a week of placebo pills between cycles. The OCPs can be discontinued after six months or continued indefinitely.

4. Danazol (Danocrine) has been highly effective in relieving the symptoms of endometriosis, but adverse effects may preclude its use. Adverse effects include headache, flushing, sweating and atrophic vaginitis. Androgenic side effects include acne, edema, hirsutism, deepening of the voice and weight gain. The initial dosage should be 800 mg per day, and the overall response rate is 84 to 92 percent.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danazol (Danocrine)</td>
<td>800 mg per day in 2 divided doses</td>
<td>Estrogen deficiency, androgenic side effects</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>1 pill per day (continuous or cyclic)</td>
<td>Headache, nausea, hypertension</td>
</tr>
<tr>
<td>Medroxyprogesterone (Provera)</td>
<td>5 to 20 mg orally per day</td>
<td>Same as with other oral progestins</td>
</tr>
<tr>
<td>Medroxyprogesterone suspension (Depo-Provera)</td>
<td>100 mg IM every 2 weeks; then 200 mg IM every month for 4 months or 150 mg IM every 3 months</td>
<td>Weight gain, depression, irregular menses or amenorrhea</td>
</tr>
<tr>
<td>Norethindrone (Aygestin)</td>
<td>5 mg per day orally for 2 weeks; then increase by 2.5 mg per day every 2 weeks up to 15 mg per day</td>
<td>Same as with other oral progestins</td>
</tr>
<tr>
<td>Leuprolide (Lupron)</td>
<td>3.75 mg IM every month for 6 months</td>
<td>Decrease in bone density, estrogen deficiency</td>
</tr>
<tr>
<td>Goserelin (Zoladex)</td>
<td>3.6 mg SC (in upper abdominal wall) every 28 days</td>
<td>Estrogen deficiency</td>
</tr>
<tr>
<td>Nafarelin (Synarel)</td>
<td>400 mg per day; 1 spray in 1 nostril in a.m.; 1 spray in other nostril in p.m.; start treatment on day 2 to 4 of menstrual cycle</td>
<td>Estrogen deficiency, bone density changes, nasal irritation</td>
</tr>
</tbody>
</table>

C. GnRH agonists. These agents (eg, leuprolide [Lupron], goserelin [Zoladex]) inhibit the secretion of gonadotropin. GnRH agonists are contraindicated in pregnancy and have hypoestrogenic side effects. They produce a mild degree of bone loss. Because of concerns about osteopenia, “add-back” therapy with low-dose estrogen has been recommended. The dosage of leuprolide is a single monthly 3.75-mg depot injection given intramuscularly. Goserelin, in a dosage of 3.6 mg, is administered subcutaneously every 28 days. A nasal spray (nafarelin [Synarel]) may be used twice daily. The response rate is similar to that with danazol; about 90 percent of patients experience pain relief.

D. Surgical treatment

1. Surgical treatment is the preferred approach to infertile patients with advanced endometriosis. Laparoscopic ablation of endometriosis lesions may result in a 13 percent increase in the probability of pregnancy.

Primary Amenorrhea

Amenorrhea (absence of menses) results from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina. It is often classified as either primary (absence of menarche by age 16) or secondary (absence of menses for more than three cycle intervals or six months in women who were previously menstruating).

I. Etiology

A. Primary amenorrhea is usually the result of a genetic or anatomic abnormality. Common etiologies of primary amenorrhea:
1. Chromosomal abnormalities causing gonadal dysgenesis: 45 percent
2. Physiologic delay of puberty: 20 percent
3. Mullerian agenesis: 15 percent
4. Transverse vaginal septum or imperforate hymen: 5 percent
5. Absent production of gonadotropin-releasing hormone (GnRH) by the hypothalamus: 5 percent
6. Anorexia nervosa: 2 percent
7. Hypopituitarism: 2 percent

<p>| Causes of Primary and Secondary Amenorrhea |</p>
<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy</td>
<td></td>
</tr>
<tr>
<td>Anatomic abnormalities</td>
<td></td>
</tr>
<tr>
<td>Congenital abnormality in Mullerian development</td>
<td>Isolated defect</td>
</tr>
<tr>
<td>Testicular feminization syndrome</td>
<td></td>
</tr>
<tr>
<td>5-Alpha-reductase deficiency</td>
<td></td>
</tr>
<tr>
<td>Vanishing testes syndrome</td>
<td></td>
</tr>
<tr>
<td>Defect in testis determining factor</td>
<td></td>
</tr>
<tr>
<td>Congenital defect of urogenital sinus development</td>
<td>Agenesis of lower vagina</td>
</tr>
<tr>
<td>Imperforate hymen</td>
<td></td>
</tr>
<tr>
<td>Acquired ablation or scarring of the endometrium</td>
<td>Asherman’s syndrome</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td></td>
</tr>
</tbody>
</table>

| Disorders of hypothalamic-pituitary ovarian axis | |
| Hypothalamic dysfunction | |
| Pituitary dysfunction | |
| Ovarian dysfunction | |

<p>| Causes of Amenorrhea due to Abnormalities in the Hypothalamic-Pituitary-Ovarian Axis |</p>
<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothalamic dysfunction</td>
<td>Functional hypothalamic amenorrhea</td>
</tr>
<tr>
<td>Weight loss, eating disorders</td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td></td>
</tr>
<tr>
<td>Stress</td>
<td></td>
</tr>
<tr>
<td>Severe or prolonged illness</td>
<td></td>
</tr>
<tr>
<td>Congenital gonadotropin-releasing hormone deficiency</td>
<td></td>
</tr>
<tr>
<td>Inflammatory or infiltrative diseases</td>
<td></td>
</tr>
<tr>
<td>Brain tumors - eg, craniopharyngioma</td>
<td></td>
</tr>
<tr>
<td>Pituitary stalk dissection or compression</td>
<td></td>
</tr>
<tr>
<td>Cranial irradiation</td>
<td></td>
</tr>
<tr>
<td>Brain injury - trauma, hemorrhage, hydrocephalus</td>
<td></td>
</tr>
<tr>
<td>Other syndromes - Prader-Willi, Laurence-Moon-Biedl</td>
<td></td>
</tr>
<tr>
<td>Pituitary dysfunction</td>
<td>Hyperprolactinemia</td>
</tr>
<tr>
<td>Other pituitary tumors - acromegaly, corticotroph adenomas (Cushing’s disease)</td>
<td></td>
</tr>
<tr>
<td>Other tumors - meningioma, glioma, glione</td>
<td></td>
</tr>
<tr>
<td>Empty sella syndrome</td>
<td></td>
</tr>
<tr>
<td>Pituitary infarct or apoplexy</td>
<td></td>
</tr>
<tr>
<td>Ovarian dysfunction</td>
<td>Ovarian failure (menopause)</td>
</tr>
<tr>
<td>Spontaneous</td>
<td></td>
</tr>
<tr>
<td>Premature (before age 40 years)</td>
<td></td>
</tr>
<tr>
<td>Surgical</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td>Exogenous androgen use</td>
<td></td>
</tr>
</tbody>
</table>

II. Diagnostic evaluation of primary amenorrhea
A. Step I: Evaluate clinical history
1. Signs of puberty may include a growth spurt, absence of axillary and pubic hair, or apocrine sweat glands, or absence of breast development. Lack of pubertal development suggests ovarian or pituitary failure or a chromosomal abnormality.
2. Family history of delayed or absent puberty suggests a familial disorder.
3. Short stature may indicate Turner syndrome or hypothalamic-pituitary disease.
4. Poor health may be a manifestation of hypothalamic-pituitary disease. Symptoms of other hypothalamic-pituitary disease include headaches, visual field defects, fatigue, or polyuria and polydipsia.
5. Virilization suggests polycystic ovary syndrome, an androgen-secreting ovarian or adrenal tumor, or the presence of Y chromosome material.
6. Recent stress, change in weight, diet, or exercise habits; or illness may suggest hypothalamic amenorrhea.
7. Heroin and methadone can alter hypothalamic gonadotropin secretion.
8. Galactorrhea is suggestive of excess prolactin. Some drugs cause amenorrhea by increasing serum prolactin concentrations, including metoclopramide and antipsychotic drugs.

B. Step II: Physical examination
1. An evaluation of pubertal development should include current height, weight, and arm span (normal arm span for adults is within 5 cm of height) and an evaluation of the growth chart.
2. Breast development should be assessed by Tanner staging.
3. The genital examination should evaluate clitoral size, pubertal hair development, intactness of the hymen, depth of the vagina, and presence of a cervix, uterus, and ovaries. If the vagina cannot be penetrated with a finger, rectal examination may allow evaluation of the internal organs. Pelvic ultrasound is also useful to determine the presence or absence of müllerian structures.
4. The skin should be examined for hirsutism, acne, striae, increased pigmentation, and vitiligo.
5. Classic physical features of Turner syndrome include low hair line, web neck, shield chest, and widely spaced nipples.

C. Step III: Basic laboratory testing
1. If a normal vagina or uterus are not obviously present on physical examination, pelvic ultrasonography should be performed to confirm the presence or absence of ovaries, uterus, and cervix. Ultrasonography can be useful to exclude vaginal or cervical outlet obstruction in patients with cyclic pain.
   a. Uterus absent
      (1) If the uterus is absent, evaluation should include a karyotype and serum testosterone. These tests should distinguish abnormal müllerian development (46,XX karyotype with normal female serum testosterone concentrations) from androgen insensitivity syndrome (46,XY karyotype and normal male serum testosterone concentrations).
      (2) Patients with 5-alpha reductase deficiency also have a 46,XY karyotype and normal male serum testosterone concentrations but, in contrast to the androgen insensitivity syndrome which is associated with a female phenotype, these patients undergo striking virilization at the time of puberty (secondary sexual hair, muscle mass, and deepening of the voice).
   b. Uterus present. For patients with a normal vagina and uterus and no evidence of an imperforate hymen, vaginal septum, or congenital absence of the vagina. Measurement of serum beta human chorionic gonadotropin to exclude pregnancy and of serum FSH, prolactin, and TSH.
      a. A high serum FSH concentration is indicative of primary ovarian failure. A karyotype is then required and may demonstrate complete or partial deletion of the X chromosome (Turner syndrome) or the presence of Y chromatin. The presence of a Y chromosome is associated with a higher risk of gonadal tumors and makes gonadectomy mandatory.
      b. A low or normal serum FSH concentration suggests functional hypothalamic amenorrhea, congenital GnRH deficiency, or other disorders of the hypothalamic-pituitary axis. Cranial MR imaging is indicated in most cases of hypogonadotropic hypogonadism to evaluate hypothalamic or pituitary disease. Cranial MRI is recommended for all women with primary hypogonadotropic hypogonadism, visual field defects, or headaches.
      c. Serum prolactin and thyrotropin (TSH) should be measured, especially if galactorrhea is present.
      d. If there are signs or symptoms of hirsutism, serum testosterone and dehydroepiandrosterone sulfate (DHEA-S) should be measured to assess for an androgen-secreting tumor.
      e. If hypertension is present, blood tests should be drawn for evaluate for CYP17 deficiency. The characteristic findings are elevations in serum progesterone (>3 ng/mL) and deoxycorticosterone and low values for serum 17-alpha-hydroxyprogesterone (<0.2 ng/mL).

III. Treatment
A. Treatment of primary amenorrhea is directed at correcting the underlying pathology; helping the woman to achieve fertility, if desired; and prevention of complications of the disease.
B. Congenital anatomic lesions or Y chromosome material usually requires surgery. Surgical correction of a vaginal outlet obstruction is necessary before menarche, or as soon as the diagnosis is made after menarche. Creation of a neovagina for patients with müllerian failure is usually delayed until the women is emotionally mature. If Y chromosome material is found, gonadectomy should be performed to prevent gonadal neoplasia. However, gonadectomy should be delayed until after puberty in patients with androgen insensitivity syndrome.
These patients have a normal pubertal growth spurt and feminize at the time of expected puberty. 

C. **Ovarian failure** requires counseling about the benefits and risks of hormone replacement therapy.

D. **Polycystic ovary syndrome** is managed with measures to reduce hirsutism, resume menses, and fertility and prevent of endometrial hyperplasia, obesity, and metabolic defects.

E. **Functional hypothalamic amenorrhea** can usually be reversed by weight gain, reduction in the intensity of exercise, or resolution of illness or emotional stress. For women who want to continue to exercise, estrogen-progesterin replacement therapy should be given to those not seeking fertility to prevent osteoporosis. Women who want to become pregnant can be treated with gonadotropins or pulsatile GnRH.

F. **Hypothalamic or pituitary dysfunction** that is not reversible (eg, congenital GnRH deficiency) is treated with either exogenous gonadotropins or pulsatile GnRH if the woman wants to become pregnant.

References: See page 282.

**Secondary Amenorrhea**

Amenorrhea (absence of menses) can be a transient, intermittent, or permanent condition resulting from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina. Amenorrhea is classified as either primary (absence of menarche by age 16 years) or secondary (absence of menses for more than three cycles or six months in women who previously had menses). Pregnancy is the most common cause of secondary amenorrhea.

I. **Diagnosis**

A. **Step 1: Rule out pregnancy.** A pregnancy test is the first step in evaluating secondary amenorrhea. Measurement of serum beta subunit of hCG is the most sensitive test.

B. **Step 2: Assess the history**

1. Recent stress; change in weight, diet or exercise habits; or illnesses that might result in hypothalamic amenorrhea should be sought.
2. Drugs associated with amenorrhea, systemic illnesses that can cause hypothalamic amenorrhea, recent initiation or discontinuation of an oral contraceptive, androgenic drugs (danazol) or high-dose progesterin, and antipsychotic drugs should be evaluated.
3. Headaches, visual field defects, fatigue, or polyuria and polydipsia may suggest hypothalamic-pituitary disease.
4. Symptoms of estrogen deficiency include hot flashes, vaginal dryness, poor sleep, or decreased libido.
5. **Galactorrhea** is suggestive of hyperprolactinemia. Hirsutism, acne, and a history of irregular menses are suggestive of hyperandrogenism.
6. A history of obstetrical catastrophe, severe bleeding, dilatation and curettage, or endometritis or other infection that might have caused scarring of the endometrial lining suggests Asherman's syndrome.

| Causes of Primary and Secondary Amenorrhea |
|------------------|------------------|
| Abnormality      | Causes           |
| Pregnancy        |                  |
| Anatomic abnormalities |                |
| Congenital abnormality in Mullerian development | Isolated defect Testicular feminization syndrome 5-Alpha-reductase deficiency Vanishing testes syndrome Defect in testis determining factor |
| Congenital defect of urogenital sinus development | Agenesis of lower vagina Imperforate hymen |
| Acquired ablation or scarring of the endometrium | Asherman's syndrome Tuberculosis |
| Disorders of hypothalamic-pituitary ovarian axis | Hypothalamic dysfunction Pituitary dysfunction Ovarian dysfunction |
Causes of Amenorrhea due to Abnormalities in the Hypothalamic-Pituitary-Ovarian Axis

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Causes</th>
</tr>
</thead>
</table>
| Hypothalamic dysfunction | Functional hypothalamic amenorrhea  
|                      | Weight loss, eating disorders  
|                      | Exercise  
|                      | Stress  
|                      | Severe or prolonged illness  
|                      | Congenital gonadotropin-releasing hormone deficiency  
|                      | Inflammatory or infiltrative diseases  
|                      | Brain tumors - eg., craniopharyngioma  
|                      | Pituitary stalk dissection or compression  
|                      | Cranial irradiation  
|                      | Brain injury - trauma, hemorrhage, hydrocephalus  
|                      | Other syndromes - Prader-Willi, Laurence-Moon-Biedl  |
| Pituitary dysfunction | Hyperprolactinemia  
|                      | Other pituitary tumors - acromegaly, corticotroph adenomas (Cushing's disease)  
|                      | Other tumors - meningioma, germinoma, glioma  
|                      | Empty sella syndrome  
|                      | Pituitary infarct or apoplexy  |
| Ovarian dysfunction  | Ovarian failure (menopause)  
|                      | Spontaneous  
|                      | Premature (before age 40 years)  
|                      | Surgical  |
| Other                | Hyperthyroidism  
|                      | Hypothyroidism  
|                      | Diabetes mellitus  
|                      | Exogenous androgen use  |

Drugs Associated with Amenorrhea

<table>
<thead>
<tr>
<th>Drugs that Increase Prolactin</th>
<th>Drugs with Estrogenic Activity</th>
</tr>
</thead>
</table>
| Antipsychotics  
| Tricyclic antidepressants  
| Calcium channel blockers  
| Digoxin, marijuana, oral contraceptives  |

C. Step 3: Physical examination. Measurements of height and weight, signs of other illnesses, and evidence of cachexia should be assessed. The skin, breasts, and genital tissues should be evaluated for estrogen deficiency. The breasts should be palpated, including an attempt to express galactorrhea. The skin should be examined for hirsutism, acne, striae, acanthosis nigricans, vitiligo, thickness or thinness, and easy bruising.

D. Step 4: Basic laboratory testing. In addition to measurement of serum hCG to rule out pregnancy, minimal laboratory testing should include measurements of serum prolactin, thyrotropin, and FSH to rule out hyperprolactinemia, thyroid disease, and ovarian failure (high serum FSH). If there is hirsutism, acne or irregular menses, serum dehydroepiandrosterone sulfate (DHEA-S) and testosterone should be measured.

E. Step 5: Follow-up laboratory evaluation

1. High serum prolactin concentration. Prolactin secretion can be transiently increased by stress or eating. Therefore, serum prolactin should be measured at least twice before cranial imaging is obtained, particularly in those women with small elevations (<50 ng/mL). These women should be screened for thyroid disease with a TSH and free T4 because hypothyroidism can cause hyperprolactinemia.

2. Women with verified high serum prolactin values should have a cranial MRI unless a very clear explanation is found for the elevation (eg, antipsychotics). Imaging should rule out a hypothalamic or pituitary tumor.

3. High serum FSH concentration. A high serum FSH concentration indicates the presence of ovarian failure. This test should be repeated monthly on three occasions to confirm. A karyotype should be considered in most women with secondary amenorrhea age 30 years or younger.

4. High serum androgen concentrations. A high serum androgen value may suggest the diagnosis of polycystic ovary syndrome or may suggest an androgen-secreting tumor of the ovary or adrenal gland. Further testing for a tumor might include a 24-hour urine collection for cortisol and 17-ketosteroids, determination of serum 17-hydroxyprogesterone after intravenous injection of corticotropin (ACTH), and a dexamethasone suppression test. Elevation of 17-ketosteroids, DHEA-S, or 17-hydroxyprogesterone is more consistent with an adrenal, rather than ovarian, source of excess androgen.
5. Normal or low serum gonadotropin concentrations and all other tests normal
   a. This result is one of the most common outcomes of laboratory testing in women with amenorrhea. Women with hypothalamic amenorrhea (caused by marked exercise or weight loss to more than 10 percent below the expected weight) have normal to low serum FSH values. Cranial MRI is indicated in all women without an a clear explanation for hypogonadotropic hypogonadism and in most women who have visual field defects or headaches. No further testing is required if the onset of amenorrhea is recent or is easily explained (eg, weight loss, excessive exercise) and there are no symptoms suggestive of other disease.
   b. High serum transferrin saturation may indicate hemochromatosis, high serum angiotensin-converting enzyme values suggest sarcoidosis, and high fasting blood glucose or hemoglobin A1c values indicate diabetes mellitus.

6. Normal serum prolactin and FSH concentrations with history of uterine instrumentation preceding amenorrhea
   a. Evaluation for Asherman’s syndrome should be completed. A progestin challenge should be performed (medroxyprogesterone acetate 10 mg for 10 days). If withdrawal bleeding occurs, an outflow tract disorder has been ruled out. If bleeding does not occur, estrogen and progestin should be administered.
   b. Oral conjugated estrogens (0.625 to 2.5 mg daily for 35 days) with medroxyprogesterone added (10 mg daily for days 26 to 35); failure to bleed upon cessation of this therapy strongly suggests endometrial scarring. In this situation, a hysterosalpingogram or hysteroscopy can confirm the diagnosis of Asherman syndrome.

II. Treatment
   A. Athletic women should be counseled on the need for increased caloric intake or reduced exercise. Resumption of menses usually occurs.
   B. Nonathletic women who are underweight should receive nutritional counseling and treatment of eating disorders.
   C. Hyperprolactinemia is treated with a dopamine agonist. Cabergoline (Dostinex) or bromocriptine (Parlodel) are used for most adenomas. Ovulation, regular menstrual cycles, and pregnancy may usually result.
   D. Ovarian failure should be treated with hormone replacement therapy.
   E. Hyperandrogenism is treated with measures to reduce hirsutism, resume menses, and fertility and preventing endometrial hyperplasia, obesity, and metabolic defects.
   F. Asherman’s syndrome is treated with hysteroscopic lysis of adhesions followed by long-term estrogen administration to stimulate regrowth of endometrial tissue.

References: See page 282.

Menopause

Menopause is defined as the cessation of menstrual periods in women. The average age of menopause is 51 years, with a range of 41-55. The diagnosis of menopause is made by the presence of amenorrhea for six to twelve months, together with the occurrence of hot flashes. If the diagnosis is in doubt, menopause is indicated by an elevated follicle-stimulating hormone (FSH) level greater than 40 mIU/mL.

I. Perimenopausal transition is defined as the two to eight years preceding menopause and the one year after the last menstrual period. It is characterized by normal ovulatory cycles interspersed with anovulatory (estrogen-only) cycles. As a result, menses become irregular, and heavy breakthrough bleeding, termed dysfunctional uterine bleeding, can occur during longer periods of anovulation.

II. Effects of estrogen deficiency after menopause
   A. Hot flashes. The most common acute change during menopause is the hot flash, which occurs in 75 percent of women. About 50 to 75 percent of women have cessation of hot flashes within five years. Hot flashes typically begin as a sudden sensation of heat centered on the face and upper chest that rapidly becomes generalized. The sensation lasts from two to four minutes and is often associated with profuse perspiration. Hot flashes occur several times per day.
   B. Sexual function. Estrogen deficiency leads to a decrease in blood flow to the vagina and vulva. This decrease is a major cause of decreased vaginal lubrication, dyspareunia, and decreased sexual function in menopausal women.
   C. Urinary incontinence. Menopause results in atrophy of the urethral epithelium with subsequent atrophic urethritis and irritation; these changes predispose to both stress and urge urinary incontinence.
   D. Osteoporosis. A long-term consequence of estrogen deficiency is the development of osteoporosis and fractures. Bone loss exceeds bone formation. Between 1 and 5 percent of the skeletal mass
can be lost per year in the first several years after
the menopause. Osteoporosis may occur in as little
as ten years.

E. Cardiovascular disease. The incidence of myo-
cardial infarction in women, although lower than in
men, increases dramatically after the menopause.

III. Estrogen replacement therapy
A. Data from the WHI and the HERS trials has deter-
mained that continuous estrogen-progestin therapy
does not appear to protect against cardiovascular
disease and increases the risk of breast cancer,
coronary heart disease, stroke, and venous
thromboembolism over an average follow-up of 5.2
years. As a result, the primary indication for estro-
gen therapy is for control of menopausal symp-
toms, such as hot flashes.

IV. Prevention and treatment of osteoporosis
A. Screening for osteoporosis. Measurement of
BMD is recommended for all women 65 years and
older regardless of risk factors. BMD should also
be measured in all women under the age of 65
years who have one or more risk factors for osteo-
porosis (in addition to menopause). The hip is the
recommended site of measurement.

B. Bisphosphonates
1. Alendronate (Fosamax) has effects compara-
tble to those of estrogen for both the treatment
of osteoporosis (10 mg/day or 70 mg once a
week) and for its prevention (5 mg/day).
Alendronate (in a dose of 5 mg/day or 35
mg/week) can also prevent osteoporosis in
postmenopausal women.
2. Risedronate (Actonel), a bisphosphonate, has
been approved for prevention and treatment of
osteoporosis at doses of 5 mg/day or 35
mg once per week. Its efficacy and side effect
profile are similar to those of alendronate.

C. Raloxifene (Evista) is a selective estrogen recep-
tor modulator. It is available for prevention and
treatment of osteoporosis. At a dose of 60 mg/day,
bone density increases by 2.4 percent in the
lumbar spine and hip over a two year period. This
effect is slightly less than with bisphosphonates.

D. Calcium. Maintaining a positive calcium balance in
postmenopausal women requires a daily intake of
1500 mg of elemental calcium; to meet this most
women require a supplement of 1000 mg daily.

E. Vitamin D. All postmenopausal women should take
a multivitamin containing at least 400 IU vitamin D
daily.

F. Exercise for at least 20 minutes daily reduces the
rate of bone loss. Weight bearing exercises are
preferable.

V. Treatment of hot flashes and vasomotor instability
A. The manifestations of vasomotor instability are hot
flashes, sleep disturbances, headache, and irrita-
bility. Most women with severe vasomotor instabil-
ity accept short-term estrogen therapy for these
symptoms.

B. Short-term estrogen therapy for relief of vaso-
motor instability and hot flashes
1. Short-term estrogen therapy remains the best
treatment for relief of menopausal symptoms,
and therefore is recommended for most
postmenopausal women, with the exception of
those with a history of breast cancer, CHD, a
previous venous thromboembolic event or
stroke, or those at high risk for these complica-
tions. Short-term therapy is continued for six
months to four or five years. Administration of
estrogen short-term is not associated with an
increased risk of breast cancer.
2. Low dose estrogen is recommended (eg, 0.3
mg conjugated estrogens [Premarin] daily or 0.5
mg estradiol [Estrace] daily). These doses are
adequate for symptom management and pre-
vention of bone loss.
3. Endometrial hyperplasia and cancer can occur
after as little as six months of unopposed estro-
gen therapy; as a result, a progestin must be
added in those women who have not had a
hysterectomy. Medroxyprogesterone (Provera),
2.5 mg, is usually given every day of the month.
4. After the planned treatment interval, the estro-
gen should be discontinued gradually to mini-
mize recurrence of the menopausal symptoms,
for example, by omitting one pill per week (6
pills per week, 5 pills per week, 4 pills per
week).

C. Treatment of vasomotor instability in women
not taking estrogen
1. Selective serotonin reuptake inhibitors
(SSRIs) also relieve the symptoms of vasomotor
instability.
   a. Venlafaxine (Effexor), at doses of 75 mg
daily, reduces hot flashes by 61 percent.
   Mouth dryness, anorexia, nausea, and con-
stipation are common.
   b. Paroxetine (Zoloft), 50 mg per day, relieves
vasomotor instability.
   c. Fluoxetine (Prozac) 20 mg per day also has
beneficial effects of a lesser magnitude.
2. Clonidine (Catapres) relieves hot flashes in
80%. In a woman with hypertension, clonidine
might be considered as initial therapy. It is
usually given as a patch containing 2.5 mg per
week. Clonidine also may be given orally in
doses of 0.1 to 0.4 mg daily. Side effects often
limit the use and include dry mouth, dizziness,
constipation, and sedation.
3. Megestrol acetate (Megace) is a synthetic progestin which decreases the frequency of hot flashes by 85 percent at a dose of 40 to 80 mg PO daily. Weight gain is the major side effect.

VI. Treatment of urogenital atrophy

A. Loss of estrogen causes atrophy of the vaginal epithelium and results in vaginal irritation and dryness, dyspareunia, and an increase in vaginal infections. Systemic estrogen therapy results in relief of symptoms.

B. Treatment of urogenital atrophy in women not taking systemic estrogen

1. Moisturizers and lubricants. Regular use of a vaginal moisturizing agent (Replens) and lubricants during intercourse are helpful. Water-soluble lubricants such as Astroglide are more effective than lubricants that become more viscous after application such as K-Y jelly. A more effective treatment is vaginal estrogen therapy.

2. Low-dose vaginal estrogen
   a. Vaginal ring estradiol (Estring), a silastic ring impregnated with estradiol, is the preferred means of delivering estrogen to the vagina. The silastic ring delivers 6 to 9 µg of estradiol to the vagina daily for a period of three months. The rings are changed once every three months by the patient. Concomitant progestin therapy is not necessary.
   b. Conjugated estrogens (Premarin), 0.5 gm of cream, or one-eighth of an applicatorful daily into the vagina for three weeks, followed by twice weekly thereafter. Concomitant progestin therapy is not necessary.
   c. Estrace cream (estradiol) can also be given by vaginal applicator at a dose of one-eighth of an applicator or 0.5 g (which contains 50 µg of estradiol) daily into the vagina for three weeks, followed by twice weekly thereafter. Concomitant progestin therapy is not necessary.
   d. Estradiol (Vagifem). A tablet containing 25 micrograms of estradiol is available and is inserted into the vagina twice per week. Concomitant progestin therapy is not necessary.

References: See page 282.

Premenstrual Syndrome and Premenstrual Dysphoric Disorder

Premenstrual syndrome (PMS) is characterized by physical and behavioral symptoms that occur repetitively in the second half of the menstrual cycle and interfere with some aspects of the woman’s life. Premenstrual dysphoric disorder (PMDD) is the most severe form of PMS, with the prominence of anger, irritability, and internal tension. PMS affects up to 75 percent of women with regular menstrual cycles, while PMDD affects only 3 to 8 percent of women.

I. Symptoms
   a. The most common physical manifestation of PMS is abdominal bloating, which occurs in 90 percent of women with this disorder; breast tenderness and headaches are also common, occurring in more than 50 percent of cases.
   b. The most common behavioral symptom of PMS is an extreme sense of fatigue which is seen in more than 90 percent. Other frequent behavioral complaints include irritability, tension, depressed mood, labile mood (80 percent), increased appetite (70 percent), and forgetfulness and difficulty concentrating (50 percent).
   c. Other common findings include acne, oversensitivity to environmental stimuli, anger, easy crying, and gastrointestinal upset. Hot flashes, heart palpitations, and dizziness occur in 15 to 20 percent of patients. Symptoms should occur in the luteal phase only.

<table>
<thead>
<tr>
<th>Symptom Clusters Commonly Noted in Patients with PMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Affective Symptoms</strong></td>
</tr>
<tr>
<td>Depression or sadness</td>
</tr>
<tr>
<td>Irritability</td>
</tr>
<tr>
<td>Tension</td>
</tr>
<tr>
<td>Anxiety</td>
</tr>
<tr>
<td>Tearfulness or crying easily</td>
</tr>
<tr>
<td>Restlessness or irritability</td>
</tr>
<tr>
<td>Anger</td>
</tr>
<tr>
<td>Loneliness</td>
</tr>
<tr>
<td>Appetite change</td>
</tr>
<tr>
<td>Food cravings</td>
</tr>
<tr>
<td>Changes in sexual interest</td>
</tr>
<tr>
<td>Pain</td>
</tr>
<tr>
<td>Headache or migraine</td>
</tr>
<tr>
<td>Back pain</td>
</tr>
<tr>
<td>Breast pain</td>
</tr>
<tr>
<td>Abdominal cramps</td>
</tr>
<tr>
<td>General or muscular pain</td>
</tr>
<tr>
<td><strong>Cognitive or performance</strong></td>
</tr>
<tr>
<td>Mood instability or mood swings</td>
</tr>
<tr>
<td>Difficulty in concentrating</td>
</tr>
<tr>
<td>Decreased efficiency</td>
</tr>
<tr>
<td>Confusion</td>
</tr>
<tr>
<td>Forgettingfulness</td>
</tr>
<tr>
<td>Accident-prone</td>
</tr>
<tr>
<td>Social avoidance</td>
</tr>
<tr>
<td>Temper outbursts</td>
</tr>
<tr>
<td>Energetic</td>
</tr>
<tr>
<td>Fluid retention</td>
</tr>
<tr>
<td>Breast tenderness or swelling</td>
</tr>
<tr>
<td>Weight gain</td>
</tr>
<tr>
<td>Abdominal bloating or swelling</td>
</tr>
<tr>
<td>Swelling of extremities</td>
</tr>
<tr>
<td><strong>General somatic</strong></td>
</tr>
<tr>
<td>Fatigue or tiredness</td>
</tr>
<tr>
<td>Dizziness or vertigo</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
</tbody>
</table>
DSM-IV Criteria for Premenstrual Dysphoric Disorder

- Five or more symptoms
- At least one of the following four symptoms:
  - Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts
  - Marked anxiety, tension, feeling of being “keyed up” or “on edge”
  - Marked affective lability
  - Persistent and marked anger or irritability or increase in interpersonal conflicts
- Additional symptoms that may be used to fulfill the criteria:
  - Decreased interest in usual activities
  - Subjective sense of difficulty in concentrating
  - Lethargy, easy fatigability, or marked lack of energy
  - Marked change in appetite, overeating, or specific food cravings
  - Hypersomnia or insomnia
  - Subjective sense of being overwhelmed or out of control
- Other physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of bloating, or weight gain
- Symptoms occurring during last week of luteal phase
- Symptoms are absent postmenstrually
- Disturbances that interfere with work or school or with usual social activities and relationships
- Disturbances that are not an exacerbation of symptoms of another disorder

UCSD Criteria for Premenstrual Syndrome

1. The presence by self report of at least one of the following somatic and affective symptoms during the five days prior to menses in each of the three menstrual cycles:
   - Affective
     - Depression
     - Angry outbursts
     - Irritability
     - Confusion
     - Social withdrawal
     - Fatigue
   - Somatic
     - Breast tenderness
     - Abdominal bloating
     - Headache
     - Swollen extremities

2. Relief of the above symptoms within four days of the onset of menses, without recurrence until at least cycle day 12.
3. The symptoms are present in the absence of any pharmacologic therapy, hormone ingestion, drug or alcohol use.
4. Identifiable dysfunction in social or economic performance by one of the following criteria:
   - Marital or relationship discord confirmed by partner
   - Difficulties in parenting
   - Poor work or school performance, attendance/tardiness
   - Increased social isolation
   - Legal difficulties
   - Suicidal ideation
   - Seeking medical attention for a somatic symptom(s)

E. Differential diagnosis

1. PMDD should be differentiated from premenstrual exacerbation of an underlying major psychiatric disorder, as well as medical conditions such as hyper- or hypothyroidism.
2. About 13 percent of women with PMS are found to have a psychiatric disorder alone with no evidence of PMS, while 38 percent had premenstrual exacerbation of underlying depressive and anxiety disorders.
3. Women who present with PMS have a much higher incidence of major depression in the past and are at greater risk for major depression in the future.
4. 39 percent of women with PMDD meet criteria for mood or anxiety disorders.
5. The assessment of patients with possible PMS or PMDD should begin with the history, physical examination, chemistry profile, complete blood count, and serum TSH. The history should focus in particular on the regularity of menstrual cycles. Appropriate gynecologic endocrine evalua-
tion should be performed if the cycles are irregular (lengths less than 25 or greater than 36 days).

6. The patient should be asked to record symptoms prospectively for two months. If the patient fails to demonstrate a symptom-free interval in the follicular phase, she should be evaluated for a mood or anxiety disorder.

II. Treatment of premenstrual dysphoric disorder

A. Serotonin reuptake inhibitors

1. Fluoxetine (Sarafem) is an effective treatment for PMDD when given in a daily dose of 20 mg/day. The response rate is 60 to 75 percent. The most common reasons for failure to continue the treatment are headache, anxiety, and nausea.

2. Other drugs that inhibit serotonin reuptake, such as clomipramine (Anafranil [given either throughout the menstrual cycle or restricted to the luteal phase]), sertraline (Zoloft) 50 to 150 mg/day throughout the menstrual cycle, and nefazodone (Serzone) 100-300 mg bid also may be effective in PMS.

3. Venlafaxine (Effexor) selectively inhibits the reuptake of both serotonin and norepinephrine and is also effective (50 to 200 mg/day).

4. Intermittent therapy given during the luteal phase only (starting on cycle day 14) has been shown to be effective.

B. Alprazolam (Xanax), 0.25 mg TID OR qid, has been shown in double-blind, placebo-controlled crossover studies to be beneficial in PMS.

C. GnRH agonists (leuprolide [Lupron] or buserelin) have shown some benefit. However, women with severe premenstrual depression are unresponsive to GnRH agonists. The physical symptoms may be more responsive than mood symptoms in women with PMS, and side effects (hypoestrogenism) may limit the use of these drugs for long-term therapy.

1. GnRH agonists and "add-back" therapy. Add-back therapy with estrogen (and a progestin if indicated) mitigates concerns about bone loss from prolonged administration of GnRH agonists. Leuprolide alone led to a 75 percent improvement in luteal phase symptom scores. This benefit was maintained (60 percent improvement) during a crossover period in which estrogen/progestin replacement was added. Alendronate can be considered in women who do not tolerate hormonal add-back therapy but need osteoporosis prophylaxis.

D. Danazol inhibits pituitary gonadotropin secretion, and is an effective therapy for PMS. However, the androgenic side effects of danazol limit its use to patients who fail to respond adequately to the above therapies.

References: See page 282.

### Treatment of Premenstrual Syndrome

| Fluoxetine (Sarafem) 5-20 mg qd |
| Sertraline (Zoloft) 25-50 mg qd |
| Paroxetine (Paxil) 5-20 mg qd |
| Buspirone (BuSpar) 25 mg qd in divided doses |
| Alprazolam (Xanax) 0.25-0.50 mg tid |
| Mefenamic acid (Ponstel) 250 mg tid with meals |
| Other |
| Spironolactone (Aldactone) 25-200 mg qd |
| Cabergoline (Dostinex) 1.25 mg - 1 mg twice a week during the luteal phase for breast pain |

### E. Treatments with possible efficacy in PMS

1. Exercise and relaxation techniques. There is suggestive evidence that exercise, relaxation, and reflexology may help to alleviate PMS symptoms.

2. Diuretics. Spironolactone (Aldactone), 25-200 mg qd, may significantly decrease in negative mood symptom scores and somatic symptom.

### F. Recommendations for the clinical management of PMS/PMDD

1. Because of the proven efficacy and safety profile, serotonin reuptake inhibitors (SSRIs) are the first line therapy. Fluoxetine (Sarafem) has been the best studied. The effective dose is 20 mg/day.

2. Approximately 15 percent of patients will experience significant side effects from an SSRI, including nausea, jitteriness, and headache. In such patients, a trial of either a lower starting dose or a second SSRI, such as sertraline (Zoloft) 25-50 mg qd, is warranted.

3. Approximately 15 percent do not respond to an SSRI over several menstrual cycles. These women are candidates for alprazolam (Xanax) 0.25 mg TID or QID in the luteal phase of the cycle.

4. Patients who do not respond to SSRIs or alprazolam are candidates for ovulation suppression agents. In patients who respond well to GnRH agonists, therapy may be extended beyond six months with an attempt at "add-back" therapy with estrogen and progesterone.
Abnormal Vaginal Bleeding

Menorrhagia (excessive bleeding) is most commonly caused by anovulatory menstrual cycles. Occasionally it is caused by thyroid dysfunction, infections or cancer.

I. Pathophysiology of normal menstruation
A. In response to gonadotropin-releasing hormone from the hypothalamus, the pituitary gland synthesizes follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which induce the ovaries to produce estrogen and progesterone.
B. During the follicular phase, estrogen stimulation causes an increase in endometrial thickness. After ovulation, progesterone causes endometrial maturation. Menstruation is caused by estrogen and progesterone withdrawal.
C. Abnormal bleeding is defined as bleeding that occurs at intervals of less than 21 days, more than 36 days, lasting longer than 7 days, or blood loss greater than 80 mL.

II. Clinical evaluation of abnormal vaginal bleeding
A. A menstrual and reproductive history should include last menstrual period, regularity, duration, frequency; the number of pads used per day, and intermenstrual bleeding.
B. Stress, exercise, weight changes and systemic diseases, particularly thyroid, renal or hepatic diseases or coagulopathies, should be sought. The method of birth control should be determined.
C. Pregnancy complications, such as spontaneous abortion, ectopic pregnancy, placenta previa and abruptio placentae, can cause heavy bleeding. Pregnancy should always be considered as a possible cause of abnormal vaginal bleeding.

III. Puberty and adolescence--menarche to age 16
A. Irregularity is normal during the first few months of menstruation; however, soaking more than 25 pads or 30 tampons during a menstrual period is abnormal.
B. Absence of premenstrual symptoms (breast tenderness, bloating, cramping) is associated with anovulatory cycles.
C. Fever, particularly in association with pelvic or abdominal pain may, indicate pelvic inflammatory disease. A history of easy bruising suggests a coagulation defect. Headaches and visual changes suggest a pituitary tumor.
D. Physical findings
1. Pallor not associated with tachycardia or signs of hypovolemia suggests chronic excessive blood loss secondary to anovulatory bleeding, adenomyosis, uterine myomas, or blood dyscrasia.
2. Fever, leukocytosis, and pelvic tenderness suggests PID.
3. Signs of impending shock indicate that the blood loss is related to pregnancy (including ectopic), trauma, sepsis, or neoplasia.
4. Pelvic masses may represent pregnancy, uterine or ovarian neoplasia, or a pelvic abscess or hematoma.
5. Fine, thinning hair, and hypoactive reflexes suggest hypothyroidism.
6. Ecchymoses or multiple bruises may indicate trauma, coagulation defects, medication use, or dietary extremes.
E. Laboratory tests
1. CBC and platelet count and a urine or serum pregnancy test should be obtained.
2. Screening for sexually transmitted diseases, thyroid function, and coagulation disorders (partial thromboplastin time, INR, bleeding time) should be completed.
3. Endometrial sampling is rarely necessary for those under age 20.
F. Treatment of infrequent bleeding
1. Therapy should be directed at the underlying cause when possible. If the CBC and other initial laboratory tests are normal and the history and physical examination are normal, reassurance is usually all that is necessary.
2. Ferrous gluconate, 325 mg bid-tid, should be prescribed.
G. Treatment of frequent or heavy bleeding
1. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) improves platelet aggregation and increases uterine vasoconstriction. NSAIDs are the first choice in the treatment of menorrhagia because they are well tolerated and do not have the hormonal effects of oral contraceptives.
   a. Mefenamic acid (Ponstel) 500 mg tid during the menstrual period.
   b. Naproxen (Anaprox, Naprosyn) 500 mg loading dose, then 250 mg tid during the menstrual period.
   c. Ibuprofen (Motrin, Nuprin) 400 mg tid during the menstrual period.
   d. Gastrointestinal distress is common. NSAIDs are contraindicated in renal failure and peptic ulcer disease.
2. Iron should also be added as ferrous gluconate 325 mg tid.
H. Patients with hypovolemia or a hemoglobin level below 7 g/dL should be hospitalized for hormonal therapy and iron replacement.
1. Hormonal therapy consists of estrogen (Premarin) 25 mg IV q6h until bleeding stops. Thereafter, oral contraceptive pills should be
administered q6h x 7 days, then taper slowly to one pill qd.
2. If bleeding continues, IV vasopressin (DDAVP) should be administered. Hysteroscopy may be necessary, and dilation and curettage is a last resort. Transfusion may be indicated in severe hemorrhage.
3. Iron should also be added as ferrous gluconate 325 mg tid.

IV. Primary childbearing years – ages 16 to early 40s
A. Contraceptive complications and pregnancy are the most common causes of abnormal bleeding in this age group. Anovulation accounts for 20% of cases.
B. Adenomyosis, endometriosis, and fibroids increase in frequency as a woman ages, as do endometrial hyperplasia and endometrial polyps. Pelvic inflammatory disease and endocrine dysfunction may also occur.

C. Laboratory tests
1. CBC and platelet count, Pap smear, and pregnancy test.
2. Screening for sexually transmitted diseases, thyroid-stimulating hormone, and coagulation disorders (partial thromboplastin time, INR, bleeding time).
3. If a non-pregnant woman has a pelvic mass, ultrasonography or hysterosonography (with uterine saline infusion) is required.

D. Endometrial sampling
1. Long-term unopposed estrogen stimulation in anovulatory patients can result in endometrial hyperplasia, which can progress to adenocarcinoma; therefore, in perimenopausal patients who have been anovulatory for an extended interval, the endometrium should be biopsied.
2. Biopsy is also recommended before initiation of hormonal therapy for women over age 30 and for those over age 20 who have had prolonged bleeding.
3. Hysteroscopy and endometrial biopsy with a Pipelle aspirator should be done on the first day of menstruation (to avoid an unexpected pregnancy) or anytime if bleeding is continuous.

E. Treatment
1. Medical protocols for anovulatory bleeding (dysfunctional uterine bleeding) are similar to those described above for adolescents.
2. Hormonal therapy
   a. In women who do not desire immediate fertility, hormonal therapy may be used to treat menorrhagia.
   b. A 21-day package of oral contraceptives is used. The patient should take one pill three times a day for 7 days. During the 7 days of therapy, bleeding should subside, and, following treatment, heavy flow will occur. After 7 days off the hormones, another 21-day package is initiated, taking one pill each day for 21 days, then no pills for 7 days.
   c. Alternatively, medroxyprogesterone (Provera), 10-20 mg per day for days 16 through 25 of each month, will result in a reduction of menstrual blood loss. Pregnancy will not be prevented.
   d. Patients with severe bleeding may have hypotension and tachycardia. These patients require hospitalization, and estrogen (Premarin) should be administered IV as 25 mg q4-6h until bleeding slows (up to a maximum of four doses). Oral contraceptives should be initiated concurrently as described above.
3. Iron should also be added as ferrous gluconate 325 mg tid.
4. Surgical treatment can be considered if childbearing is completed and medical management fails to provide relief.

V. Premenopausal, perimenopausal, and postmenopausal years--age 40 and over
A. Anovulatory bleeding accounts for about 90% of abnormal vaginal bleeding in this age group. However, bleeding should be considered to be from cancer until proven otherwise.
B. History, physical examination and laboratory testing are indicated as described above. Menopausal symptoms, personal or family history of malignancy and use of estrogen should be sought. A pelvic mass requires an evaluation with ultrasonography.

C. Endometrial carcinoma
1. In a perimenopausal or postmenopausal woman, amenorrhea preceding abnormal bleeding suggests endometrial cancer. Endometrial evaluation is necessary before treatment of abnormal vaginal bleeding.
2. Before endometrial sampling, determination of endometrial thickness by transvaginal ultrasonography is useful because biopsy is often not required when the endometrium is less than 5 mm thick.

D. Treatment
1. Cystic hyperplasia or endometrial hyperplasia without cytologic atypia is treated with depot-medroxyprogesterone, 200 mg IM, then 100 to 200 mg IM every 3 to 4 weeks for 6 to 12 months. Endometrial hyperplasia requires repeat endometrial biopsy every 3 to 6 months.
2. Atypical hyperplasia requires fractional dilation and curettage, followed by progestin therapy or hysterectomy.
3. If the patient's endometrium is normal (or atrophic) and contraception is a concern, a low-dose oral contraceptive may be used. If contraception is not needed, estrogen and progesterone therapy should be prescribed.

4. Surgical management
   a. Vaginal or abdominal hysterectomy is the most absolute curative treatment.
   b. Dilatation and curettage can be used as a temporizing measure to stop bleeding.
   c. Endometrial ablation and resection by laser, electrodiathermy "rollerball," or excisional resection are alternatives to hysterectomy.

References: See page 282.

Breast Cancer Screening and Diagnosis

Breast cancer is the second most commonly diagnosed cancer among women, after skin cancer. Approximately 182,800 new cases of invasive breast cancer are diagnosed in the United States per year. The incidence of breast cancer increases with age. White women are more likely to develop breast cancer than black women. The incidence of breast cancer in white women is about 113 cases per 100,000 women and in black women, 100 cases per 100,000.

I. Risk Factors

<table>
<thead>
<tr>
<th>Risk Factors for Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age greater than 50 years</td>
</tr>
<tr>
<td>Prior history of breast cancer</td>
</tr>
<tr>
<td>Family history</td>
</tr>
<tr>
<td>Early menarche, before age 12</td>
</tr>
<tr>
<td>Late menopause, after age 50</td>
</tr>
<tr>
<td>Nulliparity</td>
</tr>
<tr>
<td>Age greater than 30 at first birth</td>
</tr>
<tr>
<td>Obesity</td>
</tr>
<tr>
<td>High socioeconomic status</td>
</tr>
<tr>
<td>Atypical hyperplasia on biopsy</td>
</tr>
<tr>
<td>Ionizing radiation exposure</td>
</tr>
</tbody>
</table>

A. Family history is highly significant in a first-degree relative (ie, mother, sister, daughter), especially if the cancer has been diagnosed premenopausally. Women who have premenopausal first-degree relatives with breast cancer have a three- to fourfold increased risk of breast cancer. Having several second-degree relatives with breast cancer may further increase the risk of breast cancer. Most women with breast cancer have no identifiable risk factors.

B. Approximately 8 percent of all cases of breast cancer are hereditary. About one-half of these cases are attributed to mutations in the BRCA1 and BRCA2 genes. Hereditary breast cancer commonly occurs in premenopausal women. Screening tests are available that detect BRCA mutations.

II. Diagnosis and evaluation

A. Clinical evaluation of a breast mass should assess duration of the lesion, associated pain, relationship to the menstrual cycle or exogenous hormone use, and change in size since discovery. The presence of nipple discharge and its character (bloody or tea-colored, unilateral or bilateral, spontaneous or expressed) should be assessed.

B. Menstrual history. The date of last menstrual period, age of menarche, age of menopause or surgical removal of the ovaries, previous pregnancies should be determined.

C. History of previous breast biopsies, cyst aspiration, dates and results of previous mammograms should be determined.

D. Family history should document breast cancer in relatives and the age at which family members were diagnosed.

III. Physical examination

A. The breasts should be inspected for asymmetry, deformity, skin retraction, erythema, peau d'orange (breast edema), and nipple retraction, discoloration, or inversion.

B. Palpation

1. The breasts should be palpated while the patient is sitting and then supine with the ipsilateral arm extended. The entire breast should be palpated systematically. The mass should be evaluated for size, shape, texture, tenderness, fixation to skin or chest wall.

2. A mass that is suspicious for breast cancer is usually solitary, discrete and hard. In some instances, it is fixed to the skin or the muscle. A suspicious mass is usually unilateral and nontender. Sometimes, an area of thickening may represent cancer. Breast cancer is rarely bilateral.

3. The nipples should be expressed for discharge.

IV. Mammography. Screening mammograms are recommended every year for asymptomatic women 40 years and older. Unfortunately, only 60 percent of cancers are diagnosed at a local stage.
lines
20 to 39 years Clinical breast examination every three years Monthly self-examination of breasts
Age 40 years and older Annual mammogram Annual clinical breast examination Monthly self-examination of breasts

V. Methods of breast biopsy
A. Palpable masses. Fine-needle aspiration biopsy (FNAB) has a sensitivity ranging from 90-98%. Nondiagnostic aspirates require surgical biopsy.
   1. The skin is prepped with alcohol and the lesion is immobilized with the nonoperating hand. A 10 mL syringe, with a 14 gauge needle, is introduced in to the central portion of the mass at a 90° angle. When the needle enters the mass, suction is applied by retracting the plunger, and the needle is advanced. The needle is directed into different areas of the mass while maintaining suction on the syringe.
   2. Suction is slowly released before the needle is withdrawn from the mass. The contents of the needle are placed onto glass slides for pathologic examination.
   3. Excisional biopsy is done when needle biopsies are negative but the mass is clinically suspected of malignancy.
B. Stereotactic core needle biopsy. Using a computer-driven stereotactic unit, the lesion is localized in three dimensions, and an automated biopsy needle obtains samples. The sensitivity and specificity of this technique are 95-100% and 94-98%, respectively.
C. Nonpalpable lesions
   1. Needle localized biopsy
      a. Under mammographic guidance, a needle and hookwire are placed into the breast parenchyma adjacent to the lesion. The patient is taken to the operating room along with mammograms for an excisional breast biopsy.
      b. The skin and underlying tissues are infiltrated with 1% lidocaine with epinephrine. For lesions located within 5 cm of the nipple, a periareolar incision may be used or use a curved incision located over the mass and parallel to the areola. Incise the skin and subcutaneous fat, then palpate the lesion and excise the mass.
      c. After removal of the specimen, a specimen x-ray is performed to confirm that the lesion has been removed. The specimen can then be sent fresh for pathologic analysis.
      d. Close the subcutaneous tissues with a 4-0 chromic catgut suture, and close the skin with 4-0 subcuticular suture.
D. Ultrasonography. Screening is useful to differentiate between solid and cystic breast masses when a palpable mass is not well seen on a mammogram. Ultrasonography is especially helpful in young women with dense breast tissue when a palpable mass is not visualized on a mammogram. Ultrasonography is not used for routine screening because microcalcifications are not visualized and the yield of carcinomas is negligible.

References: See page 282.

Breast Disorders
Breast pain, nipple discharge and a palpable mass are the most common breast problems for which women consult a physician.

I. Nipple Discharge
A. Clinical evaluation
   1. Nipple discharge may be a sign of cancer; therefore, it must be thoroughly evaluated. About 8% of biopsies performed for nipple discharge demonstrate cancer. The duration, bilaterality or unilateralty of the discharge, and the presence of blood should be determined. A history of oral contraceptives, hormone preparations, phenothiazines, nipple or breast stimulation or lactation should be sought. Discharges that flow spontaneously are more likely to be pathologic than discharges that must be manually expressed.
   2. Unilateral, pink colored, bloody or non-milky discharge, or discharges associated with a mass are the discharges of most concern. Milky discharge can be caused by oral contraceptive agents, estrogen replacement therapy, phenothiazines, prolactinoma, or hypothyroidism. Nipple discharge secondary to malignancy is more likely to occur in older patients.
   3. Risk factors. The assessment should identify risk factors, including age over 50 years, past personal history of breast cancer, history of hyperplasia on previous breast biopsies, and family history of breast cancer in a first-degree relative (mother, sister, daughter).
B. Physical examination should include inspection of the breast for ulceration or contour changes and inspection of the nipple. Palpation should be performed with the patient in both the upright and the supine positions to determine the presence of a mass.
C. Diagnostic evaluation
1. Bloody discharge. A mammogram of the involved breast should be obtained if the patient is over 35 years old and has not had a mammogram within the preceding 6 months. Biopsy of any suspicious lesions should be completed.
2. Watery, unilateral discharge should be referred to a surgeon for evaluation and possible biopsy.
3. Non-bloody discharge should be tested for the presence of blood with a Hemoccult card. Nipple discharge secondary to carcinoma usually contains hemoglobin.
4. Milky, bilateral discharge should be evaluated with assays of prolactin and thyroid stimulating hormone to exclude an endocrinologic cause.
   a. A mammogram should be performed if the patient is due for routine mammographic screening.
   b. If results of the mammogram and the endocrinologic screening studies are normal, the patient should return for a follow-up visit in 6 months to ensure that there has been no specific change in the character of the discharge, such as development of bleeding.

II. Breast Pain
   A. Breast pain is the most common breast symptom causing women to consult primary care physicians. Mastalgia is more common in premenopausal women than in postmenopausal women, and it is rarely a presenting symptom of breast cancer.
   B. The evaluation of breast pain should determine the type of pain, its location and its relationship to the menstrual cycle. Most commonly, breast pain is associated with the menstrual cycle (cyclic mastalgia).
   C. Cyclic pain is usually bilateral and poorly localized. The pain is often relieved after the menses. Cyclic breast pain occurs more often in younger women and resolves spontaneously.
   D. Noncyclic mastalgia is most common in women 40 to 50 years of age. It is often a unilateral pain. Noncyclic mastalgia is occasionally secondary to the presence of a fibroadenoma or cyst, and the pain may be relieved by treatment of the underlying breast lesion.
   E. Evaluation. A thorough breast examination should be performed to exclude the presence of a breast mass. Women 35 years of age and older should undergo mammography unless a mammogram was obtained in the past 12 months. If a suspicious lesion is detected, biopsy is required. When the physical examination is normal, imaging studies are not indicated in women younger than 35 years of age. A follow-up clinical breast examination should be performed in 1-2 months.
   F. Mastodynia
      1. Mastodynia is defined as breast pain in the absence of a mass or other pathologic abnormality.
      2. Causes of mastodynia include menstrually related pain, costochondritis, trauma, and sclerosing adenosis.

III. Fibrocystic Complex
   A. Breast changes are usually multifocal, bilateral, and diffuse. One or more isolated fibrocystic lumps or areas of asymmetry may be present. The areas are usually tender.
   B. This disorder predominantly occurs in women with premenstrual abnormalities, nulliparous women, and nonusers of oral contraceptives.
   C. The disorder usually begins in mid-20’s or early 30’s. Tenderness is associated with menses and lasts about a week. The upper outer quadrant of the breast is most frequently involved bilaterally. There is no increased risk of cancer for the majority of patients.
   D. Suspicious areas may be evaluated by fine needle aspiration (FNA) cytology. If mammography and FNA are negative for cancer, and the clinical examination is benign, open biopsy is generally not needed.
   E. Medical management of fibrocystic complex
      1. Oral contraceptives are effective for severe breast pain in most young women. Start with a pill that contains low amounts of estrogen and relatively high amounts of progesterone (Loestrin, LoOvral, Ortho-Cept).
      2. If oral contraceptives do not provide relief, medroxyprogesterone, 5-10 mg/day from days 15-25 of each cycle, is added.
      3. A professionally fitted support bra often provides significant relief.
      4. Danazol (Danocrine), an antigonadotropin, has a response rate of 50 to 75 percent in women with cyclic pain who received danazol in a dosage of 100 to 400 mg per day. Danazol therapy is recommended only for patients with severe, activity-limiting pain. Side effects include menstrual irregularity, acne, weight gain and hirsutism.
      5. Evening primrose oil (g-linolenic acid) is effective in about 38 to 58 percent of patients with mastalgia; 2 - 4 g per day.

IV. Breast Masses
   A. The normal glandular tissue of the breast is nodular. Nodularity is a physiologic process and is not an indication of breast pathology. Dominant masses may be discrete or poorly defined, but they differ in character from the surrounding breast tissue. The differential diagnosis of a dominant
breast mass includes macrocyst (clinically evident cyst), fibroadenoma, prominent areas of fibrocystic change, fat necrosis and cancer.

B. Cystic Breast Masses
1. Cysts are a common cause of dominant breast masses in premenopausal women more than 40 years of age, but they are an infrequent cause of such masses in younger women. Cysts are usually well demarcated, firm and mobile.

2. Ultrasonography or aspiration must establish a definitive diagnosis for a cyst. Cysts require surgical biopsy if the aspirated fluid is bloody, the palpable abnormality does not resolve completely after the aspiration of fluid or the same cyst recurs multiple times in a short period of time. Routine cytologic examination of cyst fluid is not indicated.

3. Nonpalpable cysts identified by mammography and confirmed to be simple cysts by ultrasound examination require no treatment.

C. Solid Breast Masses
1. Noncystic masses in premenopausal women that are clearly different from the surrounding breast tissue require histologic sampling by fine-needle aspiration, core cutting, needle biopsy or excisional biopsy.

2. Solid Masses in Women Less Than 40 Years of Age
   a. If the physical examination reveals no evidence of a dominant breast mass, the patient should be reassured and instructed in breast self-examination. If the clinical significance of a physical finding is uncertain, a directed ultrasound examination is performed. If this examination does not demonstrate a mass, the physical examination is repeated in two to four months. In women 35 to 40 years of age who have a normal ultrasound examination, a mammogram may also be obtained.
   b. A suspicious mass is solitary, discrete, hard and adherent to adjacent tissue. Mammography should be performed before obtaining a pathologic diagnosis.
   c. If a clinically benign mass is present, an ultrasound examination and fine-needle aspiration are performed to confirm that the mass is benign. This approach is the "triple test" (clinical examination, ultrasonography [or mammography] and fine-needle aspiration).

3. Solid Masses in Women More Than 40 Years of Age. Abnormalities detected on physical examination in older women should be regarded as possible cancers until they are proven to be benign. In women more than 40 years of age, diagnostic mammography is a standard part of the evaluation of a solid breast mass.

References: See page 282.

Sexual Assault

Sexual assault is defined as any sexual act performed by one person on another without the person's consent. Sexual assault includes genital, anal, or oral penetration by a part of the accused's body or by an object. It may result from force, the threat of force, or the victim's inability to give consent. The annual incidence of sexual assault is 200 per 100,000 persons.

I. Psychological effects
   A. A woman who is sexually assaulted loses control over her life during the period of the assault. Her integrity and her life are threatened. She may experience intense anxiety, anger, or fear. After the assault, a “rape-trauma” syndrome often occurs. The immediate response may last for hours or days and is characterized by generalized pain, headache, chronic pelvic pain, eating and sleep disturbances, vaginal symptoms, depression, anxiety, and mood swings.
   B. The delayed phase is characterized by flashbacks, nightmares, and phobias.

II. Medical evaluation
   A. Informed consent must be obtained before the examination. Acute injuries should be stabilized. About 1% of injuries require hospitalization and major operative repair, and 0.1% of injuries are fatal.
   B. A history and physical examination should be performed. A chaperon should be present during the history and physical examination to reassure the victim and provide support. The patient should be asked to state in her own words what happened, identify her attacker if possible, and provide details of the act(s) performed if possible.
Clinical Care of the Sexual Assault Victim

Medical
- Obtain informed consent from the patient
- Obtain a gynecologic history
- Assess and treat physical injuries
- Obtain appropriate cultures and treat any existing infections
- Provide prophylactic antibiotic therapy and offer immunizations
- Provide therapy to prevent unwanted conception
- Offer baseline serologic tests for hepatitis B virus, human immunodeficiency virus (HIV), and syphilis
- Provide counseling
- Arrange for follow-up medical care and counseling

Legal
- Provide accurate recording of events
- Document injuries
- Collect samples (pubic hair, fingernail scrapings, vaginal secretions, saliva, blood-stained clothing)
- Report to authorities as required
- Assure chain of evidence

C. Previous obstetric and gynecologic conditions should be sought, particularly infections, pregnancy, use of contraception, and date of the last menstrual period. Preexisting pregnancy, risk for pregnancy, and the possibility of preexisting infections should be assessed.

D. Physical examination of the entire body and photographs or drawings of the injured areas should be completed. Bruises, abrasions, and lacerations should be sought. Superficial or extensive lacerations of the hymen and vagina, injury to the urethra, and occasionally rupture of the vaginal vault into the abdominal cavity may be noted. Bite marks are common.

1. Pelvic examination should assess the status of the reproductive organs, collect samples from the cervix and vagina, and test for Neisseria gonorrhoeae and Chlamydia trachomatis.

2. A Wood light should be used to find semen on the patient's body; dried semen will fluoresce. Sperm and other Y-chromosome-bearing cells may be identified from materials collected from victims.

E. A serum sample should be obtained for baseline serology for syphilis, herpes simplex virus, hepatitis B virus, and HIV.

F. Trichomonas is the most frequently acquired STD. The risk of acquiring human immunodeficiency virus (HIV) <1% during a single act of heterosexual intercourse, but the risk depends on the population involved and the sexual acts performed. The risk of acquiring gonorrhea is 6-12%, and the risk of acquiring syphilis is 3%.

G. Hepatitis B virus is 20 times more infectious than HIV during sexual intercourse. Hepatitis B immune globulin (0.06 mL of hepatitis B immune globulin per kilogram) should be administered intramuscularly as soon as possible within 14 days of exposure. It is followed by the standard three-dose immunization series with hepatitis B vaccine (0, 1, and 6 months), beginning at the time of hepatitis B immune globulin administration.

H. Emergency contraception. If the patient is found to be at risk for pregnancy as a result of the assault, emergency contraception should be offered. The risk of pregnancy after sexual assault is 2-4% in victims not already using contraception. One dose of combination oral contraceptive tablets is given at the time the victim is seen and an additional dose is given in 12 hours. Emergency contraception can be effective up to 120 hours after unprotected coitus. Metoclopramide (Reglan), 20 mg with each dose of hormone, is prescribed for nausea. A pregnancy test should be performed at the 2-week return visit if conception is suspected.

Emergency Contraception

1. Consider pretreatment one hour before each oral contraceptive pill dose, using one of the following orally administered antiemetic agents:
   - Prochlorperazine (Compazine), 5 to 10 mg
   - Promethazine (Phenergan), 12.5 to 25 mg
   - Trimethobenzamide (Tigan), 250 mg

2. Administer the first dose of oral contraceptive pill within 72 hours of intercourse, and administer the second dose 12 hours after the first dose. Brand name options for emergency contraception include the following:
   - Preven Kit—two pills per dose (0.5 mg of levonorgestrel and 100 µg of ethinyl estradiol per dose)
   - Ovral—two pills per dose (0.5 mg of levonorgestrel and 100 µg of ethinyl estradiol per dose)
   - Plan B—one pill per dose (0.75 mg of levonorgestrel per dose)
   - Norplant—four pills per dose (0.6 mg of levonorgestrel and 120 µg of ethinyl estradiol per dose)
   - Triphasil—four pills per dose (0.5 mg of levonorgestrel and 120 µg of ethinyl estradiol per dose)
Screening and Treatment of Sexually Transmissible Infections Following Sexual Assault

Initial Examination

**Infection**
- Testing for and gonorrhea and chlamydia from specimens from any sites of penetration or attempted penetration
- Wet mount and culture or a vaginal swab specimen for Trichomonas
- Serum sample for syphilis, herpes simplex virus, hepatitis B virus, and HIV

**Pregnancy Prevention**

**Prophylaxis**
- Hepatitis B virus vaccination and hepatitis B immune globulin.
- Empiric recommended antimicrobial therapy for chlamydial, gonococcal, and trichomonal infections and for bacterial vaginosis: Ceftriaxone, 125 mg intramuscularly in a single dose, plus Metronidazole, 2 g orally in a single dose, plus Doxycline 100 mg orally twice a day for 7 days. Azithromycin (Zithromax) is used if the patient is unlikely to comply with the 7 day course of doxycycline: single dose of four 250 mg caps.
  - If the patient is penicillin-allergic, ciprofloxacin 500 mg PO or ofloxacin 400 mg PO is substituted for ceftriaxone. If the patient is pregnant, erythromycin 500 mg PO qid for 7 days is substituted for doxycycline.
  - HIV prophylaxis consists of zidovudine (AZT) 200 mg PO tid, plus lamivudine (3TC) 150 mg PO bid for 4 weeks.

Follow-Up Examination (2 weeks)

- Cultures for N gonorrhoeae and C trachomatis (not needed if prophylactic treatment has been provided)
- Wet mount and culture for T vaginalis
- Collection of serum sample for subsequent serologic analysis if test results are positive

Follow-Up Examination (12 weeks)

- Serologic tests for infectious agents: T pallidum
- HIV (repeat test at 6 months)
- Hepatitis B virus (not needed if hepatitis B virus vaccine was given)

III. Emotional care

A. The physician should discuss the injuries and the probability of infection or pregnancy with the victim, and she should be allowed to express her anxieties.
B. Anxiolytic medication may be useful; lorazepam (Ativan) 1-5 mg PO tid prn anxiety.
C. The patient should be referred to personnel trained to handle rape-trauma victims within 1 week.

IV. Follow-up care

A. The patient is seen for medical follow-up in 2 weeks for documentation of healing of injuries.
B. Repeat testing includes syphilis, hepatitis B, and gonorrhea and chlamydia cultures. HIV serology should be repeated in 3 months and 6 months.
C. A pregnancy test should be performed if conception is suspected.

References: See page 282.

Osteoporosis

Over 1.3 million osteoporotic fractures occur each year in the United States. The risk of all fractures increases with age; among persons who survive until age 90, 33 percent of women will have a hip fracture. The lifetime risk of hip fracture for white women at age 50 is 16 percent. Osteoporosis is characterized by low bone mass, microarchitectural disruption, and increased skeletal fragility.

<table>
<thead>
<tr>
<th>Risk Factors for Osteoporotic Fractures</th>
<th>Personal history of fracture as an adult</th>
<th>White race</th>
<th>Advanced age</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of fracture in a first-degree relative</td>
<td>Lifelong low calcium intake</td>
<td>Alcoholicism</td>
<td>Inadequate physical activity</td>
</tr>
<tr>
<td>Current cigarette smoking</td>
<td>Recurrent falls</td>
<td>Dementia</td>
<td>Impaired eyesight despite adequate correction</td>
</tr>
<tr>
<td>Low body weight (less than 58 kg [127 lb])</td>
<td></td>
<td>Poor health/frailty</td>
<td></td>
</tr>
<tr>
<td>Female sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrogen deficiency (menopause before age 45 years or bilateral ovariectomy, prolonged premenopausal amenorrhea (greater than one year))</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I. Screening for osteoporosis and osteopenia

A. **Normal bone density** is defined as a bone mineral density (BMD) value within one standard deviation of the mean value in young adults of the same sex and race.

B. **Osteopenia** is defined as a BMD between 1 and 2.5 standard deviations below the mean.

C. **Osteoporosis** is defined as a value more than 2.5 standard deviations below the mean; this level is the fracture threshold. These values are referred to as T-scores (number of standard deviations above or below the mean value).
D. Dual x-ray absorptiometry. In dual x-ray absorptiometry (DXA), two photons are emitted from an x-ray tube. DXA is the most commonly used method for measuring bone density because it gives very precise measurements with minimal radiation. DXA measurements of the spine and hip are recommended.

E. Biochemical markers of bone turnover. Urinary deoxypyridinoline (DPD) and urinary alpha-1 to alpha-2 N-telopeptide of collagen (NTX) are the most specific and clinically useful markers of bone resorption. Biochemical markers are not useful for the screening or diagnosis of osteoporosis because the values in normal and osteoporosis overlap substantially.

II. Recommendations for screening for osteoporosis of the National Osteoporosis Foundation

A. All women should be counseled about the risk factors for osteoporosis, especially smoking cessation and limiting alcohol. All women should be encouraged to participate in regular weight-bearing and exercise.

B. Measurement of BMD is recommended for all women 65 years and older regardless of risk factors. BMD should also be measured in all women under the age of 65 years who have one or more risk factors for osteoporosis (in addition to menopause). The hip is the recommended site of measurement.

C. All adults should be advised to consume at least 1,200 mg of calcium per day and 400 to 800 IU of vitamin D per day. A daily multivitamin (which provides 400 IU) is recommended. In patients with documented vitamin D deficiency, osteoporosis, or previous fracture, two multivitamins may be reasonable, particularly if dietary intake is inadequate and access to sunlight is poor.

D. Treatment is recommended for women without risk factors who have a BMD that is 2 SD below the mean for young women, and in women with risk factors who have a BMD that is 1.5 SD below the mean.

III. Nonpharmacologic therapy of osteoporosis in women

A. Diet. An optimal diet for treatment (or prevention) of osteoporosis includes an adequate intake of calories (to avoid malnutrition), calcium, and vitamin D.

B. Calcium. Postmenopausal women should be advised to take 1000 to 1500 mg/day of elemental calcium, in divided doses, with meals.

C. Vitamin D total of 800 IU daily should be taken.

D. Exercise. Women should exercise for at least 30 minutes three times per week. Any weight-bearing exercise regimen, including walking, is acceptable.

E. Cessation of smoking is recommended for all women because smoking cigarettes accelerates bone loss.

IV. Drug therapy of osteoporosis in women

A. Selected postmenopausal women with osteoporosis or at high risk for the disease should be considered for drug therapy. Particular attention should be paid to treating women with a recent fragility fracture, including hip fracture, because they are at high risk for a second fracture.

B. Candidates for drug therapy are women who already have postmenopausal osteoporosis (less than -2.5) and women with osteopenia (T score -1 to -2.5) soon after menopause.

C. Bisphosphonates

1. Alendronate (Fosamax) (10 mg/day or 70 mg once weekly) or risedronate (Actonel) (5 mg/day or 35 mg once weekly) are good choices for the treatment of osteoporosis. Bisphosphonate therapy increases bone mass and reduces the incidence of vertebral and nonvertebral fractures.

2. Alendronate (5 mg/day or 35 mg once weekly) and risedronate (5 mg/day of 35 mg once weekly) have been approved for prevention of osteoporosis.

3. Alendronate or risedronate should be taken with a full glass of water 30 minutes before the first meal or beverage of the day. Patients should not lie down for at least 30 minutes after taking the dose to avoid the unusual complication of pill-induced esophagitis.

4. Alendronate is well tolerated and effective for at least seven years.

5. The bisphosphonates (alendronate or risedronate) and raloxifene are first-line treatments for prevention of osteoporosis. The bisphosphonates are first-line therapy for the treatment of osteoporosis. Bisphosphonates are preferred for prevention and treatment of osteoporosis because they increase bone mineral density more than raloxifene.

D. Selective estrogen receptor modulators

1. Raloxifene (Evista) (5 mg daily or a once-a-week preparation) is a selective estrogen receptor modulator (SERM) for prevention and treatment of osteoporosis. It increases bone mineral density and reduces serum total and low-density-lipoprotein (LDL) cholesterol. It also appears to reduce the incidence of vertebral fractures and is one of the first-line drugs for prevention of osteoporosis.

2. Raloxifene is somewhat less effective than the bisphosphonates for the prevention and treatment of osteoporosis. Venous thromboembolism is a risk.
### Treatment Guidelines for Osteoporosis

- Calcium supplements with or without vitamin D supplements or calcium-rich diet
- Weight-bearing exercise
- Avoidance of alcohol tobacco products
- Alendronate (Fosamax)
- Risedronate (Actonel)
- Raloxifene (Evista)

### Agents for Treating Osteoporosis

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>1,000 to 1,500 mg per day</td>
<td>Oral</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>400 IU per day (800 IU in winter)</td>
<td>Oral</td>
</tr>
<tr>
<td>Alendronate (Fosamax)</td>
<td>Prevention: 5 mg per day or 35 mg once-a-week</td>
<td>Oral</td>
</tr>
<tr>
<td>Risedronate (Actonel)</td>
<td>5 mg daily or 35 mg once weekly</td>
<td>Oral</td>
</tr>
<tr>
<td>Raloxifene (Evista)</td>
<td>60 mg per day</td>
<td>Oral</td>
</tr>
<tr>
<td>Conjugated estrogens</td>
<td>0.3 mg per day</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### E. Monitoring the response to therapy

1. Bone mineral density and a marker of bone turnover should be measured at baseline, followed by a repeat measurement of the marker in three months.
2. If the marker falls appropriately, the drug is having the desired effect, and therapy should be continued for two years, at which time bone mineral density can be measured again. The anticipated three-month decline in markers is 50 percent with alendronate.

### F. Estrogen/progestin therapy

1. Estrogen-progestin therapy is no longer a first-line approach for the treatment of osteoporosis in postmenopausal women because of increases in the risk of breast cancer, stroke, venous thromboembolism, and coronary disease.
2. Indications for estrogen-progestin in postmenopausal women include persistent menopausal symptoms and patients with an indication for antiresorptive therapy who cannot tolerate the other drugs.

### Urinary Incontinence

Women between the ages of 20 to 80 year have an overall prevalence for urinary incontinence of 53.2 percent.

### I. Types of Urinary Incontinence

#### A. Stress Incontinence

1. Stress incontinence is the involuntary loss of urine produced by coughing, laughing or exercising. The underlying abnormality is typically urethral hypermobility caused by a failure of the anatomic supports of the bladder neck. Loss of bladder neck support is often attributed to injury occurring during vaginal delivery.
2. The lack of normal intrinsic pressure within the urethra—known as intrinsic urethral sphincter deficiency—is another factor leading to stress incontinence. Advanced age, inadequate estrogen levels, previous vaginal surgery and certain neurologic lesions are associated with poor urethral sphincter function.

#### B. Overactive Bladder

Involuntary loss of urine preceded by a strong urge to void, whether or not the bladder is full, is a symptom of the condition commonly referred to as "urge incontinence." Other commonly used terms such as detrusor instability and detrusor hyperreflexia refer to involuntary detrusor contractions observed during urodynamic studies.

### II. History and Physical Examination

#### A. A preliminary diagnosis of urinary incontinence can be made on the basis of a history, physical examination and a few simple office and laboratory tests.

#### B. The medical history should assess diabetes, stroke, lumbar disc disease, chronic lung disease, fecal impaction and cognitive impairment. The obstetric and gynecologic history should include gravity, parity, the number of vaginal, instrument-assisted and cesarean deliveries; the time interval between deliveries; previous hysterectomy
Key Questions in Evaluating Patients for Urinary Incontinence

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you leak urine when you cough, laugh, lift something or sneeze?</td>
<td>How often?</td>
</tr>
<tr>
<td>Do you ever leak urine when you have a strong urge on the way to the</td>
<td></td>
</tr>
<tr>
<td>bathroom? How often?</td>
<td></td>
</tr>
<tr>
<td>How frequently do you empty your bladder during the day?</td>
<td></td>
</tr>
<tr>
<td>How many times do you get up to urinate after going to sleep?</td>
<td></td>
</tr>
<tr>
<td>Is it the urge to urinate that wakes you?</td>
<td></td>
</tr>
<tr>
<td>Do you ever leak urine during sex?</td>
<td></td>
</tr>
<tr>
<td>Do you wear pads that protect you from leaking urine?</td>
<td>How often?</td>
</tr>
<tr>
<td>How often do you have to change them?</td>
<td></td>
</tr>
<tr>
<td>Do you ever find urine on your pads or clothes and were unaware of</td>
<td></td>
</tr>
<tr>
<td>when the leakage occurred?</td>
<td></td>
</tr>
<tr>
<td>Does it hurt when you urinate?</td>
<td></td>
</tr>
<tr>
<td>Do you ever feel that you are unable to completely empty your bladder?</td>
<td></td>
</tr>
</tbody>
</table>

Drugs That Can Influence Bladder Function

<table>
<thead>
<tr>
<th>Drug</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants, antipsychotics, sedatives/</td>
<td>Sedation, retention (overflow)</td>
</tr>
<tr>
<td>hypnotics</td>
<td></td>
</tr>
<tr>
<td>Diuretics</td>
<td>Frequency, urgency (OAB)</td>
</tr>
<tr>
<td>Caffeine</td>
<td>Frequency, urgency (OAB)</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>Retention (overflow)</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Sedation, frequency (OAB)</td>
</tr>
<tr>
<td>Narcotics</td>
<td>Retention, constipation, sedation (OAB</td>
</tr>
<tr>
<td>Alpha-adrenergic blockers</td>
<td>Decreased urethral tone (stress incontinence)</td>
</tr>
<tr>
<td>Alpha-adrenergic agonists</td>
<td>Increased urethral tone, retention (overflow)</td>
</tr>
<tr>
<td>Beta-adrenergic agonists</td>
<td>Inhibited detrusor function, retention (overflow)</td>
</tr>
</tbody>
</table>

C. Because fecal impaction has been linked to urinary incontinence, a history that includes frequency of bowel movements, length of time to evacuate and whether the patient must splint her vagina or perineum during defecation should be obtained. Patients should be questioned about fecal incontinence.

D. A complete list of all prescription and nonprescription drugs should be obtained. When appropriate, discontinuation of these medications associated with incontinence or substitution of appropriate alternative medications will often cure or significantly improve urinary incontinence.

E. Physical Examination

1. Immediately before the physical examination, the patient should void as normally and completely as possible. The voided volume should be recorded. A post-void residual volume can then be determined within 10 minutes by catheterization or ultrasound examination. Post-void residual volumes more than 100 mL are considered abnormal.

2. A clean urine sample can be sent for culture and urinalysis.


4. The abdominal examination should rule out diastasis recti, masses, ascites and organomegaly. Pulmonary and cardiovascular assessment may be indicated to assess control of cough or the need for medications such as diuretics.

5. The lumbosacral nerve roots should be assessed by checking deep tendon reflexes, lower extremity strength, sharp/dull sensation and the bulbocavernous and clitoral sacral reflexes.

6. The pelvic examination should include an evaluation for inflammation, infection and atrophy. Signs of inadequate estrogen levels are thinning and paleness of the vaginal epithelium, loss of rugae, disappearance of the labia minora and presence of a urethral caruncle.

7. A urethral diverticula is usually identified as a distal bulge under the urethra. Gentle massage of the area will frequently produce a purulent discharge from the urethral meatus.

8. Testing for stress incontinence is performed by asking the patient to cough vigorously while the examiner watches for leakage of urine.

9. While performing the bimanual examination, levator ani muscle function can be evaluated by asking the patient to tighten her “vaginal muscles” and hold the contraction as long as possible. It is normal for a woman to be able to hold such a contraction for five to 10 seconds.
bimanual examination should also include a rectal examination to assess anal sphincter tone, fecal impaction, occult blood, or rectal lesions.

III. Treatment of urinary incontinence
A. Rehabilitation of the pelvic floor muscles is the common goal of treatments through the use of pelvic muscle exercises (Kegel’s exercises), weighted vaginal cones and pelvic floor electrical stimulation.

B. A set of specially designed vaginal weights can be used as mechanical biofeedback to augment pelvic muscle exercises. The weights are held inside the vagina by contracting the pelvic muscles for 15 minutes at a time.

C. Pelvic floor electrical stimulation with a vaginal or anal probe produces a contraction of the levator ani muscle. Cure or improvement in 48 percent of treated patients, compared with 13 percent of control subjects.

D. Occlusive devices, such as pessaries, can mimic the effects of a retropubic urethropexy. A properly fitted pessary prevents urine loss during vigorous coughing in the standing position with a full bladder.

E. Medications such as estrogens and alpha-adrenergic drugs may also be effective in treating women with stress incontinence. Stress incontinence may be treated with localized estrogen replacement therapy (ERT). Localized ERT can be given in the form of estrogen cream or an estradiol-impregnated vaginal ring (Estring).

<table>
<thead>
<tr>
<th>Medications Used to Treat Urinary Incontinence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
</tr>
<tr>
<td>Stress Incontinence</td>
</tr>
<tr>
<td>Pseudoephedrine (Sudafed)</td>
</tr>
<tr>
<td>Vaginal estrogen ring (Estring)</td>
</tr>
<tr>
<td>Vaginal estrogen cream</td>
</tr>
<tr>
<td>Overactive bladder</td>
</tr>
<tr>
<td>Oxybutynin ER (Ditropan XL)</td>
</tr>
<tr>
<td>Tolterodine LA (Detrol LA)</td>
</tr>
<tr>
<td>Generic oxybutynin</td>
</tr>
<tr>
<td>Tolterodine (Detrol)</td>
</tr>
<tr>
<td>Imipramine (Tofranil)</td>
</tr>
<tr>
<td>Dicyclomine (Bentyl)</td>
</tr>
<tr>
<td>Hyoscyamine (Cystospaz)</td>
</tr>
</tbody>
</table>

F. Alpha-adrenergic drugs such as pseudoephedrine improve stress incontinence by increase resting urethral tone. These drugs cause subjective improvement in 20 to 60 percent of patients.

G. Surgery to correct genuine stress incontinence is a viable option for most patients. Retropubic urethropexies (ie, Burch laparoscopic and Marshall-Marchetti-Krantz [MMK] procedures) and suburethral slings have long-term success rates consistently reported in the 80 to 96 percent range.

H. Another minimally invasive procedure for the treatment of stress incontinence caused by intrinsic sphincter deficiency is periurethral injection.

I. Overactive bladder
1. Behavioral therapy, in the form of bladder retraining and biofeedback, seeks to reestablish cortical control of the bladder by having the patient ignore urgency and void only in response to cortical signals during waking hours.

2. Pharmacologic agents may be given empirically to women with symptoms of overactive bladder. Tolterodine (Detrol) and extended-release oxybutynin chloride (Ditropan XL) have largely replaced generic oxybutynin as a first-line treatment option for overactive bladder because of favorable side effect profiles.

3. ERT is also an effective treatment for women with overactive bladder. Even in patients taking systemic estrogen, localized ERT (ie, estradiol-impregnated vaginal ring) may increase inadequate estrogen levels and decrease the symptoms associated with overactive bladder.

4. Pelvic floor electrical stimulation is also effective in treating women with overactive bladder. Pelvic floor electrical stimulation results in a 50 percent cure rate of detrusor instability.

5. Neuromodulation of the sacral nerve roots through electrodes implanted in the sacral foramina is a promising new surgical treatment
that has been found to be effective in the treatment of urge incontinence.

6. The FDA has recently approved extracorporeal magnetic innervation, a noninvasive procedure for the treatment of incontinence caused by pelvic floor weakness. Extracorporeal magnetic innervation may have a place in the treatment of women with both stress and urge incontinence.

References: See page 282.

Urinary Tract Infection

Urinary tract infections (UTIs) are a leading cause of morbidity in persons of all ages. Sexually active young women, elderly persons and those undergoing genitourinary instrumentation or catheterization are at risk.

I. Acute uncomplicated cystitis in young women
A. Sexually active young women are most at risk for UTIs.
B. Approximately 90 percent of uncomplicated cystitis episodes are caused by Escherichia coli, 10 to 20 percent are caused by coagulase-negative Staphylococcus saprophyticus and 5 percent or less are caused by other Enterobacteriaceae organisms or enterococci. Up to one-third of uropathogens are resistant to ampicillin and, but the majority are susceptible to trimethoprim-sulfamethoxazole (85 to 95 percent) and fluoroquinolones (95 percent).
C. Patients should be evaluated for pyuria by urinalysis (wet mount examination of spun urine) or a dipstick test for leukocyte esterase.

<table>
<thead>
<tr>
<th>Urinary Tract Infections in Adults</th>
<th>Category</th>
<th>Diagnostic criteria</th>
<th>First-line therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute uncomplicated cystitis</td>
<td>Urinalysis for pyuria and hematuria (culture not required)</td>
<td>TMP-SMX DS (Bactrim, Septa) Trimethoprim (Proloprim) Ciprofloxacin (Cipro) Ofloxacin (Floxin)</td>
<td>Three-day course is best. Quinolones may be used in areas of TMP-SMX resistance or in patients who cannot tolerate TMP-SMX</td>
<td></td>
</tr>
<tr>
<td>Recurrent cystitis in young women</td>
<td>Symptoms and a urine culture with a bacterial count of more than 100 CFU per mL of urine</td>
<td>If the patient has more than three cystitis episodes per year, treat prophylactically with postcoital, patient-directed or continuous daily therapy</td>
<td>Repeat therapy for seven to 10 days based on culture results and then use prophylactic therapy</td>
<td></td>
</tr>
<tr>
<td>Acute cystitis in men</td>
<td>Urine culture with a bacterial count of 1,000 to 10,000 CFU per mL of urine</td>
<td>Same as for acute uncomplicated cystitis</td>
<td>Treat for seven to 10 days</td>
<td></td>
</tr>
<tr>
<td>Acute uncomplicated pyelonephritis</td>
<td>Urine culture with a bacterial count of 100,000 CFU per mL of urine</td>
<td>If gram-negative organism, oral fluoroquinolone or ceftriaxone (Rocephin) or a fluoroquinolone if Enterococcus species, add oral or IV amoxicillin</td>
<td>Switch from IV to oral administration when the patient is able to take medication by mouth; complete a 14-day course</td>
<td></td>
</tr>
<tr>
<td>Complicated urinary tract infection</td>
<td>Urine culture with a bacterial count of more than 10,000 CFU per mL of urine</td>
<td>If gram-negative organism, oral fluoroquinolone or ceftriaxone (Rocephin) or a fluoroquinolone if Enterococcus species, add oral or IV amoxicillin</td>
<td>Treat for 10 to 14 days</td>
<td></td>
</tr>
</tbody>
</table>
D. Treatment of acute uncomplicated cystitis in young women

1. Three-day regimens appear to offer the optimal combination of convenience, low cost and an efficacy comparable to that of seven-day or longer regimens.
2. Trimethoprim-sulfamethoxazole is the most cost-effective treatment. Three-day regimens of ciprofloxacin (Cipro), 250 mg twice daily, and ofloxacin (Floxin), 200 mg twice daily, produce better cure rates with less toxicity.
3. Quinolones that are useful in treating complicated and uncomplicated cystitis include...
Ciprofloxacin, norfloxacin, ofloxacin, enoxacin (Penetrex), lomefloxacin (Maxaquin), sparfloxacin (Zagam) and levofloxacin (Levaquin).

4. Trimethoprim-sulfamethoxazole remains the antibiotic of choice in the treatment of uncomplicated UTIs in young women. Fluoroquinolones are recommended for patients who cannot tolerate sulfonamides or trimethoprim or who have a high frequency of antibiotic resistance. Three days is the optimal duration of treatment for uncomplicated cystitis. A seven-day course should be considered in pregnant women, diabetic women and women who have had symptoms for more than one week.

II. Recurrent cystitis in young women
A. Up to 20 percent of young women with acute cystitis develop recurrent UTIs. The causative organism should be identified by urine culture.
B. Women who have more than three UTI recurrences within one year can be managed using one of three preventive strategies.
   1. Acute self-treatment with a three-day course of standard therapy.
   2. Postcoital prophylaxis with one-half of a trimethoprim-sulfamethoxazole double-strength tablet (40/200 mg).
   3. Continuous daily prophylaxis for six months with trimethoprim-sulfamethoxazole, one-half tablet per day (40/200 mg); nitrofurantoin, 50 to 100 mg per day; norfloxacin (Noroxin), 200 mg per day; cephalexin (Keflex), 250 mg per day; or trimethoprim (Proloprim), 100 mg per day.

III. Complicated UTI
A. A complicated UTI is one that occurs because of enlargement of the prostate gland, blockages, or the presence of resistant bacteria.
B. Accurate urine culture and susceptibility are necessary. Treatment consists of an oral fluoroquinolone. In patients who require hospitalization, parenteral administration of ceftazidime (Fortaz) or cefoperazone (Cefobid), ceftazidime (Maxipime), aztreonam (Azactam), imipenem-cilastatin (Primaxin) or the combination of an antipseudomonal penicillin (timentin [Ticar], mezlocillin [Mezin], piperacillin [Pipracil]) with an aminoglycoside.
C. Enterococci are frequently encountered uropathogens in complicated UTIs. In areas in which vancomycin-resistant Enterococcus faecium is prevalent, quinupristin-dalfopristin (Synercid) may be useful.
D. Patients with complicated UTIs require at least a 10- to 14-day course of therapy. Follow-up urine cultures should be performed within 10 to 14 days after treatment.

IV. Uncomplicated pyelonephritis
A. Women with acute uncomplicated pyelonephritis may present with a mild cystitis-like illness and flank pain; fever, chills, nausea, vomiting, leukocytosis and abdominal pain; or a serious gram-negative bacteremia. Uncomplicated pyelonephritis is usually caused by E. coli.
B. The diagnosis should be confirmed by urinalysis and by urine culture. Urine cultures demonstrate more than 100,000 CFU per mL of urine in 80 percent of women with pyelonephritis. Blood cultures are positive in up to 20 percent of women who have this infection.
C. Empiric therapy using an oral fluoroquinolone is recommended in women with mild to moderate symptoms. Patients who are too ill to take oral antibiotics should initially be treated with a parenterally third-generation cephalosporin, aztreonam, a broad-spectrum penicillin, a quinolone or an aminoglycoside.
D. The total duration of therapy is usually 14 days. Patients with persistent symptoms after three days of antimicrobial therapy should be evaluated by renal ultrasonography for evidence of urinary obstruction or abscess.

References: See page 282.

Public Infections
I. Molluscum contagiosum
A. This disease is produced by a virus of the pox virus family and is spread by sexual or close personal contact. Lesions are usually asymptomatic and multiple, with a central umbilication. Lesions can be spread by autoinoculation and last from 6 months to many years.
B. Diagnosis. The characteristic appearance is adequate for diagnosis, but biopsy may be used to confirm the diagnosis.
C. Treatment. Lesions are removed by sharp dermal curette, liquid nitrogen cryosurgery, or electrodesiccation.

II. Pediculosis pubis (crabs)
A. Phthirus pubis is a blood sucking louse that is unable to survive more than 24 hours off the body. It is often transmitted sexually and is principally found on the pubic hairs. Diagnosis is confirmed by locating nits or adult lice on the hair shafts.
B. Treatment
   1. Permethrin cream (Elimite), 5% is the most effective treatment; it is applied for 10 minutes and washed off.
2. Kwell shampoo, lathered for at least 4 minutes, can also be used, but it is contraindicated in pregnancy or lactation.

3. All contaminated clothing and linen should be laundered.

III. Pubic scabies
A. This highly contagious infestation is caused by the Sarcoptes scabiei (0.2-0.4 mm in length). The infestation is transmitted by intimate contact or by contact with infested clothing. The female mite burrows into the skin, and after 1 month, severe pruritus develops. A multiform eruption may develop, characterized by papules, vesicles, pustules, urticarial wheals, and secondary infections on the hands, wrists, elbows, belt line, buttocks, genitalia, and outer feet.

B. Diagnosis is confirmed by visualization of burrows and observation of parasites, eggs, larvae, or red fecal compactons under microscopy.

C. Treatment. Permethrin 5% cream (Elimite) is massaged in from the neck down and removed by washing after 8 hours.

References: See page 282.

Sexually Transmissible Infections

Approximately 12 million patients are diagnosed with a sexually transmissible infection (STI) annually in the United States. Sequella of STIs include infertility, chronic pelvic pain, ectopic pregnancy, and other adverse pregnancy outcomes.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Diagnostic Methods</th>
<th>Recommended Treatment Regimens</th>
<th>Alternative Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia trachomatis</td>
<td>Direct fluorescent antibody, enzyme immunoassay, DNA probe, cell culture, DNA amplification</td>
<td>Doxycycline 100 mg PO 2 times a day for 7 days or Azithromycin (Zithromax) 1 g PO</td>
<td>Ofloxacin (Floxin) 300 mg PO 2 times a day for 7 days</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>Culture SNA probe</td>
<td>Ceftriaxone (Rocephin) 125 mg IM or Cefixime 400 mg PO or Ciprofloxacin (Cipro) 500 mg PO or Ofloxacin (Floxin) 400 mg PO plus Doxycycline 100 mg 2 times a day for 7 days or azithromycin 1 g PO</td>
<td>Levofoxacin (Levaquin) 250 mg PO once Spectromycin 2 g IM once</td>
</tr>
<tr>
<td>Treponema pallidum</td>
<td>Clinical appearance Dark-field microscopy Nonreproducible test: rapid plasma reagent, VDRL Treponemal test: MHA-TP, FTA-ABS</td>
<td>Primary and secondary syphilis and early latent syphilis (&lt;1 year duration): benzathine penicillin G 2.4 million units IM in a single dose. Penicillin allergy in patients with primary, secondary, or early latent syphilis (&lt;1 year of duration): doxycycline 100 mg PO 2 times a day for 2 weeks.</td>
<td></td>
</tr>
</tbody>
</table>

Diagnosis and Treatment of Viral Sexually Transmissible Infections

<table>
<thead>
<tr>
<th>Organism</th>
<th>Diagnostic Methods</th>
<th>Recommended Treatment Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herpes simplex virus</td>
<td>Clinical appearance Cell culture confirmation First episode: Acyclovir (Zovirax) 400 mg PO 6 times a day for 7-10 days, or famciclovir (Famvir) 250 mg PO 3 times a day for 7-10 days, or valacyclovir (Valtrex) 1 g PO 2 times a day for 7-10 days. Recurrent episodes: acyclovir 400 mg PO 3 times a day for 5 days, or famciclovir 125 mg PO 2 times a day for 5 days, or valacyclovir 500 mg PO 2 times a day for 5 days. Daily suppressive therapy: acyclovir 400 mg PO 2 times a day, or famciclovir 250 mg PO 2 times a day, or valacyclovir 250 mg PO 2 times a day. 500 mg PO 1 time a day, or 1000 mg PO 1 time a day.</td>
<td>Daily suppressive therapy: acyclovir 400 mg PO 2 times a day, or famciclovir 250 mg PO 2 times a day, or valacyclovir 250 mg PO 2 times a day. 500 mg PO 1 time a day, or 1000 mg PO 1 time a day.</td>
</tr>
<tr>
<td>Organism</td>
<td>Diagnostic Methods</td>
<td>Recommended Treatment Regimens</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>Human papilloma virus</td>
<td>Clinical appearance of condyloma papules, Cytology</td>
<td>External warts: Patient may apply podofilox 0.5% solution or gel 2 times a day for 3 days, followed by 4 days of no therapy, for a total of up to 4 cycles, or imiquimod 5% cream at bedtime 3 times a week for up to 16 weeks. Cryotherapy with liquid nitrogen or cryoprobe, repeat every 1-2 weeks; or podophyllin, repeat weekly; or TCA 80-90%, repeat weekly; or surgical removal. Vaginal warts: cryotherapy with liquid nitrogen, or TCA 80-90%, or podophyllin 10-25%</td>
</tr>
<tr>
<td>Human immunodeficiency virus</td>
<td>Enzyme immunoassay, Western blot (for confirmation), Polymerase chain reaction</td>
<td>Antiretroviral agents</td>
</tr>
</tbody>
</table>

### Treatment of Pelvic Inflammatory Disease

<table>
<thead>
<tr>
<th>Regime</th>
<th>Inpatient</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Cefotetan (Cefotan) 2 g IV q12h; or cefoxitin (Mefoxin) 2 g IV q6h plus doxycycline 100 mg IV or PO q12h.</td>
<td>Ofloxacin (Floxin) 400 mg PO bid for 14 days plus metronidazole 500 mg PO bid for 14 days.</td>
</tr>
<tr>
<td>B</td>
<td>Clindamycin 900 mg IV q6h plus gentamycin loading dose IV or IM (2 mg/kg of body weight), followed by a maintenance dose (1.5 mg/kg) q8h.</td>
<td>Ceftriaxone (Rocephin) 250 mg IM once; or cefoxitin 2 g IM plus probenecid 1 g PO; or other parenteral third-generation cephalosporin (eg, ceftizoxime, cefotaxime) plus doxycycline 100 mg PO bid for 14 days.</td>
</tr>
</tbody>
</table>

### I. Chlamydia Trachomatis
**A.** Chlamydia trachomatis is the most prevalent STI in the United States. Chlamydial infections are most common in women age 15-19 years. **B.** Routine screening of asymptomatic, sexually active adolescent females undergoing pelvic examination is recommended. Annual screening should be done for women age 20-24 years who are either inconsistent users of barrier contraceptives or who acquired a new sex partner or had more than one sexual partner in the past 3 months.

### II. Gonorrhea
Gonorrhea has an incidence of 800,000 cases annually. Routine screening for gonorrhea is recommended among women at high risk of infection, including prostitutes, women with a history of repeated episodes of gonorrhea, women under age 25 years with two or more sex partners in the past year, and women with mucopurulent cervicitis.

### III. Syphilis
A. Syphilis has an incidence of 100,000 cases annually. The rates are highest in the South, among African Americans, and among those in the 20- to 24-year-old age group. **B.** Prostitutes, persons with other STIs, and sexual contacts of persons with active syphilis should be screened.

### IV. Herpes simplex virus and human papillomavirus
**A.** An estimated 200,000-500,000 new cases of herpes simplex occur annually in the United States. New infections are most common in adolescents and young adults. **B.** Human papillomavirus affects about 30% of young, sexually active individuals.

### Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) is an acute infection of the upper genital tract in women, involving any or all of the uterus, oviducts, and ovaries. PID is a community-acquired infection initiated by a sexually transmitted agent. Pelvic inflammatory disease accounts for approximately 2.5 million outpatient visits and 200,000 hospitalizations annually.

### I. Clinical evaluation
**A.** Lower abdominal pain is the cardinal presenting symptom in women with PID, although the character of the pain may be quite subtle. The onset of pain during or shortly after menses is particularly suggestive. The abdominal pain is usually bilateral and rarely of more than two weeks’ duration. **B.** Abnormal uterine bleeding occurs in one-third or more of patients with PID. New vaginal discharge, urethritis, proctitis, fever, and chills can be associated signs.

### C. Risk factors for PID:
1. Age less than 35 years
2. Nonbarrier contraception
3. New, multiple, or symptomatic sexual partners
4. Previous episode of PID
5. Oral contraception
6. African-American ethnicity

II. Physical examination
A. Only one-half of patients with PID have fever. Abdominal examination reveals diffuse tenderness greatest in the lower quadrants, which may or may not be symmetrical. Rebound tenderness and decreased bowel sounds are common. Tenderness in the right upper quadrant does not exclude PID, because approximately 10 percent of these patients have perihepatitis (Fitz-Hugh Curtis syndrome).
B. Purulent endocervical discharge and/or acute cervical motion and adnexal tenderness by bimanual examination is strongly suggestive of PID. Rectovaginal examination should reveal the uterine adnexal tenderness.

III. Diagnosis
A. Diagnostic criteria and guidelines. The index of suspicion for the clinical diagnosis of PID should be high, especially in adolescent women.
B. The CDC has recommended minimum criteria required for empiric treatment of PID. These major determinants include lower abdominal tenderness, adnexal tenderness, and cervical motion tenderness. Minor determinants (ie, signs that may increase the suspicion of PID) include:
   1. Fever (oral temperature >101°F; >38.3°C)
   2. Vaginal discharge
   3. Documented STD
   4. Erythrocyte sedimentation rate (ESR)
   5. C-reactive protein
   6. Systemic signs
   7. Dyspareunia

C. Empiric treatment for pelvic inflammatory disease is recommended when:
   1. The examination suggests PID
   2. Demographics (risk factors) are consistent with PID
   3. Pregnancy test is negative

IV. Diagnostic testing
A. Laboratory testing for patients suspected of having PID always begins with a pregnancy test to rule out ectopic pregnancy and complications of an intrauterine pregnancy. A urinalysis and a stool for occult blood should be obtained because abnormalities in either reduce the probability of PID. Blood counts have limited value. Fewer than one-half of PID patients exhibit leukocytosis.
B. Gram stain and microscopic examination of vaginal discharge may provide useful information. If a cervical Gram stain is positive for Gram-negative intracellular diplococci, the probability of PID greatly increases; if negative, it is of little use.
C. Increased white blood cells (WBC) in vaginal fluid may be the most sensitive single laboratory test for PID (78 percent for >3 WBC per high power field). However, the specificity is only 39 percent.
D. Recommended laboratory tests:
   1. Pregnancy test
   2. Microscopic exam of vaginal discharge in saline
   3. Complete blood counts
   4. Tests for chlamydia and gonococcus
   5. Urinalysis
   6. Fecal occult blood test
   7. C-reactive protein (optional)

E. Ultrasound imaging is reserved for acutely ill patients with PID in whom a pelvic abscess is a consideration.

V. Recommendations
A. Health care providers should maintain a low threshold for the diagnosis of PID, and sexually active young women with lower abdominal, adnexal, and cervical motion tenderness should receive empiric treatment. The specificity of these clinical criteria can be enhanced by the presence of fever, abnormal cervical/vaginal discharge, elevated ESR and/or serum C-reactive protein, and the demonstration of cervical gonorrhea or chlamydia infection.
B. If clinical findings (epidemiologic, symptomatic, and physical examination) suggest PID empiric treatment should be initiated.

VI. Treatment of pelvic inflammatory disease
A. The two most important initiators of PID, Neisseria gonorrhoeae and Chlamydia trachomatis, must be treated, but coverage should also be provided for groups A and B streptococci, Gram negative enteric bacilli (Escherichia coli, Klebsiella spp., and Proteus spp.), and anaerobes.

B. Outpatient therapy
1. For outpatient therapy, the CDC recommends either oral ofloxacin (Floxin, 400 mg twice daily) or levofloxacin (Levaquin, 500 mg once daily) with or without metronidazole (Flagyl, 500 mg twice daily) for 14 days. An alternative is an initial single dose of ceftriaxone (Rocephin, 250 mg IM), cefoxitin (Mefoxin, 2 g IM plus probenecid 1 g orally), or another parenteral third-generation cephalosporin, followed by doxycycline (100 mg orally twice daily) with or without metronidazole for 14 days. Quinolones are not recommended to treat gonorrhea acquired in California or Hawaii. If the patient may have acquired the disease in Asia, Hawaii, or California, cefixime or ceftriaxone should be used.
2. Another alternative is azithromycin (Zithromax, 1 g PO for Chlamydia coverage) and amoxicillin-clavulanate (Amoxicillin, 875 mg PO) once by directly observed therapy, followed by amoxicillin-clavulanate (Amoxicillin, 875 mg PO BID) for 7 to 10 days.

C. Inpatient therapy
1. For inpatient treatment, the CDC suggests either of the following regimens:
   a. Cefotetan (Cefotan), 2 g IV Q12h, or cefoxitin (Mefoxin, 2 g IV Q6h) plus doxycycline (100 mg IV of PO Q12h)
   b. Clindamycin (Cleocin), 900 mg IV Q8h, plus gentamicin (1.5 mg/kg IV Q8h)
2. Alternative regimens:
   a. Ofloxacin (Floxin), 400 mg IV Q12h or levofloxacin (Levaquin, 500 mg IV QD) with or without metronidazole (Flagyl, 500 mg IV Q8h). Quinolones are not recommended to treat gonorrhea acquired in California or Hawaii. If the patient may have acquired the disease in Asia, Hawaii, or California, cefixime or ceftriaxone should be used.
   b. Ampicillin-sulbactam (Unasyn), 3 g IV Q6h plus doxycycline (100 mg IV or PO Q12h)
3. Parenteral administration of antibiotics should be continued for 24 hours after clinical response, followed by doxycycline (100 mg PO BID) or clindamycin (Cleocin, 450 mg PO QID) for a total of 14 days.
4. The following regimen may also be used:
   Levofloxacin (Levaquin), 500 mg IV Q24h, plus metronidazole (Flagyl, 500 mg IV Q8h).
   With this regimen, azithromycin (Zithromax, 1 g PO once) should be given as soon as the patient is tolerating oral intake. Parenteral therapy is continued until the pelvic tenderness on bimanual examination is mild or absent.

D. Annual screening is recommended for all sexually active women under age 25 and for women over 25 if they have new or multiple sexual partners. A retest for chlamydia should be completed in 3 to 4 months after chlamydia treatment because of high rates of reinfection.

E. Additional evaluation:
   1. Serology for the human immunodeficiency virus (HIV)
   2. Papanicolaou smear
   3. Hepatitis B surface antigen determination and initiation of the vaccine series for patients who are antigen negative and unvaccinated
   4. Hepatitis C virus serology
   5. Serologic tests for syphilis

References: See page 282.

Vaginitis

Vaginitis is the most common gynecologic problem encountered by primary care physicians. It may result from bacterial infections, fungal infection, protozoan infection, contact dermatitis, atrophic vaginitis, or allergic reaction.

I. Clinical evaluation of vaginal symptoms
A. The type and extent of symptoms, such as itching, discharge, odor, or pelvic pain should be determined. A change in sexual partners or sexual activity, changes in contraception method, medications (antibiotics), and history of prior genital infections should be sought.

B. Physical examination
1. Evaluation of the vagina should include close inspection of the external genitalia for excoriations, ulcerations, blisters, papillary structures, erythema, edema, mucosal thinning, or mucosal pallor.
2. The color, texture, and odor of vaginal fluid should be noted.

C. Vaginal fluid pH can be determined by immersing pH paper in the vaginal discharge. A pH level greater than 4.5 indicates the presence of bacterial vaginosis or Trichomonas vaginalis.

D. Saline wet mount:
1. One swab should be used to obtain a sample from the posterior vaginal fornix, obtaining a
"clump" of discharge. Place the sample on a slide, add one drop of normal saline, and apply a coverslip.

2. Cocccoid bacteria and clue cells (bacteria-coated, stippled, epithelial cells) are characteristic of bacterial vaginosis.

3. Trichomoniasis is confirmed by identification of trichomonads – mobile, oval flagellates. White blood cells are prevalent.

E. Potassium hydroxide (KOH) preparation

1. Place a second sample on a slide, apply one drop of 10% potassium hydroxide (KOH) and a coverslip. A pungent, fishy odor upon addition of KOH – a positive whiff test – strongly indicates bacterial vaginosis.

2. The KOH prep may reveal Candida in the form of thread-like hyphae and budding yeast.

F. Screening for STDs. Testing for gonorrhea and chlamydial infection should be completed for women with a new sexual partner, purulent cervical discharge, or cervical motion tenderness.

II. Differential diagnosis

A. The most common cause of vaginitis is bacterial vaginosis, followed by Candida albicans. The prevalence of trichomoniasis has declined in recent years.

B. Common nonvaginal etiologies include contact dermatitis from spermicidal creams, latex in condoms, or douching. Any STD can produce vaginal discharge.

Clinical Manifestations of Vaginitis

<table>
<thead>
<tr>
<th>Candidal Vaginitis</th>
<th>Nonmalodorous, thick, white, “cottage cheese-like” discharge that adheres to vaginal walls</th>
<th>Hyphal forms or budding yeast cells on wet-mount</th>
<th>Pruritus</th>
<th>Normal pH (&lt;4.5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Vaginosis</td>
<td>Thin, dark or dull grey, homogeneous, malodorous discharge that adheres to the vaginal walls</td>
<td>Elevated pH level (&gt;4.5)</td>
<td>Positive KOH (whiff test)</td>
<td>Clue cells on wet-mount microscopic evaluation</td>
</tr>
<tr>
<td>Trichomonas Vaginalis</td>
<td>Copious, yellow-gray or green, homogeneous or frothy, malodorous discharge</td>
<td>Elevated pH level (&gt;4.5)</td>
<td>Mobile, flagellated organisms and leukocytes on wet-mount microscopic evaluation</td>
<td>Vulvovaginal irritation, dysuria</td>
</tr>
<tr>
<td>Atrophic Vaginitis</td>
<td>Vaginal dryness or burning</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

III. Yeast vaginitis

A. Half of all women have had at least one episode of yeast vaginitis. Candida albicans accounts for 80% of yeast infections. The remaining 20% are caused by Candida glabrata or Candida tropicalis. Pregnancy, oral contraceptives, antibiotics, diabetes and HIV infection are contributing factors.

B. Diagnosis

1. Typical symptoms are pruritus, thick vaginal discharge, and genital irritation. Discharge is odorless and cottage cheese-like. Women may complain of dysuria.

2. Physical examination may reveal vulvar erythema and fissuring.

3. Laboratory evaluation of vaginal fluid reveals a pH of less than 4.5 and the presence of hyphae on 10% potassium hydroxide (KOH) wet mount. Elevations in pH also occur in the presence of semen or blood.

4. Microscopy will reveal hyphae. The sensitivity of the KOH wet mount is only 50% to 70%. Therefore, treatment should be instituted even when hyphae are absent but the clinical impression is otherwise consistent.

5. Culture should be considered if the diagnosis is in doubt or in recurrent cases. Dermatophyte test medium is sensitive yeast.

C. Treatment

1. Uncomplicated vaginitis. These episodes can be treated with any nonprescription short-course (up to 7-day) preparation, since all are equally effective.

<table>
<thead>
<tr>
<th>Treatment regimens for yeast vaginitis*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-day regimens</td>
</tr>
<tr>
<td>Clotrimazole vaginal tablets (Mycelex G), 500 mg hs**</td>
</tr>
<tr>
<td>Fluconazole tablets (Diffucan), 150 mg PO</td>
</tr>
<tr>
<td>Itraconazole capsules (Sporanox), 200 mg PO bid</td>
</tr>
<tr>
<td>Tioconazole 6.5% vaginal ointment (Vagistat-1), 4.6 g hs**</td>
</tr>
<tr>
<td>[5 g]</td>
</tr>
<tr>
<td>3-day regimens</td>
</tr>
<tr>
<td>Butoconazole nitrate 2% vaginal cream (Femstat 3), 5 g hs [2 g]</td>
</tr>
<tr>
<td>Clotrimazole vaginal inserts (Gyne-Lotrimin 3), 200 mg hs**</td>
</tr>
<tr>
<td>Micocalazole vaginal suppositories (Monistat 3), 200 mg hs**</td>
</tr>
<tr>
<td>Terconazole 0.0% vaginal cream (Terazol 3), 5 g hs</td>
</tr>
<tr>
<td>Terconazole vaginal suppositories (Terazol 3), 85 mg hs</td>
</tr>
<tr>
<td>Itraconazole capsules (Sporanox), 200 mg PO qd (4)</td>
</tr>
</tbody>
</table>
### 5-day regimen
Ketoconazole tablets (Nizoral), 400 mg PO bid (4)

### 7-day regimens
- Clotrimazole 1% cream (Gyne-Lotrimin, Mycelex-7), 5 g hs**
- Clotrimazole vaginal tablets (Gyne-Lotrimin, Mycelex-7, Sweet’n Fresh Clotrimazole-7), 100 mg hs**
- Miconazole 2% vaginal cream (Femizol-M, Monistat 7), 5 g hs**
- Miconazole vaginal suppositories (Monistat 7), 100 mg hs**
- Terconazole 0.4% vaginal cream (Terazol 7), 5 g hs

### 14-day regimens
Nystatin vaginal tablets (Mycostatin), 100,000 U hs
Boric acid No. 0 gelatin vaginal suppositories, 600 mg bid (2)

*Suppositories can be used if inflammation is predominantly vaginal; creams if vulvar; a combination if both. Cream-suppository combination packs available: clotrimazole (Gyne-Lotrimin, Mycelex); miconazole (Monistat, M-Zole). If diagnosis is in doubt, consider oral therapy to avoid amelioration of symptoms with use of creams. Use 1-day or 3-day regimen if compliance is an issue. Miconazole nitrate may be used during pregnancy.

**Nonprescription formulation. If nonprescription therapies fail, use terconazole 0.4% cream or 80-mg suppositories at bedtime for 7 days.

#### 2. Complicated infections are more severe and cure is more difficult. With use of nonprescription preparations, the treatment course should be longer (10 to 14 days). Since Candida species other than albicans may be more likely in complicated infections, treatment with terconazole (Terazol) should be considered. Single-dose oral fluconazole should be avoided.

### Management options for complicated or recurrent yeast vaginitis
- Extend any 7-day regimen to 10 to 14 days
- Eliminate use of nylon or tight-fitting clothing
- Consider discontinuing oral contraceptives
- Consider eating 8 oz yogurt (with Lactobacillus acidophilus culture) per day
- Improve glycemic control in diabetic patients
- For long-term suppression of recurrent vaginitis, use ketoconazole, 100 mg (½ of 200-mg tablet) qd for 6 months

#### D. Recurrent infection is defined as more than four episodes per year. Suppressive therapy for 6 months is recommended after completion of 10 to 14 days of a standard regimen. Oral ketoconazole, 100 mg daily for 6 months, has been shown to reduce the recurrence rate to 5%. If the sexual partner has balanitis, topical therapy should be prescribed.

### IV. Trichomonia

#### A. Trichomonia is responsible for less than 25% of vaginal infections. The infection is caused by Trichomonas vaginalis, which is a sexually transmitted disease. Most men are asymptomatic.

#### B. Diagnosis
1. A copious, watery discharge is common, and some patients may notice an odor. Often few symptoms are present. Usually, the vulva and vaginal mucosa are free of signs of inflammation. The discharge is thin and characterized by an elevated pH, usually 6 to 7. Occasionally, small punctate cervical hemorrhages with ulcerations (strawberry cervix) are found.
2. Microscopic examination of vaginal fluid mixed with saline solution ("wet prep") shows an increased number of leukocytes and motile trichomonads. Microscopy has a sensitivity of only 50% to 70%. Trichomonads are sometimes reported on Pap smears, but false-positive results are common.
3. Culture for identification of T vaginalis has a sensitivity of 95% and should be performed when the clinical findings are consistent with trichomonia but motile organisms are absent. A rapid DNA probe test, which has a sensitivity of 90% and a specificity of 99.8%, can also be used.

#### C. Treatment. Oral metronidazole (Flagyl, Protostat) is recommended. Treatment of male sexual partners is recommended. Metronidazole gel (MetroGel-Vaginal) is less efficacious than oral antifungal therapy. The single 2-g dose of oral metronidazole can be used safely in any trimester of pregnancy.

### Treatment options for trichomonia

#### Initial measures
- Metronidazole (Flagyl, Protostat), 2 g PO in a single dose, or metronidazole, 500 mg PO bid X 7 days, or metronidazole, 375 mg PO bid X 7 days
- Treat male sexual partners

#### Measures for treatment failure
- Treatment sexual contacts
- Re-treat with metronidazole, 500 mg PO bid X 7 days
- If infection persists, confirm with culture and re-treat with metronidazole,
- 2-4 g PO qd X 3-10 days
V. Bacterial Vaginosis
   A. Bacterial vaginosis is a polymicrobial infection caused by an overgrowth of anaerobic organisms. It is the most common cause of vaginitis, accounting for 50% of cases. Gardnerella vaginalis has been identified as one of the key organisms in bacterial vaginosis.
   
B. Diagnosis
   1. Most have vaginal discharge (90%) and foul odor (70%). Typically there is a homogeneous vaginal discharge, pH higher than 4.5, "clue cells" (epithelial cells studded with coccobacilli on microscopic examination, and a positive "whiff" test.
   2. A specimen of vaginal discharge is obtained by speculum, and the pH is determined before the specimen is diluted. Next, the "whiff" test is performed by adding several drops of 10% KOH to the specimen. The test is positive when a fishy odor is detected. Finally, the specimen is viewed by wet-mount microscopy.
   
C. Treatment consists of oral metronidazole, 500 mg twice a day for 7 days. Common side effects of metronidazole include nausea, anorexia, abdominal cramps, and a metallic taste. Alcohol may cause a disulfiram-like reaction. Use of single-dose metronidazole may result in a higher recurrence rate and an increase in gastrointestinal side effects. Topical clindamycin is an option, but the cream may weaken latex condoms and diaphragms.

VI. Other diagnoses causing vaginal symptoms
   A. One-third of patients with vaginal symptoms will not have laboratory evidence of bacterial vaginosis, Candida, or Trichomonas. Other causes of the vaginal symptoms include cervicitis, allergic reactions, and vulvodynia.
   
B. Atrophic vaginitis should be considered in postmenopausal patients if the mucosa appears pale and thin and wet-mount findings are negative.
   1. Oral estrogen (Premarin) 0.3 mg qd should provide relief.
   2. Vaginal ring estradiol (Estring), a silastic ring impregnated with estradiol, is the preferred means of delivering estrogen to the vagina. The silastic ring delivers 6 to 9 µg of estradiol to the vagina daily. The rings are changed once every three months. Concomitant progestin therapy is not necessary.
   3. Conjugated estrogens (Premarin), 0.5 gm of cream, or one-eighth of an applicatorful daily into the vagina for three weeks, followed by twice weekly thereafter. Concomitant progestin therapy is not necessary.
   4. Estrace cream (estradiol) can also by given by vaginal applicator at a dose of one-eighth of an applicatorful daily into the vagina for three weeks, followed by twice weekly thereafter. Concomitant progestin therapy is not necessary.
   
C. Allergy and chemical irritation
   1. Patients should be questioned about use of substances that cause allergic or chemical irritation, such as deodorant soaps, laundry detergent, vaginal contraceptives, bath oils, perfumed or dyed toilet paper, hot tub or swimming pool chemicals, and synthetic clothing.
   2. Topical steroids and systemic antihistamines can help alleviate the symptoms.

References: See page 282.
Prenatal Care

I. Prenatal history and physical examination

A. Diagnosis of pregnancy

1. Amenorrhea is usually the first sign of conception. Other symptoms include breast fullness and tenderness, skin changes, nausea, vomiting, urinary frequency, and fatigue.

2. Pregnancy tests. Urine pregnancy tests may be positive within days of the first missed menstrual period. Serum beta human chorionic gonadotropin (HCG) is accurate up to a few days after implantation.

3. Fetal heart tones can be detected as early as 11-12 weeks from the last menstrual period (LMP) by Doppler. The normal fetal heart rate is 120-160 beats per minute.

4. Fetal movements ("quickening") are first felt by the patient at 17-19 weeks.

5. Ultrasound will visualize a gestational sac at 5-6 weeks and a fetal pole with movement and cardiac activity by 7-8 weeks. Ultrasound can estimate fetal age accurately if completed before 24 weeks.

6. Estimated date of confinement. The mean duration of pregnancy is 40 weeks from the LMP. Estimated date of confinement (EDC) can be calculated by Nägele's rule: Add 7 days to the first day of the LMP, then subtract 3 months.

B. Contraceptive history. Recent oral contraceptive usage often causes postpill amenorrhea, and may cause erroneous pregnancy dating.

C. Gynecologic and obstetric history

1. Gravidity is the total number of pregnancies. Parity is expressed as the number of term pregnancies, preterm pregnancies, abortions, and live births.

2. The character and length of previous labors, type of delivery, complications, infant status, and birth weight are recorded.

3. Assess prior cesarean sections and determine type of C-section (low transverse or classical), and determine reason it was performed.

D. Medical and surgical history and prior hospitalizations are documented.

E. Medications and allergies are recorded.

F. Family history of medical illnesses, hereditary illness, or multiple gestation is sought.

G. Social history. Cigarettes, alcohol, or illicit drug use.

H. Review of systems. Abdominal pain, constipation, headaches, vaginal bleeding, dysuria or urinary frequency, or hemorrhoids.

I. Physical examination

1. Weight, funduscopic examination, thyroid, breast, lungs, and heart are examined.

2. An extremity and neurologic exam are completed, and the presence of a cesarean section scar is sought.

3. Pelvic examination

   a. Pap smear and culture for gonorrhea are completed routinely. Chlamydia culture is completed in high-risk patients.

   b. Estimation of gestational age by uterine size

      (1) The nongravid uterus is 3 x 4 x 7 cm. The uterus begins to change in size at 5-6 weeks.

      (2) Gestational age is estimated by uterine size: 8 weeks = 2 x normal size; 10 weeks = 3 x normal; 12 weeks = 4 x normal.

      (3) At 12 weeks the fundus becomes palpable at the symphysis pubis.

      (4) At 16 weeks, the uterus is midway between the symphysis pubis and the umbilicus.

      (5) At 20 weeks, the uterus is at the umbilicus. After 20 weeks, there is a correlation between the number of weeks of gestation and the number of centimeters from the pubic symphysis to the top of the fundus.

      (6) Uterine size that exceeds the gestational dating by 3 or more weeks suggests multiple gestation, molar pregnancy, or (most commonly) an inaccurate date for LMP. Ultrasonography will confirm inaccurate dating or intrauterine growth failure.

   c. Adnexa are palpated for masses.

II. Initial visit laboratory testing

A. CBC, AB blood typing and Rh factor, antibody screen, rubella, VDRL/RPR, hepatitis B surface Ag.

B. Pap smear, urine pregnancy test, urinalysis and urine culture. Cervical culture for gonorrhea and chlamydia.

C. Tuberculosis skin testing, HIV counseling/testing.

D. Hemoglobin electrophoresis is indicated in risks groups, such as sickle hemoglobin in African patients, B-thalassemia in Mediterranean patients, and alpha-thalassemia in Asian patients. Tay-Sachs carrier testing is indicated in Jewish patients.

III. Clinical assessment at first trimester prenatal visits
**A.** Assessment at each prenatal visit includes maternal weight, blood pressure, uterine size, and evaluation for edema, proteinuria, and glucosuria.

**B.** First Doppler heart tones should become detectable at 10-12 weeks, and they should be sought thereafter.

**C.** Routine prenatal vitamins are probably not necessary. Folic acid supplementation preconceptually and throughout the early part of pregnancy has been shown to decrease the incidence of fetal neural tube defects.

<table>
<thead>
<tr>
<th>Frequency of Prenatal Care Visits in Low-Risk Pregnancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;28 weeks</td>
</tr>
<tr>
<td>28-36 weeks</td>
</tr>
<tr>
<td>36-delivery</td>
</tr>
</tbody>
</table>

**D.** First Trimester Education. Discuss smoking, alcohol, exercise, diet, and sexuality.

**E.** Headache and backache. Acetaminophen (Tylenol) 325-650 mg every 3-4 hours is effective. Aspirin is contraindicated.

**F.** Nausea and vomiting. First-trimester morning sickness may be relieved by eating frequent, small meals, getting out of bed slowly after eating a few crackers, and by avoiding spicy or greasy foods. Promethazine (Phenergan) 12.5-50 mg PO q4-6h prn or diphenhydramine (Benadryl) 25-50 mg tid-qid is useful.

**G.** Constipation. A high-fiber diet with psyllium (Metamucil), increased fluid intake, and regular exercise should be advised. Docusate (Colace) 100 mg bid may provide relief.

**IV.** Clinical assessment at second trimester visits

**A.** Questions for each follow-up visit

1. First detection of fetal movement (quicking) should occur at around 17 weeks in a multigravida and at 19 weeks in a primigravida. Fetal movement should be documented at each visit after 17 weeks.

2. Vaginal bleeding or symptoms of preterm labor should be sought.

**B.** Fetal heart rate is documented at each visit.

**C.** Maternal serum testing at 15-16 weeks

1. Triple screen (α-fetoprotein, human chorionic gonadotropin [hCG], and estriol). In women under age 35 years, screening for fetal Down syndrome is accomplished with a triple screen. Maternal serum alpha-fetoprotein is elevated in 20-25% of all cases of Down syndrome, and it is elevated in fetal neural tube deficits. Levels of hCG are higher in Down syndrome and levels of unconjugated estriol are lower in Down syndrome.

2. If levels are abnormal, an ultrasound examination is performed and genetic amniocentesis is offered. The triple screen identifies 60% of Down syndrome cases. Low levels of all three serum analytes identifies 60-75% of all cases of fetal trisomy 18.

**D.** At 15-18 weeks, genetic amniocentesis should be offered to patients >35 years old, and it should be offered if a birth defect has occurred in the mother, father, or in previous offspring.

**E.** Screening ultrasound should usually be obtained at 16-18 weeks.

**F.** At 24-28 weeks, a one-hour Glucola (blood glucose measurement 1 hour after 50-gm oral glucose) is obtained to screen for gestational diabetes. Those with a particular risk (eg, previous gestational diabetes or fetal macrosomia), require earlier testing. If the 1 hour test result is greater than 140 mg/dL, a 3-hour glucose tolerance test is necessary.

**G.** Second trimester education. Discomforts include backache, round ligament pain, constipation, and indigestion.

**V.** Clinical assessment at third trimester visits

**A.** Fetal movement is documented. Vaginal bleeding or symptoms of preterm labor should be sought. Preeclampsia symptoms (blurred vision, headache, rapid weight gain, edema) are sought.

**B.** Fetal heart rate is documented at each visit.

**C.** At 26-30 weeks, repeat hemoglobin and hematocrit are obtained to determine the need for iron supplementation.

**D.** At 28-30 weeks, an antibody screen is obtained in Rh-negative women, and D immune globulin (RhOGAM) is administered if negative.

**E.** At 36 weeks, repeat serologic testing for syphilis is recommended for high risk groups.

**F.** Gonorrhea and chlamydia screening is repeated in the third-trimester in high-risk patients.

**G.** Screening for group B streptococcus colonization at 35-37 weeks. Lower vaginal and rectal cultures are recommended; cultures should not be collected by speculum examination. The optimal method for GBS screening is collection of a single standard culture swab of the distal vagina and rectum.

**H.** Third trimester education

1. Signs of labor. The patient should call physician when rupture of membranes or contrac-
Normal Labor

Labor consists of the process by which uterine contractions expel the fetus. A term pregnancy is 37 to 42 weeks from the last menstrual period (LMP).

I. Obstetrical history and physical examination

A. History of the present labor

1. Contractions. The frequency, duration, onset, and intensity of uterine contractions should be determined. Contractions may be accompanied by a “bloody show” (passage of blood-tinged mucus from the dilating cervical os). Braxton Hicks contractions are often felt by patients during the last weeks of pregnancy. They are usually irregular, mild, and do not cause cervical change.

2. Rupture of membranes. Leakage of fluid may occur alone or in conjunction with uterine contractions. The patient may report a large gush of fluid or increased moistness. The color of the liquid should be determined, including the presence of blood or meconium.

3. Vaginal bleeding should be assessed. Spotting or blood-tinged mucus is common in normal labor. Heavy vaginal bleeding may be a sign of placental abruption.

4. Fetal movement. A progressive decrease in fetal movement from baseline, should prompt an assessment of fetal well-being with a nonstress test or biophysical profile.

B. History of present pregnancy

1. Estimated date of confinement (EDC) is calculated as 40 weeks from the first day of the LMP.

2. Fetal heart tones are first heard with a Doppler instrument 10-12 weeks from the LMP.

3. Quickening (maternal perception of fetal movement) occurs at about 17 weeks.

4. Uterine size before 16 weeks is an accurate measure of dates.

5. Ultrasound measurement of fetal size before 24 weeks of gestation is an accurate measure of dates.

6. Prenatal history. Medical problems during this pregnancy should be reviewed, including urinary tract infections, diabetes, or hypertension.


8. Review of systems. Severe headaches, scotomas, hand and facial edema, or epigastric pain (preeclampsia) should be sought. Dysuria, urinary frequency or flank pain may indicate cystitis or pyelonephritis.

C. Obstetrical history. Past pregnancies, durations and outcomes, preterm deliveries, operative deliveries, prolonged labors, pregnancy-induced hypertension should be assessed.

D. Past medical history of asthma, hypertension, or renal disease should be sought.

II. Physical examination

A. Vital signs are assessed.

B. Head. Funduscopy should seek hemorrhages or exudates, which may suggest diabetes or hypertension. Facial, hand and ankle edema suggest preeclampsia.

C. Chest. Auscultation of the lungs for wheezes and crackles may indicate asthma or heart failure.

D. Uterine Size. Until the middle of the third trimester, the distance in centimeters from the pubic symphysis to the uterine fundus should correlate with the gestational age in weeks. Toward term, the measurement becomes progressively less reliable because of engagement of the presenting part.

E. Estimation of fetal weight is completed by palpation of the gravid uterus.

F. Leopold’s maneuvers are used to determine the position of the fetus.

1. The first maneuver determines which fetal pole occupies the uterine fundus. The breech moves with the fetal body. The vertex is rounder and harder, feels more globular than the breech, and can be moved separately from the fetal body.

2. Second maneuver. The lateral aspects of the uterus are palpated to determine on which side the fetal back or fetal extremities (the small parts) are located.

3. Third maneuver. The presenting part is moved from side to side. If movement is difficult, engagement of the presenting part has occurred.

4. Fourth maneuver. With the fetus presenting by vertex, the cephalic prominence may be palpable on the side of the fetal small parts.

G. Pelvic examination. The adequacy of the bony pelvis, the integrity of the fetal membranes, the degree of cervical dilatation and effacement, and...
Labor History and Physical

Chief compliant: Contractions, rupture of membranes.

HPI: ___ year old Gravida (number of pregnancies) Para (number of deliveries).

Gestational age, last menstrual period, estimated date of confinement.

Contractions (onset, frequency, intensity), rupture of membranes (time, color). Vaginal bleeding (consistency, quantity, bloody show); fetal movement.

Fetal Heart Rate Strip: Baseline rate, accelerations, reactivity, decelerations, contraction frequency.

Dates: First day of last menstrual period, estimated date of confinement. Ultrasound dating.

Prenatal Care: Date of first exam, number of visits; has size been equal to dates? infections, hypertension, diabetes.

Obstetrical History: Dates of prior pregnancies, gestational age, route (C-section with indications and type of uterine incision), weight, complications, length of labor, hypertension.

Gynecologic History: Menstrual history (menarche, interval, duration), herpes, gonorrhea, chlamydia, abortions; oral contraceptives.

Past Medical History: Illnesses, asthma, hypertension, diabetes, renal disease, surgeries.

Medications: Iron, prenatal vitamins.

Allergies: Penicillin, codeine?

Social History: Smoking, alcohol, drug use.

Family History: Hypertension, diabetes, bleeding disorders.

Review of Systems: Severe headaches, scotomas, blurred vision, hand and face edema, epigastric pain, pruritus, dysuria, fever.

Physical Exam

General Appearance:

Vitals: BP, pulse, respirations, temperature.

HEENT: Funduscopy, facial edema, jugular venous distention.

Chest: Wheezes, rhonchi.

Cardiovascular: Rhythm, S1, S2, murmurs.


Cervix: Dilatation, effacement, station, position, status of membranes, presentation. Vulvar herpes lesions.

Extremities: Cyanosis, clubbing, edema.

Neurologic: Deep tender reflexes, clonus.

Prenatal Labs: Obtain results of one hour post glucola, RPR/VDRL, rubella, blood type, Rh, CBC, PPD, hepatitis B surface antigen (HbsAg).

Current Labs: Hemoglobin, hematocrit, glucose, UA; urine dipstick for protein.

Assessment: Intrauterine pregnancy (IUP) at 40 weeks, admitted with the following problems:

Plan: Anticipated type of labor and delivery. List plan for each problem.

H. Extremities. Severe lower extremity or hand edema suggests preeclampsia. Deep-tendon hyperreflexia and clonus may signal impending seizures.

I. Laboratory tests

1. Prenatal labs should be documented, including CBC, blood type, Rh, antibody screen, serologic test for syphilis, rubella antibody titer, urinalysis, culture, Pap smear, cervical cultures for gonorrhea and Chlamydia, and hepatitis B surface antigen (HbsAg).

2. During labor, the CBC, urinalysis and RPR are repeated. The HBSAG is repeated for high-risk patients. A clot of blood is placed on hold.

J. Fetal heart rate. The baseline heart rate, variability, accelerations, and decelerations are recorded.

III. Normal labor

A. Labor is characterized by uterine contractions of sufficient frequency, intensity, and duration to result in effacement and dilatation of the cervix.

B. The first stage of labor starts with the onset of regular contractions and ends with complete dilatation (10 cm). This stage is further subdivided into the latent and an active phases.

1. The latent phase starts with the onset of regular uterine contractions and is characterized by slow cervical dilatation to 4 cm. The latent phase is variable in length.

2. The active phase follows and is characterized by more rapid dilatation to 10 cm. During the active phase of labor, the average rate of cervical dilatation is 1.5 cm/hour in the multipara and 1.2 cm/hour in the nullipara.

C. The second stage of labor begins with complete dilatation of the cervix and ends with delivery of the infant. It is characterized by voluntary and involuntary pushing. The average second stage of labor is one-half hour in a multipara and 1 hour in the primipara.

D. The third stage of labor begins with the delivery of the infant and ends with the delivery of the placenta.

E. Intravenous fluids. IV fluid during labor is usually Ringer’s lactate or 0.45% normal saline with 5% dextrose. Intravenous fluid infused rapidly or given as a bolus should be dextrose-free because maternal hyperglycemia can occur.

F. Activity. Patients in the latent phase of labor are usually allowed to walk.

G. Narcotic and analgesic drugs

1. Nalbuphine (Nubain) 5 to 10 mg SC or IV q2-3h.

2. Butorphanol (Stadol) 2 mg IM q3-4h or 0.5-1.0 mg IV q1.5-2.0h OR
Labor and Delivery Admitting Orders

Admit: Labor and Delivery
Diagnoses: Intrauterine pregnancy at ____ weeks.
Condition: Satisfactory
Vitals: q1 hr per routine
Activity: May ambulate as tolerated.
Nursing: I and O. Catheterize prn; external or internal monitors.
Diet: NPO except ice chips.
IV Fluids: Lactated Ringers with 5% dextrose at 125 cc/h.
Medications:
- Epidural at 4-5 cm.
- Meperidine (Demerol) 50 to 100 mg IM q3-4h or 10 to 25 mg IV q1.5-3.0 h OR
- Nalbuphine (Nubain) 5-10 mg IV/SC q2-3h prn OR
- Butorphanol (Stadol) 0.5-1 mg IV q1.5-2h prn OR
- Meperidine (Demerol) 25-75 mg slow IV q1.5-3h prn pain AND
- Promethazine (Phenergan) 25-50 mg, IV q3-4h prn nausea OR
- Hydroxyzine (Vistaril) 25-50 mg IV q3-4h prn
- Fleet enema PR prn constipation.
Labs: CBC, dipstick urine protein, blood type and Rh, antibody screen, VDRL, HBsAg, rubella, type and screen (C-section).

I. Intrapartum antibiotic prophylaxis for group B streptococcus is recommended for the following:
1. Pregnant women with a positive screening culture unless a planned Cesarean section is performed in the absence of labor or rupture of membranes
2. Pregnant women who gave birth to a previous infant with invasive GBS disease
3. Pregnant women with documented GBS bacteriuria during the current pregnancy
4. Pregnant women whose culture status is unknown (culture not performed or result not available) and who also have delivery at <37 weeks of gestation, amniotic membrane rupture for >18 hours, or intrapartum temperature ≥100.8°F (>38ºC)
5. The recommended IAP regimen is penicillin G (5 million units IV initial dose, then 2.5 million units IV Q4h). In women with non-immediate-type penicillin-allergy, cefazolin (Ancef, 2 g initial dose, then 1 g Q8h) is recommended. Clindamycin (900 mg IV Q8h) or erythromycin (500 mg IV Q6h) are recommended for patients at high risk for anaphylaxis to penicillins as long as their GBS isolate is documented to be susceptible to both clindamycin and erythromycin.

IV. Normal spontaneous vaginal delivery
A. Preparation. As the multiparous patient approaches complete dilatation or as the nulliparous patient begins to crown the fetal scalp, preparations are made for delivery.
B. Maternal position. The mother is usually placed in the dorsal lithotomy position with left lateral tilt.
C. Delivery of a fetus in an occiput anterior position
1. Delivery of the head
   a. The fetal head is delivered by extension as the flexed head passes through the vaginal introitus.
   b. Once the fetal head has been delivered, external rotation to the occiput transverse position occurs.
   c. The oropharynx and nose of the fetus are suctioned with the bulb syringe. A finger is passed into the vagina along the fetal neck to check for a nuchal cord. If one is present, it is lifted over the vertex. If this cannot be accomplished, the cord is doubly clamped and divided.
   d. If shoulder dystocia is anticipated, the shoulders should be delivered immediately.
2. Episiotomy consists of incision of the perineum, enlarging the vaginal orifice at the time of delivery. If indicated, an episiotomy should be performed when 3-4 cm of fetal scalp is visible.
   a. With adequate local or spinal anesthetic in place, a medial episiotomy is completed by incising the perineum toward the anus and into the vagina.
   b. Avoid cutting into the anal sphincter or the rectum. A short perineum may require a mediolateral episiotomy.
   c. Application of pressure at the perineal apex with a towel-covered hand helps to prevent extension of the episiotomy.
3. Delivery of the anterior shoulder is accomplished by gentle downward traction on the fetal head. The posterior shoulder is delivered by upward traction.

4. Delivery of the body. The infant is grasped around the back with the left hand, and the right hand is placed, near the vagina, under the baby’s buttocks, supporting the infant’s body. The infant’s body is rotated toward the operator and supported by the operator’s forearm, freeing the right hand to suction the mouth and nose. The baby’s head should be kept lower than the body to facilitate drainage of secretions.

5. Suctioning of the nose and oropharynx is repeated.

6. The umbilical cord is doubly clamped and cut, leaving 2-3 cm of cord.

D. Delivery of the placenta
1. The placenta usually separates spontaneously from the uterine wall within 5 minutes of delivery. Gentle fundal massage and gentle traction on the cord facilitates delivery of the placenta.
2. The placenta should be examined for missing cotyledons or blind vessels. The cut end of the cord should be examined for 2 arteries and a vein. The absence of one umbilical artery suggests a congenital anomaly.
3. Prophylaxis against excessive postpartum blood loss consists of external fundal massage and oxytocin (Pitocin), 20 units in 1000 mL of IV fluid at 100 drops/minute after delivery of the placenta. Oxytocin can cause marked hypotension if administered as a IV bolus.
4. After delivery of the placenta, the birth canal is inspected for lacerations.

Delivery Note
1. Note the age, gravida, para, and gestational age.
2. Time of birth, type of birth (spontaneous vaginal delivery), position (left occiput anterior).
3. Bulb suctioned, sex, weight, Apgar scores, nuchal cord, and number of cord vessels.
4. Placenta expressed spontaneously intact. Describe episiotomy degree and repair technique.
5. Note lacerations of cervix, vagina, rectum, perineum.
6. Estimated blood loss:
7. Disposition: Mother to recovery room in stable condition. Infant to nursery in stable condition.

Routine Postpartum Orders
Transfer: To recovery room, then postpartum ward when stable.
Vitals: Check vitals, bleeding, fundus q15min x 1 hr or until stable, then q4h.
Activity: Ambulate in 2 hours if stable
Nursing Orders: If unable to void, straight catheterize; sitz baths pm with 1:1000 Betadine prn, ice pack to perineum pm, record urine output.
Diet: Regular
IV Fluids: D5LR at 125 cch. Discontinue when stable and taking PO diet.
Medications: Oxytocin (Pitocin) 20 units in 1 L D5LR at 100 drops/minute or 10 U IM.
FeSO4 325 mg PO bid-tid.
Symptomatic Medications:
Acetaminophen/codeine (Tylenol #3) 1-2 tab PO q3-4h pm OR Oxycodone/acetaminophen (Percocet) 1 tab q6h pm pain.
Milk of magnesia 30 mL PO q6h pm constipation.
Docusate Sodium (Colace) 100 mg PO bid.
Dulcolax suppository SR pm constipation.
A and D cream or Lanolin prn if breast feeding. Breast binder or tight bra and ice packs prn if not to breast feed.
Labs: Hemoglobin/hematocrit in AM. Give rubella vaccine if titer <1:10.

Active Management of Labor
The active management of labor refers to active control over the course of labor. There are three essential elements to active management are careful diagnosis of labor by strict criteria, constant monitoring of labor, and prompt intervention (e.g., amniotomy, high dose oxytocin) if progress is unsatisfactory.

I. Criteria for active management of labor:
A. Nulliparous
B. Term pregnancy
C. Singleton infant in cephalic presentation
D. No pregnancy complications
E. Experiencing spontaneous onset of labor.

II. Diagnosis of labor
A. The diagnosis of labor is made only when contractions are accompanied by any one of the following:
   1. Bloody show
   2. Rupture of the membranes
   3. Full cervical effacement
B. Women who meet these criteria are admitted to the labor unit.

III. Management of labor
A. Rupture of membranes. Intact fetal membranes are artificially ruptured one hour after the diagnosis of labor is made to permit assessment of the quantity of fluid and the presence of meconium. Rupture of the membranes may accelerate labor.
B. Progress during the first stage of labor
   1. Satisfactory progress in the first stage of labor is confirmed by cervical dilatation of at least 1 cm per hour after the membranes have been ruptured.
   2. In the absence of medical contraindications, labor that fails to progress at the foregoing rate is treated with oxytocin.
3. Progress during the second stage of labor is measured by fetal descent and rotation.
   a. The second stage of labor is divided into two phases: the first phase is the time from full dilatation until the fetal head reaches the pelvic floor; the second phase extends from the time the head reaches the pelvic floor to delivery of the infant.
   b. The first phase of the second stage is characterized by descent of the fetal head. If the fetal head is high in the pelvis at full dilatation, the woman often has no urge to push and should not be encouraged to do so. Oxytocin treatment may be useful if the fetal head fails to descend after a period of observation.

C. Administration of oxytocin. Oxytocin is administered for treatment of failure of labor to progress, unless its use is contraindicated. Oxytocin may only be administered if the following conditions are met:
   1. Fetal membranes are ruptured
   2. Absence of meconium in amniotic fluid
   3. Singleton fetus in a vertex position
   4. No evidence of fetal distress

<table>
<thead>
<tr>
<th>High Dose Oxytocin (Pitocin) Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Begin oxytocin 6 mU per minute IV</td>
</tr>
<tr>
<td>Increase dose by 6 mU per minute every 15 minutes</td>
</tr>
<tr>
<td>Maximum dose: 40 mU per minute</td>
</tr>
</tbody>
</table>

D. Failure to progress (dystocia) is diagnosed when the cervix fails to dilate at least 1 cm per hour during the first stage of labor or when the fetal head fails to descend during the second stage of labor. Three possible causes for failure to progress are possible (excluding malpresentations and hydrocephalus):
   1. Inefficient uterine action
   2. Occiput-posterior position
   3. Cephalopelvic disproportion.

E. Inefficient uterine action is the most common cause of dystocia in the nulliparous gravida, especially early in labor. Secondary arrest of labor after previously satisfactory progress may be due to an occiput-posterior position or cephalopelvic disproportion. It is often difficult for the clinician to differentiate among these entities, thus oxytocin is administered in all cases of failure to progress (unless a contraindication exists).

F. In the first stage, progressive cervical dilatation of at least 1 cm per hour should occur within one hour of establishing efficient uterine contractions (five to seven contractions within 15 minutes) with oxytocin. The second stage is considered prolonged if it extends longer than two hours in women without epidural anesthesia and longer than three hours in women with epidural anesthesia despite adequate contractions and oxytocin augmentation.

References: See page 282.

Perineal Lacerations and Episiotomies

I. First-degree laceration
   A. A first degree perineal laceration extends only through the vaginal and perineal skin.
   B. Repair: Place a single layer of interrupted 3-0 chromic or Vicryl sutures about 1 cm apart.

II. Second-degree laceration and repair of midline episiotomy
   A. A second degree laceration extends deeply into the soft tissues of the perineum, down to, but not including, the external anal sphincter capsule. The disruption involves the bulbocavernous and transverse perineal muscles.
   B. Repair
      1. Proximate the deep tissues of the perineal body by placing 3-4 interrupted 2-0 or 3-0 chromic or Vicryl absorbable sutures. Reapproximate the superficial layers of the perineal body with a running suture extending to the bottom of the episiotomy.
      2. Identify the apex of the vaginal laceration. Suture the vaginal mucosa with running, interlocking, 3-0 chromic or Vicryl absorbable suture.
      3. Close the perineal skin with a running, subcuticular suture. Tie off the suture and remove the needle.

III. Third-degree laceration
   A. This laceration extends through the perineum and through the anal sphincter.
   B. Repair
      1. Identify each severed end of the external anal sphincter capsule, and grasp each end with an Allis clamp.
      2. Proximate the capsule of the sphincter with 4 interrupted sutures of 2-0 or 3-0 Vicryl suture, making sure the sutures do not penetrate the rectal mucosa.
      3. Continue the repair as for a second degree laceration as above. Stool softeners and sitz baths are prescribed post-partum.

IV. Fourth-degree laceration
A. The laceration extends through the perineum, anal sphincter, and extends through the rectal mucosa to expose the lumen of the rectum.

B. Repair
1. Irrigate the laceration with sterile saline solution. Identify the anatomy, including the apex of the rectal mucosal laceration.
2. Approximate the rectal submucosa with a running suture using a 3-0 chromic on a GI needle extending to the margin of the anal skin.
3. Place a second layer of running suture to invert the first suture line, and take some tension from the first layer closure.
4. Identify and grasp the torn edges of the external anal sphincter capsule with Allis clamps, and perform a repair as for a third-degree laceration. Close the remaining layers as for a second-degree laceration.
5. A low-residue diet, stool softeners, and sitz baths are prescribed post-partum.

References: See page 282.

Fetal Heart Rate Assessment

Fetal heart rate (FHR) assessment evaluates the fetal condition by identifying FHR patterns that may be associated with adverse fetal or neonatal outcome or are reassuring of fetal well-being.

I. Fetal monitoring techniques
A. Electronic fetal monitoring. The electronic fetal monitor determines the FHR and continuously records it in graphical form.
B. External fetal monitoring. The FHR is measured by focusing an ultrasound beam on the fetal heart. The fetal monitor interprets Doppler signals.
C. Internal fetal monitoring of FHR is an invasive procedure. A spiral electrode is inserted transcervically into the fetal scalp. The internal electrode detects the fetal (ECG) and calculates the fetal heart rate based upon the interval between R waves. This signal provides accurate measurement of beat-to-beat and baseline variability.
D. Biophysical profile. The biophysical profile (BPP) consists of electronic fetal heart rate evaluation combined with sonographically assessed fetal breathing movements, motor movement, gross fetal tone, and amniotic fluid volume.

II. Fetal heart rate patterns
A. The fetal heart rate pattern recorded by an electronic fetal monitor is categorized as reassuring or nonreassuring.
B. Reassuring fetal heart rate patterns
1. A baseline fetal heart rate of 120 to 160 bpm
2. Absence of FHR decelerations
3. Age appropriate FHR accelerations
C. Early decelerations (ie, shallow symmetrical decelerations in which the nadir of the deceleration occurs simultaneously with the peak of the contraction) and mild bradycardia of 100 to 119 bpm are caused by fetal head compression, and they are not associated with fetal acidosis or poor neonatal outcome.
D. The majority of fetal arrhythmias are benign and spontaneously convert to normal sinus rhythm by 24 hours after birth. Persistent tachyarrhythmias cause fetal hydrops if present for many hours to days. Persistent bradyarrhythmias are often associated with fetal heart disease (eg, cardiomyopathy related to lupus), but seldom result in hypoxia or acidosis in fetal life.
E. FHR accelerations and mild variable decelerations are indicative of a normally functioning autonomic nervous system.
F. Nonreassuring fetal heart rate patterns
1. Nonreassuring FHR patterns are nonspecific and require further evaluation. The fetus may not be acidic initially; however, continuation or worsening of the clinical situation may result in fetal acidosis.
2. Late decelerations are characterized by a smooth U-shaped fall in the fetal heart rate beginning after the contraction has started and ending after the contraction has ended. The nadir of the deceleration occurs after the peak of the contraction. Mild late decelerations are a reflex central nervous system response to hypoxia, while severe late decelerations suggest direct myocardial depression.
3. Sinusoidal heart rate is defined as a pattern of regular variability resembling a sine wave with a fixed periodicity of three to five cycles per minute and an amplitude of 5 to 40 bpm. The sinusoidal pattern is caused by moderate fetal hypoxemia, often secondary to fetal anemia.
4. Variable decelerations are characterized by the variable onset of abrupt slowing of the FHR in association with uterine contractions. Mild or moderate variable decelerations do not have a late component, are of short duration and depth, and end by rapid return to a normal baseline FHR. They are usually intermittent. This pattern is not associated with acidosis or low Apgar scores. Severe variable decelerations have a late component during which the fetal pH falls. They also may display loss of variability or rebound tachycardia and last longer than 60 seconds or fail to less than 70 bpm. They tend to
become persistent and progressively deeper and longer lasting over time.

5. Fetal distress patterns
   a. Fetal distress is likely to cause fetal or neonatal death or damage if left uncorrected. Fetal distress patterns are associated with fetal acidemia and hypoxemia.
   b. Undulating baseline. Alternating tachycardia and bradycardia, often with reduced variability between the wide swings in heart rate.
   c. Severe bradycardia. Fetal heart rate below 100 bpm for a prolonged period of time (ie, at least 10 minutes).
   d. Tachycardia with diminished variability that is unrelated to drugs or additional non-reassuring periodic patterns (eg, late decelerations or severe variable decelerations)

III. Intrapartum fetal surveillance
   A. Transient episodes of hypoxemia and hypoxia are generally well-tolerated by the fetus. Progressive or severe episodes may lead to fetal acidosis and subsequent asphyxia. One goal of intrapartum fetal surveillance is to distinguish the fetus with FHR abnormalities who is well compensated from one who is at risk for neurological impairment or death. Ancillary tests are useful for this purpose.
   B. Ancillary tests
      1. Fetal scalp stimulation. Fetal scalp stimulation is similar to the vibroacoustic stimulation test used antepartum. Absence of acidosis (ie, fetal pH greater than 7.20) is confirmed by elicitation of a FHR acceleration when an examiner stimulates the fetal vertex with the examining finger. Fetal scalp sampling is recommended to further evaluate positive test results.
      2. Fetal scalp blood sampling. Capillary blood collected from the fetal scalp typically has a pH lower than arterial blood. A pH of 7.20 was initially thought to represent the critical value for identifying serious fetal stress and an increase in the incidence of low Apgar scores. The degree of technical skill required prohibits widespread use of this modality.

IV. Management of nonreassuring FHR patterns during labor
   1. Determine the cause of the abnormality (eg, cord prolapse, maternal medication, abruption placenta)
   2. Attempt to correct the problem or initiate measures to improve fetal oxygenation (eg, change maternal position, administer oxygen and intravenous fluids, consider amnioinfusion or tocolysis)
   3. If the nonreassuring pattern does not resolve within a few minutes, perform ancillary tests to determine the fetal condition
   4. Determine whether operative intervention is needed

   B. The presence of accelerations almost always assures the absence of fetal acidosis. Therefore, if such accelerations are not observed, they should be elicited by manual or vibroacoustic stimulation. There is a 50 percent risk of fetal acidosis in fetuses in whom accelerations cannot be elicited, so further evaluation by fetal scalp sampling for pH is indicated to help clarify the fetal acid-base status. Serial evaluation every 20 to 30 minutes is necessary if the FHR pattern remains nonreassuring. Expeditious delivery is indicated for persistent nonreassuring FHR patterns.

<table>
<thead>
<tr>
<th>Management of Variant Fetal Heart Rate Patterns</th>
</tr>
</thead>
<tbody>
<tr>
<td>FHR Pattern</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>Normal rate normal variability, accelerations, no decelerations</td>
</tr>
<tr>
<td>Normal variability, accelerations, mild nonreassuring pattern (bradycardia, late decelerations, variable decelerations)</td>
</tr>
<tr>
<td>Normal variability, accelerations, moderate-severe nonreassuring pattern (bradycardia, late decelerations, variable decelerations)</td>
</tr>
<tr>
<td>FHR Pattern</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Decreasing variability, ± accelerations, moderate-severe nonreassuring patterns (bradycardia, late decelerations, variable decelerations)</td>
</tr>
<tr>
<td>Absent variability, no accelerations, moderate/severe nonreassuring patterns (bradycardia, late decelerations, variable decelerations)</td>
</tr>
</tbody>
</table>

References: See page 282.

Antepartum Fetal Surveillance

I. Antepartum fetal surveillance techniques

A. Antepartum fetal surveillance should be initiated in pregnancies in which the risk of fetal demise is known to be increased. These problems can include maternal conditions such as antiphospholipid syndrome, chronic hypertension, renal disease, systemic lupus erythematosus, or type 1 diabetes mellitus. Monitoring should also be initiated in pregnancy-related conditions such as preeclampsia, intrauterine growth restriction (IUGR), multiple gestation, poor obstetrical history, or postterm pregnancy.

B. Antepartum fetal surveillance can include the nonstress test (NST), BPP, oxytocin challenge test (OCT), or modified BPP.

C. Nonstress test

1. A NST is performed using an electronic fetal monitor. Testing is generally begun at 32 to 34 weeks. Testing is performed at daily to weekly intervals as long as the indication for testing persists.

2. The test is reactive if there are two or more fetal heart rate accelerations of 15 bpm above the baseline rate lasting for 15 seconds in a 20 minute period. A nonreactive NST does not show such accelerations over a 40 minute period. Nonreactivity may be related to fetal immaturity, a sleep cycle, drugs, fetal anomalies, or fetal hypoxemia.

3. If the NST is nonreactive, it is considered nonreassuring and further evaluation or delivery of the fetus is indicated. At term, delivery rather than further evaluation is usually warranted. A nonreassuring NST preterm usually should be assessed with ancillary tests, since the false positive rate of an isolated NST may be 50 to 60 percent.

D. Fetal movement assessment (“kick counts”)

1. A diminution in the maternal perception of fetal movement often but not invariably precedes fetal death, in some cases by several days.

2. The woman lies on her side and counts distinct fetal movements. Perception of 10 distinct movements in a period of up to 2 hours is considered reassuring. Once 10 movements have been perceived, the count may be discontinued. In the absence of a reassuring count, nonstress testing is recommended.

Indications for Antepartum Fetal Surveillance

Maternal antiphospholipid syndrome
poorly controlled hyperthyroidism
hemoglobinopathies
cyanotic heart disease
systemic lupus erythematosus
chronic renal disease
type I diabetes mellitus
hypertensive disorders

Pregnancy complications
preeclampsia
decreased fetal movement
oligohydramnios
polyhydramnios
intrauterine growth restriction
postterm pregnancy
isoimmunization
previous unexplained fetal demise
multiple gestation

E. Ancillary tests

1. Vibroacoustic stimulation is performed by placing an artificial larynx on the maternal abdomen and delivering a short burst of sound to the fetus. The procedure can shorten the duration of time needed to produce reactivity and the frequency of nonreactive NSTs, without compromising the predictive value of a reactive NST.

2. Oxytocin challenge test

   a. The oxytocin challenge test (OCT) is done by intravenously infusing dilute oxytocin until three contractions occur within ten minutes. The test is interpreted as follows:

   b. A positive test is defined by the presence of late decelerations following 50 percent or more of the contractions
c. A negative test has no late or significant variable decelerations

d. An equivocal-suspicious pattern consists of intermittent late or significant variable decelerations, while an equivocal-hypostimulatory pattern refers to fetal heart rate decelerations occurring with contractions more frequent than every two minutes or lasting longer than 90 seconds

e. An unsatisfactory test is one in which the tracing is uninterpretable or contractions are fewer than three in 10 minutes

f. A positive test indicates decreased fetal reserve and correlates with a 20 to 40 percent incidence of abnormal FHR patterns during labor. An equivocal-suspicious test with repetitive variable decelerations is also associated with abnormal FHR patterns in labor, which are often related to cord compression due to oligohydramnios.

3. Fetal biophysical profile

a. The fetal biophysical profile score refers to the sonographic assessment of four biophysical variables: fetal movement, fetal tone, fetal breathing, amniotic fluid volume and nonstress testing. Each of these five parameters is given a score of 0 or 2 points, depending upon whether specific criteria are met. Fetal BPS is a noninvasive, highly accurate means for predicting the presence of fetal asphyxia.

b. Criteria

1. A normal variable is assigned a score of two and an abnormal variable a score of zero. The maximal score is 10/10 and the minimal score is 0/10.

2. Amniotic fluid volume is based upon an ultrasound-based objective measurement of the largest visible pocket. The selected largest pocket must have a transverse diameter of at least one centimeter.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal (score = 2)</th>
<th>Abnormal (score = 0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonstress test</td>
<td>&gt;2 accelerations &gt;15 beats per minute above baseline during test lasting &gt;15 seconds in 20 minutes</td>
<td>&lt;2 accelerations</td>
</tr>
<tr>
<td>Amniotic fluid volume</td>
<td>Amniotic fluid index &gt;5 or at least 1 pocket measuring 2 cm x 2 cm in perpendicular planes</td>
<td>AFI &lt;5 or no pocket &gt;2 cm x 2 cm</td>
</tr>
<tr>
<td>Fetal breathing movement</td>
<td>Sustained FBM (&gt;30 seconds)</td>
<td>Absence of FBM or short gasps only &lt;30 seconds total</td>
</tr>
<tr>
<td>Fetal body movements</td>
<td>&gt;3 episodes of either limb or trunk movement</td>
<td>&lt;3 episodes during test</td>
</tr>
<tr>
<td>Fetal tone</td>
<td>Extremities in flexion at rest and &gt;1 episode of extension of extremity, hand or spine with return to flexion</td>
<td>Extension at rest or no return to flexion after movement</td>
</tr>
</tbody>
</table>

A total score of 8 to 10 is reassuring, a score of 6 is suspicious, and a score of 4 or less is ominous. Amniotic fluid index = the sum of the largest vertical pocket in each of four quadrants on the maternal abdomen intersecting at the umbilicus.

c. Clinical utility

1. The fetal BPS is noninvasive and highly accurate for predicting the presence of fetal asphyxia. The probability of fetal acidemia is virtually zero when the score is normal (8 to 10). The false negative rate (ie, fetal death within one week of a last test with a normal score) is exceedingly low. The likelihood of fetal compromise and death rises as the score falls.

2. The risk of fetal demise within one week of a normal test result is 0.8 per 1000 women tested. The positive predictive value of the BPS for evidence of true fetal compromise is only 50 percent, with a negative predictive value greater than 99.9 percent.

d. Indications and frequency of testing

1. ACOG recommends antepartum testing in the following situations:
   a. Women with high-risk factors for fetal asphyxia should undergo antepartum fetal surveillance with tests (eg, BPS, nonstress test)
   b. Testing may be initiated as early as 26 weeks of gestation when clinical conditions suggest early fetal compromise is likely. Initiating testing at 32 to 34 weeks of gestation is appropriate
for most pregnancies at increased risk of stillbirth.
(c) A reassuring test (eg, BPS of 8 to 10) should be repeated periodically (weekly or twice weekly) until delivery when the high-risk condition persists.
(d) Any significant deterioration in the clinical status (eg, worsening preeclampsia, decreased fetal activity) requires fetal reevaluation.
(e) Severe oligohydramnios (no vertical pocket >2 cm or amniotic fluid index <5) requires either delivery or close Maternal and fetal surveillance.
(f) Induction of labor may be attempted with abnormal antepartum testing as long as the fetal heart rate and contractions are monitored continuously and are reassuring. Cesarean delivery is indicated if there are repetitive late decelerations.
(2) The minimum gestational age for testing should reflect the lower limit that intervention with delivery would be considered. This age is now 24 to 25 weeks.
(3) Modified biophysical profile. Assessment of amniotic fluid volume and nonstress testing appear to be as reliable a predictor of long-term fetal well-being as the full BPS. The rate of stillbirth within one week of a normal modified BPS is the same as with the full BPS, 0.8 per 1000 women tested. 

<table>
<thead>
<tr>
<th>Indication</th>
<th>Initiation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-term pregnancy</td>
<td>41 weeks</td>
<td>Twice a week</td>
</tr>
<tr>
<td>Preterm rupture of membranes</td>
<td>At onset</td>
<td>Daily</td>
</tr>
<tr>
<td>Bleeding</td>
<td>26 weeks or at onset</td>
<td>Twice a week</td>
</tr>
<tr>
<td>Oligohydramnios</td>
<td>26 weeks or at onset</td>
<td>Twice a week</td>
</tr>
<tr>
<td>Polyhydramnios</td>
<td>32 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>Diabetes</td>
<td>32 weeks</td>
<td>Twice a week</td>
</tr>
<tr>
<td>Chronic or pregnancy-induced</td>
<td>28 weeks</td>
<td>Weekly. Increase to twice-weekly at 32 weeks.</td>
</tr>
<tr>
<td>hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroid-dependent or poorly</td>
<td>28 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>controlled asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>32 weeks (earlier if</td>
<td>Weekly (more often if severe)</td>
</tr>
<tr>
<td></td>
<td>symptoms)</td>
<td></td>
</tr>
<tr>
<td>Impaired renal function</td>
<td>28 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>Substance abuse</td>
<td>32 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>Prior stillbirth</td>
<td>At 2 weeks before prior</td>
<td>Weekly</td>
</tr>
<tr>
<td></td>
<td>fetal death</td>
<td></td>
</tr>
<tr>
<td>Multiple gestation</td>
<td>32 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>Congenital anomaly</td>
<td>32 weeks</td>
<td>Weekly</td>
</tr>
<tr>
<td>Fetal growth restriction</td>
<td>26 weeks</td>
<td>Twice a week or at onset</td>
</tr>
<tr>
<td>Decreased fetal movement</td>
<td>At time of complaint</td>
<td>Once</td>
</tr>
</tbody>
</table>

F. Perinatal outcome. An abnormal NST result should be interpreted with caution. Further assessment of fetal condition using the NST, OCT, or BPP should usually be performed to help determine whether the fetus is in immediate jeopardy.

G. Management of abnormal test results
1. Maternal reports of decreased fetal movement should be evaluated by an NST, CST, BPP, or modified BPP. These results, if normal, usually are sufficient to exclude imminent fetal jeopardy. A nonreactive NST or an abnormal modified BPP generally should be followed by additional testing (either a CST or a full BPP). In many circumstances, a positive CST result generally indicates that delivery is warranted.
2. A BPP score of 6 is considered equivocal; in the term fetus, this score generally should prompt delivery. In the preterm fetus, it should result in a repeat BPP in 24 hours. In the interim, maternal corticosteroid administration should be considered for pregnancies of less than 34 weeks of gestation. Repeat equivocal
scores should result either in delivery or continued intensive surveillance. A BPP score of 4 usually indicates that delivery is warranted.

3. Preterm delivery is indicated for nonreassuring antepartum fetal testing results that have been confirmed by additional testing. At term, additional testing can be omitted since the risk from delivery is small. Depending on the fetal heart rate pattern, induction of labor with continuous FHR and contraction monitoring may be attempted in the absence of obstetrical contraindications. Repetitive late decelerations or severe variable decelerations usually require cesarean delivery.

References: See page 282.

**Brief Postoperative Cesarean Section Note**

**Pre-op diagnosis:**
1. 23 year old G1P0, estimated gestational age = 40 weeks
2. Dystocia
3. Non-reassuring fetal tracing

**Post-op diagnosis:** Same as above

**Procedure:** Primary low segment transverse cesarean section

**Attending Surgeon, Assistant:**

**Anesthesia:** Epidural

**Operative Findings:** Weight and sex of infant, APGARs at 1 min and 5 min, normal uterus, tubes, ovaries.

**Cord pH:**
Specimens: Placenta, cord blood (type and Rh).

**Estimated Blood Loss:** 800 cc; no blood replaced.

**Fluids, blood and urine output:**

**Complications:** None

**Disposition:** Patient sent to recovery room in stable condition.

**Cesarean Section Operative Report**

**Preoperative Diagnosis:**
1. 23 year old G1P0, estimated gestational age = 40 weeks
2. Dystocia
3. Non-reassuring fetal tracing

**Postoperative Diagnosis:** Same as above

**Title of Operation:** Primary low segment transverse cesarean section

**Surgeon:**

**Assistant:**

**Anesthesia:** Epidural

**Findings At Surgery:** Male infant in occiput posterior presentation. Thin meconium with none below the cords, pediatrics present at delivery, APGAR’s 6/8, weight 3980 g, Normal uterus, tubes, and ovaries.

**Description of Operative Procedure:**

After ensuring informed consent, the patient was taken to the operating room and spinal anesthesia was initiated. The patient was placed in the dorsal, supine position with left lateral tilt. The abdomen was prepped and draped in sterile fashion.

A Pfannenstiel skin incision was made with a scalpel and carried through to the level of the fascia. The fascial incision was extended bilaterally with Mayo scissors. The fascial incision was then grasped with the Kocher clamps, elevated, and sharply and bluntly dissected superiorly and inferiorly from the rectus muscles. The rectus muscles were then separated in the midline, and the peritoneum was tented up, and entered sharply with Metzenbaum scissors. The peritoneal incision was then extended laterally, and a bladder flap was created. The bladder was retracted using the bladder blade. The lower uterine segment was incised in a transverse fashion with the scalpel, then extended bilaterally with bandage scissors. The bladder blade was removed, and the infants head was delivered atraumatically. The nose and mouth were suctioned and the cord clamped and cut. The infant was handed off to the pediatrician. Cord gases and cord blood were sent. The placenta was then removed manually, and the uterus was extirpated, and cleared of all clots and debris. The uterine incision was repaired with 1-O chromic in a running locking fashion. A second layer of 1-O chromic was used to obtain excellent hemostasis. The bladder flap was repaired with a 3-0 Vicryl in a running fashion. The cul-de-sac was cleared of clots and the uterus was returned to the abdomen. The peritoneum was closed with 3-0 Vicryl. The fascia was reaproximated with O Vicryl in a running fashion. The skin was closed with staples.

The patient tolerated the procedure well. Needle and sponge counts were correct times two. Two grams of Ancef was given at cord clamp, and a sterile dressing was placed over the incision.

**Estimated Blood Loss (EBL):** 800 cc; no blood replaced (normal blood loss is 500-1000 cc).

**Specimens:** Placenta, cord pH, cord blood specimens.

**Drains:** Foley to gravity.

**Fluids:** Input - 2000 cc LR; Output - 300 cc clear urine.

**Complications:** None.
Disposition: The patient was taken to the recovery room then postpartum ward in stable condition.

Postoperative Management after Cesarean Section

I. Post Cesarean Section Orders
A. Transfer: to post partum ward when stable.
B. Vital signs: q4h x 24 hours, I and O.
C. Activity: Bed rest x 6-8 hours, then ambulate; if given spinal, keep patient flat on back x 8h. Incen-
sive spirometer q1h while awake.
D. Diet: NPO x 8h, then sips of water. Advance to
clear liquids, then to regular diet as tolerated.
E. IV Fluids: IV D5 LR or D5 ½ NS at 125 cc/h. Foley
to gravity; discontinue after 12 hours. I and O catheterize pm.
F. Medications
1. Cefazolin (Ancef) 1 gm IVPB x one dose at time
of cesarean section.
2. Nalbuphine (Nubain) 5 to 10 mg SC or IV q2-3h
OR
3. Meperidine (Demerol) 50-75 mg IM q3-4h pm
pain.
4. Hydroxyzine (Vistaril) 25-50 mg IM q3-4h pm
nausea.
5. Prochlorperazine (Compazine) 10 mg IV q4-6h
pm nausea OR
6. Promethazine (Phenergan) 25-50 mg IV q3-4h
pm nausea
G. Labs: CBC in AM.

II. Postoperative Day #1
A. Assess pain, lungs, cardiac status, fundal height,
lochia, passage of flatus, bowel movement, dislent-
sion, tenderness, bowel sounds, incision.
B. Discontinue IV when taking adequate PO fluids.
C. Discontinue Foley, and I and O catheterize prn.
D. Ambulate tid with assistance; incentive spirometer
q1h while awake.
E. Check hematocrit, hemoglobin, Rh, and rubella
status.
F. Medications
1. Acetaminophen/codeine (Tylenol #3) 1-2 PO q4-6h
pain OR
2. Oxycodone/acetaminophen (Percocet) 1 tab q6h
pain.
3. FeSO4 325 mg PO bid-tid.
4. Multivitamin PO qd, Colace 100 mg PO bid.
Mylicon 80 mg PO qd pm bloating.

III. Postoperative Day #2
A. If passing gas and/or bowel movement, advance to
regular diet.
B. Laxatives: Dulcolax supp prn or Milk of magnesia
30 cc PO tid pm. Mylicon 80 mg PO qd pm bloat-
ing.

IV. Postoperative Day #3
A. If transverse incision, remove staples and place
steri-strips on day 3. If a vertical incision, remove
staples on post op day 5.
B. Discharge home on appropriate medications; follow
up in 2 and 6 weeks.

Prevention of D Isoimmunization

The morbidity and mortality of Rh hemolytic disease can
be significantly reduced by identification of women at risk
for isoimmunization and by administration of D immu-
no globulin. Administration of D immunoglobulin [RhOGAM,
Rho(D) immunoglobulin, RhIg] is very effective in the
preventing isoimmunization to the D antigen.

I. Prenatal testing
A. Routine prenatal laboratory evaluation includes
ABO and D blood type determination and antibody
test.
B. At 28-29 weeks of gestation woman who are D
negative but not D isoimmunized should be re-
tested for D antibody. If the test reveals that no D
antibody is present, prophylactic D immunoglobulin
[RhOGAM, Rho(D) immunoglobulin, RhIg] is indi-
cated.
C. If D antibody is present, D immunoglobulin will not
be beneficial, and specialized management of the
D isoimmunized pregnancy is undertaken to man-
age hemolytic disease of the fetus and hydrops
fetalis.

II. Routine administration of D immunoglobulin
A. Abortion. D sensitization may be caused by abor-
tion. D sensitization occurs more frequently after
induced abortion than after spontaneous abortion,
and it occurs more frequently after late abortion
than after early abortion. D sensitization occurs
following induced abortion in 4-5% of susceptible
women. All unsensitized, D-negative women who
have an induced or spontaneous abortion should
be treated with D immunoglobulin unless the father
is known to be D negative.
B. Dosage of D immunoglobulin is determined by the
stage of gestation. If the abortion occurs before 13
weeks of gestation, 50 mcg of D immunoglobulin
prevents sensitization. For abortions occurring at
13 weeks of gestation and later, 300-mcg is given.
C. Ectopic pregnancy can cause D sensitization. All
unsensitized, D-negative women who have an
ectopic pregnancy should be given D immunoglob-
ulin. The dosage is determined by the gestational
age, as described above for abortion.
D. Amniocentesis
1. D isoimmunization can occur after amniocentesis. D immunoglobulin, 300 mcg, should be administered to unsensitized, D-negative, susceptible patients following first- and second-trimester amniocentesis.
2. Following third-trimester amniocentesis, 300 mcg of D immunoglobulin should be administered. If amniocentesis is performed and delivery is planned within 48 hours, D immunoglobulin can be withheld until after delivery, when the newborn can be tested for D positivity. If the amniocentesis is expected to precede delivery by more than 48 hours, the patient should receive 300 mcg of D immunoglobulin at the time of amniocentesis.

E. Antepartum prophylaxis
1. Isoimmunized occurs in 1-2% of D-negative women during the antepartum period. D immunoglobulin, administered both during pregnancy and postpartum, can reduce the incidence of D isoimmunization to 0.3%.
2. Antepartum prophylaxis is given at 28-29 weeks of gestation. Antibody-negative, Rh-negative gravidas should have a repeat assessment at 28 weeks. D immunoglobulin (RhGAM, RhIG), 300 mcg, is given to D-negative women. However, if the father of the fetus is known with certainty to be D negative, antepartum prophylaxis is not necessary.

F. Postpartum D immunoglobulin
1. D immunoglobulin is given to the D negative mother as soon after delivery as cord blood findings indicate that the baby is Rh positive.
2. A woman at risk who is inadvertently not given D immunoglobulin within 72 hours after delivery should still receive prophylaxis at any time up until two weeks after delivery. If prophylaxis is delayed, it may not be effective.
3. A quantitative Kleihauer-Betke analysis should be performed in situations in which significant maternal bleeding may have occurred (eg, after maternal abdominal trauma, abruptio placentae, external cephalic version). If the quantitative determination is thought to be more than 30 mL, D immune globulin should be given to the mother in multiples of one vial (300 mcg) for each 30 mL of estimated fetal whole blood in her circulation, unless the father of the baby is known to be D negative.

G. Abruptio placentae, placenta previa, cesarean delivery, intrauterine manipulation, or manual removal of the placenta may cause more than 30 mL of fetal-to-maternal bleeding. In these conditions, testing for excessive bleeding (Kleihauer-Betke test) or inadequate D immunoglobulin dosage (indirect Coombs test) is necessary.

References: See page 282.
Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum

Nausea and vomiting affects about 70% to 85% of pregnant women. Symptoms of nausea and vomiting of pregnancy (NVP) are most common during the first trimester; however, some women have persistent nausea for their entire pregnancy. Hyperemesis often occurs in association with high levels of human chorionic gonadotropin (hCG), such as with multiple pregnancies, trophoblastic disease, and fetal anomalies such as triploidy.

### Conditions that Predispose to Excessive Nausea and Vomiting

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral gastroenteritis</td>
</tr>
<tr>
<td>Gestational trophoblastic disease</td>
</tr>
<tr>
<td>Hepatitis</td>
</tr>
<tr>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>Multifetal gestation</td>
</tr>
<tr>
<td>Gallbladder disease</td>
</tr>
<tr>
<td>Migraine</td>
</tr>
</tbody>
</table>

### I. Treatment of Nausea and Vomiting of Pregnancy

**A.** Patients should avoid odors or foods that seem to be aggravating the nausea. Useful dietary modifications include avoiding fatty or spicy foods, and stopping iron supplements. Frequent small meals also may improve symptoms. Recommendations include bland and dry foods, high-protein snacks, and crackers at the bedside to be taken first thing in the morning.

**B.** Cholecystitis, peptic ulcer disease, or hepatitis can cause nausea and vomiting and should be excluded. Gastroenteritis, appendicitis, pyelonephritis, and pancreatitis also should be excluded. Obstetric explanations for nausea and vomiting may include multiple pregnancies or a hydatidiform mole.

**C.** Non-pharmacologic remedies are adequate for up to 90% of patients with NVP. However, about 10% will require medication and about 1% have severe enough vomiting that they require hospitalization.

**D.** Vitamin therapy. Pyridoxine is effective as first-line therapy and is recommended up to 25 mg three times daily. Pyridoxine serum levels do not appear to correlate with the prevalence or degree of nausea and vomiting. Multivitamins also are effective for prevention of NVP. Premesis Rx is a prescription tablet with controlled-release vitamin B6, 75 mg, so it can be given once a day. It also contains vitamin B12 (12 mcg), folate acid (1 mg), and calcium carbonate (200 mg).

**E.** Over-the-Counter Therapy. If pyridoxine alone is not efficacious, an alternative is to combine over-the-counter doxylamine 25 mg (Unisom) and pyridoxine 25 mg. One could combine the 25 mg of pyridoxine three times daily with doxylamine 25 mg, 1 tablet every bedtime, and ½ tablet morning and afternoon. There is no evidence that doxylamine is a teratogen.

### Drug Therapy for Nausea and Vomiting of Pregnancy

<table>
<thead>
<tr>
<th>Generic name (trade name)</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihistamines</strong></td>
<td></td>
</tr>
<tr>
<td>Doxylamine (Unisom)</td>
<td>25 mg ½ tab BID, 1 tab qhs</td>
</tr>
<tr>
<td>Dimenhydrinate (Dramamine)</td>
<td>25 to 100 mg po/im/iv every 4 to 6 hr</td>
</tr>
<tr>
<td>Diphenhydramine (Benadryl)</td>
<td>25 to 50 mg po/im/iv every 4 to 6 hr</td>
</tr>
<tr>
<td>Trimethobenzamide (Tigan)</td>
<td>250 mg po every 6 to 8 hr or 200 mg im/pr every 6 to 8 hr</td>
</tr>
<tr>
<td>Meclizine (Antivert)</td>
<td>12.5 to 25 mg BID/TID</td>
</tr>
<tr>
<td><strong>Phenothiazines</strong></td>
<td></td>
</tr>
<tr>
<td>Promethazine (Phenergan)</td>
<td>12.5 to 25 mg po/im/pr every 4 to 6 hr</td>
</tr>
<tr>
<td>Prochlorperazine (Compazine)</td>
<td>5 to 10 mg po/im every 6 to 8 hr or 25 mg pr every 6 to 8 hr</td>
</tr>
<tr>
<td><strong>Prokinetic agents</strong></td>
<td></td>
</tr>
</tbody>
</table>
F. Pharmacologic Therapy
1. Prescribed medication is the next step if dietary modifications and vitamin B6 therapy with doxylamine are ineffective. The phenothiazines are safe and effective, and promethazine (Phenergan) often is tried first. One of the disadvantages of the phenothiazines is their potential for dystonic effects.
2. Metoclopramide (Reglan) is the antiemetic drug of choice in pregnancy in several European countries. There was no increased risk of birth defects.
3. Ondansetron (Zofran) has been compared with promethazine (Phenergan), and the two drugs are equally effective, but ondansetron is much more expensive. No data have been published on first trimester teratogenic risk with ondansetron.

II. Hyperemesis gravidarum
A. Hyperemesis gravidarum occurs in the extreme 0.5% to 1% of patients who have intractable vomiting. Patients with hyperemesis have abnormal electrolytes, dehydration with high urine-specific gravity, ketosis and acetonuria, and untreated fi ne weight loss >5% of body weight. Intravenous hydration is the first line of therapy for patients with severe nausea and vomiting. Administration of vitamin B1 supplements may be necessary to prevent Wernicke’s encephalopathy.
B. Antiemetics are given parenterally to patients with hyperemesis. Corticosteroids may have a benefit in hyperemesis if other antiemetic therapy has failed. One proposed regimen is methylprednisolone 15 to 20 mg given intravenously every 8 hours. A methylprednisolone oral taper regimen is more effective than oral promethazine.

References: See page 282.

Spontaneous Abortion
Abortion is defined as termination of pregnancy resulting in expulsion of an immature, nonviable fetus. A fetus of <20 weeks gestation or a fetus weighing <500 gm is considered an abortus. Spontaneous abortion occurs in 15% of all pregnancies.

I. Threatened abortion is defined as vaginal bleeding occurring in the first 20 weeks of pregnancy, without the passage of tissue or rupture of membranes.
A. Symptoms of pregnancy (nausea, vomiting, fatigue, breast tenderness, urinary frequency) are usually present.
B. Speculum exam reveals blood coming from the cervical os without amniotic fluid or tissue in the endocervical canal.
C. The internal cervical os is closed, and the uterus is soft and enlarged appropriate for gestational age.
D. Differential diagnosis
1. Benign and malignant lesions. The cervix often bleeds from an ectropion of friable tissue. Hemostasis can be accomplished by applying pressure for several minutes with a large swab or by cautery with a silver nitrate stick. Atypical cervical lesions are evaluated with colposcopy and biopsy.
2. Disorders of pregnancy
   a. Hydatidiform mole may present with early pregnancy bleeding, passage of grape-like vesicles, and a uterus that is enlarged in excess of that expected from dates. An absence of heart tones by Doppler after 12 weeks is characteristic. Hyperemesis, preeclampsia, or hyperthyroidism may be present. Ultrasonography confirms the diagnosis.
   b. Ectopic pregnancy should be excluded when first trimester bleeding is associated with pelvic pain. Orthostatic light-headedness, syncope or shoulder pain (from diaphragmatic irritation) may occur.
      (1) Abdominal tenderness is noted, and pelvic examination reveals cervical motion tenderness.
      (2) Serum beta-HCG is positive.
E. Laboratory tests
1. Complete blood count. The CBC will not reflect acute blood loss.
2. Quantitative serum beta-HCG level may be positive in nonviable gestations since beta-HCG may persist in the serum for several weeks after fetal death.
3. Ultrasonography should detect fetal heart motion by 7 weeks gestation or older. Failure to
detect fetal heart motion after 9 weeks gestation should prompt consideration of curettage.

F. Treatment of threatened abortion
1. Bed rest with sedation and abstinence from intercourse.
2. The patient should report increased bleeding (>normal menses), cramping, passage of tissue, or fever. Passed tissue should be saved for examination.

II. Inevitable abortion is defined as a threatened abortion with a dilated cervical os. Menstrual-like cramps usually occur.
A. Differential diagnosis
1. Incomplete abortion is diagnosed when tissue has passed. Tissue may be visible in the vagina or endocervical canal.
2. Threatened abortion is diagnosed when the internal os is closed and will not admit a fingertip.
3. Incompetent cervix is characterized by dilatation of the cervix without cramps.
B. Treatment of inevitable abortion
1. Surgical evacuation of the uterus is necessary.
2. D immunoglobulin (RhoGAM) is administered to Rh-negative, unsensitized patients to prevent isoimmunization. Before 13 weeks gestation, the dosage is 50 mcg IM; at 13 weeks gestation, the dosage is 300 mcg IM.

III. Incomplete abortion is characterized by cramping, bleeding, passage of tissue, and a dilated internal os with tissue present in the vagina or endocervical canal. Profuse bleeding, orthostatic dizziness, syncope, and postural pulse and blood pressure changes may occur.
A. Laboratory evaluation
1. Complete blood count. CBC will not reflect acute blood loss.
2. Rh typing
4. Karyotyping of products of conception is completed if loss is recurrent.
B. Treatment
1. Stabilization. If the patient has signs and symptoms of heavy bleeding, at least 2 large-bore IV catheters (<16 gauge) are placed. Lactate Ringer’s or normal saline with 40 U oxytocin/L is given IV at 200 mL/hour or greater.
2. Products of conception are removed from the endocervical canal and uterus with a ring forceps. Immediate removal decreases bleeding. Curettage is performed after vital signs have stabilized.
3. Suction dilation and curettage
   a. Analgesia consists of meperidine (Demerol), 35-50 mg IV over 3-5 minutes until the patient is drowsy.
   b. The patient is placed in the dorsal lithotomy position in stirrups, prepared, draped, and sedated.
   c. A weighted speculum is placed intravaginally, the vagina and cervix are cleansed, and a paracervical block is placed.
   d. Bimanual examination confirms uterine position and size, and uterine sounding confirms the direction of the endocervical canal.
   e. Mechanical dilatation is completed with dilators if necessary. Curettage is performed with an 8 mm suction curette, with a single-tooth tenaculum on the anterior lip of the cervix.
4. Post-curettage. After curettage, a blood count is ordered. If the vital signs are stable for several hours, the patient is discharged with instructions to avoid coitus, douching, or the use of tampons for 2 weeks. Ferrous sulfate and ibuprofen are prescribed for pain.
5. Rh-negative, unsensitized patients are given IM RhoGAM.
6. Methylergonovine (Methergine), 0.2 mg PO q4h for 6 doses, is given if there is continued moderate bleeding.

IV. Complete abortion
A. A complete abortion is diagnosed when complete passage of products of conception has occurred. The uterus is well contracted, and the cervical os may be closed.
B. Differential diagnosis
1. Incomplete abortion
2. Ectopic pregnancy. Products of conception should be examined grossly and submitted for pathologic examination. If no fetal tissue or villi are observed grossly, ectopic pregnancy must be excluded by ultrasound.
C. Management of complete abortion
1. Between 8 and 14 weeks, curettage is necessary because of the high probability that the abortion was incomplete.
2. D immunoglobulin (RhoGAM) is administered to Rh-negative, unsensitized patients.
3. Beta-HCG levels are obtained weekly until zero. Incomplete abortion is suspected if beta-HCG levels plateau or fail to reach zero within 4 weeks.

V. Missed abortion is diagnosed when products of conception are retained after the fetus has expired. If products are retained, a severe coagulopathy with bleeding often occurs.
A. Missed abortion should be suspected when the pregnant uterus fails to grow as expected or when fetal heart tones disappear.
B. Amenorrhea may persist, or intermittent vaginal bleeding, spotting, or brown discharge may be noted.

C. Ultrasonography confirms the diagnosis.

D. Management of missed abortion
   1. CBC with platelet count, fibrinogen level, partial thromboplastin time, and ABO blood typing and antibody screen are obtained.
   2. Evacuation of the uterus is completed after fetal death has been confirmed. Dilation and evacuation by suction curettage is appropriate when the uterus is less than 12-14 weeks gestational size.
   3. D immunoglobulin (RhOGAM) is administered to Rh-negative, unsensitized patients.

References: See page 282.

Urinary Tract Infections in Pregnancy

Urinary tract infection (UTI) is a common problem in pregnancy. Although asymptomatic bacteriuria occurs with equal frequency in pregnant and nonpregnant women, it progresses to symptomatic infection more frequently during pregnancy. The prevalence of asymptomatic bacteriuria is 5 to 9 percent. If asymptomatic bacteriuria is not treated, pyelonephritis will develop in 20 to 40 percent of pregnant patients.

I. Risk factors for UTI in pregnancy:
   A. Previous history of UTI, especially before 20 weeks of gestation
   B. Multiparity
   C. Presence of hemoglobin S
   D. Lower socioeconomic status
   E. Sexual activity
   F. Anatomical abnormalities
   G. Diabetes mellitus
   H. Advanced maternal age

II. Microbiology. Escherichia coli is responsible for 60 to 90 percent of cases of asymptomatic bacteriuria, cystitis, and pyelonephritis.

III. Asymptomatic bacteriuria
   A. Asymptomatic bacteriuria refers to the isolation of >100,000 CFU of a single organism/mL from a midstream-voided specimen in a woman without UTI symptoms. It occurs in 5 to 9 percent of pregnancies, usually developing in the first month of gestation, particularly in multiparous women.
   B. Diagnosis. The definition of a positive urine culture is >10^5 CFU/mL.
   C. Treatment
      1. Sulfisoxazole (Gantrisin) 500 mg PO TID for three days.
      2. Amoxicillin 500 mg PO TID for three days.
      3. Amoxicillin-clavulanate (Augmentin), 500 mg PO BID for three days.
      4. Nitrofurantoin (Macrodantin) 50 mg PO QID for seven days.
      5. Cefixime (Suprax) 250 mg PO QD for three days.
      6. Fosfomycin (Monurol) 3 g PO as a single dose.
      7. These drugs should be used only if the isolate has been established to be susceptible to the agent. Sulfonamides can displace bilirubin from plasma binding sites in the newborn and may cause kernicterus. Sulfonamide therapy is not recommended in the third trimester.
      8. Relapses typically occur in the first two weeks after treatment and are most common when the bacteriuria originates in the kidney (50 percent). Relapses should be treated with two weeks of oral antibiotics.
      9. Suppressive therapy is recommended for women with persistent bacteriuria (ie, >2 positive urine cultures). Nitrofurantoin (Macrodantin [50 to 100 mg orally at bedtime]) for the duration of the pregnancy or cephalaxin (Keflex [250 to 500 mg orally at bedtime]) may be used. A culture for test of cure can be obtained a week after completion of therapy and then repeated monthly until completion of the pregnancy.

IV. Cystitis
   A. Cystitis occurs in 0.3 to 1.3 percent of pregnant women. Bacteria are confined to the lower urinary tract in these patients.
   B. Clinical features and diagnosis. Acute cystitis should be considered in any gravida with symptoms of frequency, urgency, dysuria, hematuria, or suprapubic pain in the absence of fever and flank pain. Urine culture is the "gold standard" for diagnosis. However, a CFU count >10^5/mL should be considered positive on a midstream urine specimen in women with acute symptoms and pyuria.
   C. Treatment of cystitis
      1. Urine culture should be obtained in patients with signs and symptoms suggestive of cystitis, and empiric antibiotic therapy should be initiated. The treatment should be adjusted depending upon the final culture results and the patient's response to therapy. The same microorganisms associated with asymptomatic bacteriuria are responsible for cystitis.
      2. Amoxicillin 250 mg TID.
      3. Nitrofurantoin (Macrodantin) 100 mg BID.
      4. Cephalexin (Keflex) 500 mg BID to QID.
      5. Amoxicillin-clavulanate (Augmentin) 500 mg BID or 250 mg TID.
6. Trimethoprim-sulfamethoxazole (Bactrim) 1 DS BID but not in the third trimester of pregnancy.
7. Cefpodoxime (Cefzil) 100 mg BID.
8. Cefixime (Suprax) 400 mg QD.
9. All of these drugs can be used for three to seven days. Monthly urine cultures should be performed beginning one to two weeks after completion of treatment.

V. Pyelonephritis
A. Pyelonephritis complicates 1 to 2 percent of all pregnancies. Seventy-three percent of cases were identified in the antepartum period and 46 percent are diagnosed in the second trimester.
B. Clinical features and diagnosis. A combination of fever, chills, and costovertebral angle tenderness is the usual presentation. Other symptoms include dysuria, nausea, vomiting, and respiratory distress.
C. Pyuria is present in virtually all women with this disorder. Urinalysis reveals one or two bacteria per high power field (HPF) in an unspun catheterized specimen or 20 bacteria per HPF in a spun specimen; white cell casts confirm the diagnosis. Urine culture and susceptibility testing are completed.
D. Complications. Approximately 20 percent of women with pyelonephritis develop complications such as septic shock, anemia, acute respiratory distress syndrome (ARDS), renal insufficiency, perinephric abscess, and premature labor and birth.

E. Inpatient treatment
1. Pyelonephritis in pregnant women is usually treated with hospitalization and intravenous antibiotics until the woman is afebrile for 24 to 48 hours.
2. Parenteral beta lactams or gentamicin are the preferred antibiotics.
   a. Cefazolin (Ancef) 1-2 gm IVPB q8h OR
   b. Ampicillin 1 gm IVPB q4-6h AND
   c. Gentamicin 2 mg/kg IVPB then 1.5 mg/kg IV q8h OR
   d. Ampicillin-sulbactam (Unasyn) 1.5-3 gm IVPB q6h.
3. Symptoms that persist for more than 48 hours, despite adequate intravenous antibiotic therapy, require a renal ultrasound to assess for perinephric abscess or renal calculi.
4. Intravenous treatment should continue until the patient is afebrile for 48 hours. Inpatient therapy is followed by an outpatient course of antibiotics to complete 10 to 14 days of treatment.
5. Antimicrobial prophylaxis with nitrofurantoin (Macrodantin [50 to 100 mg PO qhs]) or cephalaxin (Keflex [250 to 500 mg PO qhs]), and periodic urinalysis and urine culture are recommended for the remainder of the pregnancy.

F. Outpatient treatment may be considered in the setting of uncomplicated disease (eg, absence of underlying medical conditions, anatomic abnormalities, pregnancy complications, or signs of sepsis).

References: See page 282.

Gestational Diabetes Mellitus

Poorly controlled gestational diabetes is associated with an increase in the incidence of preclampsia, polyhydramnios, fetal macrosomia, birth trauma, operative delivery, and neonatal hypoglycemia. There is an increased incidence of hyperbilirubinemia, hypocalcemia, and erythremia. The perinatal mortality is increased, as is the likelihood of development of obesity and diabetes in offspring during childhood. Later development of diabetes mellitus in the mother is also more frequent. The prevalence of gestational diabetes is higher in black, Hispanic, Native American, and Asian women than white women. The prevalence of gestational diabetes is 1.4 to 14 percent.

<table>
<thead>
<tr>
<th>Risk Factors for Gestational Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A family history of diabetes, especially in first degree relatives</td>
</tr>
<tr>
<td>Prepregnancy weight of 110 percent of ideal body weight (pre gravid weight more than 90 kg) or more or weight gain in early adulthood</td>
</tr>
<tr>
<td>Age greater than 25 years</td>
</tr>
<tr>
<td>A previous large baby (greater than 9 pounds [4.1 kg])</td>
</tr>
<tr>
<td>History of abnormal glucose tolerance</td>
</tr>
<tr>
<td>Hispanic, African, Native American, South or East Asian, and Pacific Island ancestry</td>
</tr>
<tr>
<td>A previous unexplained perinatal loss or birth of a malformed child</td>
</tr>
<tr>
<td>The mother was large at birth (greater than 9 pounds [4.1 kg])</td>
</tr>
<tr>
<td>Polycystic ovary syndrome</td>
</tr>
</tbody>
</table>

I. Screening and diagnostic criteria
A. Screening for gestational diabetes should be performed at 24 to 28 weeks of gestation. However, it can be done as early as the first prenatal visit if there is a high degree of suspicion that the pregnant woman has undiagnosed type 2 diabetes (eg, obesity, previous gestational diabetes or fetal macrosomia, age >25 years, family history of diabetes).
B. 50-g oral glucose challenge is given and venous serum or plasma glucose is measured one hour later; a value >140 mg/dL (7.8 mmol/L) is considered abnormal. Women with an abnormal value are
then given a 100-g, three-hour oral glucose tolerance test (GTT).

Criteria for Gestational Diabetes with Three Hour Oral Glucose Tolerance Test

<table>
<thead>
<tr>
<th>Time</th>
<th>Blood Sugar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>&gt;95 mg/dL</td>
</tr>
<tr>
<td>1 hour</td>
<td>&gt;180 mg/dL</td>
</tr>
<tr>
<td>2 hour</td>
<td>&gt;155 mg/dL</td>
</tr>
<tr>
<td>3 hour</td>
<td>&gt;140 mg/dL</td>
</tr>
</tbody>
</table>

Any two or more abnormal results are diagnostic of gestational diabetes.

II. Treatment of gestational diabetes mellitus

A. Diet
1. Dietary therapy should be started in women who do not meet criteria for gestational diabetes (abnormal glucose tolerance test) if they have fasting blood glucose concentrations >90 mg/dL or an abnormal glucose challenge test.
2. Caloric intake
   a. Pregnant women who are 80 to 120 percent of ideal body weight: 30 kcal per present weight in kg per day.
   b. Overweight pregnant women (120 to 150 percent of ideal body weight): 24 kcal per present weight in kg per day.
   c. Morbidly obese pregnant women (>150 percent of ideal body weight): 12 to 15 kcal per present weight in kg per day.
   d. Pregnant women who are less than 80 percent of ideal body weight: 40 kcal per present weight in kg per day.
3. Calorie distribution: 40 percent carbohydrate, 20 percent protein, and 40 percent fat.
   a. With this calorie distribution, 75 to 80 percent of women with gestational diabetes can achieve normoglycemia.
   b. Three meals and three snacks per day are recommended. Breakfast must be very small (10 percent of total calories) to prevent the blood glucose concentration one hour after breakfast from rising above 120 mg/dL. The remaining calories should be distributed as 30 percent at both lunch and dinner, with the leftover calories distributed as snacks.

Treatment Goals for Gestational Diabetes Mellitus

<table>
<thead>
<tr>
<th>Time</th>
<th>Blood Sugar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>&lt;90 mg/dL</td>
</tr>
<tr>
<td>1 hr postprandial</td>
<td>&lt;120 mg/dL</td>
</tr>
</tbody>
</table>

B. Initiation of insulin therapy
1. Approximately 15 percent of women with gestational diabetes require insulin because of elevated blood glucose despite dietary therapy.
2. Insulin should be initiated when the fasting blood glucose concentration is greater than 90 mg/dL and the one-hour postprandial blood glucose concentration is greater than 120 mg/dL on two or more occasions within a two-week interval despite dietary therapy.
3. Insulin regimen
   a. If insulin is required because the fasting blood glucose concentration is high, an intermediate-acting insulin, such as NPH insulin, is given before bedtime. The initial dose should be 0.15 U/kg body weight.
   b. If postprandial blood glucose concentrations are high, then regular insulin or insulin lispro should be given before meals at 1.5 U per 10 grams carbohydrate in the breakfast meal and 1.0 U per 10 grams carbohydrate in the lunch and dinner meals.
   c. If both preprandial and postprandial blood glucose concentrations are high, then a four-injection per day regimen should be initiated. The total dose is 0.7 U/kg for weeks six to 18, 0.8 U/kg for weeks 19 to 26, 0.9 U/kg for weeks 27 to 36, and 1.0 U/kg for weeks 37 to term.
   d. The insulin should be divided as 45 percent as NPH insulin, 30 percent before breakfast and 15 percent before bedtime, and about 55 percent as preprandial regular insulin, 22 percent before breakfast, 16.5 percent before lunch, and 16.5 percent before dinner. Insulin resistance increases as gestation proceeds, requiring an increase in insulin dose.

C. Fetal surveillance
1. Fetal surveillance should be initiated in the third trimester in women in whom gestational diabetes is not well-controlled, who require insulin, or have other complications of pregnancy (eg, hypertension). Counting fetal movements is a simple way to assess fetal well-being. Fewer than ten fetal movements in a 12-hour period is associated with a poor outcome.
2. Early delivery. Women with good glycemic control and no other complications of pregnancy ideally will deliver at 39 to 40 weeks of gestation. Indications for delivery before the 39th week include poor glycemic control and fetal abnormalities. If early delivery is indicated, lung maturity should be assessed by amniocentesis if delivery could be safely postponed in the absence of fetal pulmonary maturity.

3. Normal delivery. The great majority of women with gestational diabetes proceed to term and have a spontaneous vaginal delivery. The maternal blood glucose concentration should be maintained between 70 and 90 mg/dL. Insulin can usually be withheld during delivery, and an infusion of normal saline is usually sufficient to maintain normoglycemia.

<table>
<thead>
<tr>
<th>Blood Glucose (mg/100 mL)</th>
<th>Insulin Dosage (U/h)</th>
<th>Fluids (125 mL/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;100</td>
<td>0</td>
<td>5% dextrose/Lactated Ringer's solution</td>
</tr>
<tr>
<td>100-140</td>
<td>1.0</td>
<td>5% dextrose/Lactated Ringer's solution</td>
</tr>
<tr>
<td>141-180</td>
<td>1.5</td>
<td>Normal saline</td>
</tr>
<tr>
<td>181-220</td>
<td>2.0</td>
<td>Normal saline</td>
</tr>
<tr>
<td>&gt;220</td>
<td>2.5</td>
<td>Normal saline</td>
</tr>
</tbody>
</table>

Dilution is 25 U of regular insulin in 250 mL of normal saline, with 25 mL flushed through line, administered intravenously.

D. Postpartum concerns and follow-up
1. Nearly all women with gestational diabetes are normoglycemic after delivery. However, they are at risk for gestational diabetes, impaired glucose tolerance, and overt diabetes.
2. Immediately after delivery, blood glucose should be measured to ensure that the mother no longer has hyperglycemia. Fasting blood glucose concentrations should be below 115 mg/dL and one-hour postprandial concentrations should be below 140 mg/dL.

References: See page 282.

Diabetes Mellitus
Approximately 4 percent of pregnant women have diabetes: 88 percent have gestational diabetes mellitus, while the remaining 12 percent have pregestational diabetes. Of those with pregestational diabetes, 35 percent have type 1 and 65 percent type 2 diabetes.

I. Glycemic control and fetal and maternal complications
A. Pregnancy in diabetes is associated with an increase in risk of congenital anomalies and spontaneous abortions in women who are in poor glycemic control during the period of fetal organogenesis, which is nearly complete at seven weeks postconception.
B. Macrosomia. Another consequence of poor glycemic control in pregnant women with diabetes is fetal macrosomia, which leads to dystocia, an increased need for cesarean delivery, and an increase in fetal morbidity.
C. Glucose monitoring. Frequent measurements of blood glucose are mandatory in women with type 1 diabetes during pregnancy. If the first morning blood glucose value is high, testing should also be performed at bedtime and in middle of the night.

Testing during Pregnancy in Type I Diabetes

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin A1c</td>
<td>Every 4-6 weeks</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>4-8 times daily at home; during weekly/biweekly visits in physician's office</td>
</tr>
<tr>
<td>Urine ketones</td>
<td>During period of illness; when any blood glucose value is &gt;200 mg/dL</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Weekly/biweekly office visits</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>Each trimester</td>
</tr>
<tr>
<td>Thyroid function tests</td>
<td>Baseline measurements of serum free T4 and TSH</td>
</tr>
<tr>
<td>Eye examination</td>
<td>At baseline and as necessary per retinal specialist</td>
</tr>
</tbody>
</table>

D. Urinary ketones should be measured periodically, especially when the woman is ill or when any blood
glucose value is over 200 mg/dL. At these times ketoacidosis may occur, a complication that is associated with a high mortality rate in the fetus.

E. Target blood glucose values
1. Hemoglobin A1c (HbA1c) should be measured every four to six weeks and more frequently if the woman’s glycemic control is poor.

2. Blood glucose goals in a pregnant diabetic:
   a. Fasting capillary blood glucose concentration of 55 to 65 mg/dL, about 85 percent for the venous plasma concentration.
   b. One-hour postprandial blood glucose concentration less than 120 mg/dL.

F. Recommendations for caloric intake:
1. Woman at ideal body weight: 30 kcal/kg per day.
2. 20 to 50 percent above ideal body weight: 24 kcal/kg per day.
3. More than 50 percent above ideal body weight: 12 to 18 kcal/kg per day.
4. More than 10 percent below ideal body weight: 36 to 40 kcal/kg per day.

G. Recommended distribution of calories: 40 to 50 percent carbohydrate, 20 percent protein, and 30 to 40 percent fat. Patients should eat three meals and three snacks per day. The calorie distribution should be 10 percent of calories at breakfast, 30 percent at both lunch and dinner, and 30 percent as snacks. A daily supplement of ferrous sulfate (30 mg) and folate (400 μg) is also recommended.

H. Insulin regimen
1. Most women with type 1 diabetes require at least three injections of insulin per day. After an early rise in insulin requirements between weeks 3 and 7, there often is a significant decline between weeks 7 and 15, followed by a rise during the remainder of pregnancy.
2. The average insulin requirement in pregnant women with type 1 diabetes is 0.7 units/kg in the first trimester, often increasing to 0.8 U/kg for weeks 18 to 26, 0.9 U/kg for weeks 27 to 36, and 1.0 U/kg for weeks 37 to term.

<table>
<thead>
<tr>
<th>Time</th>
<th>Insulin dose being adjusted</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Bedtime NPH</td>
<td>If BG is &gt;90 mg/dL, check at bedtime and 3:00 AM. If bedtime value is high, increase dinner regular insulin. If bedtime value normal but 3:00 AM value is above 100 mg/dL, then raise bedtime NPH by 2 units. If 3:00 AM value is below 60 mg/dL, then decrease bedtime NPH by 2 units. If 7:30 AM value is below 60 mg/dL, reduce bedtime NPH by 2 units.</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Morning regular</td>
<td>If 1 hour postprandial value is above 140 mg/dL, increase next morning regular insulin by 2 units. If the value is &lt;110 mg/dL, decrease next morning AM regular by 2 units.</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Lunch regular</td>
<td>If 1 hour postprandial value is above 140 mg/dL, increase lunch regular insulin for the next day by 2 units. If the value is below 110 mg/dL, decrease next day’s lunch regular insulin by 2 units.</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Morning NPH</td>
<td>If BG is above 90 mg/dL, then increase morning NPH by 2 units. If 90 is below 60 mg/dL, then decrease morning NPH by 2 units.</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Dinner regular</td>
<td>If 1 hour postprandial value is above 140 mg/dL, increase dinner regular insulin by 2 units. If 1 hour value is below 110 mg/dL, decrease dinner regular insulin by 2 units.</td>
</tr>
</tbody>
</table>

3. Women with type 2 diabetes also should be treated with insulin. During the first trimester, insulin requirements are similar in women with type 1 and type 2 diabetes. However, as the pregnancy proceeds into the third trimester, insulin requirements increase proportionately more in women with type 2 than type 1 diabetes.

4. A combination of regular insulin and intermediate-acting insulin (such as NPH insulin) should be administered. The insulin is initially distributed as follows:
   a. 45 percent of the total daily dose is given as NPH insulin and 22 percent as regular insulin before breakfast.
   b. 17 percent of the total daily dose is given as both NPH and regular insulin before dinner.
   c. The premeal dose of regular insulin is given on a sliding scale according to the blood glucose value.

5. Macrosomia is defined as fetal weight greater than 4.0 to 4.5 kg or birth weight above the 90th percentile for gestational age. Macrosomic fetuses are at increased risk for a prolonged
second stage of labor, shoulder dystocia, operative delivery, and perinatal death.
6. Congenital anomalies. Ultrasonography is essential for the evaluation of congenital anomalies. Congenital anomalies that occur with higher frequency include anencephaly, microcephaly, caudal regression syndrome, and genitourinary and gastrointestinal anomalies. Congenital heart disease may include hypertrophic cardiomyopathy, aortic and ventricular septal defects, transposition of the great vessels and coarctation of the aorta.
7. Polyhydramnios can occur because of increased amniotic fluid osmolality and polyuria secondary to fetal hyperglycemia.
8. Antepartum surveillance. In women with diet-controlled gestational diabetes, fetal surveillance is usually not initiated until 40 weeks gestation, since these women are at very low risk for complications. More rigorous monitoring is recommended for women who have additional indications for closer fetal surveillance, such as hypertension. Surveillance begins earlier in women with either gestational or pregestational diabetes treated with insulin. Testing is begun at the 35th week of gestation if there is excellent glycemic control. Testing should start at 26 to 28 weeks in women with poor control, nephropathy, or hypertension.

I. Labor and delivery
1. Insulin is required before active labor and can be given subcutaneously or by intravenous infusion with a goal of maintaining blood glucose concentrations between 70 and 90 mg/dL. The insulin infusion consists of administration of 15 units of regular insulin in 150 mL of normal saline IV at a rate of one to three units per hour.
2. Normal saline may be sufficient to maintain euglycemia when labor is anticipated.
3. When active labor begins, insulin resistance rapidly decreases and insulin requirements fall rapidly. Thus, continuing insulin therapy is likely to lead to hypoglycemia. To prevent this, glucose should be infused at a rate of 2.5 mg/kg per min. Capillary blood glucose should be measured hourly. The glucose infusion should be doubled for the next hour if the blood glucose value is less than 60 mg/dL. However if the value is 120 mg/dL or more, regular insulin is given subcutaneously or intravenously until the blood glucose value falls to 70 to 90 mg/dL. The insulin dose is titrated to maintain normoglycemia while glucose is infused at a rate of 2.5 mg/kg per min.
4. If a cesarean section is planned, the bedtime NPH insulin dose may be given on the morning of surgery and every eight hours thereafter if surgery is delayed.
5. Insulin requirements drop sharply after delivery, and the new mother may not require insulin for 24 to 72 hours. Insulin requirements should be recalculated at this time at 0.6 units/kg per day based upon postpartum weight. Postpartum calorie requirements are approximately 25 kcal/kg per day, and 27 kcal/kg per day in lactating women.
6. Women in whom labor is induced should receive no morning insulin. Blood glucose monitoring and glucose and insulin infusion are managed as for active labor.

References: See page 282.

Group B Streptococcal Infection in Pregnancy

Group B streptococcus (GBS; Streptococcus agalactiae), a Gram positive coccus, is an important cause of infection in neonates, causing sepsis, pneumonia, and meningitis. GBS infection is acquired in utero or during passage through the vagina. Vaginal colonization with GBS during pregnancy may lead to premature birth, and GBS is a frequent cause of maternal urinary tract infection, chorioamnionitis, postpartum endometritis, and bacteremia.

I. Clinical evaluation
A. The primary risk factor for GBS infection is maternal GBS genitourinary or gastrointestinal colonization.
B. The rate of transmission from colonized mothers to infants is approximately 50 percent. However, only 1 to 2 percent of all colonized infants develop early-onset GBS disease.
C. Maternal obstetrical factors associated with neonatal GBS disease:
1. Delivery at less than 37 weeks of gestation
2. Premature rupture of membranes
3. Rupture of membranes for 18 or more hours before delivery
4. Chorioamnionitis
5. Temperature greater than 38°C during labor
6. Sustained intrapartum fetal tachycardia
7. Prior delivery of an infant with GBS disease
D. Manifestations of early-onset GBS disease. Early-onset disease results in bacteremia, generalized sepsis, pneumonia, or meningitis. The clinical signs usually are apparent in the first hours of life.
II. 2002 CDC guidelines for intrapartum antibiotic prophylaxis:
A. All pregnant women should be screened for GBS colonization with swabs of both the lower vagina and rectum at 35 to 37 weeks of gestation. Patients are excluded from screening if they had GBS bacteriuria earlier in the pregnancy or if they gave birth to a previous infant with invasive GBS disease. These latter patients should receive intrapartum antibiotic prophylaxis regardless of the colonization status.

B. Intrapartum antibiotic prophylaxis is recommended for the following:
1. Pregnant women with a positive screening culture unless a planned Cesarean section is performed in the absence of labor or rupture of membranes
2. Pregnant women who gave birth to a previous infant with invasive GBS disease
3. Pregnant women with documented GBS bacteriuria during the current pregnancy
4. Pregnant women whose culture status is unknown (culture not performed or result not available) and who also have delivery at <37 weeks of gestation, amniotic membrane rupture for >18 hours, or intrapartum temperature >100.3°F (>38ºC).

C. Intrapartum antibiotic prophylaxis is not recommended for the following patients:
1. Positive GBS screening culture in a previous pregnancy (unless the infant had invasive GBS disease or the screening culture is also positive in the current pregnancy)
2. Patient who undergoes a planned Cesarean section without labor or rupture of membranes
3. Pregnant women with negative GBS screening cultures at 35 to 37 weeks of gestation even if they have one or more of the above intrapartum risk factors

D. Recommended IAP regimen
1. Penicillin G (5 million units IV initial dose, then 2.5 million units IV Q4h) is recommended for most patients.
2. In women with non-immediate-type penicillin-allergy, cefazolin (Ancef, 2 g initial dose, then 1 g Q8h) is recommended.
3. Patients at high risk for anaphylaxis to penicillins are treated with clindamycin (900 mg IV Q8h) or erythromycin (500 mg IV Q8h) as long as their GBS isolate is documented to be susceptible to both clindamycin and erythromycin.
4. For patients at high risk for anaphylaxis and a GBS resistant isolate (or with unknown susceptibility) to clindamycin or erythromycin, vancomycin (1 g Q12h) should be given.
5. Antibiotic therapy is continued from hospital admission through delivery.

E. Approach to threatened preterm delivery at <37 weeks of gestation:
A patient with negative GBS cultures (after 35 weeks of gestation) should not be treated during threatened labor. If GBS cultures have not been performed, these specimens should be obtained and penicillin G administered as above; if cultures are negative at 48 hours, penicillin can be discontinued. If such a patient has not delivered within four weeks, cultures should be repeated.

F. If screening cultures taken at the time of threatened delivery or previously performed (after 35 weeks of gestation) are positive, penicillin should be continued for at least 48 hours unless delivery supervenes. Patients who have been treated for >48 hours and have not delivered should receive IAP as above when delivery occurs.

References: See page 282.
rupture increases. Chorioamnionitis, endometritis, sepsis, and neonatal infections may occur.

C. Perinatal risks with preterm PROM are primarily complications from immaturity, including respiratory distress syndrome, intraventricular hemorrhage, patent ductus arteriosus, and necrotizing enterocolitis.

D. Premature gestational age is a more significant cause of neonatal morbidity than is the duration of membrane rupture.

III. Diagnosis of premature rupture of membranes

A. Diagnosis is based on history, physical examination, and laboratory testing. The patient's history alone is correct in 90% of patients. Urinary leakage or excess vaginal discharge is sometimes mistaken for PROM.

B. Sterile speculum exam is the first step in confirming the suspicion of PROM. Digital examination should be avoided because it increases the risk of infection.

1. The general appearance of the cervix should be assessed visually, and prolapse of the umbilical cord or a fetal extremity should be excluded.

2. Cultures for group B streptococcus, gonorrhea, and chlamydia are obtained.

3. A pool of fluid in the posterior vaginal fornix supports the diagnosis of PROM.

4. The presence of amniotic fluid is confirmed by nitrazine testing for an alkaline pH. Amniotic fluid causes nitrazine paper to turn dark blue because the pH is above 6.0-6.5. Nitrazine may be false-positive with contamination from blood, semen, or vaginitis.

5. If pooling and nitrazine are both non-confirmatory, a swab from the posterior fornix should be smeared on a slide, allowed to dry, and examined under a microscope for "ferning," indicating amniotic fluid.

6. Ultrasound examination for oligohydramnios is useful to confirm the diagnosis, but oligohydramnios may be caused by other disorders besides PROM.

IV. Assessment of premature rupture of membranes

A. The gestational age must be carefully assessed. Menstrual history, prenatal exams, and previous sonograms are reviewed. An ultrasound examination should be performed.

B. The patient should be evaluated for the presence of chorioamnionitis [fever (over 38°C), leukocytosis, maternal and fetal tachycardia, uterine tenderness, foul-smelling vaginal discharge].

C. The patient should be evaluated for labor, and a sterile speculum examination should assess cervical change.

D. The fetus should be evaluated with heart rate monitoring because PROM increases the risk of umbilical cord prolapse and fetal distress caused by oligohydramnios.

V. Management of premature rupture of membranes

A. Term patients

1. At 36 weeks and beyond, management of PROM consists of delivery. Patients in active labor should be allowed to progress.

2. Patients with chorioamnionitis, who are not in labor, should be immediately induced with oxytocin (Pitocin).

3. Patients who are not yet in active labor (in the absence of fetal distress, meconium, or clinical infection) may be discharged for 48 hours, and labor usually follows. If labor has not begun within a reasonable time after rupture of membranes, induction with oxytocin (Pitocin) is appropriate. Use of prostaglandin E2 is safe for cervical ripening.

B. Preterm patients

1. Preterm patients with PROM prior to 36 weeks are managed expectantly. Delivery is delayed for the patients who are not in labor, not infected, and without evidence of fetal distress.

2. Patients should be monitored for infection. Cultures for gonococci, Chlamydia, and group B streptococci are obtained. Symptoms, vital signs, uterine tenderness, odor of the lochia, and leukocyte counts are monitored.

3. Suspected occult chorioamnionitis is diagnosed by amniocentesis for Gram stain and culture, which will reveal gram positive cocci in chains.

4. Ultrasound examination should be performed to detect oligohydramnios.

5. Intrapartum antibiotic prophylaxis group B streptococcal is recommended for the following:

a. Pregnant women with a positive screening culture unless a planned Cesarean section is performed in the absence of labor or rupture of membranes

b. Pregnant women who gave birth to a previous infant with invasive GBS disease

c. Pregnant women with documented GBS bacteriuria during the current pregnancy

d. Pregnant women whose culture status is unknown (culture not performed or result not available) and who also have delivery at <37 weeks of gestation, amniotic membrane rupture for >18 hours, or intrapartum temperature >100.4°F (>38°C)

e. The recommended IAP regimen is penicillin G (5 million units IV initial dose, then 2.5 million units IV Q4h). In women with non-immediate-type penicillin-allergy, cefazolin
Ancef, 2 g initial dose, then 1 g Q8h is recommended.
6. Prolonged continuous fetal heart rate monitoring in the initial assessment should be followed by frequent fetal evaluation.
7. Premature labor is the most common outcome of preterm PROM. Tocolytic drugs are often used and corticosteroids are recommended to accelerate fetal pulmonary maturity.
8. Expectant management consists of in-hospital observation. Delivery is indicated for chorioamnionitis, irreversible fetal distress, or premature labor. Once gestation reaches 36 weeks, the patient may be managed as any other term patient with PROM. Another option is to evaluate the fetus at less than 36 weeks for pulmonary maturity and expedite delivery once maturity is documented by testing of amniotic fluid collected by amniocentesis or from the vagina. A positive phosphatidylglycerol test indicates fetal lung maturity.

C. Preivable or preterm premature rupture of membranes
1. In patients in whom membranes rupture very early in pregnancy (eg, <25 weeks). There is a relatively low likelihood (<25%) that a surviving infant will be delivered, and infants that do survive will deliver very premature and suffer significant morbidity.
2. Fetal deformation syndrome. The fetus suffering from prolonged early oligohydramnios may develop pulmonary hypoplasia, facial deformation, limb contractures, and deformity.
3. Termination of pregnancy is advisable if the gestational age is early. If the patient elects to continue the pregnancy, expectant management with pelvic rest at home is reasonable.

D. Chorioamnionitis
1. Chorioamnionitis requires delivery (usually vaginally), regardless of the gestational age.
2. Antibiotic therapy
   a. Ampicillin 2 gm IV q4-6h AND
   b. Gentamicin 100 mg (2 mg/kg) IV load, then 100 mg (1.5 mg/kg) IV q8h.

References: See page 282.

Preterm Labor
Preterm labor is the leading cause of perinatal morbidity and mortality in the United States. It usually results in preterm birth, a complication that affects 8 to 10 percent of births.

<table>
<thead>
<tr>
<th>Risk Factors for Preterm Labor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous preterm delivery</td>
</tr>
<tr>
<td>Low socioeconomic status</td>
</tr>
<tr>
<td>Non-white race</td>
</tr>
<tr>
<td>Maternal age &lt;18 years or &gt;40 years</td>
</tr>
<tr>
<td>Preterm premature rupture of the membranes</td>
</tr>
<tr>
<td>Multiples gestation</td>
</tr>
<tr>
<td>Maternal history of one or more spontaneous second-trimester abortions</td>
</tr>
</tbody>
</table>
| Maternal complications
   --Maternal behaviors
     --Smoking
     --Illicit drug use
     --Alcohol use
     --Lack of prenatal care |
| Uterine causes
   --Myomata (particularly submucosal or subplacental)
   --Uterine septum
   --Bicornuate uterus
   --Cervical incompetence
   --Exposure to diethylstilbestrol (DES) |
| Infectious causes
   --Chorioamnionitis
   --Bacterial vaginosis
   --Asymptomatic bacteriuria
   --Acute pyelonephritis
   --Cervical/vaginal colonization |
| Fetal causes
   --Intrauterine fetal death
   --Intrauterine growth retardation
   --Congenital anomalies
   --Abnormal placentation
   --Presence of a retained intrauterine device |

I. Risk factors for preterm labor. Preterm labor is characterized by cervical effacement and/or dilatation, and increased uterine irritability that occurs before 37 weeks of gestation. Women with a history of previous preterm delivery carry the highest risk of recurrence, estimated to be between 17 and 37 percent.

II. Management of preterm labor
A. Tocolysis
1. Tocolytic therapy may offer some short-term benefit in the management of preterm labor. A delay in delivery can be used to administer corticosteroids to enhance pulmonary maturity and reduce the severity of fetal respiratory distress syndrome, and to reduce the risk of intraventricular hemorrhage. No study has convincingly demonstrated an improvement in survival or neonatal outcome with the use of tocolytic therapy alone.
2. Contraindications to tocolysis include nonreassuring fetal heart rate tracing, eclampsia or severe preeclampsia, fetal demise (singleton), chorioamnionitis, fetal maturity and maternal hemodynamic instability.
3. Tocolytic therapy is indicated for regular uterine contractions and cervical change (effacement or dilatation). Oral terbutaline (Bricanyl) following successful parenteral tocolysis is not associated
with prolonged pregnancy or reduced incidence of recurrent preterm labor.

Preterm Labor, Threatened or Actual

1. Initial assessment to determine whether patient is experiencing preterm labor
   a. Assess for the following:
      i. Uterine activity
      ii. Rupture of membranes
      iii. Vaginal bleeding
      iv. Presentation
      v. Cervical dilation and effacement
      vi. Station
   b. Reassess estimate of gestational age

2. Search for a precipitating factor/cause

3. Consider specific management strategies, which may include the following:
   a. Intravenous tocolytic therapy (decision should be influenced by gestational age, cause of preterm labor and contraindications)
   b. Corticosteroid therapy (eg, betamethasone, in a dosage of 12 mg IM every 24 hours for a total of two doses)
   c. Antibiotic therapy if specific infectious agent is identified or if preterm premature rupture of the membranes

Tocolytic Therapy for the Management of Preterm Labor

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of action</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium sulfate</td>
<td>Intracellular calcium antagonism</td>
<td>4 to 6 g loading dose; then 2 to 4 g IV every hour</td>
</tr>
<tr>
<td>Terbutaline (Bricanyl)</td>
<td>Beta2-adrenergic receptor agonist sympathomimetic; decreases free intracellular calcium ions</td>
<td>0.25 to 0.5 mg SC every three to four hours</td>
</tr>
<tr>
<td>Ritodrine (Yutopar)</td>
<td>Same as terbutaline</td>
<td>0.05 to 0.35 mg per minute IV</td>
</tr>
<tr>
<td>Nifedipine (Procardia)</td>
<td>Calcium channel blocker</td>
<td>5 to 10 mg SL every 15 to 20 minutes (up to four times), then 10 to 20 mg orally every four to six hours</td>
</tr>
<tr>
<td>Indomethacin (Indocin)</td>
<td>Prostaglandin inhibitor</td>
<td>50- to 100-mg rectal suppository, then 25 to 50 mg orally every six hours</td>
</tr>
</tbody>
</table>

Complications Associated With the Use of Tocolytic Agents

- Magnesium sulfate
  - Pulmonary edema
  - Profound hypotension
  - Profound muscular paralysis
  - Maternal tetany
  - Cardiac arrest
  - Respiratory depression
- Beta-adrenergic agents
  - Hypokalemia
  - Hyperglycemia
  - Hypotension
  - Pulmonary edema
  - Arrhythmias
  - Cardiac insufficiency
  - Myocardial ischemia
  - Maternal death

- Indomethacin (Indocin)
  - Renal failure
  - Hepatitis
  - Gastrointestinal bleeding
- Nifedipine (Procardia)
  - Transient hypotension

B. Corticosteroid therapy

1. Dexamethasone and betamethasone are the preferred corticosteroids for antenatal therapy. Corticosteroid therapy for fetal maturation reduces mortality, respiratory distress syndrome and intraventricular hemorrhage in infants between 24 and 34 weeks of gestation.

2. In women with preterm premature rupture of membranes (PPROM), antenatal corticosteroid therapy reduces the risk of respiratory distress syndrome. In women with PPROM at less than 30 to 32 weeks of gestation, in the absence of clinical chorioamnionitis, antenatal corticosteroid use is recommended because of the high risk of intraventricular hemorrhage at this early gestational age.

Recommended Antepartum Corticosteroid Regimens for Fetal Maturation in Preterm Infants

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage</th>
</tr>
</thead>
</table>

with prolonged pregnancy or reduced incidence of recurrent preterm labor.
C. Intrapartum antibiotic prophylaxis group B streptococcal is recommended for the following:
1. Pregnant women with a positive screening culture unless a planned Cesarean section is performed in the absence of labor or rupture of membranes
2. Pregnant women who gave birth to a previous infant with invasive GBS disease
3. Pregnant women with documented GBS bacteriuria during the current pregnancy
4. Pregnant women whose culture status is unknown (culture not performed or result not available) and who also have delivery at <37 weeks of gestation, amniotic membrane rupture for >18 hours, or intrapartum temperature >100.4°F (>38ºC)
5. The recommended IAP regimen is penicillin G (5 million units IV initial dose, then 2.5 million units IV Q4h). In women with non-immediate-type penicillin-allergy, cefazolin (Ancef, 2 g initial dose, then 1 g Q8h) is recommended.

D. Bed rest. Although bed rest is often prescribed for women at high risk for preterm labor and delivery, there are no conclusive studies documenting its benefit. A recent meta-analysis found no benefit to bed rest in the prevention of preterm labor or delivery.

References: See page 282.

Bleeding in the Second Half of Pregnancy

Bleeding in the second half of pregnancy occurs in 4% of all pregnancies. In 50% of cases, vaginal bleeding is secondary to placental abruption or placenta previa.

I. Clinical evaluation of bleeding second half of pregnancy
A. History of trauma or pain and the amount and character of the bleeding should be assessed.
B. Physical examination
   1. Vital signs and pulse pressure are measured. Hypotension and tachycardia are signs of serious hypovolemia.
   2. Fetal heart rate pattern and uterine activity are assessed.
   3. Ultrasound examination of the uterus, placenta and fetus should be completed.
   4. Speculum and digital pelvic examination should not be done until placenta previa has been excluded.
C. Laboratory Evaluation
   1. Hemoglobin and hematocrit.
   2. INR, partial thromboplastin time, platelet count, fibrinogen level, and fibrin split products are checked when placental abruption is suspected or if there has been significant hemorrhage.
   3. A red-top tube of blood is used to perform a bedside clot test.
   4. Blood type and cross-match.
   5. Urinalysis for hematuria and proteinuria.
   6. The APT test is used to distinguish maternal or fetal source of bleeding. (Vaginal blood is mixed with an equal part 0.25% sodium hydroxide. Fetal blood remains red; maternal blood turns brown.)
   7. Kleihauer-Betke test of maternal blood is used to quantify fetal to maternal hemorrhage.

II. Placental abruption (abruptio placentae) is defined as complete or partial placental separation from the decidua basalis after 20 weeks gestation.
A. Placental abruption occurs in 1 in 100 deliveries.
B. Factors associated with placental abruption
   1. Preeclampsia and hypertensive disorders
   2. History of placental abruption
   3. High multiparity
   4. Increasing maternal age
   5. Trauma
   6. Cigarette smoking
   7. Illicit drug use (especially cocaine)
   8. Excessive alcohol consumption
   9. Preterm premature rupture of the membranes
   10. Rapid uterine decompression after delivery of the first fetus in a twin gestation or rupture of membranes with polyhydramnios
   11. Uterine leiomyomas
C. Diagnosis of placental abruption
   1. Abruption is characterized by vaginal bleeding, abdominal pain, uterine tenderness, and uterine contractions.
   a. Vaginal bleeding is visible in 80%; bleeding is concealed in 20%.
   b. Pain is usually of sudden onset, constant, and localized to the uterus and lower back.
   c. Localized or generalized uterine tenderness and increased uterine tone are found with severe placental abruption.
   d. An increase in uterine size may occur with placental abruption when the bleeding is concealed. Concealed bleeding may be
detected by serial measurements of abdominal girth and fundal height.

e. Amniotic fluid may be bloody.
f. Fetal monitoring may detect distress.
g. Placental abruption may cause preterm labor.

2. **Uterine contractions** by tocodynamometry is the most sensitive indicator of abruption.

3. **Laboratory findings** include proteinuria and a consumptive coagulopathy, characterized by decreased fibrinogen, prothrombin, factors V and VIII, and platelets. Fibrin split products are elevated.

4. **Ultrasoundography** has a sensitivity in detecting placental abruption of only 15%.

### D. Management of placental abruption

1. **Mild placental abruption**
   - a. If maternal stability and reassuring fetal surveillance are assured and the fetus is immature, close expectant observation with fetal monitoring is justified.
   - b. Maternal hematologic parameters are monitored and abnormalities corrected.
   - c. Tocolysis with magnesium sulfate is initiated if the fetus is immature.

2. **Moderate to severe placental abruption**
   - a. Shock is aggressively managed.
   - b. **Coagulopathy**
     1. Blood is transfused to replace blood loss.
     2. Clotting factors may be replaced using cryoprecipitate or fresh-frozen plasma. One unit of fresh-frozen plasma increases fibrinogen by 10 mg/dL. Cryoprecipitate contains 250 mg fibrinogen/unit; 4 gm (15-20 U) is an effective dose.
     3. Platelet transfusion is indicated if the platelet count is less than 50,000/mcL. One unit of platelets raises the platelet count 5000-10,000/mcL; 4 to 6 U is the smallest useful dose.
   - c. Oxygen should be administered and urine output monitored with a Foley catheter.
   - d. Vaginal delivery is expedited in all but the mildest cases once the mother has been stabilized. Amniotomy and oxytocin (Pitocin) augmentation may be used. Cesarean section is indicated for fetal distress, severe abruption, or failed trial of labor.

### III. Placenta previa

Placenta previa occurs when any part of the placenta implants in the lower uterine segment. It is associated with a risk of serious maternal hemorrhage. Placenta previa occurs in 1 in 200 pregnancies. Ninety percent of placenta previas diagnosed in the second trimester resolve spontaneously.

1. **Total placenta previa** occurs when the internal cervical os is completely covered by placenta.
2. **Partial placenta previa** occurs when part of the cervical os is covered by placenta.
3. **Marginal placenta previa** occurs when the placental edge is located within 2 cm of the cervical os.

### D. Clinical evaluation

1. Placenta previa presents with a sudden onset of painless vaginal bleeding in the second or third trimester. The peak incidence occurs at 34 weeks. The initial bleeding usually resolves spontaneously and then recurs later in pregnancy.
2. One fourth of patients present with bleeding and uterine contractions.

### E. Ultrasoundography is accurate in diagnosing placenta previa.

### F. Management of placenta previa

1. In a pregnancy ≥36 weeks with documented fetal lung maturity, the neonate should be immediately delivered by cesarean section.
2. Low vertical uterine incision is probably safer in patients with an anterior placenta. Incisions through the placenta should be avoided.
3. If severe hemorrhage jeopardizes the mother or fetus, cesarean section is indicated regardless of gestational age.
4. Expectant management is appropriate for immature fetuses if bleeding is not excessive, maternal physical activity can be restricted, intercourse and douching can be prohibited, and the hemoglobin can be maintained at ≥10 mg/dL.
5. Rh immunoglobulin is administered to Rh-negative-unsensitized patients.
6. Delivery is indicated once fetal lung maturity has been documented.
7. Tocolysis with magnesium sulfate may be used for immature fetuses.

### IV. Cervical bleeding

A. Cytologic sampling is necessary.
B. Bleeding can be controlled with cauterization or packing.
C. Bacterial and viral cultures are sometimes diagnostic.

### V. Cervical polyps

A. Bleeding is usually self-limited.
B. Trauma should be avoided.
C. Polypectomy may control bleeding and yield a histologic diagnosis.

### VI. Bloody show

is a frequent benign cause of late third trimester bleeding. It is characterized by blood-tinged mucus associated with cervical change.

**References:** See page 282.
Preeclampsia-eclampsia and Chronic Hypertension

The are four major hypertensive disorders in pregnancy are preeclampsia-eclampsia, chronic hypertension, preeclampsia superimposed upon chronic hypertension, and gestational hypertension. Preeclampsia is characterized by hypertension and proteinuria developing after 20 weeks of gestation. Chronic hypertension is defined as systolic pressure >140 mm Hg, diastolic pressure >90 mm Hg, or both that antedates pregnancy or is present before the 20th week of pregnancy.

I. Incidence and risk factors for preeclampsia
A. Hypertensive disorders occur in about 12 to 22 percent of pregnancies. Preeclampsia occurs in 3 to 8 percent of pregnancies. A woman under the age of 20 years who is undergoing her first pregnancy is at increased risk for preeclampsia. The primigravid state is a predisposing factor. The incidence of preeclampsia in a second pregnancy is less than 1 percent in women who have had a normotensive first pregnancy, as compared to 5-7 percent in women who had preeclampsia during the first pregnancy.

B. Risk factors for preeclampsia:
1. Primigravid state
2. History of preeclampsia
3. A higher blood pressure at the initiation of pregnancy and a large body size
4. A family history of preeclampsia is associated with a two to fivefold increase in risk
5. Multiple pregnancy
6. Preexisting maternal hypertension
7. Gestational diabetes
8. Antiphospholipid antibody syndrome
9. Vascular or connective tissue disease
10. Advanced maternal age (>35 to 40 years)

II. Clinical manifestations of preeclampsia
A. Preeclampsia is characterized by the gradual development of hypertension, proteinuria, and edema in pregnancy, particularly in a primigravida. These findings typically become apparent in the latter part of the third trimester and progress until delivery. In some women, however, symptoms begin in the latter half of the second trimester. Signs and symptoms of preeclampsia occurring before 20 weeks of gestation are unusual unless there is an underlying molar pregnancy, drug use or withdrawal, or chromosomal aneuploidy in the fetus.

B. Hypertension. Pregnancy related hypertension is defined as a systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg in a woman who was normotensive prior to 20 weeks of gestation. Hypertension is usually the earliest clinical finding of preeclampsia. The blood pressure (BP) may rise in the second trimester, but usually does not reach the hypertensive range (>140/90) until the third trimester, often after the 37th week of gestation.

C. Proteinuria. In addition to hypertension, most patients also have proteinuria (ie, 1+ on dipstick or 30 mg/dL or proteinuria of 0.3 g or greater in a 24-hour urine specimen).

D. Eclampsia refers to the development of grand mal seizures in a woman with preeclampsia. Preeclampsia-eclampsia is caused by generalized vasospasm, activation of the coagulation system, and changes in autoregulatory systems related to blood pressure control.

E. Edema and intravascular volume. Most women with preeclampsia have edema. Although peripheral edema is common in normal pregnancy, sudden and rapid weight gain and facial edema often occur in women who develop preeclampsia.

F. Hematologic changes. Increased platelet turnover is a consistent feature of preeclampsia. The most common coagulation abnormality in preeclampsia is thrombocytopenia.

G. Liver involvement may present as right upper quadrant or epigastric pain, elevated liver enzymes and subcapsular hemorrhage or hepatic rupture.

H. Central nervous system. Headache, blurred vision, scotomata, and, rarely, cortical blindness are manifestations of preeclampsia; seizures in a preeclamptic woman are defined as eclampsia.

I. Fetus and placenta. The fetal consequences are fetal growth restriction and oligohydramnios. Severe or early onset preeclampsia result in the greatest decrements in birth weight.

III. Diagnosis
A. The diagnosis of preeclampsia is largely based upon clinical features developing after 20 weeks of gestation in a woman who was previously normotensive.

Diagnosis of Preeclampsia

Systolic blood pressure greater than 140 mm Hg or Diastolic blood pressure greater than 90 mm Hg AND A random urine protein determination of 1+ on dipstick or 30 mg/dL, or proteinuria of 0.3 g or greater in a 24-hour urine specimen
B. Plasma uric acid concentration. Preeclampsia is typically associated with a rise in the plasma urate level to above 5.5 to 6 mg/dL.

C. Laboratory evaluation:
1. Hematocrit: hemoconcentration supports the diagnosis of preeclampsia
2. Platelet count
3. Quantification of protein excretion
4. Serum creatinine concentration
5. Serum uric acid concentration
6. Serum alanine and aspartate aminotransferase concentrations (ALT, AST)
7. Lactic acid dehydrogenase concentration (LDH) and red blood cell smear may indicate the presence of microangiopathic hemolysis.

Criteria for Severe Preeclampsia

<table>
<thead>
<tr>
<th>New onset proteinuria hypertension and at least one of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms of central nervous system dysfunction:</td>
</tr>
<tr>
<td>Blurred vision, scotomata, altered mental status, severe headache</td>
</tr>
<tr>
<td>Symptoms of liver capsule distention:</td>
</tr>
<tr>
<td>Right upper quadrant or epigastric pain</td>
</tr>
<tr>
<td>Hepatocellular injury:</td>
</tr>
<tr>
<td>Serum transaminase concentration at least twice normal</td>
</tr>
<tr>
<td>Severe blood pressure elevation:</td>
</tr>
<tr>
<td>Systolic blood pressure &gt;160 mm Hg or diastolic &gt;110 mm Hg on two occasions at least six hours apart™</td>
</tr>
<tr>
<td>Thrombocytopenia:</td>
</tr>
<tr>
<td>Less than 100,000 platelets per mm³</td>
</tr>
<tr>
<td>Proteinuria:</td>
</tr>
<tr>
<td>Over 5 grams in 24 hours or 3+ or more on two random samples four hours apart</td>
</tr>
<tr>
<td>Oliguria &lt;500 mL in 24 hours</td>
</tr>
<tr>
<td>Intraterine fetal growth restriction</td>
</tr>
<tr>
<td>Pulmonary edema or cyanosis</td>
</tr>
<tr>
<td>Cerebrovascular accident</td>
</tr>
<tr>
<td>Coagulopathy</td>
</tr>
</tbody>
</table>

IV. Treatment of preeclampsia
A. The definitive treatment of preeclampsia is delivery. Delivery is recommended for women with mild preeclampsia at or near term and for most women with severe preeclampsia regardless of gestational age, except less than 33 weeks of gestation whose only criterion for severe disease is:
1. Severe proteinuria (greater than 5 g in 24 hours).
2. Mild intraterine fetal growth restriction (fifth to tenth percentile).
3. Severe preeclampsia by blood pressure criteria alone before 32 weeks of gestation, if there is blood pressure reduction and resolution of any laboratory abnormalities after hospitalization.

B. Treatment of hypertension. Antihypertensive treatment is indicated if the systolic blood pressure is >170 mm Hg. The preferred agents are methyldopa for prolonged antenatal therapy, and hydralazine, labetalol or nifedipine for peripartum treatment of acute hypertensive episodes. Sodium restriction and diuretics have no role in therapy. Restricted physical activity can lower blood pressure.

Acute Treatment of Severe Hypertension in Preeclampsia

The goal is a gradual reduction of blood pressure to a level below 160/105 mm Hg. Sudden and severe hypotension should be avoided.

Hydralazine: 5 mg IV, repeat 5 to 10 mg IV every 20 minutes to maximum cumulative total of 20 mg or until blood pressure is controlled.

Labetalol (Trandate): 20 mg IV, followed by 40 mg, then 80 mg, then 80 mg at 10 minute intervals until the desired response is achieved or a maximum total dose of 220 mg is administered.

Methyldopa (Aldomet) 250 mg BID orally, maximum dose 4 g/day

Fetal Assessment in Preeclampsia

<table>
<thead>
<tr>
<th>Mild preeclampsia</th>
<th>Daily fetal movement counting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ultrasound examination for estimation of fetal weight and amniotic fluid determination at diagnosis. Repeat in three weeks if the initial examination is normal, twice weekly if there is evidence of fetal growth restriction or oligohydramnios.</td>
</tr>
<tr>
<td></td>
<td>Noinstress test and/or biophysical profile once or twice weekly. Testing should be repeated immediately if there is an abrupt change in maternal condition.</td>
</tr>
</tbody>
</table>

Severe preeclampsia

| Daily nonstress testing and/or biophysical profile |

C. Antenatal corticosteroids to promote fetal lung maturation should be administered to women less than 34 weeks of gestation who are at high risk for delivery within the next seven days. Betamethasone (two doses of 12 mg given intramuscularly 24 hours apart) or dexamethasone (four
doses of 6 mg given intramuscularly 12 hours apart may be used.

**D. Maternal monitoring.** Laboratory evaluation (eg, hematocrit, platelet count, creatinine, urine protein, LDH, AST, ALT, uric acid) should be repeated once or twice weekly in women with mild stable preeclampsia.

**E. Women with severe preeclampsia** should be delivered or hospitalized for the duration of pregnancy. Prolonged antepartum management may be considered in selected women under 32 weeks of gestation, such as those whose condition improves after hospitalization and who have no evidence of end-organ dysfunction or fetal deterioration.

**F. Timing and indications for delivery.** Delivery at or by 40 weeks of gestation should be considered for all women with preeclampsia. Women with mild disease and a favorable cervix may benefit from induction as early as 38 weeks, while those with stable severe disease should be delivered after 32 to 34 weeks if possible (with demonstration of fetal pulmonary maturity).

<table>
<thead>
<tr>
<th>Indications for Delivery in Preeclampsia</th>
<th>Maternal indications</th>
<th>Gestational age greater than or equal to 38 weeks of gestation</th>
<th>Platelet count less than 100,000 cells per mm³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Deteriorating liver function</td>
<td>Progressive deterioration in renal function</td>
<td>Abruptio placentae</td>
</tr>
<tr>
<td></td>
<td>Persistent severe headaches or visual changes</td>
<td>Persistent severe epigastric pain, nausea, or vomiting</td>
<td></td>
</tr>
</tbody>
</table>

**G. Route of delivery.** Delivery is usually by the vaginal route, with cesarean delivery reserved for obstetrical indications. Cervical ripening agents may be used if the cervix is not favorable.

**H. Anticonvulsant therapy**

1. Anticonvulsant therapy is initiated during labor until 24 to 48 hours postpartum. Magnesium sulfate is the drug of choice for seizure prevention.
2. Magnesium regimen. A loading dose of 6 g intravenously is given, followed by 2 g/h as a continuous infusion.

**I. Postpartum course.** Hypertension due to preeclampsia resolves postpartum, often within a few days, but sometimes takes a few weeks.

**V. Management of eclampsia**

**A.** Maintenance of airway patency and prevention of aspiration are the initial management priorities. The patient should be rolled onto her left side and a padded tongue blade placed in her mouth, if possible.

**B. Control of convulsions.** Magnesium sulfate, 2 to 4 g IV push repeated every 15 minutes to a maximum of 6 g, Maintenance dose of magnesium sulfate: 2 to 3 g/hour by continuous intravenous infusion. Diazepam may also be given as 5 mg IV push repeated as needed to a maximum cumulative dose of 20 mg to stop the convulsions; however, benzodiazepines have profound depressant effects on the fetus.

**VI. Preexistent hypertension**

**A.** Methyldopa (Aldomet) has been most widely used and long-term safety to the fetus has been clearly demonstrated. ACE inhibitors should not be continued in pregnancy. ß-blockers are generally safe, although they may impair fetal growth when used early in pregnancy, particularly atenolol. Thiazide diuretics can be continued as long as volume depletion is avoided.

<table>
<thead>
<tr>
<th>Treatment of Hypertension in Pregnancy</th>
<th>Drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Methyldopa (Aldomet)</td>
<td>250 mg BID orally, maximum dose 4 g/day</td>
</tr>
<tr>
<td></td>
<td>Labetalol (Trandate)</td>
<td>100 mg BID orally, maximum dose 2400 mg/day</td>
</tr>
</tbody>
</table>

**B. Risks of chronic hypertension.** Chronic hypertension is associated with a threefold increase in perinatal mortality, a twofold increase in abruptio placentae, and an increased rate of impaired fetal growth. There is also a higher rate of preterm delivery before 35 weeks of gestation.

**C. Indications for treatment.** Indications for antihypertensive therapy are a diastolic pressure persistently above 100 mm Hg, systolic pressure >150 to 180 mm Hg or signs of hypertensive end-organ damage. Severe hypertension (blood pressure of 180/110 mmHg or higher) requires intravenous therapy. Hydralazine and labetalol are the drugs of choice for intravenous administration.

**D. Fetal surveillance** is warranted when there is preeclampsia or intrauterine growth restriction.
Serial sonographic assessment of fetal growth is indicated, with nonstress testing or biophysical profile examination weekly starting at 26 weeks, increasing to twice-weekly at 32 weeks.

E. Delivery. Woman with mild, uncomplicated chronic hypertension can be allowed to go into spontaneous labor and deliver at term. Earlier delivery can be considered for women with superimposed preeclampsia or pregnancy complications (eg, fetal growth restriction, previous stillbirth).

References: See page 262.

Herpes Simplex Virus Infections in Pregnancy

Herpes simplex virus (HSV) type 2 is primarily responsible for genital HSV disease. Maternal-fetal transmission of HSV is the major consequence of maternal HSV infection, resulting in encephalitis, disseminated disease, and skin disease. The most common mode of transmission is via contact of the fetus with infected vaginal secretions during delivery.

I. Diagnosis
A. Risk factors. Black or Hispanic race, age, and years of sexual experience are highly correlated with HSV-2 infection. Other factors include lower family income, lower level of education, multiple sexual partners, and having other sexually transmitted diseases.
B. The gold standard for diagnosis of acute HSV infection is viral culture, which may become positive within two to three days after inoculation.
C. Polymerase chain reaction (PCR) is used to rapidly detect HSV DNA from lesions or genital secretions and is superior to other tests. PCR has been used to detect HSV from pregnant women with recurrent HSV at delivery and their infants in instances in which HSV cultures were negative.

II. Clinical presentation
A. Primary genital episode genital HSV is characterized by multiple painful vesicles in clusters. They may be associated with pruritus, dysuria, vaginal discharge, and tender regional adenopathy. Fever, malaise, and myalgia often occur one to two days prior to the appearance of lesions. The lesions may last four to five days prior to crusting. The skin will reepithelialize in about 10 days. Viral shedding may last for 10 to 12 days after reepithelialization.
B. Nonprimary first-episode genital HSV refers to patients with preexisting antibodies to one of the two types of virus who acquire the other virus and develop genital lesions. Nonprimary disease is less severe with fewer systemic symptoms, and less local pain.
C. Recurrent HSV episodes are characterized by local pain or paresthesia followed by vesicular lesions. They are generally fewer in number and often unilateral but may be painful.

III. Pregnancy
A. Estimated risks of maternal-fetal transmission:
   1. Primary or nonprimary first episode with an active lesion at delivery: 50 percent
   2. Asymptomatic first episode: 33 percent
   3. Recurrent HSV with active lesion: 3 to 4 percent
   4. Asymptomatic recurrence: 0.04 percent

IV. Neonatal effects
A. HSV neonatal infection is most often acquired through the birth canal. The incidence of neonatal HSV infection is 1 in 3000. Approximately 60 to 70 percent of infected neonates are infected with HSV-2.
B. Categories of neonatal disease include localized disease of the skin, eyes, and mouth (SEM), central nervous system (CNS) disease with or without SEM involvement, and disseminated disease.
C. The mortality rate is 15 percent among children with CNS disease and 57 percent with disseminated disease.

V. Treatment
A. Primary infection
   1. Acyclovir (Zovirax) therapy (200 mg PO five times per day or 400 mg PO TID for 7 to 14 days) and analgesia is recommended. Acyclovir is safe in pregnancy. Acyclovir reduces the duration of viral shedding.
   2. Suppressive therapy (400 mg PO BID) for the remainder of pregnancy should usually be administered because acyclovir may prevent symptomatic HSV recurrences at term.
B. Recurrent infection. Acyclovir reduces shedding by 80 percent and may reduce clinical recurrences. Women with frequent HSV recurrences may benefit from suppression (acyclovir 400 mg PO BID) near term.
C. Role of cesarean section
   1. Cesarean section should be offered to women who have active lesions or symptoms of vulvar pain or burning at the time of delivery and a history of genital herpes.
   2. Prophylactic cesarean section is not recommended for women with recurrent HSV and no evidence of active lesions at the time of delivery. Lesions which have crusted fully are considered healed and not active.
   3. Cesarean section is not recommended for women with recurrent genital herpes and active nongenital HSV lesions. The lesions should be covered with an occlusive dressing.
D. Very preterm infants (<30 to 32 weeks) in preterm labor: If the mother has active HSV, delay of delivery for betamethasone therapy is appropriate. Cesarean section after either documented pulmonary maturity or betamethasone would be appropriate if active lesions are present. The use of acyclovir during this time may be helpful to shorten the time of active lesions for the mother.

E. Herpes cultures or the more sensitive PCR test is often performed on the neonate at delivery to identify exposed infants.

References: See page 282.

Dystocia and Augmentation of Labor

I. Normal labor

A. First stage of labor
   1. The first stage of labor consists of the period from the onset of labor until complete cervical dilation (10 cm). This stage is divided into the latent phase and the active phase.
   2. Latent phase
      a. During the latent phase, uterine contractions are infrequent and irregular and result in only modest discomfort. They result in gradual effacement and dilation of the cervix.
      b. A prolonged latent phase is one that exceeds 20 hours in the nullipara or one that exceeds 14 hours in the multipara.
   3. Active phase
      a. The active phase of labor occurs when the cervix reaches 3-4 cm of dilatation.
      b. The active phase of labor is characterized by an increased rate of cervical dilation and by descent of the presenting fetal part.

B. Second stage of labor
   1. The second stage of labor consists of the period from complete cervical dilatation (10 cm) until delivery of the infant. This stage is usually brief, averaging 20 minutes for parous women and 50 minutes for nulliparous women.
   2. The duration of the second stage of labor is unrelated to perinatal outcome in the absence of a nonreassuring fetal heart rate pattern as long as progress occurs.

II. Abnormal labor

A. Dystocia is defined as difficult labor or childbirth resulting from abnormalities of the cervix and uterus, the fetus, the maternal pelvis, or a combination of these factors.

B. Cephalopelvic disproportion is a disparity between the size of the maternal pelvis and the fetal head that precludes vaginal delivery. This condition can rarely be diagnosed in advance.

C. Slower-than-normal (protraction disorders) or complete cessation of progress (arrest disorder) are disorders that can be diagnosed only after the parturient has entered the active phase of labor.

III. Assessment of labor abnormalities

A. Labor abnormalities caused by inadequate uterine contractility (powers). The minimal uterine contractile pattern of women in spontaneous labor consists of 3 to 5 contractions in a 10-minute period.

B. Labor abnormalities caused by fetal characteristics (passenger)
   1. Assessment of the fetus consists of estimating fetal weight and position. Estimations of fetal size, even those obtained by ultrasonography, are frequently inaccurate.
   2. In the first stage of labor, the diagnosis of dystocia can not be made unless the active phase of labor and adequate uterine contractile forces have been present.
   3. Fetal anomalies such as hydrocephaly, encephalocele, and soft tissue tumors may obstruct labor. Fetal imaging should be considered when malpresentation or anomalies are suspected based on vaginal or abdominal examination or when the presenting fetal part is persistently high.

C. Labor abnormalities due to the pelvic passage (passage)
   1. Inefficient uterine action should be corrected before attributing dystocia to a pelvic problem.
   2. The bony pelvis is very rarely the factor that limits vaginal delivery of a fetus in cephalic presentation. Radiographic pelvimetry is of limited value in managing most cephalic presentations.
   3. Clinical pelvimetry can only be useful to qualitatively identify the general architectural features of the pelvis.

IV. Augmentation of labor

A. Uterine hypocontractility should be augmented only after both the maternal pelvis and fetal presentation have been assessed.

B. Contraindications to augmentation include placenta or vasa previa, umbilical cord prolapse, prior classical uterine incision, pelvic structural deformities, and invasive cervical cancer.

C. Oxytocin (Pitocin)
   1. The goal of oxytocin administration is to stimulate uterine activity that is sufficient to produce cervical change and fetal descent while avoiding uterine hyperstimulation and fetal compromise.
   2. Minimally effective uterine activity is 3 contractions per 10 minutes averaging greater than 25 mm Hg above baseline. A maximum of 5 contrac-
tions in a 10-minute period with resultant cervical dilatation is considered adequate.

3. **Hyperstimulation** is characterized by more than five contractions in 10 minutes, contractions lasting 2 minutes or more, or contractions of normal duration occurring within 1 minute of each other.

4. Oxytocin is administered when a patient is progressing slowly through the latent phase of labor or has a protraction or an arrest disorder of labor, or when a hypotonic uterine contraction pattern is identified.

5. A pelvic examination should be performed before initiation of oxytocin infusion.

6. Oxytocin is usually diluted 10 units in 1 liter of normal saline IVPB.

### Labor Stimulation with Oxytocin (Pitocin)

<table>
<thead>
<tr>
<th>Starting Dose (mU/min)</th>
<th>Incremental Increase (mU/min)</th>
<th>Dosage Interval (min)</th>
<th>Maximum Dose (mU/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>6</td>
<td>15</td>
<td>40</td>
</tr>
</tbody>
</table>

7. **Management of oxytocin-induced hyperstimulation**
   a. The most common adverse effect of hyperstimulation is fetal heart rate deceleration associated with uterine hyperstimulation. Stopping or decreasing the dose of oxytocin may correct the abnormal pattern.
   b. Additional measures may include changing the patient to the lateral decubitus position and administering oxygen or more intravenous fluid.
   c. If oxytocin-induced uterine hyperstimulation does not respond to conservative measures, intravenous terbutaline (0.125-0.25 mg) or magnesium sulfate (2-6 g in 10-20% dilution) may be used to stop uterine contractions.

References: See page 282.

### Shoulder Dystocia

Shoulder dystocia, defined as failure of the shoulders to deliver following the head, is an obstetric emergency. The incidence varies from 0.6% to 1.4% of all vaginal deliveries. Up to 30% of shoulder dystocias can result in brachial plexus injury; many fewer sustain serious asphyxia or death. Most commonly, size discrepancy secondary to fetal macrosomia is associated with difficult shoulder delivery. Causal factors of macrosomia include maternal diabetes, postdates gestation, and obesity. The fetus of the diabetic gravida may also have disproportionately large shoulders and body size compared with the head.

#### I. Prediction

A. The diagnosis of shoulder dystocia is made after delivery of the head. The "turtle" sign is the retraction of the chin against the perineum or retraction of the head into the birth canal. This sign demonstrates that the shoulder girdle is resisting entry into the pelvic inlet, and possibly impaction of the anterior shoulder.

B. Macrosomia has the strongest association. ACOG defines macrosomia as an estimated fetal weight (EFW) greater than 4500 g.

C. Risk factors for macrosomia include maternal birth weight, prior macrosomia, preexisting diabetes, obesity, multiparity, advanced maternal age, and a prior shoulder dystocia. The recurrence rate has been reported to be 13.8%, nearly seven times the primary rate. Shoulder dystocia occurs in 5.1% of obese women. In the antepartum period, risk factors include gestational diabetes, excessive weight gain, short stature, macrosomia, and postterm pregnancy. Intrapartum factors include prolonged second stage of labor, abnormal first stage, arrest disorders, and instrumental (especially midforceps) delivery. Many shoulder dystocias will occur in the absence of any risk factors.

#### II. Management

A. Shoulder dystocia is a medical and possibly surgical emergency. Two assistants should be called for if not already present, as well as an anesthesiologist and pediatrician. A generous episiotomy should be cut. The following sequence is suggested:

1. **McRoberts maneuver:** The legs are removed from the lithotomy position and flexed at the hips, with flexion of the knees against the abdomen. Two assistants are required. This maneuver may be performed prophylactically in anticipation of a difficult delivery.

2. **Suprapubic pressure:** An assistant is requested to apply pressure downward, above the symphysis pubis. This can be done in a lateral direction to help dislodge the anterior shoulder from behind the pubic symphysis. It can also be performed in anticipation of a difficult delivery. Fundal pressure may increase the likelihood of uterine rupture and is contraindicated.

3. **Rotational maneuvers:** The Woods' corkscrew maneuver consists of placing two fingers against the anterior aspect of the posterior shoulder.
Gentle upward rotational pressure is applied so that the posterior shoulder girdle rotates anteriorly, allowing it to be delivered first. The Rubin maneuver is the reverse of Woods’s maneuver. Two fingers are placed against the posterior aspect of the posterior (or anterior) shoulder and forward pressure applied. This results in adduction of the shoulders and displacement of the anterior shoulder from behind the symphysis pubis.

4. Posterior arm release: The operator places a hand into the posterior vagina along the infant’s back. The posterior arm is identified and followed to the elbow. The elbow is then swept across the chest, keeping the elbow flexed. The fetal forearm or hand is then grasped and the posterior arm delivered, followed by the anterior shoulder. If the fetus still remains undelivered, vaginal delivery should be abandoned and the Zavanelli maneuver performed followed by cesarean delivery.

5. Zavanelli maneuver: The fetal head is replaced into the womb. Tocolysis is recommended to produce uterine relaxation. The maneuver consists of rotation of the head to occiput anterior. The head is then flexed and pushed back into the vagina, followed abdominal delivery. Immediate preparations should be made for cesarean delivery.

6. If cephalic replacement fails, an emergency symphysiotomy should be performed. The urethra should be laterally displaced to minimize the risk of lower urinary tract injury.

B. The McRoberts maneuver alone will successfully alleviate the shoulder dystocia in 42% to 79% of cases. For those requiring additional maneuvers, vaginal delivery can be expected in more than 90%. Finally, favorable results have been reported for the Zavanelli maneuver in up to 90%.

References: See page 282.

Induction of Labor

Induction of labor refers to stimulation of uterine contractions prior to the onset of spontaneous labor. Between 1990 and 1998, the rate of labor induction doubled from 10 to 20 percent.

I. Indications for labor induction:
   A. Preeclampsia/eclampsia, and other hypertensive diseases
   B. Maternal diabetes mellitus
   C. Preeclampsia/eclampsia, and other hypertensive diseases
   D. Chorioamnionitis
   E. Intrauterine fetal growth restriction (IUGR)
   F. Ischemization
   G. In-utero fetal demise
   H. Postterm pregnancy

II. Absolute contraindications to labor induction:
   A. Prior classical uterine incision
   B. Active genital herpes infection
   C. Placenta or vasa previa
   D. Umbilical cord prolapse
   E. Fetal malpresentation, such as transverse lie

II. Requirements for induction
   A. Prior to undertaking labor induction, assessments of gestational age, fetal size and presentation, clinical pelvimetry, and cervical examination should be performed. Fetal maturity should be evaluated, and amniocentesis for fetal lung maturity may be needed prior to induction.

B. Clinical criteria that confirm term gestation:
   1. Fetal heart tones documented for 30 weeks by Doppler.
   2. Thirty-six weeks have elapsed since a serum or urine human chorionic gonadotropin (hCG) pregnancy test was positive.
   3. Ultrasound measurement of the crown-rump length at 6 to 11 weeks of gestation or biparietal diameter/femur length at 12 to 20 weeks of gestation support a clinically determined gestational age equal to or greater than 39 weeks.

C. Assessment of cervical ripeness
   1. A cervical examination should be performed before initiating attempts at labor induction.
   2. The modified Bishop scoring system is most commonly used to assess the cervix. A score is calculated based upon the station of the presenting part and cervical dilatation, effacement, consistency, and position.

<table>
<thead>
<tr>
<th>Modified Bishop Scoring System</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Dilation, cm</td>
</tr>
<tr>
<td>Effacement, percent</td>
</tr>
<tr>
<td>Station*</td>
</tr>
<tr>
<td>Cervical consistency</td>
</tr>
<tr>
<td>Position of the cervix</td>
</tr>
</tbody>
</table>
3. The likelihood of a vaginal delivery after labor induction is similar to that after spontaneous onset of labor if the Bishop score is >8.

III. Induction of labor with oxytocin
A. The uterine response to exogenous oxytocin administration is periodic uterine contractions.
B. Oxytocin regimen (Pitocin)
1. Oxytocin is given intravenously. Oxytocin is diluted by placing 10 units in 1000 mL of normal saline, yielding an oxytocin concentration of 10 mU/mL. Begin at 6 mU/min and increase by 6 mU/min every 15 minutes.
2. Active management of labor regimens use a high-dose oxytocin infusion with short incremental time intervals.

<table>
<thead>
<tr>
<th>High Dose Oxytocin Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Begin oxytocin 6 mU per minute intravenously</td>
</tr>
<tr>
<td>Increase dose by 6 mU per minute every 15 minutes</td>
</tr>
<tr>
<td>Maximum dose: 40 mU per minute</td>
</tr>
<tr>
<td>Maximum total dose administered-during-labor: 10 U</td>
</tr>
<tr>
<td>Maximum duration of administration: six hours</td>
</tr>
</tbody>
</table>

3. The dose of maximum oxytocin is usually 40 mU/min. The dose is typically increased until contractions occur at two to three minute intervals.

IV. Cervical ripening agents
A. A ripening process should be considered prior to use of oxytocin when the cervix is unfavorable.
B. Mechanical methods
1. Membrane stripping is a widely utilized technique, which causes release of either prostaglandin F2-alpha from the decidua and adjacent membranes or prostaglandin E2 from the cervix. Weekly membrane stripping beginning at 38 weeks of gestation results in delivery within a shorter period of time (8.6 versus 15 days).
2. Amniotomy is an effective method of labor induction when performed in women with partially dilated and effaced cervices. Caution should be exercised to ensure that the fetal vertex is well-applied to the cervix and the umbilical cord or other fetal part is not presenting.
3. Foley catheter. An uninflated Foley catheter can be passed through an undilated cervix and then inflated. This technique is as effective as prostaglandin E2 gel. The use of extra-amniotic saline infusion with a balloon catheter or a double balloon catheter (Atad ripener) also appears to be effective for cervical ripening.
C. Prostaglandins
1. Local administration of prostaglandins to the vagina or the endocervix is the route of choice because of fewer side effects and acceptable clinical response. Uncommon side effects include fever, chills, vomiting, and diarrhea.
2. Prepidil contains 0.5 mg of dinoprostone in 2.5 mL of gel for intracervical administration. The dose can be repeated in 6 to 12 hours if there is inadequate cervical change and minimal uterine activity following the first dose. The maximum cumulative dose is 1.5 mg (ie, 3 doses) within a 24-hour period. The time interval between the final dose and initiation of oxytocin should be 6 to 12 hours because of the potential for uterine hyperstimulation with concurrent oxytocin and prostaglandin administration.
3. Cervidil is a vaginal insert containing 10 mg of dinoprostone in a timed-release formulation. The vaginal insert administers the medication at 0.3 mg/h and should be left in place for 12 hours. Oxytocin may be initiated 30 to 60 minutes after removal of the insert.
4. An advantage of the vaginal insert over the gel formulation is that the insert can be removed in cases of uterine hyperstimulation or abnormalities of the fetal heart rate tracing.

V. Complications of labor induction
A. Hyperstimulation and tachysystole may occur with use of prostaglandin compounds or oxytocin. Hyperstimulation is defined as uterine contractions lasting at least two minutes or five or more uterine contractions in 10 minutes. Tachysystole is defined as six or more contractions in 20 minutes.
B. Prostaglandin E2 (PGE2) preparations have up to a 5 percent rate of uterine hyperstimulation. Fetal heart rate abnormalities can occur, but usually resolve upon removal of the drug. Rarely hyperstimulation or tachysystole can cause uterine rupture. Removing the PGE2 vaginal insert will usually help reverse the effects of the hyperstimulation and tachysystole. Cervical and vaginal lavage after local application of prostaglandin compounds is not helpful.
C. If oxytocin is being infused, it should be discontinued to achieve a reassuring fetal heart rate pattern. Placing the woman in the left lateral position, administering oxygen, and increasing intravenous fluids may also be of benefit. Terbutaline 0.25 mg subcutaneously (a tocolytic) may be given.

References: See page 282.
Postpartum Hemorrhage
Obstetric hemorrhage remains a leading cause of maternal mortality. Postpartum hemorrhage is defined as the loss of more than 500 mL of blood following delivery. However, the average blood loss in an uncomplicated vaginal delivery is about 500 mL, with 5% losing more than 1,000 mL.

I. Clinical evaluation of postpartum hemorrhage
A. Uterine atony is the most common cause of postpartum hemorrhage. Conditions associated with uterine atony include an overdistended uterus (eg, polyhydramnios, multiple gestation), rapid or prolonged labor, macrosomia, high parity, and chorioamnionitis.
B. Conditions associated with bleeding from trauma include forceps delivery, macrosomia, precipitous labor and delivery, and episiotomy.
C. Conditions associated with bleeding from coagulopathy and thrombocytopenia include abruptio placentae, amniotic fluid embolism, preeclampsia, coagulation disorders, autoimmune thrombocytopenia, and anticoagulants.
D. Uterine rupture is associated with previous uterine surgery, internal podalic version, breech extraction, multiple gestation, and abnormal fetal presentation. High parity is a risk factor for both uterine atony and rupture.
E. Uterine inversion is detected by abdominal vaginal examination, which will reveal a uterus with an unusual shape after delivery.

II. Management of postpartum hemorrhage
A. Following delivery of the placenta, the uterus should be palpated to determine whether atony is present. If atony is present, vigorous fundal massage should be administered. If bleeding continues despite uterine massage, it can often be controlled with bimanual uterine compression.
B. Genital tract lacerations should be suspected in patients who have a firm uterus, but who continue to bleed. The cervix and vagina should be inspected to rule out lacerations. If no laceration is found but bleeding is still profuse, the uterus should be manually examined to exclude rupture.
C. The placenta and uterus should be examined for retained placental fragments. Placenta accreta is usually manifest by failure of spontaneous placental separation.
D. Bleeding from non-genital areas (venous puncture sites) suggests coagulopathy. Laboratory tests that confirm coagulopathy include INR, partial thromboplastin time, platelet count, fibrinogen, fibrin split products, and a clot retraction test.
E. Medical management of postpartum hemorrhage
1. Oxytocin (Pitocin) is usually given routinely immediately after delivery to stimulate uterine firmness and diminish blood loss. 20 units of oxytocin in 1,000 mL of normal saline or Ringer's lactate is administered at 100 drops/minute. Oxytocin should not be given as a rapid bolus injection because of the potential for circulatory collapse.
2. Methylergonovine (Methergine) 0.2 mg can be given IM if uterine massage and oxytocin are not effective in correcting uterine atony and provided there is no hypertension.
3. 15-methyl prostaglandin F2-alpha (Hemabate), one ampule (0.25 mg), can be given IM, with repeat injections every 20min, up to 4 doses can be given if hypertension is present; it is contraindicated in asthma.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytocin</td>
<td>20 U in 1,000 mL of lactated Ringer’s as IV infusion</td>
</tr>
<tr>
<td>Methylergonovine (Methergine)</td>
<td>0.2 mg IM</td>
</tr>
<tr>
<td>Prostaglandin (15 methyl PGF2-alpha (Hemabate, Prostin/15M)</td>
<td>0.25 mg as IM every 15-60 minutes as necessary</td>
</tr>
</tbody>
</table>

F. Volume replacement
1. Patients with postpartum hemorrhage that is refractory to medical therapy require a second large-bore IV catheter. If the patient has had a major blood group determination and has a negative indirect Coombs test, type-specific blood may be given without waiting for a complete cross-match. Lactated Ringer's solution or normal saline is generously infused until blood can be replaced. Replacement consists of 3 mL of crystalloid solution per 1 mL of blood lost.
2. A Foley catheter is placed, and urine output is maintained at greater than 30 mL/h.

G. Surgical management of postpartum hemorrhage
If medical therapy fails, ligation of the uterine or uteroovarian artery, infundibulopelvic vessels, or hypogastric arteries, or hysterectomy may be indicated.

H. Management of uterine inversion
1. The inverted uterus should be immediately repositioned vaginally. Blood and/or fluids should be administered. If the placenta is still attached, it should not be removed until the uterus has been repositioned.
2. Uterine relaxation can be achieved with a halogenated anesthetic agent. Terbutaline is also useful for relaxing the uterus. Following successful uterine repositioning and placental separation, oxytocin (Pitocin) is given to contract the uterus.

References: See page 282.

Acute Endometritis

Acute endometritis is characterized by the presence of microabscesses or neutrophils within the endometrial glands.

I. Classification of endometritis

A. Acute endometritis in the nonobstetric population is usually related to pelvic inflammatory disease (PID) secondary to sexually transmitted infections or gynecologic procedures. Acute endometritis in the obstetric population occurs as a postpartum infection, usually after a labor concluded by cesarean delivery.

B. Chronic endometritis in the nonobstetric population is due to infections (eg, chlamydia, tuberculosis, and other organisms related to cervicitis and PID), intrauterine foreign bodies (eg, intrauterine device, submucous leiomyoma), or radiation therapy. In the obstetric population, chronic endometritis is associated with retained products of conception after a recent pregnancy.

C. Symptoms in both acute and chronic endometritis consist of abnormal vaginal bleeding and pelvic pain. However, patients with acute endometritis frequently have fevers in contrast to chronic endometritis.

II. Postpartum endometritis

A. Endometritis in the postpartum period refers to infection of the decidua (ie, pregnancy endometrium), frequently with extension into the myometrium (endomyometritis) and parametrial tissues (parametritis).

B. The single most important risk factor for postpartum endometritis is route of delivery. The incidence of endometritis after a vaginal birth is less than three percent, but is 5 to 10 times higher after cesarean delivery.

C. Other proposed risk factors include prolonged labor, prolonged rupture of membranes, multiple vaginal examinations, internal fetal monitoring, maternal diabetes, presence of meconium, and low socioeconomic status.

D. Microbiology. Postpartum endometritis is usually a polymicrobial infection, produced by a mixture of aerobes and anaerobes from the genital tract.

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Frequency (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram positive</strong></td>
<td></td>
</tr>
<tr>
<td>Group B streptococci</td>
<td>8</td>
</tr>
<tr>
<td>Enterococci</td>
<td>7</td>
</tr>
<tr>
<td>S. epidermidis</td>
<td>9</td>
</tr>
<tr>
<td>Lactobacilli</td>
<td>4</td>
</tr>
<tr>
<td>Diphtheroids</td>
<td>2</td>
</tr>
<tr>
<td>S. Aureus</td>
<td>1</td>
</tr>
<tr>
<td><strong>Gram negative</strong></td>
<td></td>
</tr>
<tr>
<td>G. vaginalis</td>
<td>15</td>
</tr>
<tr>
<td>E. Coli</td>
<td>6</td>
</tr>
<tr>
<td>Enterobacterium spp.</td>
<td>2</td>
</tr>
<tr>
<td>P. mirabilis</td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td>3</td>
</tr>
<tr>
<td><strong>Anaerobic</strong></td>
<td></td>
</tr>
<tr>
<td>S. bivius</td>
<td>11</td>
</tr>
<tr>
<td>Other Bacteroides spp.</td>
<td>9</td>
</tr>
<tr>
<td>Peptococci-peptostreptocc</td>
<td>22</td>
</tr>
<tr>
<td><strong>Mycoplasma</strong></td>
<td></td>
</tr>
<tr>
<td>U. urealyticum</td>
<td>39</td>
</tr>
<tr>
<td>M. hominis</td>
<td>11</td>
</tr>
<tr>
<td>C. trachomatis</td>
<td>2</td>
</tr>
</tbody>
</table>

E. Vaginal colonization with group B streptococcus (GBS) is a risk factor for postpartum endometritis. GBS colonized women at delivery have an 80 percent greater likelihood of developing postpartum endometritis.

F. Clinical manifestations and diagnosis. Endometritis is characterized by fever, uterine tenderness, foul lochia, and leukocytosis that develop within five days of delivery. A temperature greater than or equal to 100.4°F (38 °C) in the absence of other causes of fever, such as pneumonia, wound cellulitis, and urinary tract infection is the most common sign.

G. Laboratory studies are not diagnostic since leukocytosis occurs frequently in all postpartum patients. However, a rising neutrophil count associated with elevated numbers of bands is suggestive of infectious disease. Bacteremia occurs in 10 to 20 percent of patients; usually a single organism is identified despite polymicrobial infection. Blood cultures should be obtained in febrile patients following delivery.

H. Treatment

1. Postpartum endometritis is treated with broad spectrum parenteral antibiotics including coverage for beta-lactamase producing anaerobes. The standard treatment of clindamycin (900 mg q8h)
plus gentamicin (1.5 mg/kg q8h) is safe and effective, with reported cure rates of 90 to 97 percent.

### Antibiotic Regimens for Endometritis

<table>
<thead>
<tr>
<th>Antibiotic Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin (900 mg IV Q 8 hours) plus gentamicin (1.5 mg/kg IV Q 8 hours)</td>
</tr>
<tr>
<td>Ampicillin-sulbactam (Unasyn) 3 grams IV Q 6 hours</td>
</tr>
<tr>
<td>Ticarcillin-clavulanate (Timentin) 5.1 grams IV Q 4 hours</td>
</tr>
<tr>
<td>Cefoxitin (Mefoxin) 2 grams IV Q 6 hours</td>
</tr>
<tr>
<td>Ceftriaxone (Rocephin) 2 grams IV Q 24 hours plus</td>
</tr>
<tr>
<td>metronidazole 500 mg PO or IV Q 8 hours*</td>
</tr>
<tr>
<td>Levofloxacin (Levaquin) 500 mg IV Q 24 hours plus</td>
</tr>
<tr>
<td>metronidazole 500 mg PO or IV Q 8 hours*</td>
</tr>
</tbody>
</table>

* Should not be given to breastfeeding mothers.

2. Treatment should continue until the patient is clinically improved and afebrile for 24 to 48 hours. Oral antibiotic therapy is not necessary after successful parenteral treatment, unless bacteremia is present.

3. Modifications in therapy may be necessary if there is no response to the initial antibiotic regimen after 48 to 72 hours. Approximately 20 percent of treatment failures are due to resistant organisms, such as enterococci which are not covered by cephalosporins or clindamycin plus gentamicin. The addition of ampicillin (2 g q4h) to the regimen can improve the response rate. Metronidazole (500 mg PO or IV q8h) may be more effective than clindamycin against Gram negative anaerobes but is generally not used in mothers who will be breastfeeding.

**References:** See page 282.

### Postpartum Fever Workup

**History:** Postpartum fever is >100.4 F (38 degrees C) on 2 occasions >6h apart after the first postpartum day (during the first 10 days postpartum), or >101 on the first postpartum day. Dysuria, abdominal pain, distention, breast pain, calf pain.

**Predisposing Factors:** Cesarean section, prolonged labor, premature rupture of membranes, internal monitors, multiple vaginal exams, meconium, manual placenta extraction, anemia, poor nutrition.

**Physical Examination:** Temperature, throat, chest, lung exams; breasts, abdomen, Costovertebral angle tenderness, uterine tenderness, phlebitis, calf tenderness; wound exam. Speculum exam.

**Differential Diagnosis:** UTI, upper respiratory infection, atelectasis, pneumonia, wound infection, mastitis, episiotomy abscess; uterine infection, deep vein thrombosis, pyelonephritis, pelvic abscess.

**Labs:** CBC, SMA7, blood C&S x 2, catheter UA, C&S. Gonococcus culture, chlamydia; wound C&S, CXR.

**References**

References may be obtained at www.ccspublishing.com/ccs.
Commonly Used Formulas

A-a gradient = [(P_{\text{a}}-\text{P}_{\text{H}2\text{O}}) \times \text{FiO}_2 - \text{PCO}_2]/\text{R} - \text{PO}_2 \text{ arterial}

\[ = (713 \times \text{FiO}_2 - \text{pCO}_2/0.8) - \text{pO}_2 \text{ arterial} \]

\( \text{PB} = 760 \text{ mmHg}; \text{PH}_2\text{O} = 47 \text{ mmHg}; \text{R} = 0.8 \)

Normal Aa gradient <10-15 mmHg (room air)

Arterial oxygen capacity = (Hgb(gm)/100 mL) \times 1.36 mL O2/gm Hgb

Arterial O2 content = 1.36(Hgb)(SaO2)+0.003(PaO2) = NL 20 vol%

O2 delivery = CO \times \text{arterial O2 content} = \text{NL 640-1000 mL O2/min}

Cardiac output = HR \times \text{stroke volume}

\[ \text{CO} \text{ L/min} = \frac{125 \text{ mL O2/min M}^2}{8.5 \times (1.36)(	ext{Hgb})(\text{SaO2}) - (1.36)(	ext{Hgb})(\text{Sv-O2})} \]

Normal CO = 4-6 L/min

Na (mEq) deficit = 0.6 \times (\text{wt kg}) \times (\text{desired [Na]} - \text{actual [Na]})

\[ \text{SVR} = \frac{\text{MAP - CVP}}{\text{CO}_{\text{min}}} \times 80 = \text{NL 800-1200 dyne/sec/cm}^2 \]

\[ \text{PVR} = \frac{\text{PA} - \text{PCWP}}{\text{CO}_{\text{min}}} \times 80 = \text{NL 45-120 dyne/sec/cm}^2 \]

\[ \text{GFR} \text{ mL/min} = \frac{\text{[140 - age]} \times \text{wt in kg}}{72 \text{ (males)} \times \text{serum creatinine (mg/dL)}} \]

\[ = \frac{\text{85} \text{ (females)} \times \text{serum creatinine (mg/dL)}}{\text{Normal creatinine clearance} = 100-125 \text{ mL/min (males), 85-105 (females)}} \]

Body water deficit (L) = 0.6(weight kg)([measured serum Na]-140) / 140

Serum Osmolality = 2[Na] + BUN + Glucose = 270-290

\[ \text{Na (mEq) deficit} = 0.6 \times (\text{wt kg}) \times (\text{desired [Na]} - \text{actual [Na]}) \]

Fractional excreted Na = U Na/Serum Na \times 100

\[ = \text{NL<1%}} \]

\[ \text{U creatinine/Serum creatinine} \]

Anion Gap = Na - (Cl + HCO3)

For each 100 mg/dL in glucose, Na+ by 1.6 mEq/L.

Corrected \[ = \text{measured Ca mg/dL} + 0.8 \times (4 \times \text{serum Ca}^+) \text{ (mg/dL)}} \]

Predicted Maximal Heart Rate = 220 - age

**Normal ECG Intervals (sec)**

<table>
<thead>
<tr>
<th>PR</th>
<th>0.12-0.20</th>
</tr>
</thead>
<tbody>
<tr>
<td>QRS</td>
<td>0.06-0.08</td>
</tr>
<tr>
<td>Heart rate/min</td>
<td>Q-T</td>
</tr>
<tr>
<td>60</td>
<td>0.30-0.43</td>
</tr>
<tr>
<td>70</td>
<td>0.31-0.41</td>
</tr>
<tr>
<td>80</td>
<td>0.29-0.38</td>
</tr>
<tr>
<td>90</td>
<td>0.28-0.36</td>
</tr>
<tr>
<td>100</td>
<td>0.27-0.35</td>
</tr>
</tbody>
</table>

**Total Parenteral Nutrition Equations:**

**Caloric Requirements:** (Harris-Benedict Equations)

Basal energy expenditure (BEE)

- Females: 655 + (9.6 \times \text{wt in kg}) + (1.85 \times \text{ht in cm}) - (4.7 \times \text{age})
- Males: 66 + (13.7 \times \text{wt in kg}) + (5 \times \text{ht in cm}) - (6.8 \times \text{age})

A. BEE \times 1.2 = Caloric requirement for minimally stressed patient
B. BEE \times 1.3 = Caloric requirement for moderately stressed patient (inflammatory bowel disease, cancer, surgery)
C. BEE \times 1.5 = Caloric requirement for severely stressed patient (major sepsis, burns, AIDS, liver disease)
D. BEE \times 1.7 = Caloric requirement for extremely stressed patient (traumatic burns >50%, open head trauma, multiple stress)

**Protein Requirements:**

A. 0.8 gm protein/kg = Protein requirement for nonstressed patient.
B. 1.0-1.5 gm protein/kg = Protein requirement for patients with decreased visceral protein states (hyperalbuminaemia), recent weight loss, or hypercatabolic states.
C. >1.5 gm protein/kg = Protein requirement for patients with negative nitrogen balance receiving 1.5 gm protein/kg

**Estimation of Ideal Body Weight:**

A. Females: 5 feet (allow 100 lbs) + 5 lbs for each inch
**Drug Levels of Commonly Used Medications**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>THERAPEUTIC RANGE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>Peak 25-30; trough &lt;10 mcg/mL</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>100-250 ng/mL</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>4-10 mcg/mL</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Peak 10-15; trough &lt;5 mcg/mL</td>
</tr>
<tr>
<td>Desipramine</td>
<td>150-300 ng/mL</td>
</tr>
<tr>
<td>Digitoxin</td>
<td>10-30 mg/mL</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.5-2.0 mg/mL</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>2-5 mcg/mL</td>
</tr>
<tr>
<td>Doxepin</td>
<td>75-200 mcg/mL</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>40-100 mcg/mL</td>
</tr>
<tr>
<td>Flecainide</td>
<td>0.2-1.0 mg/mL</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Peak 6.0-8.0; trough &lt;2.0 mcg/mL</td>
</tr>
<tr>
<td>Imipramine</td>
<td>150-300 ng/mL</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>2-5 mg/mL</td>
</tr>
<tr>
<td>Lithium</td>
<td>0.5-1.4 mEq/L</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>50-150 ng/mL</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>10-30 mgEq/mL</td>
</tr>
<tr>
<td>Phenytoin**</td>
<td>8-20 mcg/mL</td>
</tr>
<tr>
<td>Procainamide</td>
<td>4.0-8.0 mcg/mL</td>
</tr>
<tr>
<td>Quinidine</td>
<td>2.5-5.0 mcg/mL</td>
</tr>
<tr>
<td>Salicylate</td>
<td>15-25 mg/dL</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>Peak 10-20; trough &lt;5 mcg/mL</td>
</tr>
<tr>
<td>Theophylline</td>
<td>8-20 mcg/mL</td>
</tr>
<tr>
<td>Tocainide</td>
<td>4-10 mcg/mL</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>50-100 mcg/mL</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Peak 30-40; trough &lt;10 mcg/mL</td>
</tr>
</tbody>
</table>

* The therapeutic range of some drugs may vary depending on the reference lab used.
** Therapeutic range of phenytoin is 4-10 mcg/mL in presence of significant azotemia and/or hypoalbuminemia.

**Pediatric and Obstetric Formulas**

- Normal urine output = 50 ml/kg/d
- Oliguria = 0.5 ml/kg/h
- Normal feedings = 5 oz/kg/d
- Formula = 20 calories/ounce, 24 cal/oz, 27 cal/oz
- Ounce = 30 cc
- Caloric Needs = 100 cal/kg/d
- Calories/Kg = cc of formula x 30 cc/oz x 20 calories/oz divided by weight.

  - Weight in Kg = pounds divided by 2.2
  - Weight in Kg = [age in years x 2] + 10

- Blood volume (ml) = 80 ml/kg x weight (kg)

**Blood Products:**
- 10 cc/kg RBC will raise Hct 5%
- 0.1 unit/kg platelets will raise platelet count, 25000/mm³.
- 1 U/kg of Factor VIII will raise level by 2%.

- Naegel's Rule: LMP minus 3 months plus 7 days = Estimated date of confinement.

- GFR = (140 - age) x wt in Kg
  \[ \text{in} \ x \ 1.73 \text{ m}^2 \]

- Normal Cr clearance = 85-105